Famotidine	I-Entity
-	O
associated	O
delirium	I-Entity
.	O

Famotidine	I-Entity
is	O
a	O
histamine	O
H2-receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	I-Entity
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2-receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	I-Entity
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	I-Entity
.	O

The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	I-Entity
-	O
associated	O
delirium	I-Entity
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	I-Entity
.	O

The	O
pharmacokinetics	O
of	O
famotidine	I-Entity
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen	O
.	O

The	O
implications	O
of	O
using	O
famotidine	I-Entity
in	O
elderly	O
persons	O
are	O
discussed	O
.	O



Indomethacin	I-Entity
induced	O
hypotension	I-Entity
in	O
sodium	I-Entity
and	O
volume	O
depleted	O
rats	O
.	O

After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
indomethacin	I-Entity
(	O
IDM	I-Entity
)	O
to	O
sodium	I-Entity
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodium	I-Entity
repleted	O
animals	O
indomethacin	I-Entity
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased	O
.	O

Thus	O
,	O
indomethacin	I-Entity
by	O
inhibition	O
of	O
prostaglandin	I-Entity
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin	O
-	O
angiotensin	I-Entity
system	O
in	O
sodium	I-Entity
and	O
volume	O
depletion	O
.	O



Late	O
-	O
onset	O
scleroderma	B-Entity
renal	I-Entity
crisis	I-Entity
induced	O
by	O
tacrolimus	I-Entity
and	O
prednisolone	I-Entity
:	O
a	O
case	O
report	O
.	O

Scleroderma	B-Entity
renal	I-Entity
crisis	I-Entity
(	O
SRC	I-Entity
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-Entity
sclerosis	I-Entity
(	O
SSc	I-Entity
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O

Moderate	O
to	O
high	O
dose	O
corticosteroid	I-Entity
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	I-Entity
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-Entity
microangiopathy	I-Entity
precipitated	O
by	O
cyclosporine	I-Entity
in	O
patients	O
with	O
SSc	I-Entity
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	I-Entity
induced	O
by	O
tacrolimus	I-Entity
and	O
corticosteroids	I-Entity
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	I-Entity
use	O
in	O
patients	O
with	O
SSc	I-Entity
.	O



The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	I-Entity
psychosis	I-Entity
in	O
methamphetamine	I-Entity
-	O
dependent	O
patients	O
in	O
Malaysia	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	I-Entity
-	O
induced	O
psychosis	I-Entity
in	O
patients	O
with	O
methamphetamine	I-Entity
dependence	O
.	O

The	O
association	O
between	O
psychiatric	O
co	O
-	O
morbidity	O
and	O
methamphetamine	I-Entity
-	O
induced	O
psychosis	I-Entity
was	O
also	O
studied	O
.	O

Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	I-Entity
based	O
on	O
DSM	O
-	O
IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
M.I.N.I.	O
)	O
for	O
methamphetamine	I-Entity
-	O
induced	O
psychosis	I-Entity
and	O
other	O
Axis	O
I	O
psychiatric	B-Entity
disorders	I-Entity
.	O

Of	O
292	O
subjects	O
,	O
47.9%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	B-Entity
symptoms	I-Entity
and	O
13.0%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	B-Entity
symptoms	I-Entity
.	O

Co	O
-	O
morbid	O
major	O
depressive	B-Entity
disorder	I-Entity
(	O
OR=7.18	O
,	O
95	O
CI=2.612	O
-	O
19.708	O
)	O
,	O
bipolar	B-Entity
disorder	I-Entity
(	O
OR=13.807	O
,	O
95	O
CI=5.194	O
-	O
36.706	O
)	O
,	O
antisocial	B-Entity
personality	I-Entity
disorder	I-Entity
(	O
OR=12.619	O
,	O
95	O
CI=6.702	O
-	O
23.759	O
)	O
and	O

heavy	O
methamphetamine	I-Entity
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	I-Entity
-	O
induced	O
psychosis	I-Entity
after	O
adjusted	O
for	O
other	O
factors	O
.	O

Major	B-Entity
depressive	I-Entity
disorder	I-Entity
(	O
OR=2.870	O
,	O
CI=1.154	O
-	O
7.142	O
)	O
and	O
antisocial	B-Entity
personality	I-Entity
disorder	I-Entity
(	O
OR=3.299	O
,	O
95	O
CI=1.375	O
-	O
7.914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	I-Entity
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	I-Entity
in	O
patients	O
with	O
methamphetamine	I-Entity
dependence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
morbid	O
affective	B-Entity
disorder	I-Entity
,	O
antisocial	B-Entity
personality	I-Entity
,	O
and	O
heavy	O
methamphetamine	I-Entity
use	O
.	O

It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	I-Entity
dependence	O
should	O
be	O
screened	O
for	O
psychotic	B-Entity
symptoms	I-Entity
.	O



motor	O
cortical	O
plasticity	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
:	O

clues	O
from	O
dyskinetic	I-Entity
patients	O
.	O

The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
and	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
(	O
LIDs	I-Entity
)	O
is	O
severely	O
impaired	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	I-Entity
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation	O
.	O

The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	I-Entity
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	I-Entity
and	O
PAS	O
-	O
induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral	O
,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function	O
,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	B-Entity
involuntary	I-Entity
movements	I-Entity
.	O



The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
in	O
rats	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	I-Entity
(	O
CYP)-induced	I-Entity
cystitis	I-Entity
in	O
rats	O
.	O

injected	O
with	O
CYP	I-Entity
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i.p	O
.	O

injected	O
with	O
CYP	I-Entity
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	I-Entity
and	O
GR	B-Entity
82334	I-Entity
.	O

Spontaneous	O
pain	I-Entity
behaviors	O
following	O
the	O
administration	O
of	O
CYP	I-Entity
were	O
observed	O
.	O

RESULTS	O
:	O
Cyclophosphamide	I-Entity
treatment	O
increased	O
the	O
spontaneous	O
pain	I-Entity
behaviors	O
scores	O
.	O

Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	I-Entity
,	O
vasodilation	O
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

In	O
CYP	I-Entity
-	O
induced	O
cystitis	I-Entity
,	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
increased	O
in	O
urothelium	O
and/or	O
suburothelium	O
.	O



Acute	O
hepatitis	I-Entity
associated	O
with	O
clopidogrel	I-Entity
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Drug	O
-	O
induced	O
hepatotoxicity	I-Entity
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	I-Entity
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
case	O
of	O
clopidogrel	I-Entity
-	O
related	O
acute	O
hepatitis	I-Entity
.	O

Reports	O
about	O
cases	O
of	O
hepatotoxicity	I-Entity
due	O
to	O
clopidogrel	I-Entity
are	O
increasing	O
in	O
the	O
last	O
few	O
years	O
,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
hepatic	B-Entity
injury	I-Entity
when	O
clopidogrel	I-Entity
is	O
prescribed	O
.	O



Bortezomib	I-Entity
and	O
dexamethasone	I-Entity
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O

refractory	O
multiple	B-Entity
myeloma	I-Entity
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O

Bortezomib	I-Entity

(	O
bort)-dexamethasone	I-Entity
(	O
dex	I-Entity
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-Entity
myeloma	I-Entity
(	O
MM	I-Entity
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	I-Entity
(	O
1.3	O
mg	O
/	O
m(2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	I-Entity
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	I-Entity
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R	O
/	O
R	O
MM	I-Entity
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	I-Entity
-	O
dex	I-Entity
.	O

The	O
median	O
number	O
of	O
bort	I-Entity
-	O
dex	I-Entity
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-Entity
neuropathy	I-Entity
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	I-Entity
-	O
dex	I-Entity
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort	I-Entity
-	O
dex	I-Entity
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	I-Entity
patients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O



Pubertal	O
exposure	O
to	O
Bisphenol	B-Entity
A	I-Entity
increases	O
anxiety	I-Entity
-	O
like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

The	O
negative	O
effects	O
of	O
Bisphenol	B-Entity
A	I-Entity
(	O
BPA	I-Entity
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	I-Entity
-	O
like	O
behavior	O
.	O

This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	I-Entity
exposure	O
during	O
puberty	O
.	O

On	O
postnatal	O
day	O
(	O
PND	O
)	O
35	O
,	O
male	O
mice	O
were	O
exposed	O
to	O
50	O
mg	O
BPA	I-Entity
/	O
kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days	O
.	O

Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	I-Entity
-	O
like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	I-Entity
.	O

AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	I-Entity
compared	O
to	O
control	O
mice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
and	O
cerebellum	O
.	O

Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	I-Entity
exposure	O
increased	O
anxiety	I-Entity
-	O
like	O
behavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	I-Entity
-	O
like	O
behaviors	O
.	O



Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	I-Entity
.	O

Cardiovascular	B-Entity
diseases	I-Entity
(	O
CVDs	I-Entity
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
in	O
rats	O
.	O

The	O
subcutaneous	O
injection	O
of	O
isoproterenol	I-Entity
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	I-Entity
dehydrogenase	O
,	O
creatine	I-Entity
phosphokinase	O
,	O
alanine	I-Entity
transaminase	O
,	O
aspartate	I-Entity
transaminase	O
,	O
and	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	I-Entity
,	O
triglycerides	I-Entity
,	O
free	O
serum	O
fatty	B-Entity
acid	I-Entity
,	O
cardiac	O
tissue	O
malondialdehyde	I-Entity
(	O
MDA	I-Entity
)	O
,	O
and	O
nitric	B-Entity
oxide	I-Entity
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	I-Entity
and	O
superoxide	I-Entity
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pretreatment	O
with	O
S.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	I-Entity
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O

Captopril	I-Entity
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O

The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	I-Entity
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	I-Entity
-	O
treated	O
rats	O
.	O



""""	O
Real	O
-	O
world	O
""""	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	I-Entity
and	O
dexamethasone	I-Entity
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-Entity
myeloma	I-Entity
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice	O
:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	I-Entity
Study	O
Group	O
.	O

Lenalidomide	I-Entity
and	O
dexamethasone	I-Entity
(	O
RD	I-Entity
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed	O
/	O
refractory	O
multiple	B-Entity
myeloma	I-Entity
(	O
RRMM	I-Entity
)	O
,	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
""""	O
real	O
world	O
""""	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition	O
.	O

We	O
studied	O
212	O
RRMM	I-Entity
patients	O
who	O
received	O
RD	I-Entity
in	O
RW	O
.	O

Median	O
time	O
to	O
CR	O
when	O
RD	I-Entity
was	O
given	O
as	O
2nd	O
or	O
>	O
2(nd)-line	O
treatment	O
at	O
4	O
and	O
11	O
months	O
,	O
respectively	O
.	O

Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	I-Entity
or	O
bortezomib	I-Entity
.	O

Median	O
duration	O
of	O
response	O
was	O
34.4	O
months	O
,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	I-Entity
until	O
progression	O
(	O
not	O
reached	O
versus	O
19	O
months	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Adverse	O
events	O
were	O
reported	O
in	O
68.9	O
%	O
of	O
patients	O
(	O
myelosuppression	I-Entity
in	O
49.4	O
%	O
)	O
and	O
12.7	O
%	O
of	O
patients	O
needed	O
hospitalization	O
.	O

Peripheral	B-Entity
neuropathy	I-Entity
was	O
observed	O
only	O
in	O
2.5	O
%	O
of	O
patients	O
and	O
deep	B-Entity
vein	I-Entity
thrombosis	I-Entity
in	O
5.7	O
%	O
.	O

Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	I-Entity
dose	O
predicted	O
for	O
treatment	O
discontinuation	O
.	O

Our	O
study	O
confirms	O
that	O
RD	I-Entity
is	O
effective	O
and	O
safe	O
in	O
RRMM	I-Entity
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	O
.	O



The	O
cytogenetic	O
action	O
of	O
ifosfamide	I-Entity
,	O
mesna	I-Entity
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	I-Entity
(	O
IFO	I-Entity
)	O
is	O
an	O
alkylating	O
nitrogen	I-Entity
mustard	O
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

This	O
side	O
effect	O
of	O
IFO	I-Entity
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B-Entity
2-sulfanylethanesulfonate	I-Entity
(	O
Mesna	I-Entity
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	I-Entity
and	O
Mesna	I-Entity
were	O
administrated	O
separately	O
on	O
rabbit	O
's	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Mesna	I-Entity
's	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	I-Entity
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	I-Entity
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	I-Entity
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	I-Entity
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	I-Entity
significantly	O
reduces	O
IFO	I-Entity
's	O
genotoxicity	I-Entity
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O



Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Chronic	O
pulsatile	O
levodopa	I-Entity
therapy	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	I-Entity
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	I-Entity
.	O

This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	I-Entity
on	O
uninterrupted	O
levodopa	I-Entity
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
predictors	O
of	O
dyskinesia	I-Entity
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

Dyskinesia	I-Entity
was	O
present	O
in	O
44%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	I-Entity
therapy	O
of	O
3	O
years	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	I-Entity
had	O
clinical	O
fluctuations	O
.	O

Patients	O
with	O
dyskinesia	I-Entity
had	O
lower	O
onset	O
age	O
(	O
p	O

<	O
0.001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	I-Entity
therapy	O
(	O
p	O

<	O
0.001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	I-Entity
dose	O
(	O
p	O

<	O
0.001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005	O
)	O
than	O
patients	O
without	O
dyskinesia	I-Entity
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	I-Entity
were	O
duration	O
of	O
levodopa	I-Entity
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	I-Entity
dose	O
.	O

The	O
prevalence	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
in	O
our	O
patients	O
was	O
44%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	I-Entity
therapy	O
,	O
total	O
daily	O
levodopa	I-Entity
dose	O
,	O
and	O
onset	O
age	O
.	O



An	O
unexpected	O
diagnosis	O
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
proteinuria	I-Entity
treated	O
with	O
everolimus	I-Entity
:	O
AL	I-Entity
amyloidosis	I-Entity
.	O

Proteinuria	I-Entity
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	I-Entity
inhibitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	I-Entity
and	O
tubular	O
atrophy	I-Entity
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	I-Entity
.	O

In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	I-Entity
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
pre	O
-	O
transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	I-Entity
after	O
conversion	O
from	O
tacrolimus	I-Entity
to	O
everolimus	I-Entity
.	O



An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	B-Entity
injury	I-Entity
in	O
HIV	O
-	O
positive	O
persons	O
exposed	O
to	O
tenofovir	B-Entity
disoproxil	I-Entity
fumarate	I-Entity
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(	O
MHRA	O
database	O
)	O
.	O

The	O
potential	O
for	O
tenofovir	I-Entity
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials	O
.	O

We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV	O
-	O
positive	O
persons	O
taking	O
tenofovir	B-Entity
disoproxil	I-Entity
fumarate	I-Entity
(	O
TDF	I-Entity
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(	O
MHRA	O
)	O
with	O
suspected	O
kidney	O
adverse	O
effects	O
.	O

Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
,	O
kidney	B-Entity
tubular	I-Entity
dysfunction	I-Entity
and	O
Fanconi	B-Entity
syndrome	I-Entity
.	O

Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF	I-Entity
-	O
related	O
kidney	B-Entity
disease	I-Entity
,	O
of	O
which	O
53	O
(	O
50%	O
)	O
had	O
features	O
of	O
kidney	B-Entity
tubular	I-Entity
dysfunction	I-Entity
,	O
35	O
(	O
33%	O
)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	B-Entity
dysfunction	I-Entity
and	O
18	O
(	O
17%	O
)	O
had	O
Fanconi	B-Entity
syndrome	I-Entity
.	O

The	O
median	O
TDF	I-Entity
exposure	O
was	O
316	O
days	O
(	O
interquartile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	I-Entity
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	B-Entity
syndrome	I-Entity
.	O

Cessation	O
of	O
TDF	I-Entity
was	O
associated	O
with	O
complete	O
restoration	O
of	O
kidney	O
function	O
in	O
up	O
half	O
of	O
the	O
patients	O
in	O
this	O
report	O
.	O



Incidence	O
of	O
postoperative	B-Entity
delirium	I-Entity
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

Postoperative	B-Entity
delirium	I-Entity
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	B-Entity
delirium	I-Entity
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery	O
.	O

Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	I-Entity
or	O
other	O
potentially	O
confounding	O
neurological	B-Entity
dysfunctions	I-Entity
.	O

Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	I-Entity
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure	O
.	O

Early	O
postoperative	B-Entity
delirium	I-Entity
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models	O
.	O

According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	B-Entity
delirium	I-Entity
.	O

The	O
use	O
of	O
thiopentone	I-Entity
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higher	O
risk	O
for	O
delirium	I-Entity
compared	O
to	O
propofol	I-Entity
(	O
57.1%	O

CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	B-Entity
delirium	I-Entity
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery	O
,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

Thiopentone	I-Entity
was	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
its	O
relative	O
risk	O
.	O



A	O
single	O
neurotoxic	I-Entity
dose	O
of	O
methamphetamine	I-Entity
induces	O
a	O
long	O
-	O
lasting	O
depressive	I-Entity
-	O
like	O
behaviour	O
in	O
mice	O
.	O

Methamphetamine	I-Entity
(	O
METH	I-Entity
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	I-Entity
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	B-Entity
symptoms	I-Entity
during	O
drug	O
withdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	I-Entity
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressive	I-Entity
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits	O
.	O

Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive	I-Entity
-	O
like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long	O
-	O
term	O
periods	O
following	O
a	O
single	O
high	O
METH	I-Entity
dose	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

METH	I-Entity
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task	O
.	O

However	O
,	O
METH	I-Entity
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

This	O
depressive	I-Entity
-	O
like	O
profile	O
induced	O
by	O
METH	I-Entity
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	I-Entity
,	O
DOPAC	I-Entity
and	O
HVA	I-Entity
,	O
tyrosine	I-Entity
hydroxylase	O
and	O
serotonin	I-Entity
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	I-Entity
--	O
astroglial	O
dysfunction	O
--	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days	O
.	O

These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	I-Entity
induces	O
long	O
-	O
lasting	O
depressive	I-Entity
-	O
like	O
behaviour	O
in	O
mice	O
associated	O
with	O
a	O
persistent	O
disruption	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
homoeostasis	O
.	O



Linezolid	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	B-Entity
of	I-Entity
vision	I-Entity
associated	O
with	O
linezolid	I-Entity
therapy	O
.	O

A	O
45-year	O
-	O
old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second	O
-	O
line	O
anti	O
-	O
tuberculous	O
drugs	O
including	O
linezolid	I-Entity
and	O
ethambutol	I-Entity
for	O
extensively	B-Entity
drug	I-Entity
-	I-Entity
resistant	I-Entity
tuberculosis	I-Entity
(	O
XDR	B-Entity
-	I-Entity
TB	I-Entity
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	B-Entity
of	I-Entity
vision	I-Entity
in	O
both	O
eyes	O
.	O

Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	B-Entity
disc	I-Entity
edema	I-Entity
in	O
both	O
eyes	O
.	O

Ethambutol	I-Entity
-	O
induced	O
toxic	B-Entity
optic	I-Entity
neuropathy	I-Entity
was	O
suspected	O
and	O
tablet	O
ethambutol	I-Entity
was	O
withdrawn	O
.	O

Deterioration	B-Entity
of	I-Entity
vision	I-Entity
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	I-Entity
.	O

Discontinuation	O
of	O
linezolid	I-Entity
resulted	O
in	O
marked	O
improvement	O
of	O
vision	O
.	O

Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long	O
-	O
term	O
linezolid	I-Entity
treatment	O
.	O



Resuscitation	O
with	O
lipid	O
,	O
epinephrine	I-Entity
,	O
or	O
both	O
in	O
levobupivacaine	I-Entity
-	O
induced	O
cardiac	B-Entity
toxicity	I-Entity
in	O
newborn	O
piglets	O
.	O

The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	I-Entity
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	I-Entity
(	O
LAST	O
)	O
.	O

Newborn	O
piglets	O
received	O
levobupivacaine	I-Entity
until	O
cardiovascular	B-Entity
collapse	I-Entity
occurred	O
.	O

Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	B-Entity
tachycardia	I-Entity
,	O
fibrillation	I-Entity
,	O
or	O
QRS	O
prolongation	O
.	O

Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
)	O
,	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	I-Entity
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	I-Entity
.	O

The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	I-Entity
and	O
epinephrine	I-Entity
plus	O
lipid	O
groups	O
(	O
P<0.05	O
)	O
.	O

Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	I-Entity
,	O
or	O
epinephrine	I-Entity
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST	O
.	O

Epinephrine	I-Entity
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	O
compared	O
with	O
lipid	O
emulsion	O
alone	O
.	O



Incidence	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	B-Entity
type	I-Entity
II	I-Entity
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients	O
:	O
a	O
retrospective	O
cohort	O
analysis	O
.	O

Thrombocytopenia	I-Entity
in	O
patients	O
with	O
end	B-Entity
-	I-Entity
stage	I-Entity
liver	I-Entity
disease	I-Entity
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	B-Entity
hypertension	I-Entity
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	I-Entity
.	O

The	O
impact	O
of	O
immune	O
-	O
mediated	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	B-Entity
type	I-Entity
II	I-Entity
(	O
HIT	B-Entity
type	I-Entity
II	I-Entity
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	I-Entity
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	I-Entity
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	B-Entity
type	I-Entity
II	I-Entity
.	O

We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full	O
-	O
size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	B-Entity
-	I-Entity
stage	I-Entity
or	I-Entity
malignant	I-Entity
liver	I-Entity
disease	I-Entity
.	O

Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	B-Entity
type	I-Entity
II	I-Entity
were	O
analyzed	O
.	O

A	O
total	O
of	O
155	O
(	O
75.6%	O
)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	I-Entity
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End	B-Entity
-	I-Entity
Stage	I-Entity
Liver	I-Entity
Disease	I-Entity
score	O
and	O
liver	B-Entity
cirrhosis	I-Entity
.	O

The	O
platelet	O
count	O
exceeded	O
100,000/uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medium	O
of	O
7	O
d.	O
Regarding	O
HIT	B-Entity
II	I-Entity
,	O
there	O
were	O
four	O
(	O
1.95%	O
)	O

patients	O
with	O
a	O
background	O
of	O
HIT	B-Entity
type	I-Entity
II	I-Entity
.	O

The	O
incidence	O
of	O
HIT	I-Entity
in	O
patients	O
with	O
end	B-Entity
-	I-Entity
stage	I-Entity
hepatic	I-Entity
failure	I-Entity
is	O
,	O
with	O
about	O
1.95%	O
,	O
rare	O
.	O

For	O
further	O
reduction	O
of	O
HIT	B-Entity
type	I-Entity
II	I-Entity
,	O
the	O
use	O
of	O
intravenous	O
heparin	I-Entity
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	I-Entity
after	O
normalization	O
of	O
platelet	O
count	O
.	O



Takotsubo	B-Entity
syndrome	I-Entity
(	O
or	O
apical	B-Entity
ballooning	I-Entity
syndrome	I-Entity
)	O
secondary	O
to	O
Zolmitriptan	I-Entity
.	O

Takotsubo	B-Entity
syndrome	I-Entity
(	O
TS	I-Entity
)	O
,	O
also	O
known	O
as	O
broken	B-Entity
heart	I-Entity
syndrome	I-Entity
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-Entity
coronary	I-Entity
syndrome	I-Entity
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54-year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B-Entity
valve	I-Entity
prolapse	I-Entity
and	O
migraines	I-Entity
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-Entity
pain	I-Entity
and	O
electrocardiogram	O
demonstrated	O
1/2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	I-Entity
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	I-Entity
sparingly	O
only	O
when	O
she	O
had	O
migraines	I-Entity
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	I-Entity
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-Entity
headache	I-Entity
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B-Entity
migrainosus	I-Entity
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-Entity
artery	I-Entity
vasospasm	I-Entity
secondary	O
to	O
zolmitriptan	I-Entity
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	I-Entity
.	O



Depression	I-Entity
,	O
impulsiveness	I-Entity
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3,4-methylenedioxymethamphetamine	I-Entity
(	O
MDMA	I-Entity
,	O
ecstasy	I-Entity
)	O
.	O

RATIONALE	O
:	O
Ecstasy	I-Entity
(	O
3,4-methylenedioxymethamphetamine	I-Entity
,	O
MDMA	I-Entity
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O

The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	I-Entity
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O

A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
)	O
,	O
alcohol	I-Entity
/	O
nicotine	I-Entity
(	O
AN	I-Entity
)	O
,	O
cannabis	I-Entity
/	O
alcohol	I-Entity
/	O
nicotine	I-Entity
(	O
CAN	I-Entity
)	O
,	O
non	O
-	O
ecstasy	I-Entity
polydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstasy	I-Entity
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	I-Entity
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	I-Entity
)	O
.	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	I-Entity
Inventory	O
,	O
Barratt	O
Impulsiveness	I-Entity
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

While	O
the	O
CAN	I-Entity
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	I-Entity
and	O
EX	O
-	O
MDMA	I-Entity
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O

Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4.98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
)	O
,	O
past	O
ecstasy	I-Entity
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O

Compared	O
with	O
present	O
ecstasy	I-Entity
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O

Given	O
this	O
record	O
of	O
impaired	B-Entity
memory	I-Entity
and	O
clinically	O
significant	O
levels	O
of	O
depression	I-Entity
,	O
impulsiveness	I-Entity
,	O
and	O
sleep	B-Entity
disturbance	I-Entity
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	I-Entity
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O



Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	I-Entity
adverse	O
effects	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
patients	O
.	O

Levodopa	I-Entity
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	I-Entity
and	O
visual	B-Entity
hallucinations	I-Entity
.	O

HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	I-Entity
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O

This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	I-Entity
therapy	O
.	O

A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B-Entity
Parkinson	I-Entity
's	I-Entity
disease	I-Entity
were	O
investigated	O
.	O

The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	I-Entity
(	O
prevalence	O
ratio	O
(	O
PR)=0.615	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.426	O
-	O
0.887	O
,	O
P=0.009	O
)	O
and	O
visual	B-Entity
hallucinations	I-Entity
(	O
PR=0.515	O
,	O
95%	O
CI	O
0.295	O
-	O
0.899	O
,	O
P=0.020	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	I-Entity
adverse	O
effects	O
.	O



Crocin	I-Entity
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	I-Entity
exposure	O
through	O
ERK1/2	O
pathway	O
in	O
rat	O
liver	O
.	O

Diazinon	I-Entity
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	I-Entity
insecticides	O
in	O
agriculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	I-Entity
may	O
interfere	O
with	O
lipid	O
metabolism	O
.	O

Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	I-Entity
has	O
been	O
established	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	I-Entity
.	O

Furthermore	O
ameliorating	O
effect	O
of	O
crocin	I-Entity
on	O
diazinon	I-Entity
induced	O
disturbed	O
cholesterol	I-Entity
homeostasis	O
was	O
studied	O
.	O

24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	O
oil	O
(	O
control	O
)	O
,	O
diazinon	I-Entity
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	I-Entity
(	O
12.5	O
and	O
25mg	O
/	O

kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	I-Entity
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
levels	O
of	O
cholesterol	I-Entity
,	O
triglyceride	I-Entity
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	I-Entity
significantly	O
increased	O
concentrations	O
of	O
cholesterol	I-Entity
,	O
triglyceride	I-Entity
and	O
LDL	O
.	O

Moreover	O
diazinon	I-Entity
decreased	O
ERK1/2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O

Crocin	I-Entity
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	I-Entity
-	O
induced	O
hyperlipemia	I-Entity
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O

Crocin	I-Entity
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	I-Entity
-	O
induced	O
hyperlipemia	I-Entity
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O



GEM	I-Entity
-	O
P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	B-Entity
lymphoma	I-Entity
.	O

Hodgkin	B-Entity
lymphoma	I-Entity
(	O
HL	I-Entity
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	I-Entity
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	I-Entity
.	O

Gemcitabine	I-Entity
and	O
cisplatin	I-Entity
have	O
activity	O
in	O
HL	I-Entity
,	O
non	O
-	O
overlapping	O
toxicity	I-Entity
with	O
first	O
-	O
line	O
chemotherapeutics	O
,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting	O
.	O

In	O
this	O
retrospective	O
single	O
-	O
centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	I-Entity
treated	O
with	O
gemcitabine	I-Entity
1,000	O
mg	O
/	O
m(2	O
)	O
day	O
(	O
D)1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	I-Entity
1,000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	I-Entity
100	O
mg	O
/	O
m(2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM	I-Entity
-	O
P	O
)	O
were	O
included	O
.	O

Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	I-Entity
data	O
were	O
recorded	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
cycles	O
of	O
GEM	I-Entity
-	O
P	O
were	O
administered	O
in	O
total	O
(	O
median	O
3	O
cycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

patients	O
received	O
GEM	I-Entity
-	O
P	O
as	O
second	O
-	O
line	O
treatment	O
and	O
11/41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therapy	O
.	O

Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM	I-Entity
-	O
P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
37	O
%	O
,	O
partial	O
response	O
44	O
%	O
)	O
with	O
14/15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
patients	O
.	O

3/4	O
toxicities	I-Entity
were	O
haematological	O
:	O
neutropenia	I-Entity
54	O
%	O
and	O
thrombocytopenia	I-Entity
51	O
%	O
.	O

Median	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	I-Entity
-	O
P	O
was	O
4.5	O
years	O
.	O

Following	O
GEM	I-Entity
-	O
P	O
,	O
5-year	O
progression	O
-	O
free	O
survival	O
was	O
46	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5-year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

GEM	I-Entity
-	O
P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates	O
,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients	O
,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	I-Entity
.	O



Basal	O
functioning	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	I-Entity
polydrug	O
users	O
.	O

RATIONALE	O
:	O
Ecstasy	I-Entity
(	O
MDMA	I-Entity
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	B-Entity
dysfunction	I-Entity
.	O

The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	I-Entity
-	O
polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	I-Entity
across	O
the	O
diurnal	O
period	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy	I-Entity
-	O
polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy	I-Entity
-	O
polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	I-Entity
sampling	O
(	O
on	O
awakening	O
,	O
30	O
min	O
post	O
awakening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime	O
)	O
.	O

Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	I-Entity
and	O
depression	I-Entity
than	O
nonusers	O
.	O

On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	I-Entity
profile	O
,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre	O
-	O
bed	O
.	O

On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	I-Entity
-	O
polydrug	O
users	O
demonstrated	O
elevated	O
pre	O
-	O
bed	O
levels	O
compared	O
to	O
non	O
-	O
users	O
.	O

Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	I-Entity
levels	O
and	O
in	O
overall	O
cortisol	I-Entity
secretion	O
across	O
the	O
day	O
.	O

The	O
increases	O
in	O
anxiety	I-Entity
and	O
depression	I-Entity
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	I-Entity
-	O
polydrug	O
users	O
.	O

Dysregulated	O
diurnal	O
cortisol	I-Entity
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	I-Entity
.	O



Ifosfamide	I-Entity
related	O
encephalopathy	I-Entity
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation	O
.	O

Ifosfamide	I-Entity
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	I-Entity
including	O
sarcomas	I-Entity
,	O
lymphoma	I-Entity
,	O
gynecologic	B-Entity
and	I-Entity
testicular	I-Entity
cancers	I-Entity
.	O

Encephalopathy	I-Entity
has	O
been	O
reported	O
in	O
10	O
-	O
40%	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
IV	O
ifosfamide	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	I-Entity
related	O
encephalopathy	I-Entity
.	O

Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	I-Entity
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	I-Entity
related	O
acute	O
encephalopathy	I-Entity
.	O

All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	I-Entity
soon	O
after	O
(	O
within	O
12	O
h-2	O
days	O
)	O
receiving	O
ifosfamide	I-Entity
.	O

Two	O
patients	O
developed	O
generalized	O
convulsions	I-Entity
while	O
one	O
patient	O
developed	O
continuous	O
non	B-Entity
-	I-Entity
convulsive	I-Entity
status	I-Entity
epilepticus	I-Entity
(	O
NCSE	I-Entity
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation	O
.	O

CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	I-Entity
related	O
encephalopathy	I-Entity
correlates	O
with	O
EEG	O
changes	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	I-Entity
who	O
develop	O
features	O
of	O
encephalopathy	I-Entity
.	O



Incidence	O
of	O
contrast	I-Entity
-	O
induced	O
nephropathy	I-Entity
in	O
hospitalised	O
patients	O
with	O
cancer	I-Entity
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	I-Entity
-	O
induced	O
nephropathy	I-Entity
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	I-Entity
.	O

Patients	O
with	O
risk	O
factors	O
for	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
were	O
excluded	O
.	O

Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast	I-Entity
-	O
enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
days	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	I-Entity
(	O
Cr	I-Entity
)	O
of	O
0.5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	I-Entity
to	O
25	O
%	O
over	O
baseline	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	I-Entity
/	O
irinotecan	I-Entity
(	O
P	O
=	O
0.021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	I-Entity
(	O
P	O
=	O
0.044	O
)	O
.	O

CIN	O
developed	O
4.5-times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	I-Entity
who	O
had	O
undergone	O
recent	O
chemotherapy	O
.	O

Hypertension	I-Entity
and	O
the	O
combination	O
of	O
bevacizumab	I-Entity
/	O
irinotecan	I-Entity
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development	O
.	O

Contrast	I-Entity
-	O
induced	O
nephropathy	I-Entity
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT	O
.	O
.	O

Hypertension	I-Entity
and	O
treatment	O
with	O
bevacizumab	I-Entity
appear	O
to	O
be	O
additional	O
risk	O
factors	O
.	O



Syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
antidiuretic	I-Entity
hormone	I-Entity
secretion	O
associated	O
with	O
desvenlafaxine	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
anti	I-Entity
-	I-Entity
diuretic	I-Entity
hormone	I-Entity
(	O
SIADH	I-Entity
)	O
secretion	O
associated	O
with	O
desvenlafaxine	I-Entity
.	O

A	O
57-year	O
old	O
female	O
with	O
hyponatraemia	I-Entity
.	O

Her	O
medications	O
included	O
desvenlafaxine	I-Entity
,	O
and	O
symptoms	O
included	O
nausea	I-Entity
,	O
anxiety	I-Entity
and	O
confusion	I-Entity
.	O

The	O
serum	O
sodium	I-Entity
at	O
this	O
time	O
was	O
120	O
mmol	O
/	O
L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urine	O
osmolality	O

410	O
mosmol	O
/	O
kg	O
and	O
urine	O
sodium	I-Entity
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	I-Entity
.	O

Desvenlafaxine	I-Entity
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O

After	O
4	O
days	O
the	O
sodium	I-Entity
increased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	I-Entity
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatment	O
with	O
mirtazapine	I-Entity
.	O

SIADH	I-Entity
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	O
.	O

This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	I-Entity
might	O
cause	O
clinically	O
significant	O
hyponatremia	I-Entity
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	I-Entity
,	O
and	O
take	O
appropriate	O
corrective	O
action	O
where	O
necessary	O
.	O



Oxidative	O
stress	O
on	O
cardiotoxicity	I-Entity
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	I-Entity
.	O

The	O
mechanism	O
of	O
doxorubicin	I-Entity
(	O
DOX)-induced	I-Entity
cardiotoxicity	I-Entity
remains	O
controversial	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	I-Entity
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(	O
-24	O
h	O
,	O
n	O
=	O
8)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8)	O
a	O
single	O
dose	O
of	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
determine	O
the	O
DOX	I-Entity
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronological	O
effects	O
.	O

Single	O
dose	O
of	O
DOX	I-Entity
was	O
associated	O
with	O
increased	O
cardiac	B-Entity
disarrangement	I-Entity
,	O
necrosis	I-Entity
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	O
)	O
and	O
decreased	O
TAP	O
.	O

The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(	O
R	O
=	O
-0.99	O
,	O
p	O
=	O
0.011	O
)	O
,	O
necrosis	I-Entity
(	O
R	O
=	O
1.00	O
,	O
p	O
=	O
0.004	O
)	O
,	O
TAP	O
(	O

DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-0.98	O
,	O
p	O
=	O
0.018	O
)	O
,	O
and	O
necrosis	I-Entity

Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	I-Entity
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	I-Entity
only	O
.	O

Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	I-Entity
.	O

Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	I-Entity
versus	O
chronic	O
toxicity	I-Entity
.	O



Tacrolimus	I-Entity
-	O
related	O
seizure	I-Entity
after	O
pediatric	O
liver	O
transplantation	O
--	O
a	O
single	O
-	O
center	O
experience	O
.	O

To	O
identify	O
the	O
risk	O
factors	O
for	O
new	O
-	O
onset	O
seizures	I-Entity
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long	O
-	O
term	O
prognosis	O
.	O

Patients	O
were	O
divided	O
into	O
seizures	I-Entity
group	O
and	O
a	O
non	O
-	O
seizures	I-Entity
group	O
.	O

Seizures	I-Entity
occurred	O
in	O
four	O
children	O
,	O
an	O
incidence	O
of	O
14.8%	O
.	O

All	O
exhibited	O
generalized	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizures	I-Entity
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	I-Entity
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end	B-Entity
-	I-Entity
stage	I-Entity
liver	I-Entity
disease	I-Entity
score	O
before	O
surgery	O
,	O
Child	O
-	O
Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	I-Entity
after	O
surgery	O
,	O
and	O
trough	O
TAC	I-Entity
level	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	I-Entity
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	I-Entity
.	O

All	O
children	O
who	O
experienced	O
seizures	I-Entity
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	I-Entity
-	O
free	O
without	O
anti	O
-	O
epileptic	I-Entity
drugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
33.7	O
+	O
14.6	O
months	O
.	O

High	O
trough	O
TAC	I-Entity
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	I-Entity
in	O
the	O
early	O
post	O
-	O
operative	O
period	O
after	O
pediatric	O
LT	O
.	O

High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post	O
-	O
operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	I-Entity
-	O
related	O
seizures	I-Entity
.	O



The	O
flavonoid	I-Entity
apigenin	I-Entity
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats	O
.	O

The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	I-Entity
apigenin	I-Entity
(	O
20	O
mg	O
/	O
kg	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisition	O
)	O
,	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoidance	O
task	O
,	O
in	O
young	O
male	O
Wistar	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
saline-	O
and	O
apigenin	I-Entity
-	O
treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial	O
.	O

Furthermore	O
,	O
apigenin	I-Entity
did	O
not	O
prevent	O
the	O
amnesia	I-Entity
induced	O
by	O
scopolamine	I-Entity
(	O
1mg	O
/	O
kg	O
,	O
i.p	O
.	O

The	O
saline-	O
and	O
apigenin	I-Entity
-	O
treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut	O
-	O
off	O
time	O
(	O
540	O
s	O
)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O

In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
memory	B-Entity
loss	I-Entity
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task	O
.	O

At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	I-Entity
still	O
did	O
not	O
step	O
through	O
.	O

These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	I-Entity
delays	O
the	O
long	O
-	O
term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	I-Entity
on	O
the	O
passive	O
avoidance	O
conditioning	O
is	O
mediated	O
by	O
mechanisms	O
that	O
do	O
not	O
implicate	O
its	O
action	O
on	O
the	O
muscarinic	O
cholinergic	O
system	O
.	O



Cholecystokinin	B-Entity
-	I-Entity
octapeptide	I-Entity
restored	O
morphine	I-Entity
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	O
.	O

Cholecystokinin	B-Entity
-	I-Entity
octapeptide	I-Entity
(	O
CCK-8	I-Entity
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK-8	I-Entity
significantly	O
alleviated	O
morphine	I-Entity
-	O
induced	O
amnesia	I-Entity
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	I-Entity
-	O
treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK-8	I-Entity
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP)-granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	I-Entity
-	O
treated	O
rats	O
.	O

Acute	O
morphine	I-Entity

treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK-8	I-Entity
(	O
1ug	O
,	O
i.c.v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	I-Entity
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK-8	I-Entity
(	O
0.1	O
and	O
1ug	O
,	O
i.c.v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
rats	O
.	O

Pre	O
-	O
treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L-365,260	O
(	O
10ug	O
,	O
i.c.v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK-8	I-Entity
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L-364,718	O
(	O
10ug	O
,	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK-8	I-Entity
attenuates	O
the	O
effect	O
of	O
morphine	I-Entity
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK-8	I-Entity
on	O
morphine	I-Entity
-	O
induced	O
memory	B-Entity
impairment	I-Entity
.	O



Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	I-Entity
:	O
the	O
key	O
events	O
in	O
Streptozotocin	I-Entity
(	O
ICV	O
)	O
induced	O
memory	B-Entity
impairment	I-Entity
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	I-Entity
in	O
ICV	O
Streptozotocin	I-Entity
(	O
STZ	I-Entity
)	O
induced	O
memory	B-Entity
impaired	I-Entity
rats	O
was	O
explored	O
.	O

In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B-Entity
deficit	I-Entity
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	I-Entity
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administration	O
.	O

STZ	I-Entity
causes	O
increased	O
expression	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	I-Entity
.	O

STZ	I-Entity
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	I-Entity
,	O
Ca(2	I-Entity
+	O
)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	I-Entity
.	O

Increased	O
expression	O
and	O
activity	O
of	O
Caspase-3	O
was	O
also	O
observed	O
in	O
STZ	I-Entity
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O

STZ	I-Entity
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD-95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP-25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	I-Entity
.	O

Oral	O
treatment	O
with	O
Memantine	I-Entity
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	I-Entity
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O

STZ	I-Entity
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	I-Entity
in	O
rat	O
brain	O
.	O

Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7	O
-	O
9	O
days	O
after	O
STZ	I-Entity
treatment	O
.	O

The	O
level	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitrite	I-Entity
levels	O
were	O
increased	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca(2	I-Entity
+	O
)	O
levels	O
remained	O
unaffected	O
.	O

Collective	O
data	O
indicates	O
that	O
neuroinflammatory	I-Entity
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O

Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	I-Entity
are	O
the	O
key	O
factors	O
in	O
STZ	I-Entity
induced	O
memory	B-Entity
impairment	I-Entity
and	O
neuronal	O
cell	O
death	O
.	O



Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
with	O
diltiazem	I-Entity
in	O
prevention	O
of	O
contrast	I-Entity
-	O
induced	O
nephropathy	I-Entity
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	I-Entity
-	O
induced	O
nephropathy	I-Entity
(	O
CIN	O
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
with	O
sodium	B-Entity
bicarbonate	I-Entity
infusion	O
and	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
infusion	O
with	O
diltiazem	I-Entity
,	O
a	O
calcium	I-Entity
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	I-Entity
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	I-Entity
values	O
between	O
1.1	O
and	O
3.1	O
mg	O
/	O
dL.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O

The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5%	O
dextrose	I-Entity
and	O
sodium	B-Entity
bicarbonate	I-Entity
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
before	O
and	O
after	O
the	O
contrast	I-Entity
injection	O
.	O

The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	I-Entity
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	I-Entity
injection	O
.	O

All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
(	O
BUN	I-Entity
)	O
and	O
creatinine	I-Entity
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	I-Entity
material	O
.	O

The	O
basal	O
creatinine	I-Entity
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
(	O
ARF	I-Entity
)	O
on	O
the	O
second	O
day	O
after	O
contrast	I-Entity
material	O
was	O
injected	O
(	O
26.6%	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	I-Entity
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25%	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
,	O
sodium	B-Entity
bicarbonate	I-Entity
and	O
isotonic	O
sodium	B-Entity
chloride	I-Entity
with	O
diltiazem	I-Entity
application	O
in	O
prevention	O
of	O
CIN	O
.	O



Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	O
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
protocols	O
(	O
ACCL0131	O
)	O
:	O
a	O
methotrexate	I-Entity
consequence	O
?	O

Concerns	O
about	O
long	O
-	O
term	O
methotrexate	I-Entity
(	O
MTX	I-Entity
)	O

neurotoxicity	I-Entity
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	O
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	I-Entity
administration	O
in	O
children	O
with	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
.	O

In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	I-Entity
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(	O
CNS)-directed	O
therapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
""""	O
standard	O
-	O
risk	O
""""	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
,	O
1.00	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	I-Entity
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	I-Entity
compared	O
with	O
P9201	O
patients	O
(	O
68%	O
,	O
95%	O
confidence	O
interval	O
49%-83%	O
vs.	O
22%	O
,	O
95%	O
confidence	O
interval	O
5%-44%	O
;	O
P=0.001	O
)	O
identified	O
as	O
late	O
as	O
7.7	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	B-Entity
problems	I-Entity
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(	O
82%	O
,	O
14/17	O
measures	O
vs.	O
24%	O
,	O
4/17	O
measures	O
)	O
.	O

This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	I-Entity
exposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
late	O
effects	O
.	O



Tranexamic	B-Entity
acid	I-Entity
overdosage	O
-	O
induced	O
generalized	O
seizure	I-Entity
in	O
renal	B-Entity
failure	I-Entity
.	O

We	O
report	O
a	O
45-year	O
-	O
old	O
lady	O
with	O
chronic	B-Entity
kidney	I-Entity
disease	I-Entity
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	B-Entity
disease	I-Entity
.	O

She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	I-Entity
due	O
to	O
menorrhagia	I-Entity
and	O
deterioration	B-Entity
of	I-Entity
renal	I-Entity
function	I-Entity
.	O

Tranexamic	B-Entity
acid	I-Entity
(	O
TNA	I-Entity
)	O

1	O
g	O
8-hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	I-Entity
per	O
vaginum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	I-Entity
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B-Entity
clonic	I-Entity
convulsions	I-Entity
.	O

TNA	I-Entity
was	O
discontinued	O
.	O

Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	B-Entity
system	I-Entity
abnormalities	I-Entity
that	O
could	O
have	O
provoked	O
the	O
convulsions	I-Entity
.	O

She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	I-Entity
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	I-Entity
was	O
believed	O
to	O
be	O
an	O
overdose	I-Entity
of	O
TNA	I-Entity
.	O



Pre	O
-	O
treatment	O
of	O
bupivacaine	I-Entity
-	O
induced	O
cardiovascular	B-Entity
depression	I-Entity
using	O
different	O
lipid	O
formulations	O
of	O
propofol	I-Entity
.	O

Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	I-Entity
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	I-Entity
may	O
alleviate	O
bupivacaine	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	I-Entity
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Rats	O
were	O
anaesthetised	O
with	O
ketamine	I-Entity
and	O
were	O
given	O
0.5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	I-Entity
in	O
intralipid	O
(	O
Group	O
P	O
)	O
,	O
propofol	I-Entity
in	O
medialipid	O
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O

bupivacaine	I-Entity
0.5%	O
was	O
infused	O
.	O

We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	I-Entity
occurrence	O
,	O
respective	O
times	O
to	O
25%	O
and	O
50%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	I-Entity
and	O
total	O
amount	O
of	O
bupivacaine	I-Entity
consumption	O
.	O

Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	I-Entity
.	O

The	O
time	O
to	O
first	O
dysrhythmia	I-Entity
occurrence	O
,	O
time	O
to	O
25%	O
and	O
50%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	I-Entity
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O

The	O
cumulative	O
bupivacaine	I-Entity
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	I-Entity
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	I-Entity
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	I-Entity
in	O
intralipid	O
,	O
compared	O
with	O
propofol	I-Entity
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	I-Entity
-	O
induced	O
cardiotoxic	I-Entity
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	I-Entity
levels	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	I-Entity
levels	O
of	O
propofol	I-Entity
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O



Drug	B-Entity
-	I-Entity
Induced	I-Entity
Acute	I-Entity
Liver	I-Entity
Injury	I-Entity

Within	O
12	O
Hours	O
After	O
Fluvastatin	I-Entity
Therapy	O
.	O

Although	O
statins	I-Entity
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	B-Entity
-	I-Entity
induced	I-Entity
liver	I-Entity
injury	I-Entity
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52-year	O
-	O
old	O
Chinese	O
man	O
reported	O
with	O
liver	B-Entity
damage	I-Entity
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	I-Entity
.	O

Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	I-Entity
,	O
anorexia	I-Entity
,	O
and	O
upper	O
abdominal	B-Entity
pain	I-Entity
.	O

His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	I-Entity
kinase	O
and	O
transaminases	O
.	O

The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	I-Entity
.	O

Therefore	O
,	O
when	O
prescribing	O
statins	O
,	O
the	O
possibility	O
of	O
hepatic	B-Entity
damage	I-Entity
should	O
be	O
taken	O
into	O
account	O
.	O



Fluconazole	I-Entity
associated	O
agranulocytosis	I-Entity
and	O
thrombocytopenia	I-Entity
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	I-Entity
associated	O
agranulocytosis	I-Entity
with	O
thrombocytopenia	I-Entity
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O

The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	I-Entity
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation	O
.	O

This	O
case	O
highlights	O
that	O
drug	O
-	O
induced	O
blood	B-Entity
dyscrasias	I-Entity
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
""""	O
safe	O
""""	O
.	O

According	O
to	O
Naranjo	O
's	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
's	O
agranulocytosis	I-Entity
and	O
thrombocytopenia	I-Entity
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	I-Entity
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	B-Entity
marrow	I-Entity
suppression	I-Entity
to	O
the	O
initiation	O
of	O
fluconazole	I-Entity
and	O
the	O
abatement	O
of	O
symptoms	O
that	O
rapidly	O
reversed	O
immediately	O
following	O
discontinuation	O
.	O



Two	O
-	O
dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	I-Entity
during	O
epirubicine	I-Entity
-	O
based	O
chemotherapy	O
.	O

To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	B-Entity
strain	I-Entity
and	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	B-Entity
dysfunction	I-Entity
in	O
patients	O
after	O
epirubicin	I-Entity
exposure	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
patients	O
with	O
non	B-Entity
-	I-Entity
Hodgkin	I-Entity
lymphoma	I-Entity
treated	O
with	O
epirubicin	I-Entity
were	O
studied	O
.	O

Cardiotoxicity	I-Entity
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O

5%	O
to	O
<	O
55%	O
with	O
symptoms	O
of	O
heart	B-Entity
failure	I-Entity
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O

RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18.67%	O
)	O
developed	O
cardiotoxicity	I-Entity
after	O
treatment	O
.	O

AUC	O
=	O
0.757	O
;	O
P	O
=	O
0.005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	I-Entity
.	O

The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	I-Entity
(	O
P	O
=	O
0.000	O
)	O
.	O

GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invasive	O
method	O
to	O
predict	O
cardiac	B-Entity
dysfunction	I-Entity
in	O
patients	O
receiving	O
anthracycline	I-Entity
-	O
based	O
chemotherapy	O
.	O



Prevention	O
of	O
etomidate	I-Entity
-	O
induced	O
myoclonus	I-Entity
:	O
which	O
is	O
superior	O
:	O

Fentanyl	I-Entity
,	O
midazolam	I-Entity
,	O
or	O
a	O
combination	O
?	O

In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	I-Entity
,	O
midazolam	I-Entity
,	O
and	O
a	O
combination	O
of	O
fentanyl	I-Entity
and	O
midazolam	I-Entity
to	O
prevent	O
etomidate	I-Entity
-	O
induced	O
myoclonus	I-Entity
.	O

Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	I-Entity
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	I-Entity
1	O
ug.kg-1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	I-Entity
0.03	O
mg.kg-1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	I-Entity
0.015	O
mg.kg-1	O
+	O
fentanyl	I-Entity

Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg-1	O
etomidate	I-Entity
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myoclonic	B-Entity
movements	I-Entity
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	I-Entity
injection	O
.	O

The	O
severity	O
of	O
pain	I-Entity
due	O
to	O
etomidate	I-Entity
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O

Study	O
results	O
showed	O
that	O
myoclonus	I-Entity
incidence	O
was	O
85%	O
,	O
40%	O
,	O
70%	O
,	O
and	O
25%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	I-Entity
or	O
combination	O
of	O
fentanyl	I-Entity
and	O
midazolam	I-Entity
was	O
effective	O
in	O
preventing	O
etomidate	I-Entity
-	O
induced	O
myoclonus	I-Entity
.	O



Cholestatic	I-Entity
presentation	O
of	O
yellow	O
phosphorus	I-Entity
poisoning	I-Entity
.	O

Yellow	O
phosphorus	I-Entity
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	I-Entity
.	O

Poisoning	I-Entity
with	O
yellow	O
phosphorus	I-Entity
classically	O
manifests	O
with	O
acute	B-Entity
hepatitis	I-Entity
leading	O
to	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
which	O
may	O
need	O
liver	O
transplantation	O
.	O

We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	I-Entity
poisoning	I-Entity
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	I-Entity
highlighting	O
the	O
fact	O
that	O
cholestasis	I-Entity
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	I-Entity
hepatotoxicity	I-Entity
.	O



Vasovagal	B-Entity
syncope	I-Entity
and	O
severe	O
bradycardia	I-Entity
following	O
intranasal	O
dexmedetomidine	I-Entity
for	O
pediatric	O
procedural	O
sedation	O
.	O

We	O
report	O
syncope	I-Entity
and	O
bradycardia	I-Entity
in	O
an	O
11-year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	I-Entity
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O

The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	I-Entity
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation	O
.	O

The	O
bradycardia	I-Entity
lasted	O
~2	O
h	O
,	O
and	O
further	O
cardiac	O
workup	O
revealed	O
no	O
underlying	O
abnormality	O
.	O



Paradoxical	O
severe	O
agitation	I-Entity
induced	O
by	O
add	O
-	O
on	O
high	O
-	O
doses	O
quetiapine	I-Entity
in	O
schizo	B-Entity
-	I-Entity
affective	I-Entity
disorder	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
35-year	O
-	O
old	O
patient	O
suffering	O
from	O
schizo	B-Entity
-	I-Entity
affective	I-Entity
disorder	I-Entity
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first	O
-	O
generation	O
antipsychotics	O
,	O
zuclopenthixol	I-Entity
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithium	I-Entity
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
serum	O
lithium=0.85	I-Entity
mEq	O
/	O
l	O
)	O
.	O

This	O
patient	O
had	O
no	O
associated	O
personality	B-Entity
disorder	I-Entity
(	O
particularly	O
no	O
antisocial	B-Entity
disorder	I-Entity
)	O
and	O
no	O
substance	B-Entity
abuse	I-Entity
disorder	I-Entity
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	I-Entity
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	I-Entity
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	I-Entity
or	O
personality	B-Entity
disorder	I-Entity
.	O

The	O
diagnoses	O
of	O
manic	I-Entity
shift	O
and	O
akathisia	I-Entity
were	O
dismissed	O
.	O

The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	I-Entity
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	I-Entity
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	I-Entity
specifically	O
to	O
quetiapine	I-Entity
.	O



Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
rat	O
.	O

Dexamethasone-	I-Entity
(	O
Dex-	I-Entity
)	O
induced	O
hypertension	I-Entity
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	I-Entity
-	O
binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	I-Entity
upon	O
Dex	I-Entity
administration	O
.	O

Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	I-Entity
(	O
30	O
u	O

In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	I-Entity
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Plasma	O
hydrogen	B-Entity
peroxide	I-Entity
(	O
H2O2	I-Entity
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	I-Entity
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	I-Entity
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	O
lowered	O
(	O
P	O
<	O
0.01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0.001	O
)	O
Dex	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

LF	O
prevented	O
body	O
weight	B-Entity
loss	I-Entity
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	I-Entity
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	I-Entity
-	O
induced	O
hypertension	I-Entity
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O



The	O
association	O
between	O
tranexamic	B-Entity
acid	I-Entity
and	O
convulsive	I-Entity
seizures	I-Entity
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	I-Entity
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	I-Entity
seizure	I-Entity
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B-Entity
involuntary	I-Entity
motor	I-Entity
movements	I-Entity
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	I-Entity
.	O

A	O
total	O
of	O
100	O
(	O
0.9%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	I-Entity
seizures	I-Entity
.	O

Generalised	B-Entity
and	I-Entity
focal	I-Entity
seizures	I-Entity
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
,	O
respectively	O
.	O

)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	I-Entity
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	I-Entity
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	O
of	O
ascending	O
aorta	O
,	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
,	O
deep	O
hypothermic	I-Entity
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-Entity
acid	I-Entity
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B-Entity
acid	I-Entity
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	I-Entity
(	O
OR	O
14.3	O
,	O
95%	O

Patients	O
with	O
convulsive	I-Entity
seizures	I-Entity
had	O
2.5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	I-Entity
seizures	I-Entity
.	O

h	O
in	O
patients	O
with	O
convulsive	I-Entity
seizures	I-Entity
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O

h	O
in	O
patients	O
without	O
seizures	I-Entity
(	O
p	O
<	O
0.001	O
)	O
.	O

Convulsive	I-Entity
seizures	I-Entity
are	O
a	O
serious	O
postoperative	B-Entity
complication	I-Entity
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	B-Entity
acid	I-Entity
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg(-1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	I-Entity
.	O



Dysfunctional	B-Entity
overnight	I-Entity
memory	I-Entity
consolidation	O
in	O
ecstasy	I-Entity
users	O
.	O

Previous	O
studies	O
indicate	O
that	O
ecstasy	I-Entity
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep	B-Entity
-	I-Entity
related	I-Entity
impairments	I-Entity
.	O

We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	I-Entity
users	O
(	O
n=12	O
)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(	O
n=26	O
)	O
.	O

Ecstasy	I-Entity
users	O
demonstrated	O
impaired	B-Entity
overnight	I-Entity
memory	I-Entity
consolidation	O
,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference	O
.	O

Additionally	O
,	O
ecstasy	I-Entity
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry	O
,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory	O
,	O
long	O
-	O
term	O
memory	O
,	O
encoding	O
,	O
working	O
memory	O
and	O
complex	O
planning	O
.	O

We	O
suggest	O
that	O
ecstasy	I-Entity
-	O
associated	O
dysfunction	O
in	O
fronto	O
-	O
temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	B-Entity
impairments	I-Entity
in	O
regular	O
ecstasy	I-Entity
users	O
.	O



Normoammonemic	O
encephalopathy	I-Entity
:	O
solely	O
valproate	I-Entity
induced	O
or	O
multiple	O
mechanisms	O
?	O

A	O
77-year	O
-	O
old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	I-Entity
,	O
aggression	I-Entity
,	O
auditory	B-Entity
hallucinations	I-Entity
and	O
delusions	I-Entity
.	O

In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	I-Entity
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	I-Entity
for	O
presumed	O
hemiplegic	B-Entity
migraine	I-Entity
.	O

Valproate	I-Entity
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O

Valproate	I-Entity
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	I-Entity
,	O
and	O
low	O
titre	O

N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient	O
.	O

The	O
possible	O
aetiologies	O
of	O
valproate	I-Entity
-	O
induced	O
encephalopathy	I-Entity
and	O
NMDA	I-Entity
receptor	O
-	O
associated	O
encephalitis	I-Entity
present	O
a	O
diagnostic	O
dilemma	O
.	O



Cerebellar	B-Entity
and	I-Entity
oculomotor	I-Entity
dysfunction	I-Entity
induced	O
by	O
rapid	O
infusion	O
of	O
pethidine	I-Entity
.	O

Pethidine	I-Entity
is	O
an	O
opioid	O
that	O
gains	O
its	O
popularity	O
for	O
the	O
effective	O
pain	I-Entity
control	O
through	O
acting	O
on	O
the	O
opioid	O
-	O
receptors	O
.	O

However	O
,	O
rapid	O
pain	I-Entity
relief	O
sometimes	O
brings	O
about	O
unfavourable	O
side	O
effects	O
that	O
largely	O
limit	O
its	O
clinical	O
utility	O
.	O

Common	O
side	O
effects	O
include	O
nausea	I-Entity
,	O
vomiting	I-Entity
and	O
hypotension	I-Entity
.	O

In	O
patients	O
with	O
impaired	B-Entity
renal	I-Entity
and	I-Entity
liver	I-Entity
function	I-Entity
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
pain	I-Entity
control	O
,	O
pethidine	I-Entity
may	O
cause	O
excitatory	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
effects	O
through	O
its	O
neurotoxic	I-Entity
metabolite	O
,	O
norpethidine	I-Entity
,	O
resulting	O
in	O
irritability	I-Entity
and	O
seizure	I-Entity
attack	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
clinically	O
apparent	O
,	O
pethidine	I-Entity
potentially	O
causes	O
inhibitory	O
impacts	O
on	O
the	O
CNS	O
and	O
impairs	O
normal	O
cerebellar	O
and	O
oculomotor	O
function	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
case	O
report	O
,	O
we	O
highlight	O
opioid	O
's	O
inhibitory	O
side	O
effects	O
on	O
the	O
cerebellar	O
structure	O
that	O
causes	O
dysmetria	I-Entity
,	O
dysarthria	I-Entity
,	O
reduced	O
smooth	O
pursuit	O
gain	O
and	O
decreased	O
saccadic	O
velocity	O
.	O



Baboon	B-Entity
syndrome	I-Entity
induced	O
by	O
ketoconazole	I-Entity
.	O

A	O
27-year	O
-	O
old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	B-Entity
eruption	I-Entity
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	I-Entity
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
drug	O
-	O
induced	O
baboon	B-Entity
syndrome	I-Entity
based	O
on	O
his	O
history	O
,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	I-Entity
,	O
a	O
physical	O
examination	O
,	O
and	O
histopathological	O
findings	O
.	O

Baboon	B-Entity
syndrome	I-Entity
is	O
a	O
drug-	O
or	O
contact	O
allergen	O
-	O
related	O
maculopapular	B-Entity
eruption	I-Entity
that	O
typically	O
involves	O
the	O
flexural	O
and	O
gluteal	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole	I-Entity
-	O
induced	O
baboon	B-Entity
syndrome	I-Entity
in	O
the	O
English	O
literature	O
.	O



A	O
Case	O
of	O
Sudden	B-Entity
Cardiac	I-Entity
Death	I-Entity
due	O
to	O
Pilsicainide	I-Entity
-	O
Induced	O
Torsades	B-Entity
de	I-Entity
Pointes	I-Entity
.	O

An	O
84-year	O
-	O
old	O
male	O
received	O
oral	O
pilsicainide	I-Entity
,	O
a	O
pure	O
sodium	I-Entity
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
his	O
paroxysmal	O
atrial	B-Entity
fibrillation	I-Entity
to	O
a	O
sinus	O
rhythm	O
;	O
the	O
patient	O
developed	O
sudden	B-Entity
cardiac	I-Entity
death	I-Entity
two	O
days	O
later	O
.	O

The	O
Holter	O
electrocardiogram	O
,	O
which	O
was	O
worn	O
by	O
chance	O
,	O
revealed	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
with	O
gradually	O
prolonged	O
QT	O
intervals	O
.	O

Although	O
the	O
patient	O
's	O
renal	O
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	I-Entity
was	O
low	O
,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	I-Entity
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
in	O
the	O
octogenarian	O
.	O

Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs	O
,	O
including	O
pilsicainide	I-Entity
,	O
is	O
effective	O
to	O
terminate	O
atrial	B-Entity
fibrillation	I-Entity
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drugs	O
to	O
octogenarians	O
.	O



All	B-Entity
-	I-Entity
trans	I-Entity
retinoic	I-Entity
acid	I-Entity
-	O
induced	O
inflammatory	O
myositis	I-Entity
in	O
a	O
patient	O
with	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
.	O

All	B-Entity
-	I-Entity
trans	I-Entity
retinoic	I-Entity
acid	I-Entity
(	O
ATRA	I-Entity
)	O
,	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
(	O
APL	I-Entity
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treatable	O
adverse	O
effects	O
involving	O
numerous	O
organ	O
systems	O
,	O
including	O
rare	O
skeletal	O
muscle	O
involvement	O
.	O

Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA	I-Entity
-	O
induced	O
myositis	I-Entity
in	O
children	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiology	O
literature	O
.	O

We	O
present	O
such	O
a	O
case	O
in	O
a	O
15-year	O
-	O
old	O
boy	O
with	O
APL	I-Entity
,	O
where	O
recognition	O
of	O
imaging	O
findings	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnosis	O
and	O
facilitated	O
prompt	O
,	O
effective	O
treatment	O
.	O



Tolerability	O
of	O
lomustine	I-Entity
in	O
combination	O
with	O
cyclophosphamide	I-Entity
in	O
dogs	O
with	O
lymphoma	I-Entity
.	O

This	O
retrospective	O
study	O
describes	O
toxicity	I-Entity
associated	O
with	O
a	O
protocol	O
of	O
lomustine	I-Entity
(	O
CCNU	I-Entity
)	O
and	O
cyclophosphamide	I-Entity
(	O
CTX	I-Entity
)	O
in	O
dogs	O
with	O
lymphoma	I-Entity
.	O

CCNU	I-Entity
was	O
administered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
targeted	O
dosage	O
of	O
60	O
mg	O
/	O
m(2	O
)	O
body	O
surface	O
area	O
on	O
day	O
0	O
,	O
CTX	I-Entity
was	O
administered	O
PO	O
at	O
a	O
targeted	O
dosage	O
of	O
250	O
mg	O
/	O
m(2	O
)	O
divided	O
over	O
days	O
0	O
through	O
4	O
,	O
and	O
all	O
dogs	O
received	O
prophylactic	O
antibiotics	O
.	O

Neutropenia	I-Entity
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	I-Entity
after	O
the	O
first	O
treatment	O
of	O
CCNU	I-Entity
/	O
CTX	I-Entity
was	O
30%	O
(	O
95%	O
confidence	O
interval	O
,	O
19	O
-	O
43%	O
)	O
.	O

The	O
mean	O
body	O
weight	O
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	I-Entity
(	O
19.7	O
kg	O
+	O
13.4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	O
weight	O
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	I-Entity
(	O
31.7	O
kg	O
+	O
12.4	O
kg	O
;	O
P	O
=	O
.005	O
)	O
.	O

One	O
dog	O
(	O
3%	O
)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	I-Entity
.	O

No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	B-Entity
toxicity	I-Entity
or	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein	O
,	O
a	O
dose	O
of	O
60	O
mg	O
/	O
m(2	O
)	O
of	O
CCNU	I-Entity
combined	O
with	O
250	O
mg	O
/	O
m(2	O
)	O
of	O
CTX	I-Entity
(	O
divided	O
over	O
5	O
days	O
)	O

4	O
wk	O
is	O
tolerable	O
in	O
tumor	I-Entity
-	O
bearing	O
dogs	O
.	O



Nelarabine	I-Entity
neurotoxicity	I-Entity
with	O
concurrent	O
intrathecal	O
chemotherapy	O
:	O

Severe	O
nelarabine	I-Entity
neurotoxicity	I-Entity
in	O
a	O
patient	O
who	O
received	O
concurrent	O
intrathecal	O

A	O
37-year	O
-	O
old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T	B-Entity
-	I-Entity
cell	I-Entity
lymphoblastic	I-Entity
lymphoma	I-Entity
was	O
admitted	O
for	O
relapsed	O
disease	O
.	O

She	O
developed	O
relapsed	O
disease	O
10	O
months	O
later	O
with	O
leukemic	I-Entity
involvement	O
.	O

She	O
was	O
re	O
-	O
induced	O
with	O
nelarabine	I-Entity
1500	O
mg	O
/	O
m(2	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	I-Entity
100	O
mg	O
on	O
day	O
2	O
as	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
prophylaxis	O
.	O

At	O
the	O
time	O
of	O
treatment	O
,	O
she	O
was	O
on	O
continuous	O
renal	O
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	B-Entity
lysis	I-Entity
syndrome	I-Entity
(	O
TLS	I-Entity
)	O
.	O

She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	I-Entity
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later	O
.	O

Predominantly	O
sensory	O
,	O
though	O
also	O
motor	O
and	O
autonomic	O
,	O
peripheral	B-Entity
neuropathy	I-Entity
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximally	O
to	O
the	O
mid	O
-	O
thoracic	O
region	O
,	O
and	O
eventually	O
included	O
her	O
distal	O
upper	O
extremities	O
.	O

Nelarabine	I-Entity
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symptoms	O
.	O

Her	O
neuropathy	I-Entity
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
reduced	O
-	O
intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission	O
,	O
but	O
relapsed	O
disease	O
10	O
weeks	O
later	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	I-Entity
caused	O
by	O
nelarabine	I-Entity
in	O
a	O
patient	O
who	O
received	O
concurrent	O
IT	O
chemotherapy	O
.	O



Valproate	I-Entity
-	O
induced	O
hyperammonemic	I-Entity
encephalopathy	I-Entity
in	O
a	O
renal	O
transplanted	O
patient	O
.	O

Neurological	B-Entity
complications	I-Entity
after	O
renal	O
transplantation	O
constitute	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Valproate	I-Entity
-	O
induced	O
hyperammonemic	I-Entity
encephalopathy	I-Entity
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	I-Entity
treatment	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15-year	O
-	O
old	O
girl	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
therapy	O
with	O
valproate	I-Entity
due	O
to	O
epilepsy	I-Entity
and	O
revealed	O
impaired	B-Entity
consciousness	I-Entity
with	O
hyperammonemia	I-Entity
12	O
days	O
after	O
renal	O
transplantation	O
.	O

After	O
withdraw	O
of	O
valproate	I-Entity
,	O
patients	O
'	O
symptoms	O
resolved	O
within	O
24	O
h.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	I-Entity
,	O
especially	O
in	O
transplanted	O
patients	O
.	O



Necrotising	B-Entity
fasciitis	I-Entity
after	O
bortezomib	I-Entity
and	O
dexamethasone	I-Entity
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B-Entity
macroglobulinaemia	I-Entity
.	O

Bortezomib	I-Entity
and	O
high	O
-	O
dose	O
dexamethasone	I-Entity
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B-Entity
infections	I-Entity
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76-year	O
-	O
old	O
man	O
with	O
Waldenstrom	B-Entity
macroglobulinaemia	I-Entity
who	O
suffered	O
necrotising	B-Entity
fasciitis	I-Entity
without	O
neutropenia	I-Entity
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	I-Entity
,	O
high	O
-	O
dose	O
dexamethasone	I-Entity
and	O
rituximab	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B-Entity
infections	I-Entity
related	O
to	O
bortezomib	I-Entity
plus	O
high	O
-	O
dose	O
dexamethasone	I-Entity
in	O
elderly	O
patients	O
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O



An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Many	O
efficacious	O
cancer	I-Entity
treatments	O
cause	O
significant	O
cardiac	O
morbidity	O
,	O
yet	O
biomarkers	O
or	O
functional	O
indices	O
of	O
early	O
damage	O
,	O
which	O
would	O
allow	O
monitoring	O
and	O
intervention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	I-Entity
(	O
DOX)-induced	I-Entity
cardiomyopathy	I-Entity
,	O
applying	O
multiple	O
approaches	O
,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	I-Entity
.	O

Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1.25	O
mg	O
/	O
kg	O
DOX	I-Entity
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
dosing	O
""""	O
recovery	O
""""	O
period	O
.	O

Electron	O
microscopy	O
of	O
the	O
myocardium	O
revealed	O
subcellular	B-Entity
degeneration	I-Entity
and	O
marked	O
mitochondrial	O
changes	O
after	O
a	O
single	O
dose	O
.	O

Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	B-Entity
degeneration	I-Entity
,	O
hypertrophy	I-Entity
/	O
cytomegaly	O
,	O
and	O
extensive	O
vacuolation	O
after	O
two	O
doses	O
.	O

Extensive	O
replacement	O
fibrosis	I-Entity
(	O
quantified	O
by	O
Sirius	O
red	O
staining	O
)	O
developed	O
during	O
the	O
off	O
-	O
dosing	O
period	O
.	O

Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(	O
including	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
cardiac	O
output	O
,	O
and	O
E	O
/	O
A	O
ratio	O
)	O
declined	O
progressively	O
,	O
reaching	O
statistical	O
significance	O
after	O
two	O
doses	O
and	O
culminating	O
in	O
""""	O
clinical	O
""""	O
LV	B-Entity
dysfunction	I-Entity
by	O
12	O
weeks	O
.	O

Troponin	O
I	O
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	I-Entity
contrast	O
enhancement	O
,	O
histopathological	O
grading	O
,	O
and	O
diastolic	B-Entity
dysfunction	I-Entity
.	O

In	O
summary	O
,	O
subcellular	O
cardiomyocyte	B-Entity
degeneration	I-Entity
was	O
the	O
earliest	O
marker	O
,	O
followed	O
by	O
progressive	O
functional	O
decline	O
and	O
histopathological	O
manifestations	O
.	O

However	O
,	O
all	O
indices	O
predated	O
""""	O
clinical	O
""""	O
LV	B-Entity
dysfunction	I-Entity
and	O
thus	O
warrant	O
further	O
evaluation	O
as	O
predictive	O
biomarkers	O
.	O



Intradermal	O
glutamate	I-Entity
and	O
capsaicin	I-Entity
injections	O
:	O
intra-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
.	O

Intradermal	O
injections	O
of	O
glutamate	I-Entity
and	O
capsaicin	I-Entity
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	I-Entity
models	O
because	O
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	B-Entity
disorders	I-Entity
.	O

Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	I-Entity
and	O
capsaicin	I-Entity
in	O
the	O
volar	O
forearm	O
.	O

Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	I-Entity
and	O
brush	O
-	O
evoked	O
allodynia	I-Entity
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(	O
gauges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brush	O
strokes	O
.	O

Areas	O
of	O
secondary	B-Entity
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
were	O
quantified	O
immediately	O
after	O
injection	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Secondary	O
pinprick	O
hyperalgesia	I-Entity
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O

<	O
0.001	O
)	O
after	O
glutamate	I-Entity
injection	O
.	O

For	O
capsaicin	I-Entity
,	O
secondary	O
pinprick	O
hyperalgesia	I-Entity
was	O
detected	O
with	O
all	O
von	O
Frey	O
gauges	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Glutamate	I-Entity
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0.60	O
)	O
and	O
brush	O
strokes	O
(	O
ICC	O
>	O
0.83	O
)	O
.	O

Capsaicin	I-Entity
injection	O
was	O
reproducible	O
for	O
secondary	B-Entity
hyperalgesia	I-Entity
(	O
ICC	O
>	O
0.70	O
)	O
and	O
allodynia	I-Entity

Intra	O
-	O
individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	B-Entity
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
.	O

In	O
conclusion	O
,	O
glutamate	I-Entity
and	O
capsaicin	I-Entity
yield	O
reproducible	O
hyperalgesic	I-Entity
and	O
allodynic	I-Entity
responses	O
,	O
and	O
the	O
present	O
model	O
is	O
well	O
suited	O
for	O
basic	O
research	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulation	O
of	O
central	O
phenomena	O
.	O



Ocular	O
-	O
specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	I-Entity
in	O
murine	O
glucocorticoid	O
-	O
induced	O
glaucoma	I-Entity
.	O

Administration	O
of	O
glucocorticoids	O
induces	O
ocular	B-Entity
hypertension	I-Entity
in	O
some	O
patients	O
.	O

If	O
untreated	O
,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	I-Entity
that	O
resembles	O
primary	B-Entity
open	I-Entity
-	I-Entity
angle	I-Entity
glaucoma	I-Entity
(	O
POAG	I-Entity
)	O
.	O

The	O
underlying	O
pathology	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	I-Entity
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O

Here	O
,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	I-Entity
that	O
exhibits	O
glaucoma	I-Entity
features	O
that	O
are	O
observed	O
in	O
patients	O
.	O

Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0.1%	O
dexamethasone	I-Entity
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	B-Entity
ganglion	I-Entity
cells	O
,	O
and	O
axonal	B-Entity
degeneration	I-Entity
,	O
resembling	O
glucocorticoid	O
-	O
induced	O
glaucoma	I-Entity
in	O
human	O
patients	O
.	O

Furthermore	O
,	O
dexamethasone	I-Entity
-	O
induced	O
ocular	B-Entity
hypertension	I-Entity
was	O
associated	O
with	O
chronic	O
ER	O
stress	O
of	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patients	O
,	O
withdrawal	O
of	O
dexamethasone	I-Entity
treatment	O
reduced	O
elevated	O
IOP	O
and	O
ER	O
stress	O
in	O
this	O
animal	O
model	O
.	O

Dexamethasone	I-Entity
induced	O
the	O
transcriptional	O
factor	O
CHOP	O
,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress	O
,	O
in	O
the	O
anterior	O
segment	O
tissues	O
,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone	I-Entity
-	O
induced	O
ocular	B-Entity
hypertension	I-Entity
.	O

Furthermore	O
,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	B-Entity
4-phenylbutyrate	I-Entity
prevented	O
dexamethasone	I-Entity
-	O
induced	O
ocular	B-Entity
hypertension	I-Entity
in	O
WT	O
mice	O
.	O

Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid	O
-	O
induced	O
ocular	B-Entity
hypertension	I-Entity
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid	O
-	O
induced	O
glaucoma	I-Entity
.	O



Effects	O
of	O
ginsenosides	I-Entity
on	O
opioid	O
-	O
induced	O
hyperalgesia	I-Entity
in	O
mice	O
.	O

Opioid	O
-	O
induced	O
hyperalgesia	I-Entity
(	O
OIH	I-Entity
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	O
use	O
.	O

OIH	I-Entity
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B-Entity
addiction	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B-Entity
,	I-Entity
Rg1	I-Entity
,	I-Entity
and	I-Entity
Rb1	I-Entity
ginsenosides	I-Entity
,	O
the	O
bioactive	O
components	O
of	O
ginseng	O
,	O
on	O
OIH	I-Entity
.	O

OIH	I-Entity
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	I-Entity
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O

During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	O
were	O
administered	O
Re	I-Entity
,	O
Rg1	I-Entity
,	O
or	O
Rb1	I-Entity
intragastrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Entity
acid	I-Entity
-	O
induced	O
writhing	O
test	O
.	O

Re	I-Entity
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	I-Entity
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Entity
acid	I-Entity
-	O
induced	O
writhing	O
test	O
.	O

However	O
,	O
the	O
Rg1	B-Entity
and	I-Entity
Rb1	I-Entity
ginsenosides	I-Entity
failed	O
to	O
prevent	O
OIH	I-Entity
in	O
either	O
test	O
.	O

Furthermore	O
,	O
Rg1	I-Entity
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	I-Entity
in	O
the	O
acetic	B-Entity
acid	I-Entity
-	O
induced	O
writhing	O
test	O
.	O

Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-Entity
Re	I-Entity
,	O
but	O
not	O
Rg1	I-Entity
or	O
Rb1	I-Entity
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	I-Entity
.	O



A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	I-Entity
and	O
propofol	I-Entity
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O

Dexmedetomidine	I-Entity
and	O
propofol	I-Entity
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	I-Entity
and	O
propofol	I-Entity
.	O

INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	I-Entity
or	O
propofol	I-Entity
.	O

A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	I-Entity
and	O
237	O
propofol	I-Entity
)	O
were	O
included	O
in	O
the	O
analysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
group	O
)	O
by	O
propensity	O
score	O
.	O

The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	I-Entity
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	I-Entity
(	O
heart	O
rate	O
<	O
50	O
beats	O
/	O
min	O
)	O
during	O
sedative	O
infusion	O
.	O

When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	I-Entity
or	O
bradycardia	I-Entity
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts	O
.	O

Severe	O
hypotension	I-Entity
and	O
bradycardia	I-Entity
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	I-Entity
or	O
propofol	I-Entity
.	O

Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	I-Entity
or	O
bradycardia	I-Entity
before	O
starting	O
either	O
sedative	O
.	O



Hydroxytyrosol	I-Entity
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B-Entity
dysfunction	I-Entity
in	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
in	O
rats	O
with	O
breast	B-Entity
cancer	I-Entity
.	O

Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	I-Entity
,	O
aging	O
and	O
cardiovascular	B-Entity
disease	I-Entity
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	I-Entity
.	O

Doxorubicin	I-Entity
causes	O
significant	O
cardiotoxicity	I-Entity
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	B-Entity
dysfunction	I-Entity
.	O

Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin	I-Entity
-	O
associated	O
chronic	O
cardiac	B-Entity
toxicity	I-Entity
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	I-Entity
in	O
rats	O
with	O
breast	B-Entity
cancer	I-Entity
.	O

Thirty	O
-	O
six	O
rats	O
bearing	O
breast	B-Entity
tumors	I-Entity
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	I-Entity
(	O
0.5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
doxorubicin	I-Entity
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxorubicin	I-Entity
plus	O
hydroxytyrosol	I-Entity
.	O

Cardiac	B-Entity
disturbances	I-Entity
at	O
the	O
cellular	O
and	O
mitochondrial	O
level	O
,	O
mitochondrial	O
electron	O
transport	O
chain	O
complexes	O
I	O
-	O
IV	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
and	O
oxidative	O
stress	O
markers	O
have	O
been	O
analyzed	O
.	O

Hydroxytyrosol	I-Entity
improved	O
the	O
cardiac	B-Entity
disturbances	I-Entity
enhanced	O
by	O
doxorubicin	I-Entity
by	O
significantly	O
reducing	O
the	O
percentage	O
of	O
altered	O
mitochondria	O
and	O
oxidative	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
hydroxytyrosol	I-Entity
improve	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
.	O

This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	I-Entity
protect	O
rat	O
heart	B-Entity
damage	I-Entity
provoked	O
by	O
doxorubicin	I-Entity
decreasing	O
oxidative	O
damage	O
and	O
mitochondrial	O
alterations	O
.	O



Amiodarone	I-Entity
-	O
induced	O
myxoedema	B-Entity
coma	I-Entity
.	O

A	O
62-year	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	I-Entity
,	O
hypothermia	I-Entity
and	O
respiratory	B-Entity
failure	I-Entity
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	I-Entity
therapy	O
for	O
atrial	B-Entity
fibrillation	I-Entity
.	O

0.3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
thyroxine	I-Entity
(	O
FT4	O
)	O
was	O
<	O
0.2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O

He	O
received	O
intravenous	O
fluids	O
,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	I-Entity
;	O
he	O
was	O
intubated	O
and	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	I-Entity
in	O
the	O
first	O
18	O
h	O
of	O
therapy	O
,	O
and	O
150	O
ug	O
intravenous	O
daily	O
thereafter	O
.	O

The	O
patient	O
was	O
maintained	O
on	O
levothyroxine	I-Entity
175	O
(	O
g	O
POorally	O
daily	O
.	O

The	O
24	O
hour	O
excretion	O
of	O
iodine	I-Entity
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

The	O
only	O
two	O
cases	O
of	O
amiodarone	I-Entity
-	O
induced	O
myxoedema	B-Entity
coma	I-Entity
in	O
the	O
literature	O
report	O
patient	O
death	O
despite	O
supportive	O
therapy	O
and	O
thyroid	O
hormone	O
replacement	O
.	O

This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone	I-Entity
-	O
induced	O
myxoedema	B-Entity
coma	I-Entity
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	B-Entity
disease	I-Entity
.	O



Use	O
of	O
argatroban	I-Entity
and	O
catheter	O
-	O
directed	O
thrombolysis	I-Entity
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
with	O
thrombosis	I-Entity
.	O

The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
with	O
thrombosis	I-Entity
(	O
HITT	I-Entity
)	O
and	O
was	O
treated	O
with	O
argatroban	I-Entity
plus	O
catheter	O
-	O
directed	O
thrombolysis	I-Entity
(	O
CDT	O
)	O
with	O
alteplase	O
is	O
presented	O
.	O

A	O
63-year	O
-	O
old	O
Caucasian	O
man	O
with	O
renal	O
amyloidosis	I-Entity
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper	B-Entity
-	I-Entity
extremity	I-Entity
deep	I-Entity
venous	I-Entity
thrombosis	I-Entity
(	O
DVT	I-Entity
)	O
and	O
pulmonary	B-Entity
embolism	I-Entity
secondary	O
to	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
.	O

infusion	O
of	O
argatroban	I-Entity
was	O
initiated	O
,	O
and	O
the	O
patient	O
was	O
managed	O
on	O
the	O
general	O
medical	O
floor	O
.	O

After	O
one	O
week	O
of	O
therapy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	B-Entity
vena	I-Entity
cava	I-Entity
(	I-Entity
SVC	I-Entity
)	I-Entity
syndrome	I-Entity
.	O

A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted	O
,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	I-Entity
.	O

The	O
epistaxis	I-Entity
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	I-Entity
.	O

Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	I-Entity
was	O
withheld	O
,	O
and	O
complete	O
patency	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
was	O
achieved	O
after	O
three	O
days	O
of	O
therapy	O
.	O

Alteplase	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	I-Entity
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfarin	I-Entity
for	O
long	O
-	O
term	O
anticoagulation	O
.	O

Although	O
the	O
patient	O
recovered	O
,	O
he	O
experienced	O
permanent	O
vision	B-Entity
and	I-Entity
hearing	I-Entity
loss	I-Entity
,	O
as	O
well	O
as	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
.	O

A	O
63-year	O
-	O
old	O
man	O
with	O
renal	O
amyloidosis	I-Entity
and	O
SVC	B-Entity
syndrome	I-Entity
secondary	O
to	O
HITT	I-Entity
was	O
successfully	O
treated	O
with	O
argatroban	I-Entity
and	O
CDT	O
with	O
alteplase	O
.	O



Effects	O
of	O
dehydroepiandrosterone	I-Entity
in	O
amphetamine	I-Entity
-	O
induced	O
schizophrenia	I-Entity
models	O
in	O
mice	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	I-Entity
(	O
DHEA	I-Entity
)	O
on	O
animal	O
models	O
of	O
schizophrenia	I-Entity
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	I-Entity
-	O
free	O
(	O
control	O
)	O
,	O
amphetamine	I-Entity
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	I-Entity
.	O

The	O
DHEA	I-Entity
was	O
administered	O
intraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
days	O
.	O

Amphetamine	I-Entity
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
hyper	I-Entity
locomotion	O
,	O
apomorphine	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O

subcutaneously	O
[	O
sc	O
]	O
)	O
induced	O
climbing	O
,	O
and	O
haloperidol	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
sc	O
)	O
induced	O
catalepsy	I-Entity
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	I-Entity
.	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
hyper	I-Entity
locomotion	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	I-Entity
tests	O
.	O

In	O
the	O
amphetamine	I-Entity
-	O
induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	I-Entity
-	O
free	O
group	O
.	O

Both	O
DHEA	I-Entity
50	O
mg	O
/	O
kg	O
(	O
p<0.05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p<0.01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	I-Entity
-	O
induced	O
locomotion	O
group	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
test	O
(	O
p<0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	I-Entity
-	O
induced	O
climbing	O
test	O
(	O
p>0.05	O
)	O
.	O

We	O
observed	O
that	O
DHEA	I-Entity
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	I-Entity
at	O
both	O
doses	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior	O
.	O

We	O
suggest	O
that	O
DHEA	I-Entity
displays	O
typical	O
neuroleptic	O
-	O
like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	I-Entity
.	O



Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B-Entity
prolongation	I-Entity
.	O

Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K(+	I-Entity
)	O
channel	O
and	O
Ca(2	I-Entity
+	O
)	O
channel	O
blocker	O
effects	O
on	O
QT	O
interval	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B-Entity
prolongation	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B-Entity
prolongation	I-Entity
induced	O
by	O
multichannel	O
blockers	O
.	O

IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca(2	I-Entity
+	O
)	O
channel	O
blockers	O
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O

Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	I-Entity
,	O
Paroxetine	I-Entity
,	O
Terfenadine	I-Entity
and	O
Citalopram	I-Entity
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	I-Entity
and	O
Citalopram	I-Entity
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-Entity
de	I-Entity
Pointes	I-Entity
(	O
TdP	I-Entity
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	I-Entity
potential	O
.	O



Dermal	O
developmental	O
toxicity	I-Entity
of	O
N	O
-	O
phenylimide	O
herbicides	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
S-53482	I-Entity
and	O
S-23121	I-Entity
are	O
N	O
-	O
phenylimide	O
herbicides	O
and	O
produced	O
embryolethality	I-Entity
,	O
teratogenicity	I-Entity
(	O
mainly	O
ventricular	B-Entity
septal	I-Entity
defects	I-Entity
and	O
wavy	O
ribs	O
)	O
,	O
and	O
growth	B-Entity
retardation	I-Entity
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	I-Entity
studies	O
.	O

Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	I-Entity
via	O
the	O
dermal	O
route	O
,	O
which	O
is	O
more	O
relevant	O
to	O
occupational	O
exposure	O
,	O
hence	O
better	O
addressing	O
human	O
health	O
risks	O
.	O

S-53482	I-Entity
was	O
administered	O
dermally	O
to	O
rats	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organogenesis	O
,	O
and	O
S-23121	I-Entity
was	O
administered	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maximum	O
applicable	O
dose	O
level	O
)	O
.	O

RESULTS	O
:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S-53482	I-Entity
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	I-Entity
similar	O
to	O
those	O
resulting	O
from	O
oral	O
exposure	O
.	O

Toxicity	I-Entity
included	O
embryolethality	I-Entity
,	O
teratogenicity	I-Entity
,	O
and	O
growth	B-Entity
retardation	I-Entity
.	O

Dermal	O
administration	O
of	O
S-23121	I-Entity
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	B-Entity
death	I-Entity
and	O
ventricular	B-Entity
septal	I-Entity
defect	I-Entity
,	O
but	O
retarded	O
fetal	O
growth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oral	O
exposure	O
to	O
S-23121	I-Entity
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
results	O
,	O
S-53482	I-Entity
and	O
S-23121	I-Entity
were	O
teratogenic	I-Entity
when	O
administered	O
dermally	O
to	O
pregnant	O
rats	O
as	O
were	O
the	O
compounds	O
administered	O
orally	O
.	O



Rates	O
of	O
Renal	B-Entity
Toxicity	I-Entity
in	O
Cancer	I-Entity
Patients	O

Receiving	O
Cisplatin	I-Entity

With	O
and	O
Without	O
Mannitol	I-Entity
.	O

Cisplatin	I-Entity
is	O
a	O
widely	O
used	O
antineoplastic	O
.	O

One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	I-Entity
use	O
is	O
dose	O
-	O
limiting	O
nephrotoxicity	I-Entity
.	O

There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	I-Entity
,	O
including	O
the	O
use	O
of	O
mannitol	I-Entity
as	O
a	O
nephroprotectant	O
in	O
combination	O
with	O
hydration	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
in	O
cancer	I-Entity
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	I-Entity
with	O
and	O
without	O
mannitol	I-Entity
.	O

This	O
single	O
-	O
center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	I-Entity
shortage	O
.	O

Data	O
were	O
collected	O
on	O
adult	O
cancer	I-Entity
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	I-Entity
as	O
an	O
outpatient	O
from	O
January	O
2011	O
to	O
September	O
2012	O
.	O

The	O
primary	O
outcome	O
was	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
(	O
AKI	I-Entity
)	O
.	O

We	O
evaluated	O
143	O
patients	O
who	O
received	O
single	O
-	O
agent	O
cisplatin	I-Entity
;	O
97.2%	O
of	O
patients	O
had	O
head	B-Entity
and	I-Entity
neck	I-Entity
cancer	I-Entity
as	O
their	O
primary	O
malignancy	I-Entity
.	O

Patients	O
who	O
did	O
not	O
receive	O
mannitol	I-Entity
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	I-Entity
:	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.646	O
(	O
95%	O
CI	O
=	O
1.008	O
,	O
6.944	O
;	O
P	O
=	O
0.048	O
)	O
.	O

Patients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m(2	O
)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	I-Entity
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	I-Entity
:	O
OR	O
=	O
11.494	O
(	O
95%	O
CI	O
=	O
4.149	O
,	O
32.258	O
;	O

CONCLUSIONS	O
:	O
When	O
limited	O
quantities	O
of	O
mannitol	I-Entity
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	O
particularly	O
high	O
risk	O
of	O
nephrotoxicity	I-Entity
.	O

Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg	O
/	O
m(2	O
)	O
cisplatin	I-Entity
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	I-Entity
are	O
at	O
the	O
greatest	O
risk	O
of	O
nephrotoxicity	I-Entity
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	I-Entity
.	O



Metformin	I-Entity
protects	O
against	O
seizures	I-Entity
,	O
learning	B-Entity
and	I-Entity
memory	I-Entity
impairments	I-Entity
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole	I-Entity
-	O
induced	O
kindling	O
in	O
mice	O
.	O

Cognitive	B-Entity
impairment	I-Entity
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	I-Entity
,	O
greatly	O
diminishes	O
the	O
quality	O
of	O
life	O
.	O

However	O
,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	I-Entity
can	O
also	O
cause	O
untoward	O
cognitive	O
effects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	I-Entity
and	O
cognition	B-Entity
deficits	I-Entity
.	O

Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B-Entity
deficits	I-Entity
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential	O
.	O

Metformin	I-Entity
,	O
the	O
most	O
commonly	O
prescribed	O
antidiabetic	O
oral	O
drug	O
,	O
has	O
antioxidant	O
properties	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	I-Entity
on	O
seizures	I-Entity
,	O
cognitive	B-Entity
impairment	I-Entity
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole	I-Entity
-	O
induced	O
kindling	O
animals	O
.	O

Male	O
C57BL/6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	I-Entity
(	O
37	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injections	O
.	O

Metformin	I-Entity
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg	O
/	O

kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	I-Entity
.	O

We	O
found	O
that	O
metformin	I-Entity
suppressed	O
the	O
progression	O
of	O
kindling	O
,	O
ameliorated	O
the	O
cognitive	B-Entity
impairment	I-Entity
and	O
decreased	O
brain	O
oxidative	O
stress	O
.	O

Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	I-Entity
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	I-Entity
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	B-Entity
impairment	I-Entity
induced	O
by	O
seizures	I-Entity
.	O



P53	O
inhibition	O
exacerbates	O
late	O
-	O
stage	O
anthracycline	I-Entity
cardiotoxicity	I-Entity
.	O

AIMS	O
:	O
Doxorubicin	I-Entity
(	O
DOX	I-Entity
)	O
is	O
an	O
effective	O
anti	O
-	O
cancer	I-Entity
therapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late	O
-	O
stage	O
cardiotoxicity	I-Entity
.	O

Children	O
are	O
particularly	O
sensitive	O
to	O
DOX	I-Entity
-	O
induced	O
heart	B-Entity
failure	I-Entity
.	O

Here	O
,	O
the	O
impact	O
of	O
p53	O
inhibition	O
on	O
acute	O
vs.	O
late	O
-	O
stage	O
DOX	I-Entity
cardiotoxicity	I-Entity
was	O
examined	O
in	O
a	O
juvenile	O
model	O
.	O

littermates	O
received	O
weekly	O
DOX	I-Entity
injections	O
for	O
5	O
weeks	O
(	O
25	O
mg	O
/	O
kg	O
cumulative	O
dose	O
)	O
.	O

One	O
week	O
after	O
the	O
last	O
DOX	I-Entity
treatment	O
(	O
acute	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
mice	O
exhibited	O
improved	O
cardiac	O
function	O
and	O
lower	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
the	O
NON	O
-	O
TXG	O
mice	O
.	O

Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	I-Entity
treatment	O
(	O
late	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
progressive	O
decrease	O
in	O
cardiac	O
function	O
and	O
higher	O
rates	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
NON	O
-	O
TXG	O
mice	O
.	O

p53	O
inhibition	O
blocked	O
transient	O
DOX	I-Entity
-	O
induced	O
STAT3	O
activation	O
in	O
MHC	O
-	O
CB7	O
mice	O
,	O
which	O
was	O
associated	O
with	O
enhanced	O
induction	O
of	O
the	O
DNA	O
repair	O
proteins	O
Ku70	O
and	O
Ku80	O
.	O

Mice	O
with	O
cardiomyocyte	O
-	O
restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function	O
,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	I-Entity
treatment	O
during	O
the	O
acute	O
stage	O
when	O
compared	O
with	O
control	O
animals	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53-dependent	O
cardioprotective	O
pathway	O
,	O
mediated	O
via	O
STAT3	O
activation	O
,	O
mitigates	O
DOX	I-Entity
-	O
induced	O
myocardial	O
stress	O
during	O
drug	O
delivery	O
.	O

Furthermore	O
,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and	O
,	O
paradoxically	O
,	O
enhanced	O
cardiotoxicity	I-Entity
long	O
after	O
the	O
cessation	O
of	O
drug	O
treatment	O
.	O



Metronidazole	I-Entity
-	O
induced	O
encephalopathy	I-Entity
:	O
an	O
uncommon	O
scenario	O
.	O

Metronidazole	I-Entity
can	O
produce	O
neurological	O
complications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	I-Entity
following	O
prolonged	O
metronidazole	I-Entity
intake	O
.	O

The	O
diagnosis	O
of	O
metronidazole	I-Entity
toxicity	I-Entity
was	O
made	O
by	O
the	O
MRI	O
findings	O
and	O
supported	O
clinically	O
.	O



Aconitine	I-Entity
-	O
induced	O
Ca2	I-Entity
+	O
overload	O
causes	O
arrhythmia	I-Entity
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats	O
.	O

Aconitine	I-Entity
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na(+	I-Entity
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	I-Entity
of	O
aconitine	I-Entity
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca(2	I-Entity
+	O
)	O
in	O
aconitine	I-Entity
poisoning	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca(2	I-Entity
+	O
)	O
signaling	O
in	O
aconitine	I-Entity
poisoning	I-Entity
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca(2	I-Entity
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	I-Entity
in	O
conscious	O
freely	O
moving	O
rats	O
.	O

To	O
investigate	O
effects	O
of	O
aconitine	I-Entity
on	O
myocardial	B-Entity
injury	I-Entity
,	O
we	O
performed	O
cytotoxicity	I-Entity
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	I-Entity
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	O
.	O

The	O
results	O
showed	O
that	O
aconitine	I-Entity
resulted	O
in	O
myocardial	B-Entity
injury	I-Entity
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O

transferase	O
-	O
mediated	O
dUTP	I-Entity
-	O
biotin	I-Entity
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	I-Entity
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca(2	I-Entity
+	O
)	O

handling	O
proteins	O
demonstrated	O
that	O
aconitine	I-Entity
promoted	O
Ca(2	I-Entity
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca(2	I-Entity
+	O
)	O
handling	O
proteins	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	I-Entity
significantly	O
aggravates	O
Ca(2	I-Entity
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	I-Entity
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O



Chronic	O
treatment	O
with	O
metformin	I-Entity
suppresses	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
following	O
myocardial	B-Entity
infarction	I-Entity
.	O

Acute	O
treatment	O
with	O
metformin	I-Entity
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-Entity
infarction	I-Entity
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP	I-Entity
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	I-Entity
on	O
cardiac	B-Entity
dysfunction	I-Entity
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B-Entity
infarction	I-Entity
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed	O
.	O

Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n=6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	I-Entity
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O

kg	O
of	O
metformin	I-Entity
twice	O
daily	O
for	O
14	O
days	O
.	O

Isoproterenol	I-Entity
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
.	O

Isoproterenol	I-Entity
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O

The	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O

kg	O
of	O
metformin	I-Entity
.	O

Metfromin	O
markedly	O
lowered	O
isoproterenol	I-Entity
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
,	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
)	O
,	O
tumor	I-Entity
necrosis	I-Entity
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleukin	O
6	O
(	O
IL-6	O
)	O
in	O
the	O
heart	O
tissues	O
.	O

kg	O
of	O
metformin	I-Entity
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O

Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	I-Entity
reduces	O
post	O
-	O
myocardial	B-Entity
infarction	I-Entity
cardiac	O
dysfunction	O
and	O
suppresses	O
inflammatory	O
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	O
activities	O
.	O



Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	I-Entity
and	O
tiapride	I-Entity
in	O
a	O
Japanese	O
patient	O
with	O
Huntington	B-Entity
's	I-Entity
disease	I-Entity
at	O
the	O
terminal	O
stage	O
of	O
recurrent	O
breast	B-Entity
cancer	I-Entity
.	O

We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81-year	O
-	O
old	O
Japanese	O
woman	O
with	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	I-Entity
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabenazine	I-Entity
(	O
12.5	O
mg	O
/	O
day	O
)	O
for	O
Huntington	B-Entity
's	I-Entity
disease	I-Entity
.	O

The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	I-Entity
or	O
tetrabenazine	I-Entity
alone	O
without	O
any	O
adverse	O
effects	O
before	O
the	O
administration	O
of	O
the	O
combination	O
therapy	O
.	O

She	O
also	O
had	O
advanced	O
breast	B-Entity
cancer	I-Entity
when	O
the	O
combination	O
therapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
occurrence	O
of	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	I-Entity
and	O
tiapride	I-Entity
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrabenazine	I-Entity
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	B-Entity
drugs	I-Entity
,	O
particularly	O
in	O
patients	O
with	O
a	O
worsening	O
general	O
condition	O
.	O



A	O
metoprolol	I-Entity
-	O
terbinafine	I-Entity
combination	O
induced	O
bradycardia	I-Entity
.	O

To	O
report	O
a	O
sinus	B-Entity
bradycardia	I-Entity
induced	O
by	O
metoprolol	I-Entity
and	O
terbinafine	I-Entity
drug	O
-	O
drug	O
interaction	O
and	O
its	O
management	O
.	O

A	O
63	O
year	O
-	O
old	O
Caucasian	O
man	O
on	O
metoprolol	I-Entity
200	O
mg	O
/	O
day	O
for	O
stable	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
was	O
prescribed	O
a	O
90-day	O
course	O
of	O
oral	O
terbinafine	I-Entity
250	O
mg	O
/	O
day	O
for	O
onychomycosis	I-Entity
.	O

On	O
the	O
49th	O
day	O
of	O
terbinafine	I-Entity
therapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status	O
,	O
confusion	I-Entity
and	O
falls	O
.	O

The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats	O
/	O
min	O
sinus	B-Entity
bradycardia	I-Entity
.	O

A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	B-Entity
drug	I-Entity
reaction	I-Entity
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
's	O
sinus	B-Entity
bradycardia	I-Entity
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	I-Entity
and	O
terbinafine	I-Entity
.	O

The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	I-Entity
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	I-Entity
and	O
the	O
heart	O
rate	O
remained	O
normal	O
.	O

By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6	O
,	O
terbinafine	I-Entity
had	O
decreased	O
metoprolol	I-Entity
's	O
clearance	O
,	O
leading	O
in	O
metoprolol	I-Entity
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	B-Entity
bradycardia	I-Entity
.	O



Optochiasmatic	O
and	O
peripheral	B-Entity
neuropathy	I-Entity
due	O
to	O
ethambutol	I-Entity
overtreatment	O
.	O

Ethambutol	I-Entity
is	O
known	O
to	O
cause	O
optic	B-Entity
neuropathy	I-Entity
and	O
,	O
more	O
rarely	O
,	O
axonal	O
polyneuropathy	I-Entity
.	O

We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72-year	O
-	O
old	O
man	O
who	O
developed	O
visual	B-Entity
loss	I-Entity
and	O
paresthesias	I-Entity
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	I-Entity
.	O

This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	I-Entity
toxicity	I-Entity
.	O



Testosterone	I-Entity
ameliorates	O
streptozotocin	I-Entity
-	O
induced	O
memory	B-Entity
impairment	I-Entity
in	O
male	O
rats	O
.	O

AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	I-Entity
on	O
streptozotocin	I-Entity
(	O
STZ)-induced	I-Entity
memory	B-Entity
impairment	I-Entity
in	O
male	O
rats	O
.	O

Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	I-Entity
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	I-Entity
.	O

Testosterone	I-Entity
(	O
1	O
mg.kg(-1).d(-1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgen	I-Entity
receptor	O
antagonist	O
flutamide	I-Entity
(	O
10	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrogen	I-Entity
receptor	O
antagonist	O
tamoxifen	I-Entity
(	O
1	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	I-Entity
(	O
4	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	I-Entity
.	O

STZ	I-Entity
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O

Testosterone	I-Entity
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats	O
,	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	I-Entity
-	O
treated	O
rats	O
.	O

Administration	O
of	O
flutamide	I-Entity
,	O
letrozole	I-Entity
or	O
tamoxifen	I-Entity
significantly	O
impaired	B-Entity
the	I-Entity
memory	I-Entity
in	O
intact	O
rats	O
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	I-Entity
replacement	O
in	O
improving	O
STZ-	I-Entity
and	O
castration	O
-	O
induced	O
memory	B-Entity
impairment	I-Entity
.	O

Testosterone	I-Entity
administration	O
ameliorates	O
STZ-	I-Entity
and	O
castration	O
-	O
induced	O
memory	B-Entity
impairment	I-Entity
in	O
male	O
Wistar	O
rats	O
.	O



Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	B-Entity
FC	I-Entity
in	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

Garcinielliptone	B-Entity
FC	I-Entity
(	O
GFC	I-Entity
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart	O
.	O

It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-Entity
diseases	I-Entity
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	I-Entity
and	O
inflammatory	B-Entity
diseases	I-Entity
.	O

However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	I-Entity
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	I-Entity
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	I-Entity
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	B-Entity
acid	I-Entity
(	O
r	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA	I-Entity
)	O
,	O
glutamine	I-Entity
,	O
aspartate	I-Entity
and	O
glutathione	I-Entity
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	I-Entity
.	O

GFC	I-Entity
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	I-Entity
,	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20.12	O
+	O
2.20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20.95	O
+	O
2.21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23.43	O
+	O
1.99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
addition	O
,	O
GABA	I-Entity
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
of	O
46.90%	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
aspartate	I-Entity
,	O
glutamine	I-Entity
and	O
glutamate	I-Entity
levels	O
detected	O
a	O
decrease	O
of	O
5.21%	O
,	O
13.55%	O
and	O
21.80%	O
,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

The	O
results	O
indicate	O
that	O
GFC	I-Entity
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	I-Entity
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	I-Entity
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	I-Entity
model	O
by	O
modulating	O
the	O
GABA	I-Entity
and	O
glutamate	I-Entity
contents	O
and	O
of	O
AChE	O
activity	O
in	O
seized	O
mice	O
hippocampus	O
.	O



Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
:	O
a	O
prospective	O
,	O
clinical	O
,	O
non	O
-	O
interventional	O
,	O
observational	O
study	O
.	O

Acute	B-Entity
kidney	I-Entity
injury	I-Entity
(	O
AKI	I-Entity
)	O
occurs	O
in	O
7%	O
of	O
hospitalized	O
and	O
66%	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(	O
standard	O
operating	O
procedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoxic	I-Entity
antibiotics	O
and	O
the	O
occurrence	O
of	O
AKI	I-Entity
.	O

163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	I-Entity
,	O
gentamicin	I-Entity
,	O
or	O
tobramycin	I-Entity
;	O
were	O
>	O
18	O
years	O
;	O
and	O
treated	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

AKI	I-Entity
was	O
defined	O
according	O
to	O
RIFLE	O
criteria	O
.	O

Development	O
of	O
AKI	I-Entity
was	O
compared	O
between	O
groups	O
with	O
exact	O
Chi2-test	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0.05	O
)	O
.	O

AKI	I-Entity
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36%	O
versus	O
21%	O
in	O
HAG	O
(	O
P	O
=	O
0.035	O
)	O
.	O

Basic	O
characteristics	O
were	O
comparable	O
,	O
except	O
an	O
increased	O
rate	O
of	O
soft	O
tissue	O
infections	I-Entity
in	O
LAG	O
.	O

Multivariate	O
analysis	O
revealed	O
an	O
odds	O
ratio	O
of	O
2.5-fold	O
for	O
LAG	O
to	O
develop	O
AKI	I-Entity
compared	O
with	O
HAG	O
(	O
95%	O
confidence	O
interval	O
1.195	O
to	O
5.124	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	I-Entity
antibiotics	O
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
AKI	I-Entity
.	O



Rhabdomyolysis	I-Entity
in	O
a	O
hepatitis	B-Entity
C	I-Entity
virus	I-Entity
infected	I-Entity
patient	O
treated	O
with	O
telaprevir	I-Entity
and	O
simvastatin	I-Entity
.	O

A	O
46-year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B-Entity
C	I-Entity
virus	I-Entity
infection	I-Entity
received	O
triple	O
therapy	O
with	O
ribavirin	I-Entity
,	O
pegylated	B-Entity
interferon	I-Entity
and	O
telaprevir	I-Entity
.	O

The	O
patient	O
also	O
received	O
simvastatin	I-Entity
.	O

One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	I-Entity
.	O

At	O
admission	O
simvastatin	I-Entity
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	I-Entity
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O

The	O
creatine	I-Entity
kinase	O
peaked	O
at	O
62,246	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O

Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	I-Entity
kinase	O
level	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
discharged	O
.	O

Telaprevir	I-Entity
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	I-Entity
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O

The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4-mediated	O
simvastatin	I-Entity
clearance	O
.	O

Simvastatin	I-Entity
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	I-Entity
induced	O
muscle	B-Entity
toxicity	I-Entity
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	I-Entity
in	O
blood	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	I-Entity
as	O
well	O
as	O
statins	I-Entity
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug	O
-	O
drug	O
interactions	O
.	O



Combination	O
of	O
bortezomib	I-Entity
,	O
thalidomide	I-Entity
,	O
and	O
dexamethasone	I-Entity
(	O
VTD	O
)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	B-Entity
myeloma	I-Entity
in	O
Japanese	O
patients	O
.	O

Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	B-Entity
myeloma	I-Entity
(	O
MM	I-Entity
)	O
has	O
been	O
widely	O
adopted	O
to	O
improve	O
treatment	O
response	O
following	O
autologous	O
stem	O
cell	O
transplantation	O
.	O

In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	I-Entity
,	O
thalidomide	I-Entity
,	O
and	O
dexamethasone	I-Entity
(	O
VTD	O
)	O
as	O
consolidation	O
therapy	O
in	O
24	O
Japanese	O
patients	O
with	O
newly	O
diagnosed	O
MM	I-Entity
.	O

VTD	O
consisted	O
of	O
bortezomib	I-Entity
at	O
a	O
dose	O
of	O
1.3	O
mg	O
/	O
m(2	O
)	O
and	O
dexamethasone	I-Entity
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
day	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35-day	O
cycle	O
,	O
with	O
daily	O
oral	O
thalidomide	I-Entity
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
day	O
.	O

Grade	O
3	O
-	O
4	O
neutropenia	I-Entity
and	O
thrombocytopenia	I-Entity
were	O
documented	O
in	O
four	O
and	O
three	O
patients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
drug	O
dose	O
reduction	O
due	O
to	O
cytopenia	I-Entity
was	O
not	O
required	O
in	O
any	O
case	O
.	O

Peripheral	B-Entity
neuropathy	I-Entity
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
severe	O
grade	O
3	O
-	O
4	O
peripheral	B-Entity
neuropathy	I-Entity
was	O
not	O
observed	O
.	O



Conversion	O
to	O
sirolimus	I-Entity
ameliorates	O
cyclosporine	I-Entity
-	O
induced	O
nephropathy	I-Entity
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
,	O
urine	O
,	O
gene	O
,	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O

Protocols	O
of	O
conversion	O
from	O
cyclosporin	B-Entity
A	I-Entity
(	O
CsA	I-Entity
)	O
to	O
sirolimus	I-Entity
(	O
SRL	I-Entity
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	I-Entity
-	O
induced	O
nephropathy	I-Entity
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	I-Entity
-	O
to	O
-	O
SRL	I-Entity
conversion	O
in	O
a	O
rat	O
model	O
.	O

Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	I-Entity
,	O
SRL	I-Entity
,	O
and	O
conversion	O
(	O
CsA	I-Entity
for	O
3	O
weeks	O
followed	O
by	O
SRL	I-Entity
for	O
6	O
weeks	O
)	O
.	O

Renal	B-Entity
lesions	I-Entity
were	O
analyzed	O
in	O
hematoxylin	I-Entity
and	O
eosin	I-Entity
,	O
periodic	O
acid	O
-	O
Schiff	O
,	O
and	O
Masson	O
's	O
trichrome	O
stains	O
.	O

SRL	I-Entity
-	O
treated	O
rats	O
presented	O
proteinuria	I-Entity
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B-Entity
impairment	I-Entity
.	O

Short	O
CsA	I-Entity
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B-Entity
lesions	I-Entity
and	O
TGF	O
-	O
b	O
,	O
NF-	O
kb	O
,	O
mTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM-1	O
,	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O

Prolonged	O
CsA	I-Entity
exposure	O
aggravated	O
renal	B-Entity
damage	I-Entity
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF-	O
b	O
and	O
IL-7	O
,	O
TBARs	O
clearance	O
,	O
and	O
kidney	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O

Conversion	O
to	O
SRL	I-Entity
prevented	O
CsA	I-Entity
-	O
induced	O
renal	B-Entity
damage	I-Entity
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
)	O
,	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	I-Entity
replacement	O
to	O
SRL	I-Entity
.	O



cisplatin	I-Entity
-	O
induced	O
acute	B-Entity
renal	I-Entity
injury	I-Entity
.	O

Cisplatin	I-Entity
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies	O
;	O
however	O
,	O
this	O
drug	O
can	O
induce	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	O
function	O
,	O
augment	O
serum	O
levels	O
of	O
creatinine	I-Entity
and	O
urea	I-Entity
,	O
increase	O
the	O
acute	B-Entity
tubular	I-Entity
necrosis	I-Entity
score	O
and	O
up	O
-	O
regulate	O
cytokines	O
(	O
e.g.	O
,	O
IL-1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	I-Entity
process	O
,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression	O
,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	B-Entity
nephropathy	I-Entity
status	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin	I-Entity
-	O
induced	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	I-Entity
.	O

Additionally	O
,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	I-Entity
administration	O
.	O

B2	O
receptor	O
-	O
deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice	O
,	O
as	O
shown	O
by	O
reduced	O
weight	B-Entity
loss	I-Entity
,	O
better	O
preservation	O
of	O
kidney	O
function	O
,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	O
and	O
less	O
acute	B-Entity
tubular	I-Entity
necrosis	I-Entity
.	O

Moreover	O
,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	I-Entity
and	O
blood	O
urea	I-Entity
after	O
cisplatin	I-Entity
administration	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin	I-Entity
-	O
induced	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
by	O
mediating	O
the	O
necrotic	I-Entity
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
,	O
thus	O
resulting	O
in	O
declined	O
renal	O
function	O
.	O

These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	I-Entity
induced	O
by	O
cisplatin	I-Entity
therapy	O
.	O



Safety	O
and	O
efficacy	O
of	O
fluocinolone	B-Entity
acetonide	I-Entity
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
birdshot	B-Entity
retinochoroidopathy	I-Entity
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	B-Entity
acetonide	I-Entity
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
patients	O
with	O
birdshot	B-Entity
retinochoroidopathy	I-Entity
whose	O
disease	O
is	O
refractory	O
or	O
intolerant	O
to	O
conventional	O
immunomodulatory	O
therapy	O
.	O

A	O
retrospective	O
case	O
series	O
involving	O
11	O
birdshot	B-Entity
retinochoroidopathy	I-Entity
patients	O
(	O
11	O
eyes	O
)	O
.	O

Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
underwent	O
surgery	O
for	O
fluocinolone	B-Entity
acetonide	I-Entity
implant	O
(	O
0.59	O
mg	O
)	O
.	O

Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	O
baseline	O
,	O
before	O
fluocinolone	B-Entity
acetonide	I-Entity
implant	O
,	O
and	O
then	O
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
.	O

Disease	O
activity	O
markers	O
,	O
including	O
signs	O
of	O
ocular	O
inflammation	I-Entity
,	O
evidence	O
of	O
retinal	B-Entity
vasculitis	I-Entity
,	O
Swedish	O
interactive	O
threshold	O
algorithm	O
-	O
short	O
wavelength	O
automated	O
perimetry	O
Humphrey	O
visual	O
field	O
analysis	O
,	O
electroretinographic	O
parameters	O
,	O
and	O
optical	O
coherence	O
tomography	O
were	O
recorded	O
.	O

Data	O
on	O
occurrence	O
of	O
cataract	I-Entity
and	O
raised	B-Entity
intraocular	I-Entity
pressure	I-Entity
were	O
collected	O
in	O
all	O
eyes	O
.	O

RESULTS	O
:	O
Intraocular	O
inflammation	I-Entity
was	O
present	O
in	O
54.5	O
,	O
9.9	O
,	O
11.1	O
,	O
and	O
0%	O
of	O
patients	O
at	O
baseline	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
after	O
receiving	O
the	O
implant	O
,	O
respectively	O
.	O

Active	O
vasculitis	I-Entity
was	O
noted	O
in	O
36.3%	O
patients	O
at	O
baseline	O
and	O
0%	O
at	O
3	O
years	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20%	O
(	O
47.61	O
-	O
67.2%	O
)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	B-Entity
macular	I-Entity
edema	I-Entity
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
.	O

Adverse	O
events	O
included	O
increased	B-Entity
intraocular	I-Entity
pressure	I-Entity
(	O
54.5%	O
)	O
and	O
cataract	I-Entity
formation	O
(	O
100%	O
)	O
.	O

The	O
data	O
suggest	O
that	O
fluocinolone	B-Entity
acetonide	I-Entity
implant	O
(	O
0.59	O
mg	O
)	O
helps	O
to	O
control	O
inflammation	I-Entity
in	O
otherwise	O
treatment	O
-	O
refractory	O
cases	O
of	O
birdshot	B-Entity
retinochoroidopathy	I-Entity
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	I-Entity
and	O
ocular	B-Entity
hypertension	I-Entity
requiring	O
treatment	O
.	O



Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	I-Entity
to	O
decrease	O
fasciculation	I-Entity
and	O
myalgia	I-Entity
following	O
succinylcholine	I-Entity
administration	O
.	O

Succinylcholine	I-Entity
commonly	O
produces	O
frequent	O
adverse	O
effects	O
,	O
including	O
muscle	B-Entity
fasciculation	I-Entity
and	O
myalgia	I-Entity
.	O

The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	I-Entity
to	O
prevent	O
succinylcholine	I-Entity
-	O
induced	O
fasciculation	I-Entity
and	O
myalgia	I-Entity
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	I-Entity
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	I-Entity
.	O

/	O
kg	O
rocuronium	I-Entity
as	O
a	O
precurarizing	O
dose	O
.	O

All	O
patients	O
received	O
succinylcholine	I-Entity

1.5	O
mg	O
/	O
kg	O
at	O
2	O
minutes	O
after	O
the	O
precurarization	O
,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	I-Entity
,	O
while	O
myalgia	I-Entity
was	O
assessed	O
at	O
24	O
hours	O
after	O
surgery	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	B-Entity
fasciculation	I-Entity
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	I-Entity
(	O
P	O
<	O
0.001	O
)	O
.	O

Those	O
of	O
myalgia	I-Entity
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	I-Entity
,	O
but	O
there	O
was	O
no	O
significance	O
(	O
P	O
=	O
0.072	O
)	O
.	O

The	O
onset	O
time	O
of	O
succinylcholine	I-Entity
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	I-Entity
(	O
P	O
<	O
0.001	O
)	O
.	O

Precurarization	O
with	O
0.04	O
mg	O
/	O
kg	O
rocuronium	I-Entity
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	I-Entity
and	O
myalgia	I-Entity
with	O
acceptable	O
onset	O
time	O
,	O
and	O
the	O
safe	O
and	O
effective	O
precurarization	O
.	O



Absence	O
of	O
PKC	O
-	O
alpha	O
attenuates	O
lithium	I-Entity
-	O
induced	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
.	O

Lithium	I-Entity
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
(	O
NDI	I-Entity
)	O
in	O
40%	O
of	O
patients	O
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	I-Entity
acutely	O
disrupting	O
the	O
cAMP	I-Entity
pathway	O
and	O
chronically	O
reducing	O
urea	I-Entity
transporter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
water	O
channel	O
(	O
AQP2	O
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
.	O

)	O
controls	O
were	O
treated	O
with	O
lithium	I-Entity
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	I-Entity
for	O
6	O
weeks	O
.	O

Lithium	I-Entity
-	O
treated	O
WT	O
mice	O
had	O
19-fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4-fold	O
increase	O
in	O
output	O
.	O

AQP2	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	I-Entity
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice	O
,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2-fold	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	I-Entity
,	O
potassium	I-Entity
and	O
calcium	I-Entity
were	O
elevated	O
in	O
lithium	I-Entity
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	I-Entity
-	O
fed	O
PKCa	O
KO	O
mice	O
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	I-Entity
-	O
induced	O
NDI	I-Entity
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	I-Entity
associated	O
with	O
lithium	I-Entity
therapy	O
.	O



Is	O
Dysguesia	I-Entity
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side	O
-	O
effect	O
of	O
Amlodipine	I-Entity
?	O

A	O
very	O
rare	O
side	O
-	O
effect	O
of	O
amlodipine	I-Entity
is	O
dysguesia	I-Entity
.	O

We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	O
hypertension	I-Entity
on	O
drug	O
treatment	O
with	O
amlodipine	I-Entity
developed	O
loss	B-Entity
of	I-Entity
taste	I-Entity
sensation	I-Entity
.	O

We	O
conclude	O
that	O
amlodipine	I-Entity
can	O
cause	O
dysguesia	I-Entity
.	O

Here	O
,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	I-Entity
and	O
dysguesia	I-Entity
.	O



Rhabdomyolysis	I-Entity
in	O
association	O
with	O
simvastatin	I-Entity
and	O
dosage	O
increment	O
in	O
clarithromycin	I-Entity
.	O

Clarithromycin	I-Entity
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	I-Entity
.	O

This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	I-Entity
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	I-Entity
.	O

The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	O
without	O
any	O
obvious	O
cardiac	O
issues	O
,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	I-Entity
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	I-Entity
on	O
the	O
structure	O
and	O
function	O
of	O
cardiac	O
muscle	O
.	O

Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	I-Entity
or	O
inhibit	O
the	O
CYP3A4	O
enzyme	O
.	O

Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	I-Entity
induced	O
rhabdomyolysis	I-Entity
,	O
which	O
may	O
warrant	O
further	O
studies	O
.	O



Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	I-Entity
with	O
suxamethonium	I-Entity
.	O

Butyrylcholinesterase	B-Entity
deficiency	I-Entity
is	O
characterized	O
by	O
prolonged	O
apnea	I-Entity
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	I-Entity
or	O
mivacurium	I-Entity
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	I-Entity
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(	O
c.695T	O
>	O
A	O
,	O
p	O
.	O

Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	I-Entity
(	O
BTC	I-Entity
)	O
and	O
benzoylcholine	I-Entity
,	O
and	O
values	O
of	O
dibucaine	I-Entity
and	O
fluoride	I-Entity
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O

BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	I-Entity
as	O
the	O
substrate	O
.	O

Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	I-Entity
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	I-Entity
.	O

Val204Asp	O
is	O
disruption	O
of	O
hydrogen	I-Entity
bonding	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O



Delayed	O
anemia	I-Entity
after	O
treatment	O
with	O
injectable	O
artesunate	I-Entity
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
:	O
a	O
manageable	O
issue	O
.	O

Cases	O
of	O
delayed	O
hemolytic	B-Entity
anemia	I-Entity
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	I-Entity
,	O
the	O
current	O
World	O
Health	O
Organization	O
(	O
WHO)-recommended	O
first	O
-	O
line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	I-Entity
.	O

>	O
5	O
years	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatment	O
with	O
injectable	O
artesunate	I-Entity
for	O
severe	O
malaria	I-Entity
in	O
hospitals	O
and	O
health	O
centers	O
of	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

All	O
cases	O
of	O
delayed	O
anemia	I-Entity
were	O
clinically	O
manageable	O
and	O
resolved	O
within	O
one	O
month	O
.	O



Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	I-Entity
attenuates	O
isoproterenol	I-Entity
-	O
induced	O
acute	O
myocardial	B-Entity
injury	I-Entity
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	I-Entity
on	O
acute	O
myocardial	B-Entity
ischemia	I-Entity
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O

Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	I-Entity
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
days	O
.	O

Acute	O
myocardial	B-Entity
ischemic	I-Entity
injury	I-Entity
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	I-Entity
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consecutive	O
days	O
.	O

Oral	O
administration	O
of	O
betaine	I-Entity
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B-Entity
remodeling	I-Entity
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	I-Entity
-	O
induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	I-Entity
treatment	O
in	O
myocardium	O
.	O

Furthermore	O
,	O
betaine	I-Entity
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl-2	O
and	O
reduced	O
the	O
level	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl-2/Bax	O
.	O

The	O
protective	O
role	O
of	O
betaine	I-Entity
on	O
myocardial	B-Entity
damage	I-Entity
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	I-Entity
pretreatment	O
attenuated	O
isoproterenol	I-Entity
-	O
induced	O
acute	O
myocardial	B-Entity
ischemia	I-Entity
via	O
the	O
regulation	O
of	O
STAT3	O
and	O
apoptotic	O
pathways	O
.	O



Quetiapine	I-Entity
-	O
induced	O
neutropenia	I-Entity
in	O
a	O
bipolar	I-Entity
patient	O
with	O
hepatocellular	B-Entity
carcinoma	I-Entity
.	O

OBJECTIVE	O
:	O
Quetiapine	I-Entity
is	O
a	O
dibenzothiazepine	O
derivative	O
,	O
similar	O
to	O
clozapine	I-Entity
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	B-Entity
dyscrasias	I-Entity
,	O
especially	O
neutropenia	I-Entity
.	O

There	O
are	O
some	O
case	O
reports	O
about	O
this	O
side	O
effect	O
of	O
quetiapine	I-Entity
,	O
but	O
possible	O
risk	O
factors	O
are	O
seldom	O
discussed	O
and	O
identified	O
.	O

A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	B-Entity
carcinoma	I-Entity
that	O
developed	O
neutropenia	I-Entity
after	O
treatment	O
with	O
quetiapine	I-Entity
is	O
described	O
here	O
.	O

CASE	O
REPORT	O
:	O
A	O
62-year	O
-	O
old	O
Taiwanese	O
widow	O
with	O
bipolar	B-Entity
disorder	I-Entity
was	O
diagnosed	O
with	O
hepatocellular	B-Entity
carcinoma	I-Entity
at	O
age	O
60	O
.	O

She	O
developed	O
leucopenia	I-Entity
after	O
being	O
treated	O
with	O
quetiapine	I-Entity
.	O

After	O
quetiapine	I-Entity
was	O
discontinued	O
,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal	O
.	O

CONCLUSIONS	O
:	O
Although	O
neutropenia	I-Entity
is	O
not	O
a	O
common	O
side	O
effect	O
of	O
quetiapine	I-Entity
,	O
physicians	O
should	O
be	O
cautious	O
about	O
its	O
presentation	O
and	O
associated	O
risk	O
factors	O
.	O

Hepatic	B-Entity
dysfunction	I-Entity
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors	O
,	O
and	O
concomitant	O
fever	I-Entity
may	O
be	O
a	O
diagnostic	O
marker	O
for	O
adverse	O
reaction	O
to	O
quetiapine	I-Entity
.	O



Lateral	O
antebrachial	O
cutaneous	O
neuropathy	I-Entity
after	O
steroid	I-Entity
injection	O
at	O
lateral	O
epicondyle	O
.	O

This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	I-Entity
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
steroid	I-Entity
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	B-Entity
epicondylitis	I-Entity
in	O
a	O
40-year	O
-	O
old	O
woman	O
.	O

A	O
40-year	O
-	O
old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	I-Entity
over	O
her	O
right	O
lateral	O
forearm	O
;	O
the	O
paresthesia	I-Entity
had	O
occurred	O
after	O
a	O
steroid	I-Entity
injection	O
in	O
the	O
right	O
lateral	O
epicondyle	O
3	O
months	O
before	O
.	O

Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	I-Entity
was	O
diminished	O
over	O
the	O
lateral	O
side	O
of	O
the	O
right	O
forearm	O
and	O
wrist	O
area	O
.	O

This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	I-Entity
injection	O
for	O
the	O
treatment	O
of	O
lateral	B-Entity
epicondylitis	I-Entity
.	O



Curcumin	I-Entity
prevents	O
maleate	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	I-Entity
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I.	O
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	I-Entity
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-Entity
injury	I-Entity
induced	O
by	O
maleate	I-Entity
was	O
evaluated	O
.	O

Tubular	O
proteinuria	I-Entity
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	I-Entity
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O

Maleate	I-Entity
-	O
induced	O
renal	B-Entity
injury	I-Entity
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	I-Entity
,	O
sodium	I-Entity
,	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acetyl	O
b	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
,	O
upregulation	O
of	O
kidney	B-Entity
injury	I-Entity
molecule	O
(	O
KIM)-1	O
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin-2	O
expression	O
besides	O
of	O
necrosis	I-Entity
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels	O
.	O

Maleate	I-Entity
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	I-Entity
species	O
(	O
ROS	O
)	O
production	O
in	O
LLC	O
-	O
PK1	O
cells	O
in	O
culture	O
.	O

In	O
addition	O
,	O
maleate	I-Entity
treatment	O
reduced	O
oxygen	I-Entity
consumption	O
in	O
ADP	I-Entity
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	I-Entity
/	O
glutamate	I-Entity
as	O
substrate	O
.	O

All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	I-Entity
.	O

It	O
is	O
concluded	O
that	O
curcumin	I-Entity
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	I-Entity
-	O
induced	O
nephropathy	I-Entity
and	O
in	O
vitro	O
cell	O
damage	O
.	O

The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	I-Entity
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	O
production	O
.	O



Incidence	O
of	O
solid	O
tumours	I-Entity
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	I-Entity
insecticide	O
diazinon	I-Entity
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
an	O
updated	O
analysis	O
.	O

OBJECTIVE	O
:	O
Diazinon	I-Entity
,	O
a	O
common	O
organophosphate	I-Entity
insecticide	O
with	O
genotoxic	O
properties	O
,	O
was	O
previously	O
associated	O
with	O
lung	B-Entity
cancer	I-Entity
in	O
the	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
cohort	O
,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon	I-Entity
-	O
associated	O
cancer	I-Entity
risk	O
.	O

We	O
used	O
updated	O
diazinon	I-Entity
exposure	O
and	O
cancer	I-Entity
incidence	O
information	O
to	O
evaluate	O
solid	O
tumour	I-Entity
risk	O
in	O
the	O
AHS	O
.	O

Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	I-Entity
use	O
at	O
enrolment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cancer	I-Entity
incidence	O
was	O
assessed	O
through	O
2010(North	O
Carolina)/2011(Iowa	O
)	O
.	O

Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure	O
-	O
response	O
patterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(	O
RRs	O
)	O
and	O
95%	O
CI	O
for	O
cancer	I-Entity
sites	O
with	O
>	O
10	O
exposed	O
cases	O
for	O
both	O
lifetime	O
(	O
LT	O
)	O
exposure	O
days	O
and	O
intensity	O
-	O
weighted	O
(	O
IW	O
)	O
lifetime	O
exposure	O
days	O
(	O
accounting	O
for	O
factors	O
impacting	O
exposure	O
)	O
.	O

We	O
observed	O
elevated	O
lung	B-Entity
cancer	I-Entity
risks	O
(	O
N=283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR=1.60	O
;	O
95%	O
CI	O
1.11	O
to	O
2.31	O
;	O
Ptrend=0.02	O
)	O
and	O
IW	O
days	O
of	O
diazinon	I-Entity
use	O
(	O
RR=1.41	O
;	O
95%	O
CI	O
0.98	O
to	O
2.04	O
;	O
Ptrend=0.08	O
)	O
.	O

Kidney	B-Entity
cancer	I-Entity
(	O
N=94	O
)	O

risks	O
were	O
non	O
-	O
significantly	O
elevated	O
(	O
RRLT	O
days=1.77	O
;	O
95%	O
CI	O
0.90	O
to	O
3.51	O
;	O
Ptrend=0.09	O
;	O
RRIW	O
days	O
1.37	O
;	O
95%	O
CI	O
0.64	O
to	O
2.92	O
;	O
Ptrend=0.50	O
)	O
,	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	B-Entity
cancer	I-Entity
(	O
N=656	O
)	O
.	O

Our	O
updated	O
evaluation	O
of	O
diazinon	I-Entity
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	B-Entity
cancer	I-Entity
risk	O
.	O

Newly	O
identified	O
links	O
to	O
kidney	B-Entity
cancer	I-Entity
and	O
associations	O
with	O
aggressive	O
prostate	B-Entity
cancer	I-Entity
require	O
further	O
evaluation	O
.	O



Associations	O
of	O
Ozone	I-Entity
and	O
PM2.5	O
Concentrations	O
With	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Among	O
Participants	O
in	O
the	O
Agricultural	O
Health	O
Study	O
.	O

This	O
study	O
describes	O
associations	O
of	O
ozone	I-Entity
and	O
fine	O
particulate	B-Entity
matter	I-Entity
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
observed	O
among	O
farmers	O
in	O
North	O
Carolina	O
and	O
Iowa	O
.	O

:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self	O
-	O
reported	O
,	O
doctor	O
-	O
diagnosed	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

We	O
observed	O
positive	O
associations	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
with	O
ozone	I-Entity
(	O
odds	O
ratio	O
=	O
1.39	O
;	O
95%	O
CI	O
:	O
0.98	O
to	O
1.98	O
)	O
and	O
fine	O
particulate	B-Entity
matter	I-Entity
(	O
odds	O
ratio	O
=	O
1.34	O
;	O
95%	O
CI	O
:	O
0.93	O
to	O
1.93	O
)	O
in	O
North	O
Carolina	O
but	O
not	O
in	O
Iowa	O
.	O

The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
risk	O
is	O
supported	O
by	O
experimental	O
data	O
demonstrating	O
damage	O
to	O
dopaminergic	O
neurons	O
at	O
relevant	O
concentrations	O
.	O



Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	I-Entity
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	I-Entity
exposure	O
.	O

UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	I-Entity
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B-Entity
growth	I-Entity
retardation	I-Entity
(	O
IUGR	I-Entity
)	O
of	O
offspring	O
.	O

Recent	O
research	O
suggested	O
that	O
IUGR	I-Entity
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	I-Entity
.	O

However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	I-Entity
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	I-Entity
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O

A	O
rat	O
model	O
of	O
IUGR	I-Entity
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O

The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	I-Entity
as	O
well	O
as	O
interstitial	B-Entity
fibrosis	I-Entity
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	I-Entity
and	O
urine	O
protein	O
.	O

Renal	O
angiotensin	B-Entity
II	I-Entity
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	O
angiotensin	B-Entity
II	I-Entity
receptor	O
type	O
1a	O
(	O
AT1aR)/AT2R	O
expression	O
ratio	O
was	O
increased	O
.	O

Moreover	O
,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	O
-	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF)/tyrosine	I-Entity
kinase	O
receptor	O
(	O
c	O
-	O
Ret	O
)	O
signaling	O
pathway	O
.	O

These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B-Entity
of	I-Entity
fetal	I-Entity
kidneys	I-Entity
as	O
well	O
as	O
glomerulosclerosis	I-Entity
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	I-Entity
.	O



1,3-Butadiene	I-Entity
,	O
CML	I-Entity
and	O
the	O
t(9:22	O
)	O

Epidemiological	O
studies	O
of	O
1,3-butadiene	I-Entity
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	B-Entity
myeloid	I-Entity
leukemia	I-Entity
(	O
CML	I-Entity
)	O
.	O

CML	I-Entity
has	O
a	O
well	O
-	O
documented	O
association	O
with	O
ionizing	O
radiation	O
,	O
but	O
reports	O
of	O
associations	O
with	O
chemical	O
exposures	O
have	O
been	O
questioned	O
.	O

Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML	I-Entity
-	O
associated	O
t(9:22	O
)	O

translocation	O
(	O
Philadelphia	B-Entity
chromosome	I-Entity
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O

We	O
have	O
proposed	O
that	O
1,3-butadiene	I-Entity
metabolites	O
be	O
so	O
tested	O
as	O
a	O
reality	O
check	O
on	O
the	O
epidemiological	O
reports	O
.	O

Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1,3-butadiene	I-Entity
are	O
discussed	O
.	O



Cancer	I-Entity
incidence	O
and	O
metolachlor	I-Entity
use	O
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O

Metolachlor	I-Entity
,	O
a	O
widely	O
used	O
herbicide	O
,	O
is	O
classified	O
as	O
a	O
Group	O
C	O
carcinogen	O
by	O
the	O
U.S.	O
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	B-Entity
neoplasms	I-Entity
in	O
female	O
rats	O
.	O

Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	I-Entity
have	O
been	O
limited	O
.	O

We	O
evaluated	O
cancer	I-Entity
incidence	O
through	O
2010/2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49,616	O
applicators	O
,	O
53%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	I-Entity
.	O

We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	I-Entity
use	O
(	O
lifetime	O
days	O
,	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
)	O
and	O
cancer	I-Entity
incidence	O
.	O

We	O
saw	O
no	O
association	O
between	O
metolachlor	I-Entity
use	O
and	O
incidence	O
of	O
all	O
cancers	I-Entity
combined	O
(	O
n	O
=	O
5,701	O
with	O
a	O
5-year	O
lag	O
)	O
or	O
most	O
site	O
-	O
specific	O
cancers	I-Entity
.	O

For	O
liver	B-Entity
cancer	I-Entity
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers	O
,	O
elevations	O
observed	O
at	O
higher	O
categories	O
of	O
use	O
were	O
not	O
statistically	O
significant	O
.	O

However	O
,	O
trends	O
for	O
both	O
lifetime	O
and	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
of	O
metolachor	I-Entity
use	O
were	O
positive	O
and	O
statistically	O
significant	O
with	O
an	O
unexposed	O
reference	O
group	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	B-Entity
cell	I-Entity
lymphoma	I-Entity
,	O
but	O
no	O
other	O
lymphoma	I-Entity
subtypes	O
.	O

An	O
earlier	O
suggestion	O
of	O
increased	O
lung	B-Entity
cancer	I-Entity
risk	O
at	O
high	O
levels	O
of	O
metolachlor	I-Entity
use	O
in	O
this	O
cohort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	I-Entity
and	O
liver	B-Entity
cancer	I-Entity
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	B-Entity
neoplasms	I-Entity
in	O
some	O
animal	O
studies	O
.	O

However	O
,	O
our	O
findings	O
for	O
both	O
liver	B-Entity
cancer	I-Entity
and	O
follicular	O
cell	O
lymphoma	I-Entity
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	I-Entity
use	O
from	O
other	O
factors	O
.	O



Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	I-Entity

Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B-Entity
arsenic	I-Entity
(	O
iAs	I-Entity
)	O
in	O
their	O
drinking	O
water	O
.	O

Inorganic	B-Entity
As	I-Entity
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	I-Entity
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	I-Entity
.	O

This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	I-Entity
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	I-Entity
exposure	O
.	O

DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	I-Entity
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	I-Entity
exposure	O
elicits	O
latent	O
carcinogenic	O
effects	O
.	O

Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	I-Entity
exposure	O
and	O
cancer	I-Entity
development	O
later	O
in	O
life	O
.	O



On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N	O
-	O
substituted	O
piperazine	I-Entity
derivative	O
of	O
trans-2-amino-3-hydroxy-1	B-Entity
,	I-Entity
2	I-Entity
,	I-Entity
3	I-Entity
,	I-Entity
4-tetrahydroanaphthalene	I-Entity
.	O

The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	B-Entity
hydrochloride	I-Entity
,	O
referred	O
to	O
as	O
P11	I-Entity
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
anaesthesized	O
rabbits	O
.	O

Four	O
types	O
of	O
experimental	O
arrhythmia	I-Entity
are	O
used	O
--	O
with	O
BaCl2	I-Entity
,	O
with	O
chloroform	I-Entity
-	O
adrenaline	I-Entity
,	O
with	O
strophantine	B-Entity
G	I-Entity
and	O
with	O
aconitine	I-Entity
.	O

The	O
compound	O
P11	I-Entity
is	O
introduced	O
in	O
doses	O
of	O
0.25	O
and	O
0.50	O
mg	O
/	O
kg	O
intravenously	O
and	O
10	O
mg	O
/	O
kg	O
orally	O
.	O

The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	I-Entity
used	O
,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	I-Entity
induced	O
by	O
chloroform	I-Entity
-	O
adrenaline	I-Entity
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	I-Entity
(	O
in	O
84	O
per	O
cent	O
)	O
.	O



Experimental	O
progressive	O
muscular	B-Entity
dystrophy	I-Entity
and	O
its	O
treatment	O
with	O
high	O
doses	O
anabolizing	O
agents	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	B-Entity
dystrophy	I-Entity
in	O
man	O
.	O

Myopathy	I-Entity
due	O
to	O
lack	O
of	O
vitamin	B-Entity
E	I-Entity
and	O
myopathy	I-Entity
induced	O
by	O
certain	O
viruses	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
pathologically	O
with	O
the	O
human	O
form	O
.	O

The	O
authors	O
induced	O
myodystrophy	I-Entity
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	B-Entity
E.	I-Entity
The	O
pharmacological	O
characteristics	O
of	O
vitamin	B-Entity
E	I-Entity
and	O
the	O
degenerative	O
changes	O
brought	O
about	O
by	O
its	O
deficiency	O
,	O
especially	O
in	O
the	O
muscles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	I-Entity
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	I-Entity
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre	O
,	O
Florence	O
.	O

The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	I-Entity
patients	O
by	O
using	O
anabolizing	O
steroids	I-Entity
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	I-Entity
,	O
CIBA	I-Entity
)	O
at	O
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	I-Entity
by	O
a	O
diet	O
deficient	O
in	O
vitamin	B-Entity
E.	I-Entity

In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	O
weight	O
(	O
increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	O
a	O
dose	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolizing	O
agent	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histological	O
changes	O
due	O
to	O
""""	O
regenerative	O
""""	O
changes	O
in	O
the	O
muscle	O
tissue	O
,	O
which	O
however	O
maintained	O
its	O
myopathic	I-Entity
characteristics	O
in	O
the	O
control	O
animals	O
that	O
were	O
not	O
treated	O
with	O
the	O
anabolizing	O
agent	O
.	O

The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	I-Entity
in	O
experimental	O
myopathic	B-Entity
disease	I-Entity
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field	O
,	O
where	O
high	O
dosage	O
can	O
not	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility	O
;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
stage	O
vis	O
-	O
a	O
-	O
vis	O
the	O
""""	O
regeneration	O
""""	O
of	O
the	O
muscle	O
tissue	O
;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	B-Entity
E	I-Entity
but	O
something	O
as	O
yet	O
unknown	O
.	O



Fetal	O
risks	O
due	O
to	O
warfarin	I-Entity
therapy	O
during	O
pregnancy	O
.	O

Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	I-Entity
during	O
pregnancy	O
.	O

In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	I-Entity
with	O
heparin	I-Entity
.	O

The	O
baby	O
died	O
of	O
cerebral	B-Entity
and	I-Entity
pulmonary	I-Entity
hemorrhage	I-Entity
.	O

The	O
baby	O
showed	O
warfarin	I-Entity
-	O
induced	O
embryopathy	I-Entity
with	O
nasal	B-Entity
hypoplasia	I-Entity
and	O
stippled	B-Entity
epiphyses	I-Entity
(	O
chondrodysplasia	B-Entity
punctata	I-Entity
)	O
.	O

Nasal	B-Entity
hypoplasia	I-Entity
with	O
or	O
without	O
stippled	B-Entity
epiphyses	I-Entity
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	I-Entity
during	O
the	O
first	O
trimester	O
,	O
and	O
a	O
causal	O
association	O
is	O
probable	O
.	O



Isradipine	I-Entity
treatment	O
for	O
hypertension	I-Entity
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

A	O
6-week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	I-Entity
treatment	O
was	O
conducted	O
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	I-Entity
entered	O
the	O
study	O
.	O

The	O
main	O
side	O
-	O
effects	O
were	O
headache	I-Entity
,	O
dizziness	I-Entity
,	O
palpitation	I-Entity
and	O
flushing	I-Entity
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	I-Entity
or	O
with	O
placebo	O
.	O

Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	B-Entity
hypotension	I-Entity
.	O



Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	I-Entity
in	O
asthmatics	I-Entity
.	O

High	O
doses	O
of	O
inhaled	O
salbutamol	I-Entity
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	I-Entity
,	O
and	O
are	O
associated	O
with	O
dose	O
-	O
dependent	O
systemic	O
beta	O
-	O
adrenoceptor	O
responses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	I-Entity
.	O

Twelve	O
asthmatic	I-Entity
patients	O
(	O
FEV1	O
,	O
81	O

were	O
given	O
a	O
14-day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	I-Entity
(	O
HDS	O
)	O
,	O
4,000	O
micrograms	O
daily	O
,	O
low	O
dose	O
inhaled	O
salbutamol	I-Entity
(	O
LDS	O
)	O
,	O
800	O
micrograms	O
daily	O
,	O
or	O
placebo	O
(	O
PI	O
)	O
by	O
metered	O
-	O
dose	O
inhaler	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
crossover	O
design	O
.	O

During	O
the	O
14-day	O
run	O
-	O
in	O
and	O
during	O
washout	O
periods	O
,	O
inhaled	O
beta	O
-	O
agonists	O
were	O
withheld	O
and	O
ipratropium	B-Entity
bromide	I-Entity
was	O
substituted	O
for	O
rescue	O
purposes	O
.	O

chronotropic	O
(	O
HR	O
)	O
,	O
tremor	I-Entity
,	O
and	O
metabolic	O
(	O
K	I-Entity
,	O
Glu	I-Entity
)	O
responses	O
were	O
measured	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4,000	O
micrograms	O
)	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
K	I-Entity
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
Glu	I-Entity
(	O
p	O
less	O
than	O
0.005	O
)	O
were	O
attenuated	O
after	O
treatment	O
with	O
HDS	O
compared	O
with	O
PI	O
.	O

There	O
were	O
also	O
differences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
Glu	I-Entity
(	O
p	O
less	O
than	O
0.05	O
)	O
responses	O
.	O

Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS	O
:	O
tremor	I-Entity
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
palpitations	I-Entity
(	O
p	O
less	O
than	O
0.001).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Increased	O
anxiogenic	O
effects	O
of	O
caffeine	I-Entity
in	O
panic	B-Entity
disorders	I-Entity
.	O

The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavioral	O
ratings	O
,	O
somatic	O
symptoms	O
,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3-methoxy-4-hydroxyphenethyleneglycol	I-Entity
(	O
MHPG	I-Entity
)	O
and	O
cortisol	I-Entity
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM	O
-	O
III	O
criteria	O
for	O
agoraphobia	I-Entity
with	O
panic	B-Entity
attacks	I-Entity
or	O
panic	B-Entity
disorder	I-Entity
.	O

Caffeine	I-Entity
produced	O
significantly	O
greater	O
increases	O
in	O
subject	O
-	O
rated	O
anxiety	I-Entity
,	O
nervousness	O
,	O
fear	O
,	O
nausea	I-Entity
,	O
palpitations	I-Entity
,	O
restlessness	I-Entity
,	O
and	O
tremors	I-Entity
in	O
the	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O

In	O
the	O
patients	O
,	O
but	O
not	O
the	O
healthy	O
subjects	O
,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	I-Entity
levels	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	I-Entity
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	B-Entity
attacks	I-Entity
.	O

Caffeine	I-Entity
did	O
not	O
alter	O
plasma	O
MHPG	I-Entity
levels	O
in	O
either	O
the	O
healthy	O
subjects	O
or	O
patients	O
.	O

Caffeine	I-Entity
increased	O
plasma	O
cortisol	I-Entity
levels	O
equally	O
in	O
the	O
patient	O
and	O
healthy	O
groups	O
.	O

Because	O
caffeine	I-Entity
is	O
an	O
adenosine	I-Entity
receptor	O
antagonist	O
,	O
these	O
results	O
suggest	O
that	O
some	O
panic	B-Entity
disorder	I-Entity
patients	O
may	O
have	O
abnormalities	B-Entity
in	I-Entity
neuronal	I-Entity
systems	I-Entity
involving	O
adenosine	I-Entity
.	O

Patients	O
with	O
anxiety	B-Entity
disorders	I-Entity
may	O
benefit	O
by	O
avoiding	O
caffeine	I-Entity
-	O
containing	O
foods	O
and	O
beverages	O
.	O



intestinal	O
polypeptide	O
:	O
decrease	O
with	O
heart	B-Entity
failure	I-Entity
.	O

Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	B-Entity
failure	I-Entity
in	O
two	O
canine	O
models	O
.	O

In	O
the	O
first	O
,	O
cobalt	I-Entity
cardiomyopathy	I-Entity
was	O
induced	O
in	O
eight	O
dogs	O
;	O
VIP	O
(	O
by	O
radioimmunoassay	O
)	O
decreased	O
from	O
35	O
+	O
/-	O

In	O
six	O
dogs	O
with	O
doxorubicin	I-Entity
-	O
induced	O
heart	B-Entity
failure	I-Entity
,	O
VIP	O
decreased	O
from	O
31	O
+	O
/-	O

In	O
addition	O
,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(	O
five	O
with	O
rheumatic	B-Entity
disease	I-Entity
,	O
nine	O
with	O
myxomatous	B-Entity
degeneration	I-Entity
)	O
receiving	O
mitral	O
valve	O
prostheses	O
.	O

The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	B-Entity
disease	I-Entity
(	O
one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses	O
)	O
(	O
6.3	O
+	O
/-	O

The	O
hearts	O
without	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
(	O
average	O
ejection	O
fraction	O
of	O
this	O
group	O
62%	O
+	O
/-	O

7.9	O
pg	O
/	O
mg	O
protein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	B-Entity
disease	I-Entity
and	O
the	O
hearts	O
of	O
patients	O
receiving	O
a	O
transplant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Myocardial	O
catecholamines	I-Entity
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0.57	O
,	O
P	O
less	O
than	O
0.05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	I-Entity
was	O
noted.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	I-Entity
among	O
inbred	O
mice	O
.	O

Acute	O
toxic	O
dosage	O
-	O
dependent	O
behavioral	O
effects	O
of	O
caffeine	I-Entity
were	O
compared	O
in	O
adult	O
males	O
from	O
seven	O
inbred	O
mouse	O
strains	O
(	O
A	O
/	O
J	O
,	O
BALB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C57BL/6J	O
,	O
DBA/2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C57BL/6J	O
,	O
chosen	O
as	O
a	O
""""	O
prototypic	O
""""	O
mouse	O
strain	O
,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffeine	I-Entity
doses	O
.	O

Five	O
phenotypic	O
characteristics	O
--	O
locomotor	O
activity	O
,	O
righting	O
ability	O
,	O
clonic	B-Entity
seizure	I-Entity
induction	O
,	O
stress	O
-	O
induced	O
lethality	O
,	O
death	O
without	O
external	O
stress	O
--	O
were	O
scored	O
at	O
various	O
caffeine	I-Entity
doses	O
in	O
drug	O
-	O
naive	O
animals	O
under	O
empirically	O
optimized	O
,	O
rigidly	O
constant	O
experimental	O
conditions	O
.	O

Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume	O
/	O
g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	I-Entity
in	O
doses	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	B-Entity
seizures	I-Entity
was	O
scored	O
as	O
to	O
time	O
of	O
onset	O
and	O
severity	O
for	O
20	O
min	O
after	O
drug	O
administration	O
.	O

When	O
these	O
proceeded	O
to	O
tonic	B-Entity
seizures	I-Entity
,	O
death	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water	O
,	O
and	O
death	O
-	O
producing	O
tonic	B-Entity
seizures	I-Entity
were	O
scored	O
for	O
2	O
min	O
.	O

In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	I-Entity
administration	O
.	O

By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria	O
,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	I-Entity
doses	O
were	O
observed	O
between	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	I-Entity
testing	O
of	O
alkylxanthines	I-Entity
in	O
a	O
single	O
mouse	O
strain	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toxic	O
responses	O
of	O
the	O
central	O
nervous	O
system	O
to	O
this	O
class	O
of	O
compounds	O
are	O
genetically	O
influenced	O
in	O
mammals	O
.	O



Invasive	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
pelvis	I-Entity
following	O
cyclophosphamide	I-Entity
therapy	O
for	O
nonmalignant	O
disease	O
.	O

A	O
47-year	O
-	O
old	O
woman	O
with	O
right	O
hydroureteronephrosis	I-Entity
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	O
hematuria	I-Entity
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	I-Entity
for	O
cerebral	B-Entity
vasculitis	I-Entity
.	O

A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	I-Entity
.	O

The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
pelvis	I-Entity
.	O

Although	O
the	O
ability	O
of	O
cyclophosphamide	I-Entity
to	O
cause	O
hemorrhagic	B-Entity
cystitis	I-Entity
and	O
urine	O
cytologic	O
abnormalities	O
indistinguishable	O
from	O
high	O
grade	O
carcinoma	I-Entity
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
urinary	I-Entity
tract	I-Entity
.	O

Twenty	O
carcinomas	B-Entity
of	I-Entity
the	I-Entity
urinary	I-Entity
bladder	I-Entity
and	O
one	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
prostate	I-Entity
have	O
been	O
reported	O
in	O
association	O
with	O
its	O
use	O
.	O

The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
pelvis	I-Entity
reported	O
in	O
association	O
with	O
cyclophosphamide	I-Entity
treatment	O
.	O

It	O
is	O
the	O
third	O
urinary	B-Entity
tract	I-Entity
cancer	I-Entity
reported	O
in	O
association	O
with	O
cyclophosphamide	I-Entity
treatment	O
for	O
nonmalignant	O
disease	O
.	O

The	O
association	O
of	O
the	O
tumor	I-Entity
with	O
preexisting	O
hydroureteronephrosis	I-Entity
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	I-Entity
.	O

Patients	O
who	O
are	O
candidates	O
for	O
long	O
-	O
term	O
cyclophosphamide	I-Entity
treatment	O
should	O
be	O
routinely	O
evaluated	O
for	O
obstructive	B-Entity
uropathy	I-Entity
.	O



Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	I-Entity
administered	O
after	O
normal	O
vaginal	O
birth	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carbetocin	I-Entity
(	O
a	O
long	O
-	O
acting	O
synthetic	O
analogue	O
of	O
oxytocin	I-Entity
)	O
,	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	O
term	O
.	O

Carbetocin	I-Entity
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	O
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	O
term	O
.	O

Dosage	O
groups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
microg	O
carbetocin	I-Entity
were	O
assigned	O
to	O
blocks	O
of	O
three	O
women	O
according	O
to	O
the	O
continual	O
reassessment	O
method	O
(	O
CRM	O
)	O
.	O

Recorded	O
were	O
dose	O
-	O
limiting	O
adverse	O
events	O
:	O
hyper-	B-Entity
or	I-Entity
hypotension	I-Entity
(	O
three	O
)	O
,	O
severe	O
abdominal	B-Entity
pain	I-Entity
(	O
0	O
)	O
,	O
vomiting	I-Entity
(	O
0	O
)	O
and	O
retained	B-Entity
placenta	I-Entity
(	O
four	O
)	O
.	O

Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B-Entity
loss	I-Entity
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion	O
.	O

Maximum	O
blood	B-Entity
loss	I-Entity
was	O
greatest	O
at	O
the	O
upper	O
and	O
lower	O
dose	O
levels	O
,	O
and	O
lowest	O
in	O
the	O
70	O
-	O
125	O
microg	O
dose	O
range	O
.	O

Four	O
out	O
of	O
six	O
cases	O
with	O
blood	B-Entity
loss	I-Entity
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
microg	O
group	O
.	O

The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
microg	O
carbetocin	I-Entity
.	O



A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	I-Entity
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
.	O

STUDY	O
OBJECTIVE	O
:	O
Chest	B-Entity
pain	I-Entity
in	O
the	O
setting	O
of	O
cocaine	I-Entity
use	O
poses	O
a	O
diagnostic	O
dilemma	O
.	O

Dobutamine	I-Entity
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	O
ischemia	I-Entity
.	O

Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	I-Entity
in	O
the	O
setting	O
of	O
cocaine	I-Entity
use	O
,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
.	O

Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	I-Entity
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	B-Entity
pain	I-Entity
and	O
had	O
a	O
normal	O
ECG	O
and	O
tropinin	O
I	O
level	O
.	O

Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	I-Entity
toxicity	I-Entity
were	O
excluded	O
from	O
the	O
study	O
.	O

Two	O
patients	O
had	O
inadequate	O
resting	O
images	O
,	O
one	O
DSE	O
was	O
terminated	O
because	O
of	O
inferior	O
hypokinesis	I-Entity
,	O
another	O
DSE	O
was	O
terminated	O
because	O
of	O
a	O
rate	O
-	O
related	O
atrial	O
conduction	O
deficit	O
,	O
and	O
1	O
patient	O
did	O
not	O
reach	O
the	O
target	O
heart	O
rate	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	I-Entity
(	O
excluding	O
sinus	B-Entity
tachycardia	I-Entity
)	O
.	O

Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
13	O
(	O
65%	O
)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	I-Entity
to	O
reach	O
their	O
target	O
heart	O
rates	O
.	O

No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	I-Entity
was	O
administered	O
to	O
patients	O
with	O
cocaine	I-Entity
-	O
related	O
chest	B-Entity
pain	I-Entity
.	O



Amiodarone	I-Entity
-	O
induced	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
during	O
bladder	O
irrigation	O
:	O
an	O
unusual	O
presentation	O
--	O
a	O
case	O
report	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(	O
within	O
4	O
days	O
)	O
development	O
of	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TdP	I-Entity
)	O
associated	O
with	O
oral	O
amiodarone	I-Entity
therapy	O
.	O

Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	I-Entity
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	I-Entity
and	O
digoxin	I-Entity
excess	O
.	O

Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP.	I-Entity
It	O
is	O
well	O
known	O
that	O
bradycardia	I-Entity
exacerbates	O
acquired	O
TdP.	I-Entity

The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	I-Entity
therapy	O
resulted	O
in	O
amiodarone	I-Entity
-	O
induced	O
proarrhythmia	I-Entity
.	O

In	O
the	O
absence	O
of	O
amiodarone	I-Entity
therapy	O
,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	I-Entity
despite	O
hypokalemia	I-Entity
and	O
hypomagnesemia	I-Entity
.	O



Acute	B-Entity
renal	I-Entity
insufficiency	I-Entity
after	O
high	O
-	O
dose	O
melphalan	I-Entity
in	O
patients	O
with	O
primary	B-Entity
systemic	I-Entity
amyloidosis	I-Entity
during	O
stem	O
cell	O
transplantation	O
.	O

Patients	O
with	O
primary	B-Entity
systemic	I-Entity
amyloidosis	I-Entity
(	O
AL	I-Entity
)	O
have	O
a	O
poor	O
prognosis	O
.	O

High	O
-	O
dose	O
intravenous	O
melphalan	I-Entity
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy	O
,	O
but	O
treatment	O
mortality	O
can	O
be	O
high	O
.	O

The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	B-Entity
renal	I-Entity
insufficiency	I-Entity
immediately	O
after	O
melphalan	I-Entity
conditioning	O
.	O

METHODS	O
:	O
Consecutive	O
AL	I-Entity
patients	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrospectively	O
.	O

Acute	B-Entity
renal	I-Entity
insufficiency	I-Entity
(	O
ARI	I-Entity
)	O
after	O
high	O
-	O
dose	O
melphalan	I-Entity
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0.5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
serum	O
creatinine	I-Entity
level	O
that	O
is	O
greater	O
than	O
50%	O
of	O
baseline	O
immediately	O
after	O
conditioning	O
.	O

Of	O
the	O
80	O
patients	O
studied	O
,	O
ARI	I-Entity
developed	O
in	O
18.8%	O
of	O
the	O
patients	O
after	O
high	O
-	O
dose	O
melphalan	I-Entity
.	O

Univariate	O
analysis	O
identified	O
age	O
,	O
hypoalbuminemia	I-Entity
,	O
heavy	O
proteinuria	I-Entity
,	O
diuretic	O
use	O
,	O
and	O
urine	O
sediment	O
score	O
(	O
>	O
3	O
)	O
as	O
risk	O
factors	O
.	O

Patients	O
who	O
had	O
ARI	I-Entity
after	O
high	O
-	O
dose	O
melphalan	I-Entity
underwent	O
dialysis	O
more	O
often	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
had	O
a	O
worse	O
1-year	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
timing	O
of	O
renal	B-Entity
injury	I-Entity
strongly	O
suggests	O
melphalan	I-Entity
as	O
the	O
causative	O
agent	O
.	O

Ongoing	O
tubular	B-Entity
injury	I-Entity
may	O
be	O
a	O
prerequisite	O
for	O
renal	B-Entity
injury	I-Entity
by	O
melphalan	I-Entity
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment	O
.	O

Development	O
of	O
ARI	I-Entity
adversely	O
affected	O
the	O
outcome	O
after	O
PBSCT	O
.	O

Effective	O
preventive	O
measures	O
may	O
help	O
decrease	O
the	O
treatment	O
mortality	O
of	O
PBSCT	O
in	O
AL	I-Entity
patients	O
.	O



Impaired	B-Entity
fear	I-Entity
recognition	I-Entity
in	O
regular	O
recreational	O
cocaine	I-Entity
users	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	I-Entity
users	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
groups	O
,	O
comprised	O
of	O
21	O
cocaine	I-Entity
naive	O
participants	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
cocaine	I-Entity
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recreational	O
cocaine	I-Entity
(	O
RC	O
)	O
users	O
,	O
were	O
compared	O
.	O

There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
""""	O
eyes	O
task	O
""""	O
performance	O
,	O
but	O
the	O
RC	O
group	O
,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	O
group	O
,	O
exhibited	O
impaired	B-Entity
fear	I-Entity
recognition	I-Entity
accuracy	O
compared	O
to	O
the	O
OC	O
and	O
CN	O
groups	O
.	O

The	O
selective	O
deficit	B-Entity
in	I-Entity
fear	I-Entity
recognition	I-Entity
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
can	O
not	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	I-Entity
,	O
or	O
ecstasy	I-Entity
,	O
because	O
recent	O
and	O
less	O
recent	O
users	O
of	O
these	O
drugs	O
within	O
this	O
group	O
were	O
similarly	O
impaired	O
.	O

Possible	O
parallels	O
between	O
RC	O
users	O
and	O
psychopaths	I-Entity
with	O
respect	O
to	O
impaired	B-Entity
fear	I-Entity
recognition	I-Entity
,	O
amygdala	B-Entity
dysfunction	I-Entity
,	O
and	O
etiology	O
are	O
discussed	O
.	O



Corneal	B-Entity
ulcers	I-Entity
associated	O
with	O
aerosolized	O
crack	B-Entity
cocaine	I-Entity
use	O
.	O

We	O
report	O
4	O
cases	O
of	O
corneal	B-Entity
ulcers	I-Entity
associated	O
with	O
drug	B-Entity
abuse	I-Entity
.	O

The	O
pathogenesis	O
of	O
these	O
ulcers	I-Entity
and	O
management	O
of	O
these	O
patients	O
are	O
also	O
reviewed	O
.	O

METHODS	O
:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	B-Entity
ulcers	I-Entity
associated	O
with	O
drug	B-Entity
abuse	I-Entity
seen	O
at	O
our	O
institution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESULTS	O
:	O
Four	O
patients	O
with	O
corneal	B-Entity
ulcers	I-Entity
associated	O
with	O
crack	B-Entity
cocaine	I-Entity
use	O
were	O
reviewed	O
.	O

All	O
corneal	B-Entity
ulcers	I-Entity
were	O
cultured	O
,	O
and	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
intensive	O
topical	O
antibiotic	O
treatment	O
.	O

Each	O
patient	O
received	O
comprehensive	O
health	O
care	O
,	O
including	O
medical	O
and	O
substance	B-Entity
abuse	I-Entity
consultations	O
.	O

The	O
infections	I-Entity
responded	O
to	O
antibiotic	O
treatment	O
.	O

Two	O
patients	O
needed	O
a	O
lateral	O
tarsorrhaphy	O
for	O
persistent	O
epithelial	B-Entity
defects	I-Entity
.	O

CONCLUSIONS	O
:	O
Aerosolized	O
crack	B-Entity
cocaine	I-Entity
use	O
can	O
be	O
associated	O
with	O
the	O
development	O
of	O
corneal	B-Entity
ulcers	I-Entity
.	O

Drug	B-Entity
abuse	I-Entity
provides	O
additional	O
challenges	O
for	O
management	O
.	O

Not	O
only	O
treatment	O
of	O
their	O
infections	I-Entity
but	O
also	O
the	O
overall	O
poor	O
health	O
of	O
the	O
patients	O
and	O
increased	O
risk	O
of	O
noncompliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	B-Entity
abuse	I-Entity
,	O
improve	O
their	O
overall	O
health	O
,	O
and	O
prevent	O
future	O
corneal	O
complications	O
.	O



Levetiracetam	I-Entity
as	O
an	O
adjunct	O
to	O
phenobarbital	I-Entity
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	B-Entity
epilepsy	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
assess	O
pharmacokinetics	O
,	O
efficacy	O
,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	I-Entity
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	I-Entity
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	B-Entity
epilepsy	I-Entity
.	O

ANIMALS	O
:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	B-Entity
epilepsy	I-Entity
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	I-Entity
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	I-Entity
.	O

Cats	O
were	O
treated	O
with	O
levetiracetam	I-Entity
(	O
20	O
mg	O
/	O
kg	O
[	O
9.1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment	O
,	O
serum	O
levetiracetam	I-Entity
concentrations	O
were	O
measured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
drug	O
administration	O
,	O
and	O
maximum	O
and	O
minimum	O
serum	O
concentrations	O
and	O
elimination	O
half	O
-	O
life	O
were	O
calculated	O
.	O

Seizure	I-Entity
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	I-Entity
treatment	O
were	O
compared	O
,	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O

Median	O
maximum	O
serum	O
levetiracetam	I-Entity
concentration	O
was	O
25.5	O
microg	O
/	O
mL	O
,	O
median	O
minimum	O
serum	O
levetiracetam	I-Entity
concentration	O
was	O
8.3	O
microg	O
/	O
mL	O
,	O
and	O
median	O
elimination	O
half	O
-	O
life	O
was	O
2.9	O
hours	O
.	O

Median	O
seizure	I-Entity
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	I-Entity
(	O
2.1	O
seizures	I-Entity
/	O
mo	O
)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	I-Entity
frequency	O
after	O
initiation	O
of	O
levetiracetam	I-Entity
treatment	O
(	O
0.42	O
seizures	I-Entity
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	I-Entity
treatment	O
(	O
ie	O
,	O
reduction	O
in	O
seizure	I-Entity
frequency	O
of	O
>	O
or=50%	O
)	O
.	O

Two	O
cats	O
had	O
transient	O
lethargy	I-Entity
and	O
inappetence	I-Entity
.	O

Results	O
suggested	O
that	O
levetiracetam	I-Entity
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	I-Entity
treatment	O
in	O
cats	O
with	O
idiopathic	B-Entity
epilepsy	I-Entity
.	O



Bilateral	O
haemorrhagic	B-Entity
infarction	I-Entity
of	I-Entity
the	I-Entity
globus	I-Entity
pallidus	I-Entity
after	O
cocaine	I-Entity
and	O
alcohol	I-Entity
intoxication	O
.	O

Cocaine	I-Entity
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B-Entity
and	I-Entity
haemorrhagic	I-Entity
stroke	I-Entity
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31-year	O
-	O
old	O
man	O
with	O
bilateral	O
ischemia	B-Entity
of	I-Entity
the	I-Entity
globus	I-Entity
pallidus	I-Entity
after	O
excessive	O
alcohol	I-Entity
and	O
intranasal	O
cocaine	I-Entity
use	O
.	O

Drug	O
-	O
related	O
globus	B-Entity
pallidus	I-Entity
infarctions	I-Entity
are	O
most	O
often	O
associated	O
with	O
heroin	I-Entity
.	O

Bilateral	O
basal	B-Entity
ganglia	I-Entity
infarcts	I-Entity
after	O
the	O
use	O
of	O
cocaine	I-Entity
,	O
without	O
concurrent	O
heroin	I-Entity
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	O
,	O
transient	O
cardiac	B-Entity
arrhythmia	I-Entity
or	O
respiratory	B-Entity
dysfunction	I-Entity
related	O
to	O
cocaine	I-Entity
and/or	O
ethanol	I-Entity
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B-Entity
hypoperfusion	I-Entity
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
after	O
high	O
-	O
dose	O
methotrexate	I-Entity
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
.	O

High	O
-	O
dose	O
methotrexate	I-Entity
(	O
HD	O
-	O
MTX	I-Entity
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	B-Entity
lymphoma	I-Entity
,	O
but	O
can	O
cause	O
hepatic	B-Entity
and	I-Entity
renal	I-Entity
toxicity	I-Entity
when	O
its	O
clearance	O
is	O
delayed	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
after	O
HD	O
-	O
MTX	I-Entity
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
,	O
The	O
patient	O
was	O
a	O
3-year	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
living	O
-	O
related	O
liver	O
transplantation	O
for	O
congenital	O
biliary	B-Entity
atresia	I-Entity
.	O

At	O
day	O
833	O
after	O
the	O
transplantation	O
,	O
he	O
was	O
diagnosed	O
with	O
PTLD	I-Entity
(	O
post	B-Entity
-	I-Entity
transplantation	I-Entity
lymphoproliferative	I-Entity
disorder	I-Entity
,	O
Burkitt	B-Entity
-	I-Entity
type	I-Entity
malignant	I-Entity
lymphoma	I-Entity
)	O
.	O

Subsequent	O
HD	O
-	O
MTX	I-Entity
therapy	O
caused	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
that	O
required	O
continuous	O
hemodialysis	O
.	O

We	O
supposed	O
that	O
intravascular	O
hypovolemia	I-Entity
due	O
to	O
substantial	O
drainage	O
from	O
the	O
ileostoma	O
caused	O
acute	B-Entity
prerenal	I-Entity
failure	I-Entity
.	O

After	O
recovery	O
of	O
his	O
renal	O
function	O
,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD	O
-	O
MTX	I-Entity
therapy	O
by	O
controlling	O
drainage	O
from	O
ileostoma	O
with	O
total	O
parenteral	O
nutrition	O
.	O



Antithrombotic	O
drug	O
use	O
,	O
cerebral	B-Entity
microbleeds	I-Entity
,	O
and	O
intracerebral	B-Entity
hemorrhage	I-Entity
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Entity
microbleeds	I-Entity
(	O
MB	I-Entity
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-Entity
hemorrhage	I-Entity
(	O
ICH	I-Entity
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	O
drugs	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	I-Entity
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	I-Entity
and	O
ischemic	B-Entity
stroke	I-Entity
(	O
IS)/transient	B-Entity
ischemic	I-Entity
attack	I-Entity
(	O
TIA	I-Entity
)	O
.	O

:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	I-Entity
or	O
TIA	I-Entity
to	O
compare	O
the	O
presence	O
of	O
MB	I-Entity
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	I-Entity
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	I-Entity
/	O
TIA	I-Entity
;	O
and	O
(	O
3	O
)	O
ICH	I-Entity
vs	O
ischemic	I-Entity
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O

We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	I-Entity
in	O
antithrombotic	O
users	O
with	O
MB	I-Entity
.	O

In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	I-Entity
and	O
3817	O
IS	I-Entity
/	O
TIA	I-Entity
,	O
MB	I-Entity
were	O
more	O
frequent	O
in	O
ICH	I-Entity
vs	O

IS	I-Entity
/	O
TIA	I-Entity
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2.8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2.3	O
-	O
3.5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5.7	O
(	O
range	O
,	O
3.4	O
-	O
9.7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8.0	O
(	O
range	O
,	O
3.5	O
-	O
17.8	O
)	O
in	O
warfarin	I-Entity
users	O
(	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
also	O
an	O
excess	O
of	O
MB	I-Entity
in	O
warfarin	I-Entity
users	O
vs	O
nonusers	O
with	O
ICH	I-Entity
(	O
OR	O
,	O
2.7	O
;	O
95%	O
CI	O
,	O
1.6	O
-	O
4.4	O
;	O
P<0.001	O
)	O
but	O
none	O
in	O
warfarin	I-Entity
users	O
with	O
IS	I-Entity
/	O
TIA	I-Entity
(	O
OR	O
,	O
1.3	O
;	O
95%	O
CI	O
,	O
0.9	O
-	O
1.7	O
;	O
P=0.33	O
;	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	I-Entity
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	I-Entity
(	O
OR	O
,	O
1.7	O
;	O
95%	O
CI	O
,	O
1.3	O
-	O
2.3	O
;	O
P<0.001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	I-Entity
/	O
TIA	I-Entity
(	O
OR	O
,	O
1.4	O
;	O
95%	O
CI	O
,	O
1.2	O
-	O
1.7	O
;	O
P<0.001	O
;	O
P	O
difference=0.25	O
)	O
.	O

In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	I-Entity
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	I-Entity
(	O
OR	O
,	O
12.1	O
;	O
95%	O
CI	O
,	O
3.4	O
-	O
42.5	O
;	O
P<0.001	O
)	O
.	O

The	O
excess	O
of	O
MB	I-Entity
in	O
warfarin	I-Entity
users	O
with	O
ICH	I-Entity
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	I-Entity
increase	O
the	O
risk	O
of	O
warfarin	I-Entity
-	O
associated	O
ICH	I-Entity
.	O



Verapamil	I-Entity
stimulation	O
test	O
in	O
hyperprolactinemia	I-Entity
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect	O
.	O

Verapamil	I-Entity
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	I-Entity
,	O
but	O
with	O
conflicting	O
results	O
.	O

Macroprolactinemia	I-Entity
was	O
never	O
considered	O
in	O
those	O
previous	O
studies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	I-Entity
in	O
a	O
population	O
who	O
were	O
all	O
screened	O
for	O
macroprolactinemia	I-Entity
.	O

Prolactin	O
responses	O
to	O
verapamil	I-Entity
in	O
65	O
female	O
patients	O
(	O
age	O
:	O
29.9	O
+	O
/-	O

8.1	O
years	O
)	O
with	O
hyperprolactinemia	I-Entity
were	O
tested	O
in	O
a	O
descriptive	O
,	O
matched	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
Verapamil	I-Entity
80	O
mg	O
,	O
p.o	O
.	O

Verapamil	I-Entity
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	O
levels	O
(	O
PRL	O
)	O
.	O

Verapamil	I-Entity
significantly	O
increased	O
PRL	O
levels	O
in	O
healthy	O
controls	O
(	O
N.	O
8	O
,	O
PRL	O
:	O
183%	O
)	O
,	O
macroprolactinoma	I-Entity
(	O
N.	O
8	O
,	O
PRL	O
:	O
7%	O
)	O
,	O
microprolactinoma	I-Entity
(	O
N.	O
19	O
,	O
PRL	O
:	O
21%	O
)	O
,	O
macroprolactinemia	I-Entity

but	O
not	O
in	O
pseudoprolactinoma	I-Entity
(	O
N.	O
8	O
,	O
PRL	O
:	O
0.8%	O
)	O
,	O
and	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
(	O
N.	O
7	O
,	O

ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	I-Entity
defined	O
as	O
PRL	O

<	O
0.001	O
,	O
CI	O
:	O
0.768	O
-	O
0.942	O
)	O
associated	O
with	O
pseudoprolactinoma	I-Entity
or	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Verapamil	I-Entity
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	I-Entity
.	O

However	O
,	O
verapamil	I-Entity
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(	O
i.e.	O
,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	I-Entity
with	O
varying	O
degrees	O
of	O
responsiveness	O
.	O



The	O
effect	O
of	O
clonidine	I-Entity
,	O
naphazoline	I-Entity
and	O
xylometazoline	I-Entity
on	O
analgesia	O
induced	O
by	O
morphine	I-Entity
,	O
codeine	I-Entity
,	O
fentanyl	I-Entity
and	O
pentazocine	I-Entity
,	O
and	O
on	O
cataleptic	I-Entity
effect	O
of	O
morphine	I-Entity
,	O
codine	I-Entity
and	O
fentanyl	I-Entity
was	O
studied	O
in	O
rats	O
.	O

The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	O
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	I-Entity
(	O
NA	I-Entity
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
NA	I-Entity
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	I-Entity
induced	O
by	O
morphine	I-Entity
and	O
fentanyl	I-Entity
.	O

Codeine	I-Entity
catalepsy	I-Entity
was	O
increased	O
by	O
clonidine	I-Entity
and	O
decreased	O
by	O
naphazoline	I-Entity
and	O
xylometazoline	I-Entity
.	O

The	O
brain	O
concentration	O
of	O
NA	I-Entity
was	O
not	O
changed	O
by	O
morphine	I-Entity
and	O
fentanyl	I-Entity
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	I-Entity
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enhanced	O
it	O
.	O

Pentazocine	I-Entity
dose	O
-	O
dependently	O
decreased	O
the	O
brain	O
level	O
of	O
NA	I-Entity
.	O

The	O
rate	O
of	O
NA	I-Entity
turnover	O
was	O
not	O
altered	O
by	O
analgesics	O
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	I-Entity
(	O
0.2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearance	O
of	O
NA	I-Entity
from	O
the	O
brain	O
was	O
diminished	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
NA	I-Entity
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	I-Entity
in	O
the	O
behavioural	O
activity	O
of	O
potent	O
analgesics	O
.	O



Modification	O
by	O
propranolol	I-Entity
of	O
cardiovascular	O
effects	O
of	O
induced	O
hypoglycaemia	I-Entity
.	O

The	O
cardiovascular	O
effects	O
of	O
hypoglycaemia	I-Entity
,	O
with	O
and	O
without	O
beta	O
-	O
blockade	O
,	O
were	O
compared	O
in	O
fourteen	O
healthy	O
men	O
.	O

Eight	O
received	O
insulin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulin	O
-	O
only	O
group	O
,	O
were	O
given	O
propranolol	I-Entity
and	O
insulin	O
.	O

In	O
the	O
insulin	O
-	O
group	O
the	O
period	O
of	O
hypoglycaemia	I-Entity
was	O
associated	O
with	O
an	O
increase	O
in	O
heart	O
-	O
rate	O
and	O
a	O
fall	O
in	O
diastolic	O
blood	O
-	O
pressure	O
.	O

In	O
the	O
propranolol	I-Entity
-	O
insulin	O
group	O
there	O
was	O
a	O
significant	O
fall	O
in	O
heart	O
-	O
rate	O
in	O
most	O
subjects	O
and	O
an	O
increase	O
in	O
diastolic	O
pressure	O
.	O

/	O
T	O
changes	O
occurred	O
in	O
the	O
insulin	O
-	O
group	O
but	O
in	O
none	O
of	O
the	O
propranolol	I-Entity
-	O
insulin	O
group	O
.	O

Hypertension	I-Entity
in	O
diabetics	I-Entity
prone	O
to	O
hypoglycaemia	I-Entity
attacks	O
should	O
not	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
because	O
these	O
drugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blood	O
-	O
pressure	O
in	O
such	O
patients	O
.	O



Prevention	O
and	O
treatment	O
of	O
endometrial	B-Entity
disease	I-Entity
in	O
climacteric	O
women	O
receiving	O
oestrogen	I-Entity
therapy	O
.	O

The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	B-Entity
disease	I-Entity
among	O
850	O
climacteric	O
women	O
receiving	O
oestrogen	I-Entity
therapy	O
.	O

Cystic	O
hyperplasia	I-Entity
was	O
associated	O
with	O
unopposed	O
oestrogen	I-Entity
therapy	O
without	O
progestagen	I-Entity
.	O

Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	I-Entity
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	I-Entity
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	I-Entity
.	O

4	O
cases	O
of	O
endometrial	B-Entity
carcinoma	I-Entity
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	I-Entity
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	I-Entity
from	O
malignancy	I-Entity
.	O

Cyclical	O
low	O
-	O
dose	O
oestrogen	I-Entity
therapy	O
with	O
7	O
-	O
-13	O
days	O
of	O
progestagen	I-Entity
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	B-Entity
hyperplasia	I-Entity
or	O
carcinoma	I-Entity
.	O



Pure	B-Entity
red	I-Entity
cell	I-Entity
aplasia	I-Entity
,	O
toxic	B-Entity
dermatitis	I-Entity
and	O
lymphadenopathy	I-Entity
in	O
a	O
patient	O
taking	O
diphenylhydantoin	I-Entity
.	O

A	O
patient	O
taking	O
diphenylhydantoin	I-Entity
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	B-Entity
rash	I-Entity
,	O
lymphadenopathy	I-Entity
and	O
pure	B-Entity
red	I-Entity
cell	I-Entity
aplasia	I-Entity
.	O

Skin	B-Entity
rash	I-Entity
is	O
a	O
well	O
-	O
known	O
complication	O
of	O
diphenylhydantoin	I-Entity
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	I-Entity
.	O

Pure	B-Entity
red	I-Entity
cell	I-Entity
aplasia	I-Entity
associated	O
with	O
diphenylhydantoin	I-Entity
medication	O
has	O
been	O
reported	O
in	O
3	O
patients	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	I-Entity
exerts	O
its	O
toxic	O
effects	O
is	O
not	O
known	O
.	O

In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	I-Entity
and	O
the	O
occurrence	O
of	O
the	O
skin	B-Entity
rash	I-Entity
,	O
lymphadenopathy	I-Entity
and	O
pure	B-Entity
red	I-Entity
cell	I-Entity
aplasia	I-Entity
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connection	O
.	O



Continuous	O
infusion	O
tobramycin	I-Entity
combined	O
with	O
carbenicillin	I-Entity
for	O
infections	I-Entity
in	O
cancer	I-Entity
patients	O
.	O

The	O
cure	O
rate	O
of	O
infections	I-Entity
in	O
cancer	I-Entity
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	I-Entity
(	O
less	O
than	O
1,000/mm3	O
)	O
.	O

In	O
particular	O
,	O
patients	O
with	O
severe	O
neutropenia	I-Entity
(	O
less	O
than	O
100/mm3	O
)	O
have	O
shown	O
a	O
poor	O
response	O
to	O
antibiotics	O
.	O

To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	I-Entity
,	O
tobramycin	I-Entity
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	I-Entity
.	O

Tobramycin	I-Entity
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenicillin	I-Entity
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	I-Entity
patients	O
receiving	O
myelosuppressive	O
chemotherapy	O
.	O

Pneumonia	I-Entity
was	O
the	O
most	O
common	O
infection	I-Entity
and	O
61%	O
of	O
59	O
episodes	O
were	O
cured	O
.	O

Gram	O
-	O
negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69%	O
of	O
these	O
infections	I-Entity
were	O
cured	O
.	O

The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	I-Entity
and	O
this	O
,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa	O
,	O
accounted	O
for	O
74%	O
of	O
all	O
gram	B-Entity
-	I-Entity
negative	I-Entity
bacillary	I-Entity
infections	I-Entity
.	O

Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	I-Entity
.	O

Azotemia	I-Entity
was	O
the	O
major	O
side	O
effect	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11%	O
of	O
episodes	O
.	O

Major	O
azotemia	I-Entity
(	O
serum	O
creatinine	I-Entity
greater	O
than	O
2.5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2%	O
.	O

Azotemia	I-Entity
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	I-Entity
concentration	O
.	O

This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	B-Entity
toxicity	I-Entity
for	O
these	O
patients	O
.	O



Recurrent	O
subarachnoid	B-Entity
hemorrhage	I-Entity
associated	O
with	O
aminocaproic	B-Entity
acid	I-Entity
therapy	O
and	O
acute	B-Entity
renal	I-Entity
artery	I-Entity
thrombosis	I-Entity
.	O

Epsilon	B-Entity
aminocaproic	I-Entity
acid	I-Entity
(	O
EACA	I-Entity
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	B-Entity
hemorrhage	I-Entity
(	O
SAH	I-Entity
)	O
.	O

Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding	O
,	O
several	O
reports	O
have	O
described	O
thrombotic	I-Entity
complications	O
of	O
EACA	I-Entity
therapy	O
.	O

These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	B-Entity
vascular	I-Entity
thrombosis	I-Entity
in	O
patients	O
with	O
SAH	I-Entity
,	O
arteriolar	O
and	O
capillary	O
fibrin	O

thrombi	I-Entity
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	I-Entity
,	O
or	O
other	O
thromboembolic	B-Entity
phenomena	I-Entity
.	O

Since	O
intravascular	O
fibrin	O
thrombi	I-Entity
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders	O
,	O
EACA	I-Entity
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	I-Entity
in	O
patients	O
with	O
disseminated	B-Entity
intravascular	I-Entity
coagulation	I-Entity
or	O
other	O
""""	O
consumption	B-Entity
coagulopathies	I-Entity
.	O

""""	O
This	O
report	O
describes	O
subtotal	O
infarction	I-Entity
of	O
the	O
kidney	O
due	O
to	O
thrombosis	B-Entity
of	I-Entity
a	I-Entity
normal	I-Entity
renal	I-Entity
artery	I-Entity
.	O

This	O
occlusion	O
occurred	O
after	O
EACA	I-Entity
therapy	O
in	O
a	O
patient	O
with	O
SAH	I-Entity
and	O
histopathological	O
documentation	O
of	O
recurrent	O
SAH	I-Entity
.	O

The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	I-Entity
and	O
abrupt	O
neurological	O
deterioration	O
.	O



Long	O
-	O
term	O
propranolol	I-Entity
therapy	O
in	O
pregnancy	O
:	O
maternal	O
and	O
fetal	O
outcome	O
.	O

Propranolol	I-Entity
,	O
a	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
has	O
found	O
an	O
important	O
position	O
in	O
the	O
practice	O
of	O
medicine	O
.	O

Ten	O
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	I-Entity
has	O
been	O
administered	O
.	O

Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	I-Entity
therapy	O
are	O
also	O
examined	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	I-Entity
,	O
hyperbilirubinemia	I-Entity
,	O
polycythemia	I-Entity
,	O
neonatal	B-Entity
apnea	I-Entity
,	O
and	O
bradycardia	I-Entity
are	O
not	O
invariable	O
and	O
can	O
not	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	I-Entity
therapy	O
.	O

Growth	B-Entity
retardation	I-Entity
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O



Use	O
of	O
propranolol	I-Entity
in	O
the	O
treatment	O
of	O
idiopathic	B-Entity
orthostatic	I-Entity
hypotension	I-Entity
.	O

Five	O
patients	O
with	O
idiopathic	B-Entity
orthostatic	I-Entity
hypotension	I-Entity
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	O
dysfunction	O
were	O
included	O
in	O
the	O
study	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	I-Entity
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	I-Entity
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	I-Entity
.	O

Treatment	O
with	O
propanolol	I-Entity
administered	O
intravenously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
increases	O
in	O
supine	O
and	O
upright	O
blood	O
pressure	O
in	O
4	O
of	O
the	O
5	O
individuals	O
with	O
rises	O
ranging	O
from	O
11/6	O
to	O
22/11	O
mmHg	O
.	O

Chronic	O
oral	O
administration	O
of	O
propranolol	I-Entity
(	O
40	O
-	O
160	O
mg	O
/	O
day	O
)	O
also	O
elevated	O
the	O
blood	O
pressures	O
of	O
these	O
individuals	O
with	O
increases	O
in	O
the	O
order	O
of	O
20	O
-	O
35/15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
patient	O
,	O
marked	O
hypertension	I-Entity
was	O
induced	O
by	O
propranolol	I-Entity
and	O
the	O
drug	O
had	O
to	O
be	O
withdrawn	O
.	O

Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	I-Entity
therapy	O
.	O

The	O
studies	O
suggest	O
that	O
propranolol	I-Entity
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	B-Entity
orthostatic	I-Entity
hypotension	I-Entity
.	O



Total	O
intravenous	O
anesthesia	O
with	O
etomidate	I-Entity
.	O

An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	I-Entity
required	O
to	O
maintain	O
sleep	O
in	O
adults	O
undergoing	O
surgery	O
under	O
regional	O
local	O
anesthesia	O
.	O

Premedication	O
of	O
diazepam	I-Entity
10	O
mg	O
and	O
atropine	I-Entity
0.5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	I-Entity
0.1/mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patient	O
would	O
open	O
his	O
eyes	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dose	O
of	O
etomidate	I-Entity
17.4	O
microgram	O
/	O
kg	O
/	O
min	O
.	O

The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side	O
-	O
effects	O
,	O
particularly	O
pain	I-Entity
and	O
myoclonia	I-Entity
,	O
which	O
caused	O
the	O
technique	O
to	O
be	O
abandoned	O
in	O
two	O
cases	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etomidate	I-Entity
will	O
prove	O
to	O
be	O
the	O
hypnotic	O
of	O
choice	O
for	O
a	O
totally	O
intravenous	O
anesthetic	O
technique	O
in	O
adults	O
because	O
of	O
the	O
high	O
incidence	O
of	O
myoclonia	I-Entity
after	O
prolonged	O
administration	O
.	O



A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	I-Entity
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta	O
-	O
mimetics	O
.	O

A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	I-Entity
as	O
a	O
displacement	O
-	O
time	O
curve	O
is	O
described	O
,	O
using	O
a	O
test	O
system	O
with	O
simple	O
amplitude	O
calibration	O
.	O

By	O
means	O
of	O
a	O
computer	O
program	O
,	O
periods	O
and	O
amplitudes	O
of	O
tremor	I-Entity
oscillations	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
actions	O
of	O
fenoterol	B-Entity
-	I-Entity
hydrobromide	I-Entity
,	O
ritodrin	B-Entity
-	I-Entity
HCl	I-Entity
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double	O
-	O
blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method	O
.	O

At	O
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	I-Entity
amplitude	O
to	O
about	O
three	O
times	O
the	O
control	O
level	O
.	O

After	O
the	O
end	O
of	O
fenoterol	B-Entity
-	I-Entity
hydrobromide	I-Entity
infusion	O
,	O
tremor	I-Entity
amplitudes	O
decreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodrin	B-Entity
-	I-Entity
HCl	I-Entity
infusion	O
.	O



Bilateral	O
retinal	B-Entity
artery	I-Entity
and	I-Entity
choriocapillaris	I-Entity
occlusion	I-Entity
following	O
the	O
injection	O
of	O
long	O
-	O
acting	O
corticosteroid	I-Entity
suspensions	O
in	O
combination	O
with	O
other	O
drugs	O
:	O
I.	O
Clinical	O
studies	O
.	O

Two	O
well	O
-	O
documented	O
cases	O
of	O
bilateral	O
retinal	B-Entity
artery	I-Entity
and	I-Entity
choriocapillaris	I-Entity
occlusions	I-Entity
with	O
blindness	I-Entity
following	O
head	O
and	O
neck	O
soft	O
-	O
tissue	O
injection	O
with	O
methylprednisolone	B-Entity
acetate	I-Entity
in	O
combination	O
with	O
lidocaine	I-Entity
,	O
epinephrine	I-Entity
,	O
or	O
penicillin	I-Entity
are	O
reported	O
.	O

The	O
acute	O
observations	O
included	O
hazy	O
sensorium	O
,	O
superior	O
gaze	O
palsy	I-Entity
,	O
pupillary	B-Entity
abnormalities	I-Entity
,	O
and	O
conjunctival	O
hemorrhages	I-Entity
with	O
edema	I-Entity
.	O

Follow	O
-	O
up	O
changes	O
showed	O
marked	O
visual	B-Entity
loss	I-Entity
,	O
constricted	O
visual	O
fields	O
,	O
optic	O
nerve	O
pallor	O
,	O
vascular	O
attenuation	O
,	O
and	O
chorioretinal	B-Entity
atrophy	I-Entity
.	O



Cephalothin	I-Entity
-	O
induced	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
.	O

A	O
patient	O
with	O
renal	B-Entity
disease	I-Entity
developed	O
Coombs	O
-	O
positive	O
hemolytic	B-Entity
anemia	I-Entity
while	O
receiving	O
cephalothin	I-Entity
therapy	O
.	O

An	O
anti	O
-	O
cephalothin	I-Entity
IgG	O
antibody	O
was	O
detected	O
in	O
the	O
patient	O
's	O
serum	O
and	O
in	O
the	O
eluates	O
from	O
her	O
erythrocytes	O
.	O

In	O
addition	O
,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient	O
's	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin	I-Entity
-	O
coated	O
normal	O
red	O
cells	O
was	O
demonstrated	O
.	O

Skin	O
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	I-Entity
and	O
also	O
to	O
ampicillin	I-Entity
.	O

Careful	O
investigation	O
of	O
drug	O
-	O
induced	O
hemolytic	B-Entity
anemias	I-Entity
reveals	O
the	O
complexity	O
of	O
the	O
immune	O
mechanisms	O
involved	O
.	O



Kaliuretic	O
effect	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
treatment	O
in	O
parkinsonian	I-Entity
patients	O
.	O

Hypokalemia	I-Entity
,	O
sometimes	O
severe	O
,	O
was	O
observed	O
in	O
some	O
L	B-Entity
-	I-Entity
dopa	I-Entity
-	O
treated	O
parkinsonian	I-Entity
patients	O
.	O

The	O
influence	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
on	O
the	O
renal	O
excretion	O
of	O
potassium	I-Entity
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	I-Entity
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
,	O
plasma	O
concentration	O
of	O
potassium	I-Entity
and	O
sodium	I-Entity
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	I-Entity
,	O
sodium	I-Entity
and	O
aldosterone	I-Entity
.	O

L	B-Entity
-	I-Entity
Dopa	I-Entity
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	I-Entity
,	O
and	O
sometimes	O
also	O
of	O
sodium	I-Entity
,	O
in	O
the	O
hypokalemic	O
but	O
not	O
in	O
the	O
normokalemic	O
patients	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	I-Entity
production	O
and	O
this	O
renal	O
effect	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
.	O



Phenytoin	I-Entity
encephalopathy	I-Entity
as	O
probable	O
idiosyncratic	O
reaction	O
:	O
case	O
report	O
.	O

A	O
case	O
of	O
phenytoin	I-Entity
(	O
DPH	I-Entity
)	O

encephalopathy	I-Entity
with	O
increasing	O
seizures	I-Entity
and	O
EEG	O
and	O
mental	O
changes	O
is	O
described	O
.	O

Despite	O
adequate	O
oral	O
dosage	O
of	O
DPH	I-Entity
(	O
5	O
mg	O
/	O
kg	O
/	O
daily	O
)	O
the	O
plasma	O
level	O
was	O
very	O
low	O
(	O
2.8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
encephalopathy	I-Entity
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	O
reaction	O
.	O

In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	I-Entity
was	O
normal	O
,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	I-Entity
during	O
DPH	I-Entity
treatment	O
,	O
the	O
protidogram	O
was	O
normal	O
,	O
and	O
an	O
intradermic	O
DPH	I-Entity
injection	O
had	O
no	O
local	O
effect	O
.	O

The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	I-Entity
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	I-Entity
,	O
with	O
EEG	O
and	O
mental	O
changes	O
occurring	O
simultaneously	O
,	O
should	O
alert	O
the	O
physician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	I-Entity
from	O
the	O
therapeutic	O
regimen	O
,	O
even	O
if	O
plasma	O
concentrations	O
are	O
low	O
.	O



Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
.	O

The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
was	O
studied	O
in	O
male	O
rats	O
.	O

The	O
exercise	O
-	O
isoproterenol	I-Entity
(	O
E-1	O
)	O
and	O
exercise	O
control	O
(	O
EC	O
)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	O
1	O
mph	O
,	O
2%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary	O
-	O
isoproterenol	I-Entity
(	O
S	O
-	O
I	O
)	O
group	O
remained	O
sedentary	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exercise	O
period	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	I-Entity
(	O
250	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Animals	O
of	O
the	O
S	O
-	O
I	O
group	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0.05	O
)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	I-Entity
than	O
animals	O
of	O
the	O
E	O
-	O
I	O
group	O
.	O

Serum	O
CPK	O
activity	O
for	O
E	O
-	O
I	O
animals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	I-Entity
injection	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	I-Entity
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions	O
,	O
changes	O
in	O
heart	O
weight	O
,	O
or	O
heart	O
weight	O
to	O
body	O
weight	O
ratios	O
.	O

The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	I-Entity
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	I-Entity
.	O



Effect	O
of	O
D	B-Entity
-	I-Entity
Glucarates	I-Entity
on	O
basic	O
antibiotic	O
-	O
induced	O
renal	B-Entity
damage	I-Entity
in	O
rats	O
.	O

Dehydrated	I-Entity
rats	O
regularly	O
develop	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
single	O
injection	O
of	O
aminoglycoside	I-Entity
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only	O
.	O

Oral	O
administration	O
of	O
2,5-di	B-Entity
-	I-Entity
O	I-Entity
-	I-Entity
acetyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
glucaro-1,4	I-Entity
-	I-Entity
6,3-dilactone	I-Entity
protected	O
rats	O
against	O
renal	B-Entity
failure	I-Entity
induced	O
by	O
kanamycin	I-Entity
-	O
dextran	O
.	O

The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D	B-Entity
-	I-Entity
glucarates	I-Entity
,	O
and	O
also	O
to	O
other	O
saccharic	B-Entity
acid	I-Entity
,	O
hexauronic	B-Entity
acids	I-Entity
and	O
hexaaldonic	B-Entity
acids	I-Entity
,	O
although	O
to	O
a	O
lesser	O
degree	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
sugar	B-Entity
alcohols	I-Entity
,	O
substances	O
inthe	O
TCA	I-Entity
cycle	O
and	O
other	O
acidic	O
compounds	O
.	O

D	B-Entity
-	I-Entity
Glucarates	I-Entity
were	O
effective	O
against	O
renal	B-Entity
damage	I-Entity
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	I-Entity
antibitocis	O
.	O

Dose	O
-	O
responses	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D	B-Entity
-	I-Entity
Glucarates	I-Entity
.	O

With	O
a	O
D	B-Entity
-	I-Entity
glucarate	I-Entity
of	O
a	O
fixed	O
size	O
of	O
dose	O
,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	B-Entity
damages	I-Entity
induced	O
by	O
different	O
basic	O
antibiotics	O
despite	O
large	O
disparities	O
in	O
administration	O
doses	O
of	O
different	O
antibiotics	O
.	O

D	B-Entity
-	I-Entity
Glucarates	I-Entity
had	O
the	O
ability	O
to	O
prevent	O
renal	B-Entity
damage	I-Entity
but	O
not	O
to	O
cure	O
it	O
.	O

Rats	O
excreted	O
acidic	O
urine	O
when	O
they	O
were	O
spared	O
from	O
renal	B-Entity
lesions	I-Entity
by	O
monosaccharides	I-Entity
.	O

The	O
reduction	O
effect	O
of	O
D	B-Entity
-	I-Entity
glucarates	I-Entity
against	O
nephrotoxicity	I-Entity
of	O
basic	O
antibiotics	O
was	O
discussed	O
.	O



Paraplegia	I-Entity
following	O
intrathecal	O
methotrexate	I-Entity
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

A	O
patient	O
who	O
developed	O
paraplegia	I-Entity
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	I-Entity
is	O
discribed	O
.	O

The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication	O
:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	B-Entity
nervous	I-Entity
system	I-Entity
leukemia	I-Entity
,	O
and	O
epidural	O
cerebrospinal	O
leakage	O
;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	I-Entity
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	I-Entity
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults	O
;	O
the	O
presence	O
of	O
neurotoxic	I-Entity
preservatives	O
in	O
commercially	O
available	O
methotrexate	I-Entity
preparations	O
and	O
diluents	O
;	O
and	O
the	O
use	O
of	O
methotrexate	I-Entity
diluents	O
of	O
unphysiologic	O
pH	O
,	O
ionic	O
content	O
and	O
osmolarity	O
.	O

The	O
role	O
of	O
methotrexate	I-Entity
contaminants	O
,	O
local	O
folate	B-Entity
deficiency	I-Entity
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	I-Entity
toxicity	I-Entity
is	O
unclear	O
.	O

The	O
incidence	O
of	O
neurotoxicity	I-Entity
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	I-Entity
in	O
the	O
presence	O
of	O
central	B-Entity
nervous	I-Entity
system	I-Entity
leukemia	I-Entity
,	O
in	O
older	O
children	O
and	O
adults	O
,	O
and	O
in	O
the	O
presence	O
of	O
epidural	O
leakage	O
.	O

Only	O
preservative	O
-	O
free	O
methotrexate	I-Entity
in	O
Elliott	O
's	O
B	O
Solution	O
at	O
a	O
concentration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
intrathecal	O
administration	O
.	O

Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	I-Entity
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	I-Entity
.	O



Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	I-Entity
in	O
anesthetized	O
rats	O
.	O

injection	O
of	O
carbachol	I-Entity
(	O
1	O
mug	O
)	O
in	O
anesthetized	O
rats	O
was	O
analyzed	O
.	O

injection	O
of	O
guanethidine	I-Entity
(	O
5	O
mg	O
)	O
,	O
hexamethonium	I-Entity
(	O
10	O
mg	O
)	O
or	O
phentolamine	I-Entity
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentiated	O
by	O
i.v	O
.	O

desmethylimipramine	I-Entity
(	O
0.3	O
mg	O
)	O
,	O
while	O
propranolol	I-Entity
(	O
0.5	O
mg	O
)	O
i.v	O
.	O

selectively	O
inhibited	O
the	O
enlargement	B-Entity
of	I-Entity
pulse	I-Entity
pressure	I-Entity
and	O
the	O
tachycardia	I-Entity
following	O
i.c	O
.	O

carbachol	I-Entity
(	O
1	O
mug	O
)	O
.	O

carbachol	I-Entity
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
blocked	O
by	O
i.c	O
.	O

atropine	I-Entity
(	O
3	O
mug	O
)	O
or	O
hexamethonium	I-Entity
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
reduced	O
by	O
i.c	O
.	O

chlorpromazine	I-Entity
(	O
50	O
mug	O
)	O
but	O

desmethylimipramine	I-Entity
(	O
30	O
mug	O
)	O
.	O

carbachol	I-Entity
(	O
1	O
mug	O
)	O
remained	O
unchanged	O
after	O
sectioning	O
of	O
the	O
bilateral	O
cervical	O
vagal	O
nerves	O
but	O
disappeared	O
after	O
sectioning	O
of	O
the	O
spinal	O
cord	O
(	O
C7-C8	O
)	O
.	O

carbachol	I-Entity
ortral	O
and	O
peripheral	O
adrenergic	O
mechanisms	O
,	O
and	O
that	O
the	O
sympathetic	O
trunk	O
is	O
the	O
main	O
pathway	O
.	O



Hyperglycemic	I-Entity
effect	O
of	O
amino	I-Entity
compounds	O
structurally	O
related	O
to	O
caproate	I-Entity
in	O
rats	O
.	O

The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(	O
0.3	O
-	O
3%	O
of	O
diet	O
weight	O
)	O
of	O
certain	O
amino	I-Entity
derivatives	O
of	O
caproate	I-Entity
resulted	O
in	O
hyperglycemia	I-Entity
,	O
an	O
elevated	O
glucose	I-Entity
tolerance	O
curve	O
and	O
,	O
occasionally	O
,	O
glucosuria	I-Entity
.	O

Effective	O
compounds	O
included	O
norleucine	I-Entity
,	O
norvaline	I-Entity
,	O
glutamate	I-Entity
,	O
epsilon	B-Entity
-	I-Entity
aminocaproate	I-Entity
,	O
methionine	I-Entity
,	O
and	O
leucine	I-Entity
.	O



Fatty	B-Entity
liver	I-Entity
induced	O
by	O
tetracycline	I-Entity
in	O
the	O
rat	O
.	O

Dose	O
-	O
response	O
relationships	O
,	O
biochemical	O
mechanisms	O
,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	B-Entity
liver	I-Entity
induced	O
by	O
tetracycline	I-Entity
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	O
in	O
vitro	O
.	O

In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	I-Entity
and	O
hepatic	O
accumulation	O
of	O
triglyceride	I-Entity
.	O

With	O
provision	O
of	O
adequate	O
oleic	B-Entity
acid	I-Entity
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver	O
,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	I-Entity
and	O
both	O
accumulation	O
of	O
triglyceride	I-Entity
in	O
the	O
liver	O
and	O
depression	I-Entity
of	O
output	O
of	O
triglyceride	I-Entity
by	O
livers	O
from	O
male	O
and	O
female	O
rats	O
.	O

Marked	O
differences	O
were	O
observed	O
between	O
female	O
and	O
male	O
rats	O
with	O
regard	O
to	O
base	O
line	O
(	O
control	O
)	O
hepatic	O
concentration	O
of	O
triglyceride	I-Entity
and	O
output	O
of	O
triglyceride	I-Entity
.	O

Accumulation	O
of	O
hepatic	O
triglyceride	I-Entity
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values	O
,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	I-Entity
,	O
did	O
not	O
differ	O
significantly	O
between	O
male	O
,	O
female	O
and	O
pregnant	O
rat	O
livers	O
.	O

However	O
,	O
livers	O
from	O
female	O
,	O
and	O
especially	O
pregnant	O
female	O
rats	O
,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	I-Entity
on	O
depression	I-Entity
of	O
output	O
of	O
triglyceride	I-Entity
under	O
these	O
experimental	O
conditions	O
.	O

These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	I-Entity
or	O
altered	O
uptake	O
of	O
oleic	B-Entity
acid	I-Entity
.	O

Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	I-Entity
accounted	O
only	O
for	O
30	O
to	O
50%	O
of	O
accumulated	O
hepatic	O
triglyceride	I-Entity
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	I-Entity
-	O
rich	O
fatty	B-Entity
liver	I-Entity
in	O
response	O
to	O
tetracycline	I-Entity
.	O



Fatal	O
myeloencephalopathy	I-Entity
due	O
to	O
intrathecal	O
vincristine	I-Entity
administration	O
.	O

Vincristine	I-Entity
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	I-Entity
,	O
producing	O
sensory	B-Entity
and	I-Entity
motor	I-Entity
dysfunction	I-Entity
followed	O
by	O
encephalopathy	I-Entity
and	O
death	O
.	O

Separate	O
times	O
for	O
administering	O
vincristine	I-Entity
and	O
intrathecal	O
therapy	O
is	O
recommended	O
.	O



Progesterone	I-Entity
potentiation	O
of	O
bupivacaine	I-Entity
arrhythmogenicity	O
in	O
pentobarbital	I-Entity
-	O
anesthetized	O
rats	O
and	O
beating	O
rat	O
heart	O
cell	O
cultures	O
.	O

The	O
effects	O
of	O
progesterone	I-Entity
treatment	O
on	O
bupivacaine	I-Entity
arrhythmogenicity	O
in	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
and	O
on	O
anesthetized	O
rats	O
were	O
determined	O
.	O

After	O
determining	O
the	O
bupivacaine	I-Entity
AD50	O
(	O
the	O
concentration	O
of	O
bupivacaine	I-Entity
that	O
caused	O
50%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	I-Entity
)	O
,	O
we	O
determined	O
the	O
effect	O
of	O
1-hour	O
progesterone	I-Entity
HCl	I-Entity
exposure	O
on	O
myocyte	O
contractile	O
rhythm	O
.	O

Each	O
concentration	O
of	O
progesterone	I-Entity
(	O
6.25	O
,	O
12.5	O
,	O
25	O
,	O
and	O
50	O
micrograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
concentration	O
-	O
dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	I-Entity
.	O

Estradiol	I-Entity
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	I-Entity
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	I-Entity
.	O

Neither	O
progesterone	I-Entity
nor	O
estradiol	I-Entity
effects	O
on	O
bupivacaine	I-Entity
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	I-Entity
.	O

Chronic	O
progesterone	I-Entity
pretreatment	O

(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
days	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	I-Entity
arrhythmogenicity	O
in	O
intact	O
pentobarbital	I-Entity
-	O
anesthetized	O
rats	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	I-Entity
as	O
compared	O
with	O
control	O
nonprogesterone	O
-	O
treated	O
rats	O
(	O
6.2	O
+	O
/-	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	I-Entity
can	O
potentiate	O
bupivacaine	I-Entity
arrhythmogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potentiation	O
of	O
bupivacaine	I-Entity
arrhythmia	I-Entity
in	O
myocyte	O
cultures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myocyte	O
level	O
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
occurring	O
during	O
intravenous	O
desferrioxamine	I-Entity
therapy	O
:	O
recovery	O
after	O
haemodialysis	O
.	O

A	O
patient	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	I-Entity
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	I-Entity
(	O
DFX	I-Entity
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy	O
.	O

Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump	O
,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	B-Entity
insufficiency	I-Entity
.	O

Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values	O
,	O
despite	O
adequate	O
medical	O
treatment	O
,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	I-Entity
.	O

From	O
the	O
results	O
obtained	O
,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
caused	O
by	O
desferrioxamine	I-Entity
.	O



Neuroleptic	I-Entity
-	O
associated	O
hyperprolactinemia	I-Entity
.	O

Can	O
it	O
be	O
treated	O
with	O
bromocriptine	I-Entity
?	O

Six	O
stable	O
psychiatric	O
outpatients	O
with	O
hyperprolactinemia	I-Entity
and	O
amenorrhea	I-Entity
/	O
oligomenorrhea	I-Entity
associated	O
with	O
their	O
neuroleptic	B-Entity
medications	I-Entity
were	O
treated	O
with	O
bromocriptine	I-Entity
.	O

Daily	O
dosages	O
of	O
5	O
-	O
10	O
mg	O
corrected	O
the	O
hyperprolactinemia	I-Entity
and	O
restored	O
menstruation	O
in	O
four	O
of	O
the	O
six	O
patients	O
.	O

One	O
woman	O
,	O
however	O
,	O
developed	O
worsened	O
psychiatric	B-Entity
symptoms	I-Entity
while	O
taking	O
bromocriptine	I-Entity
,	O
and	O
it	O
was	O
discontinued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	I-Entity
.	O

This	O
suggests	O
that	O
bromocriptine	I-Entity
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic	I-Entity
-	O
associated	O
hyperprolactinemia	I-Entity
and	O
amenorrhea	I-Entity
/	O
galactorrhea	I-Entity
.	O



Ethacrynic	B-Entity
acid	I-Entity
-	O
induced	O
convulsions	I-Entity
and	O
brain	O
neurotransmitters	O
in	O
mice	O
.	O

Intracerebroventricular	O
injection	O
of	O
ethacrynic	B-Entity
acid	I-Entity
(	O
50%	O
convulsive	I-Entity
dose	O

;	O
50	O
micrograms	O
/	O
mouse	O
)	O
accelerated	O
the	O
synthesis	O
/	O
turnover	O
of	O
5-hydroxytryptamine	I-Entity
(	O
5-HT	I-Entity
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
and	O
acetylcholine	I-Entity
in	O
mouse	O
brain	O
.	O

These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate	I-Entity
/	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
antagonist	O
,	O
aminophosphonovaleric	B-Entity
acid	I-Entity
.	O

In	O
ethacrynic	B-Entity
acid	I-Entity
-	O
induced	O
convulsions	I-Entity
,	O
these	O
neurotransmitter	O
systems	O
may	O
be	O
differentially	O
modulated	O
,	O
probably	O
through	O
activation	O
of	O
glutaminergic	O
neurons	O
in	O
the	O
brain	O
.	O



Pharmacology	O
of	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acidA	I-Entity
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta	B-Entity
-	I-Entity
carboline	I-Entity
derivative	O
abecarnil	I-Entity
.	O

In	O
rodents	O
,	O
the	O
effect	O
of	O
the	O
beta	B-Entity
-	I-Entity
carboline	I-Entity
derivative	O
isopropyl-6-	B-Entity
benzyloxy-4-methoxymethyl	I-Entity
-	I-Entity
beta	I-Entity
-	I-Entity
carboline-3-carboxylate	I-Entity
(	O
abecarrnil	I-Entity
)	O
,	O
a	O
new	O
ligand	O
for	O
benzodiazepine	I-Entity
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties	O
,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA)A	I-Entity
receptor	O
complex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation	O
,	O
abecarnil	I-Entity
increased	O
[	O
3H]GABA	I-Entity
binding	O
,	O
enhanced	O
muscimol	I-Entity
-	O
stimulated	O
36Cl-	O
uptake	O
and	O
reduced	O
the	O
binding	O
of	O
t-[35S]butylbicyclophosphorothionate	I-Entity
(	O
[	B-Entity
35S]TBPS	I-Entity
)	O
.	O

These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	I-Entity
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	B-Entity
16	I-Entity
-	I-Entity
6028	I-Entity
(	O
tert	B-Entity
-	I-Entity
butyl-(S)-8-bromo-11,12,13,13a	I-Entity
-	I-Entity
tetrahydro-9-oxo-9H-	I-Entity
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	I-Entity
)	O
showed	O
very	O
weak	O
efficacy	O
in	O
these	O
biochemical	O
tests	O
.	O

injection	O
to	O
rats	O
,	O
abecarnil	I-Entity
and	O
diazepam	I-Entity
decreased	O
in	O
a	O
time	O
-	O
dependent	O
and	O
dose	O
-	O
related	O
(	O
0.25	O
-	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

manner	O
[	B-Entity
35S]TBPS	I-Entity
binding	O
measured	O
ex	O
vivo	O
in	O
the	O
cerebral	O
cortex	O
.	O

Moreover	O
,	O
both	O
drugs	O
at	O
the	O
dose	O
of	O
0.5	O
mg	O
/	O
kg	O
antagonized	O
completely	O
the	O
convulsant	O
activity	O
and	O
the	O
increase	O
of	O
[	B-Entity
35S]TBPS	I-Entity
binding	O
induced	O
by	O
isoniazide	I-Entity
(	O
350	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O

as	O
well	O
as	O
the	O
increase	O
of	O
[	B-Entity
35S]TBPS	I-Entity
binding	O
induced	O
by	O
foot	O
-	O
shock	O
stress	O
.	O

To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects	O
,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	I-Entity
on	O
[	B-Entity
35S]TBPS	I-Entity
binding	O
,	O
exploratory	O
motility	O
and	O
on	O
isoniazid	I-Entity
-	O
induced	O
biochemical	O
and	O
pharmacological	O
effects	O
in	O
mice	O
.	O

In	O
these	O
animals	O
,	O
abecarnil	I-Entity
produced	O
a	O
paralleled	O
dose	O
-	O
dependent	O
(	O
0.05	O
-	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
reduction	O
of	O
both	O
motor	O
behavior	O
and	O
cortical	O
[	O
35S]TBPS	O
binding	O
.	O

kg	O
of	O
this	O
beta	B-Entity
-	I-Entity
carboline	I-Entity
reduced	O
markedly	O
the	O
increase	O
of	O
[	B-Entity
35S]TBPS	I-Entity
binding	O
and	O
the	O
convulsions	I-Entity
induced	O
by	O
isoniazid	I-Entity
(	O
200	O
mg	O
/	O
kg	O
s.c.).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Recurrent	O
myocardial	B-Entity
infarction	I-Entity
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	I-Entity
.	O

Myocardial	B-Entity
infarction	I-Entity
in	O
puerperium	O
is	O
infrequently	O
reported	O
.	O

Spasm	I-Entity
,	O
coronary	O
dissection	O
,	O
or	O
atheromatous	O
etiology	O
has	O
been	O
described	O
.	O

Bromocriptine	I-Entity
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	B-Entity
infarction	I-Entity
in	O
the	O
puerperium	O
.	O

Although	O
generally	O
regarded	O
as	O
""""	O
safe	O
,	O
""""	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	I-Entity
should	O
be	O
acknowledged	O
.	O



Asterixis	I-Entity
induced	O
by	O
carbamazepine	I-Entity
therapy	O
.	O

There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	I-Entity
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
psychopharmacologic	O
agents	O
.	O

In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	I-Entity
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	I-Entity
(	O
CBZ	I-Entity
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O

Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	I-Entity
were	O
in	O
a	O
higher	O
range	O
.	O

We	O
consider	O
asterixis	I-Entity
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	I-Entity
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	I-Entity
or	O
clozapine	I-Entity
are	O
used	O
in	O
combination	O
with	O
CBZ	I-Entity
.	O



Pharmacodynamics	O
of	O
the	O
hypotensive	I-Entity
effect	O
of	O
levodopa	I-Entity
in	O
parkinsonian	I-Entity
patients	O
.	O

levodopa	I-Entity
were	O
examined	O
in	O
parkinsonian	I-Entity
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	I-Entity
.	O

The	O
magnitude	O
of	O
the	O
hypotensive	I-Entity
effect	O
of	O
levodopa	I-Entity
was	O
concentration	O
dependent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
model	O
in	O
fluctuating	O
responders	O
.	O

Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	I-Entity
response	O
.	O

Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients	O
;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	I-Entity
effects	O
.	O

Antiparkinsonian	O
effects	O
of	O
levodopa	I-Entity
temporally	O
correlated	O
with	O
blood	O
pressure	O
changes	O
.	O

Phenylalanine	I-Entity
,	O
a	O
large	O
neutral	O
amino	B-Entity
acid	I-Entity
(	O
LNAA	O
)	O
competing	O
with	O
levodopa	I-Entity
for	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
reduced	O
the	O
hypotensive	I-Entity
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	I-Entity
.	O

We	O
conclude	O
that	O
levodopa	I-Entity
has	O
a	O
central	O
hypotensive	I-Entity
action	O
that	O
parallels	O
the	O
motor	O
effects	O
in	O
fluctuating	O
patients	O
.	O

The	O
hypotensive	I-Entity
effect	O
appears	O
to	O
be	O
related	O
to	O
the	O
higher	O
baseline	O
blood	O
pressure	O
we	O
observed	O
in	O
fluctuating	O
patients	O
relative	O
to	O
stable	O
patients	O
.	O



Syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
secretion	I-Entity
of	I-Entity
antidiuretic	I-Entity
hormone	I-Entity
after	O
infusional	O
vincristine	I-Entity
.	O

A	O
77-year	O
-	O
old	O
woman	O
with	O
refractory	O
multiple	B-Entity
myeloma	I-Entity
was	O
treated	O
with	O
a	O
4-day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	I-Entity
and	O
doxorubicin	I-Entity
and	O
4	O
days	O
of	O
oral	O
dexamethasone	I-Entity
.	O

Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	I-Entity
and	O
weakness	I-Entity
associated	O
with	O
hyponatremia	I-Entity
.	O

Evaluation	O
revealed	O
the	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
secretion	I-Entity
of	I-Entity
antidiuretic	I-Entity
hormone	I-Entity
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	I-Entity
infusion	O
.	O

After	O
normal	O
serum	O
sodium	I-Entity
levels	O
returned	O
,	O
further	O
doxorubicin	I-Entity
and	O
dexamethasone	I-Entity
chemotherapy	O
without	O
vincristine	I-Entity
did	O
not	O
produce	O
this	O
complication	O
.	O



Heart	B-Entity
failure	I-Entity
:	O
to	O
digitalise	O
or	O
not	O
?	O

Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	I-Entity
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
patients	O
with	O
atrial	B-Entity
fibrillation	I-Entity
digoxin	I-Entity
is	O
beneficial	O
for	O
ventricular	O
rate	O
control	O
.	O

For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	B-Entity
failure	I-Entity
the	O
situation	O
is	O
less	O
clear	O
.	O

Digoxin	I-Entity
has	O
a	O
narrow	O
therapeutic	O
:	O
toxic	O
ratio	O
and	O
concentrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
drugs	O
.	O

Also	O
,	O
digoxin	I-Entity
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands	O
,	O
and	O
causing	O
arrhythmias	I-Entity
.	O

More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	I-Entity
improves	O
symptoms	O
or	O
exercise	O
capacity	O
.	O

Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	I-Entity
may	O
increase	O
mortality	O
after	O
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
.	O

Angiotensin	I-Entity
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
level	O
monitoring	O
,	O
modify	O
progression	O
of	O
disease	O
,	O
relieve	O
symptoms	O
,	O
improve	O
exercise	O
tolerance	O
and	O
reduce	O
mortality	O
.	O

Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	I-Entity
until	O
large	O
mortality	O
trials	O
are	O
completed	O
showing	O
either	O
benefit	O
or	O
harm	O
.	O

Until	O
then	O
digoxin	I-Entity
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
therapy	O
.	O



Intravascular	O
hemolysis	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
intermittent	O
rifampin	I-Entity
therapy	O
.	O

Renal	B-Entity
failure	I-Entity
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	I-Entity
.	O

Intravascular	O
hemolysis	I-Entity
leading	O
to	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
rifampin	I-Entity
therapy	O
is	O
extremely	O
rare	O
.	O

Two	O
patients	O
with	O
leprosy	I-Entity
who	O
developed	O
hemolysis	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
rifampin	I-Entity
are	O
reported	O
.	O



Zidovudine	I-Entity
-	O
induced	O
hepatitis	I-Entity
.	O

A	O
case	O
of	O
acute	O
hepatitis	I-Entity
induced	O
by	O
zidovudine	I-Entity
in	O
a	O
38-year	O
-	O
old	O
patient	O
with	O
AIDS	I-Entity
is	O
presented	O
.	O

The	O
mechanism	O
whereby	O
the	O
hepatitis	I-Entity
was	O
induced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
patient	O
tolerated	O
well	O
an	O
alternative	O
reverse	O
transcriptase	O
inhibitor	O
,	O
2'3	B-Entity
'	I-Entity
dideoxyinosine	I-Entity
.	O

Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	I-Entity
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complication	O
.	O



Thoracic	B-Entity
hematomyelia	I-Entity
secondary	O
to	O
coumadin	I-Entity
anticoagulant	O
therapy	O
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
thoracic	B-Entity
hematomyelia	I-Entity
secondary	O
to	O
anticoagulant	O
therapy	O
is	O
presented	O
.	O



Mania	I-Entity
associated	O
with	O
fluoxetine	I-Entity
treatment	O
in	O
adolescents	O
.	O

Fluoxetine	I-Entity
,	O
a	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitor	O
,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	I-Entity
.	O

Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults	O
,	O
fluoxetine	I-Entity
has	O
been	O
reported	O
to	O
induce	O
mania	I-Entity
.	O

The	O
cases	O
of	O
five	O
depressed	I-Entity
adolescents	O
,	O
14	O
-	O
16	O
years	O
of	O
age	O
,	O
who	O
developed	O
mania	I-Entity
during	O
pharmacotherapy	O
with	O
fluoxetine	I-Entity
,	O
are	O
reported	O
here	O
.	O

Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	I-Entity
or	O
hypomania	I-Entity
during	O
fluoxetine	I-Entity
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention	B-Entity
-	I-Entity
deficit	I-Entity
hyperactivity	I-Entity
disorder	I-Entity
and	O
affective	O
instability	O
;	O
major	O
depression	I-Entity
with	O
psychotic	I-Entity
features	O
;	O
a	O
family	O
history	O
of	O
affective	B-Entity
disorder	I-Entity
,	O
especially	O
bipolar	B-Entity
disorder	I-Entity
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	B-Entity
disorder	I-Entity
.	O

Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	I-Entity
induced	O
mania	I-Entity
in	O
adolescents	O
.	O



Gemfibrozil	I-Entity
-	O
lovastatin	I-Entity
therapy	O
for	O
primary	O
hyperlipoproteinemias	I-Entity
.	O

The	O
specific	O
aim	O
of	O
this	O
retrospective	O
,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long	O
-	O
term	O
(	O
21	O
months	O
/	O
patient	O
)	O
,	O
open	O
-	O
label	O
,	O
gemfibrozil	I-Entity
-	O
lovastatin	I-Entity
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	I-Entity
(	O
68%	O
of	O
whom	O
had	O
atherosclerotic	B-Entity
vascular	I-Entity
disease	I-Entity
)	O
.	O

Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	I-Entity
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	I-Entity
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cholesterol	I-Entity
/	O
HDL	O
cholesterol	I-Entity
less	O
than	O
4.5	O
mg	O
/	O
dl	O
)	O
with	O
diet	O
plus	O
a	O
single	O
drug	O
,	O
gemfibrozil	I-Entity
(	O
1.2	O
g	O
/	O
day)-lovastatin	I-Entity
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
treatment	O
was	O
given	O
.	O

Follow	O
-	O
up	O
visits	O
were	O
scheduled	O
with	O
2-drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
average	O
of	O
10.3	O
visits	O
per	O
patient	O
,	O
with	O
741	O
batteries	O
of	O
6	O
liver	O
function	O
tests	O
and	O
714	O
creatine	I-Entity
phosphokinase	O
levels	O
measured	O
.	O

Of	O
the	O
714	O
creatine	I-Entity
phosphokinase	O
levels	O
,	O
9%	O
were	O
high	O
;	O
only	O
1	O
(	O
0.1%	O
)	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

With	O
2-drug	O
therapy	O
,	O
mean	O
total	O
cholesterol	I-Entity
decreased	O
22%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyceride	I-Entity
levels	O
decreased	O
35%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesterol	I-Entity
decreased	O
26%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesterol	I-Entity
/	O
HDL	O
cholesterol	I-Entity
ratio	O
decreased	O
24%	O
from	O
7.1	O
to	O
5.4	O
,	O
all	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.0001	O
.	O

Myositis	I-Entity
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it	O
,	O
occurred	O
in	O
3%	O
of	O
patients	O
,	O
and	O
in	O
1%	O
with	O
concurrent	O
high	O
creatine	I-Entity
phosphokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patients	O
had	O
rhabdomyolysis	I-Entity
or	O
myoglobinuria.(ABSTRACT	I-Entity
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Hepatocellular	B-Entity
carcinoma	I-Entity
in	O
Fanconi	B-Entity
's	I-Entity
anemia	I-Entity
treated	O
with	O
androgen	I-Entity
and	O
corticosteroid	I-Entity
.	O

The	O
case	O
of	O
an	O
11-year	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi	B-Entity
's	I-Entity
anemia	I-Entity
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	I-Entity
,	O
corticosteroids	I-Entity
and	O
transfusions	O
.	O

Two	O
weeks	O
before	O
his	O
death	O
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	I-Entity
and	O
marked	O
abnormalities	O
in	O
liver	O
function	O
and	O
died	O
of	O
hemorrhagic	B-Entity
bronchopneumonia	I-Entity
.	O

At	O
autopsy	O
peliosis	I-Entity
and	O
multiple	O
hepatic	B-Entity
tumors	I-Entity
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well	O
-	O
differentiated	O
hepatocellular	B-Entity
carcinoma	I-Entity
.	O

This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non	O
-	O
metastasizing	O
hepatic	B-Entity
neoplasms	I-Entity
and	O
peliosis	I-Entity
can	O
develop	O
in	O
patients	O
with	O
androgen-	I-Entity
and	O
corticosteroid	I-Entity
-	O
treated	O
Fanconi	B-Entity
's	I-Entity
anemia	I-Entity
.	O



Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
neurogenic	O
tone	O
in	O
conscious	O
,	O
unrestrained	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartic	I-Entity
acid	I-Entity
.	O

The	O
restimulation	O
of	O
this	O
area	O
with	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartic	I-Entity
acid	I-Entity
15	O
days	O
postlesion	O
failed	O
to	O
produce	O
a	O
pressor	O
response	O
.	O

The	O
ganglionic	O
blocker	O
trimethaphan	I-Entity
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O

The	O
trimethaphan	I-Entity
-	O
induced	O
hypotension	I-Entity
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	I-Entity
in	O
lesioned	O
rats	O
(	O
-32	O

13	O
beats	O
per	O
minute	O
)	O
but	O
a	O
tachycardia	I-Entity
in	O
sham	O
rats	O
(	O
+	O
33	O
+	O
/-	O

Therefore	O
,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	I-Entity
in	O
conscious	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	I-Entity
in	O
the	O
lesioned	O
rats	O
.	O



Damage	B-Entity
of	I-Entity
substantia	I-Entity
nigra	I-Entity
pars	I-Entity
reticulata	I-Entity
during	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
in	O
the	O
rat	O
:	O
immunohistochemical	O
study	O
of	O
neurons	O
,	O
astrocytes	O
and	O
serum	O
-	O
protein	O
extravasation	O
.	O

The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	B-Entity
seizure	I-Entity
activity	O
.	O

Additionally	O
,	O
in	O
models	O
of	O
prolonged	B-Entity
status	I-Entity
epilepticus	I-Entity
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	B-Entity
derangement	I-Entity
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR	O
.	O

In	O
this	O
study	O
,	O
status	B-Entity
epilepticus	I-Entity
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	I-Entity
in	O
rats	O
.	O

Animals	O
surviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	B-Entity
epilepticus	I-Entity
were	O
perfusion	O
-	O
fixed	O
,	O
and	O
brains	O
processed	O
for	O
immunohistochemical	O
staining	O
of	O
SNR	O
.	O

Nissl	O
-	O
staining	O
and	O
antibodies	O
against	O
the	O
neuron	O
-	O
specific	O
calcium	I-Entity
-	O
binding	O
protein	O
,	O
parvalbumin	O
,	O
served	O
to	O
detect	O
neuronal	B-Entity
damage	I-Entity
in	O
SNR	O
.	O

Antibodies	O
against	O
the	O
astroglia	O
-	O
specific	O
cytoskeletal	O
protein	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
glial	O
calcium	I-Entity
-	O
binding	O
protein	O
,	O
S-100	O
protein	O
,	O
were	O
used	O
to	O
assess	O
the	O
status	O
of	O
astrocytes	O
.	O

Immunohistochemical	O
staining	O
for	O
serum	O
-	O
albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood	O
-	O
brain	O
barrier	O
disturbances	O
and	O
vasogenic	B-Entity
edema	I-Entity
formation	O
.	O

Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP	O
-	O
staining	O
already	O
at	O
30	O
min	O
after	O
induction	O
of	O
seizures	I-Entity
in	O
an	O
oval	O
focus	O
situated	O
in	O
the	O
center	O
of	O
SNR	O
while	O
sparing	O
medial	O
and	O
lateral	O
aspects	O
.	O

By	O
2	O
hours	O
,	O
parvalbumin	O
-	O
staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	B-Entity
damage	I-Entity
,	O
and	O
Nissl	O
-	O
staining	O
visualized	O
some	O
neuronal	O
distortion	O
.	O

By	O
6	O
h	O
,	O
vasogenic	B-Entity
edema	I-Entity
covered	O
the	O
lesioned	B-Entity
SNR	I-Entity
.	O

In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days	O
,	O
conventional	O
paraffin	O
-	O
sections	O
confirmed	O
the	O
neuronal	O
and	O
glial	O
damage	B-Entity
of	I-Entity
SNR	I-Entity
.	O

Both	O
cell	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	B-Entity
dysfunction	I-Entity
as	O
occur	O
during	O
massive	O
status	B-Entity
epilepticus	I-Entity
.	O



Reduced	O
cardiotoxicity	I-Entity
of	O
doxorubicin	I-Entity
given	O
in	O
the	O
form	O
of	O
N-(2-hydroxypropyl)methacrylamide	I-Entity
conjugates	O
:	O
and	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	I-Entity
and	O
the	O
late	O
cardiotoxicity	I-Entity
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	I-Entity
(	O
DOX	I-Entity
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N-(2-hydroxypropyl)methacrylamide	I-Entity
(	O
HPMA	I-Entity
)	O

In	O
these	O
HPMA	I-Entity
copolymers	O
,	O
DOX	I-Entity
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non	O
-	O
biodegradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly	B-Entity
-	I-Entity
Phe	I-Entity
-	I-Entity
Leu	I-Entity
-	I-Entity
Gly	I-Entity
)	O
.	O

In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	I-Entity
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	O
.	O

administration	O
of	O
free	O
and	O
polymer	O
-	O
bound	O
DOX	I-Entity
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	O
weight	O
.	O

However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer	O
-	O
bound	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	I-Entity
copolymer	O
and	O
free	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Throughout	O
the	O
study	O
(	O
20	O
weeks	O
)	O
,	O
deaths	O
related	O
to	O
cardiotoxicity	I-Entity
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	I-Entity
or	O
the	O
mixture	O
of	O
HPMA	I-Entity
copolymer	O
and	O
free	O
DOX	I-Entity
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Sequential	O
measurements	O
of	O
cardiac	O
output	O
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	I-Entity
or	O
the	O
mixture	O
of	O
HPMA	I-Entity
copolymer	O
and	O
free	O
DOX	I-Entity
showed	O
a	O
reduction	O
of	O
approximately	O
30%	O
in	O
function	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
drug	O
administration	O
.	O

Animals	O
that	O
were	O
given	O
the	O
HPMA	I-Entity
copolymer	O
conjugates	O
containing	O
DOX	I-Entity
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	O
output	O
throughout	O
the	O
study	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	I-Entity
in	O
the	O
form	O
of	O
HPMA	I-Entity
copolymer	O
conjugates	O
and	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O



Topical	O
0.025%	O
capsaicin	I-Entity
in	O
chronic	O
post	B-Entity
-	I-Entity
herpetic	I-Entity
neuralgia	I-Entity
:	O
efficacy	O
,	O
predictors	O
of	O
response	O
and	O
long	O
-	O
term	O
course	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
efficacy	O
,	O
time	O
-	O
course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	I-Entity
,	O
39	O
patients	O
with	O
chronic	O
post	B-Entity
-	I-Entity
herpetic	I-Entity
neuralgia	I-Entity
(	O
PHN	I-Entity
)	O
,	O
median	O
duration	O
24	O
months	O
,	O
were	O
treated	O
with	O
0.025%	O
capsaicin	I-Entity
cream	O
for	O
8	O
weeks	O
.	O

During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	I-Entity
on	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verbal	O
outcome	O
scale	O
.	O

Nineteen	O
patients	O
(	O
48.7%	O
)	O
substantially	O
improved	O
after	O
the	O
8-week	O
trial	O
;	O
5	O
(	O
12.8%	O
)	O
discontinued	O
therapy	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
intolerable	O
capsaicin	I-Entity
-	O
induced	O
burning	O
sensations	O
(	O
4	O
)	O
or	O
mastitis	I-Entity
(	O
1	O
)	O
;	O
15	O
(	O
38.5%	O
)	O
reported	O
no	O
benefit	O
.	O

Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient	O
's	O
age	O
,	O
duration	O
or	O
localization	O
of	O
PHN	I-Entity
(	O
trigeminal	O
involvement	O
was	O
excluded	O
)	O
,	O
sensory	B-Entity
disturbance	I-Entity
or	O
pain	I-Entity
character	O
.	O

Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence	O
,	O
time	O
-	O
course	O
or	O
severity	O
of	O
capsaicin	I-Entity
-	O
induced	O
burning	O
.	O

If	O
confirmed	O
in	O
controlled	O
trials	O
,	O
the	O
long	O
-	O
term	O
results	O
of	O
this	O
open	O
,	O
non	O
-	O
randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	I-Entity
in	O
PHN	I-Entity
is	O
mediated	O
by	O
both	O
interference	O
with	O
neuropeptide	O
metabolism	O
and	O
morphological	O
changes	O
(	O
perhaps	O
degeneration	O
)	O
of	O
nociceptive	O
afferents	O
.	O



Serotonin	I-Entity
reuptake	O
inhibitors	O
,	O
paranoia	I-Entity
,	O
and	O
the	O
ventral	O
basal	O
ganglia	O
.	O

Antidepressants	O
have	O
previously	O
been	O
associated	O
with	O
paranoid	I-Entity
reactions	O
in	O
psychiatric	O
patients	O
.	O

Five	O
cases	O
of	O
paranoid	I-Entity
exacerbation	O
with	O
the	O
serotonin	I-Entity
reuptake	O
inhibitors	O
fluoxetine	I-Entity
and	O
amitriptyline	I-Entity
are	O
reported	O
here	O
.	O

Elements	O
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	I-Entity
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	B-Entity
and	I-Entity
psychotic	I-Entity
symptoms	I-Entity
.	O

Complicated	O
depressive	B-Entity
disorders	I-Entity
(	O
including	O
atypicality	O
of	O
course	O
and	O
symptomatology	O
,	O
chronicity	O
,	O
psychosis	I-Entity
,	O
bipolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	I-Entity
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	I-Entity
exacerbations	O
associated	O
with	O
serotonin	I-Entity
reuptake	O
inhibitors	O
.	O

Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	I-Entity
remain	O
cryptic	O
,	O
several	O
mechanisms	O
,	O
including	O
5HT3	O
receptor	O
-	O
mediated	O
dopamine	I-Entity
release	O
,	O
beta	O
-	O
noradrenergic	O
receptor	O
downregulation	O
,	O
or	O
GABAB	O
receptor	O
upregulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
ventral	O
basal	O
ganglia	O
(	O
possibly	O
in	O
lateral	O
orbitofrontal	O
or	O
anterior	O
cingulate	O
circuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomenon	O
.	O

These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	I-Entity
exacerbations	O
with	O
serotonin	I-Entity
reuptake	O
blockers	O
in	O
select	O
patients	O
and	O
raise	O
neurobiological	O
considerations	O
regarding	O
paranoia	I-Entity
.	O



Five	O
cases	O
of	O
encephalitis	I-Entity
during	O
treatment	O
of	O
loiasis	I-Entity
with	O
diethylcarbamazine	I-Entity
.	O

Five	O
cases	O
of	O
encephalitis	I-Entity
following	O
treatment	O
with	O
diethylcarbamazine	I-Entity
(	O
DEC	I-Entity
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	I-Entity
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
complication	O
occurred	O
in	O
three	O
patients	O
hospitalized	O
before	O
treatment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therapeutic	O
precautions	O
were	O
taken	O
,	O
i.e.	O
,	O
initial	O
dose	O
less	O
than	O
10	O
mg	O
of	O
DEC	I-Entity
,	O
very	O
gradual	O
dose	O
increases	O
,	O
and	O
associated	O
anti	O
-	O
allergic	O
treatment	O
.	O

The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	I-Entity
and	O
the	O
decrease	O
in	O
microfilaremia	I-Entity
is	O
evident	O
.	O



Delirium	I-Entity
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	I-Entity
.	O

Misoprostol	I-Entity
has	O
been	O
associated	O
with	O
adverse	O
reactions	O
,	O
including	O
gastrointestinal	O
symptoms	O
,	O
gynecologic	O
problems	O
,	O
and	O
headache	I-Entity
.	O

We	O
present	O
a	O
case	O
in	O
which	O
an	O
89-year	O
-	O
old	O
woman	O
in	O
a	O
long	O
-	O
term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	I-Entity
therapy	O
.	O

Her	O
delirium	I-Entity
significantly	O
improved	O
after	O
misoprostol	I-Entity
was	O
discontinued	O
and	O
her	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
a	O
week	O
.	O

Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly	O
,	O
the	O
delirium	I-Entity
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	I-Entity
therapy	O
.	O



Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	O
ischemia	I-Entity
-	O
reperfusion	B-Entity
injury	I-Entity
.	O

Reperfusion	O
of	O
ischemic	I-Entity
intestine	O
results	O
in	O
acute	O
liver	B-Entity
dysfunction	I-Entity
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma	O
,	O
reduction	O
in	O
bile	O
flow	O
rate	O
,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver	O
.	O

The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	B-Entity
injury	I-Entity
is	O
unknown	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	O
are	O
associated	O
with	O
the	O
hepatic	B-Entity
injury	I-Entity
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirect	O
methods	O
of	O
assessing	O
oxidant	O
exposure	O
in	O
vivo	O
.	O

Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	O
ischemia	I-Entity
-	O
reperfusion	B-Entity
injury	I-Entity
.	O

Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	B-Entity
and	I-Entity
reduced	I-Entity
glutathione	I-Entity
.	O

There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	I-Entity
following	O
intestinal	O
ischemia	I-Entity
-	O
reperfusion	B-Entity
injury	I-Entity
.	O

Oxidized	B-Entity
glutathione	I-Entity
(	O
GSSG	I-Entity
)	O
increased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfusion	O
.	O

An	O
increase	O
in	O
GSSG	I-Entity
within	O
hepatic	O
tissue	O
during	O
intestinal	O
reperfusion	O
suggests	O
exposure	O
of	O
hepatocytes	O
to	O
an	O
oxidant	O
stress	O
.	O

These	O
data	O
also	O
suggest	O
that	O
the	O
measurement	O
of	O
tissue	O
GSSG	I-Entity
may	O
be	O
a	O
more	O
sensitive	O
indicator	O
of	O
oxidant	O
stress	O
than	O
measurement	O
of	O
products	O
of	O
lipid	O
peroxidation	O
.	O



Diphenhydramine	I-Entity
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	I-Entity
in	O
ICU	O
patients	O
.	O

Cimetidine	I-Entity
,	O
a	O
histamine	I-Entity
2	O
(	O
H2	O
)	O
antagonist	O
,	O
produces	O
a	O
decrease	O
in	O
arterial	O
pressure	O
due	O
to	O
vasodilatation	O
,	O
especially	O
in	O
critically	O
ill	O
patients	O
.	O

This	O
may	O
be	O
because	O
cimetidine	I-Entity
acts	O
as	O
a	O
histamine	I-Entity
agonist	O
.	O

We	O
,	O
therefore	O
,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	I-Entity
1(H1	O
)	O
receptor	O
antagonist	O
,	O
diphenhydramine	I-Entity
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	I-Entity
in	O
ICU	O
patients	O
.	O

In	O
a	O
random	O
fashion	O
,	O
they	O
received	O
cimetidine	I-Entity
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatment	O
of	O
diphenhydramine	I-Entity
40	O
mg	O
iv	O
with	O
cimetidine	I-Entity
200	O
mg	O
iv	O
.	O

11.4	O
mmHg	O
(	O
P	O
less	O
than	O
0.01	O
)	O
two	O
minutes	O
after	O
cimetidine	I-Entity
.	O

We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	I-Entity
caused	O
by	O
iv	O
cimetidine	I-Entity
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	I-Entity
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
receptor	O
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
due	O
to	O
rifampicin	I-Entity
.	O

A	O
23-year	O
-	O
old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	B-Entity
tuberculosis	I-Entity
was	O
treated	O
with	O
the	O
various	O
regimens	O
of	O
antituberculosis	O
drugs	O
for	O
nearly	O
15	O
months	O
.	O

Rifampicin	I-Entity
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	I-Entity
,	O
vomiting	I-Entity
and	O
fever	I-Entity
with	O
chills	O
and	O
rigors	O
.	O



Severe	O
polyneuropathy	I-Entity
and	O
motor	O
loss	O
after	O
intrathecal	O

thiotepa	I-Entity
combination	O
chemotherapy	O
:	O

Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	B-Entity
toxicity	I-Entity
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(	O
IT	O
)	O
combination	O
chemotherapy	O
including	O
thiotepa	I-Entity
(	O
TSPA	I-Entity
)	O
are	O
presented	O
.	O

Both	O
cases	O
developed	O
axonal	B-Entity
neuropathy	I-Entity
with	O
motor	O
predominance	O
in	O
the	O
lower	O
extremities	O
1	O
and	O
6	O
months	O
after	O
IT	O
chemotherapy	O
was	O
administered	O
.	O

Neurologic	B-Entity
toxicities	I-Entity
have	O
been	O
described	O
with	O
IT	O
-	O
methotrexate	I-Entity
,	O
IT	O
-	O
cytosine	B-Entity
arabinoside	I-Entity
and	O
IT	O
-	O
TSPA	I-Entity
.	O

To	O
our	O
knowledge	O
,	O
however	O
,	O
axonal	B-Entity
neuropathy	I-Entity

In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	I-Entity
is	O
a	O
useful	O
IT	O
agent	O
,	O
its	O
combination	O
with	O
MTX	I-Entity
,	O
ara	B-Entity
-	I-Entity
C	I-Entity
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	I-Entity
.	O

This	O
unexpected	O
complication	O
indicates	O
the	O
need	O
for	O
further	O
toxicology	O
research	O
on	O
IT	O
-	O
TSPA	I-Entity
.	O



Effects	O
of	O
cromakalim	I-Entity
and	O
pinacidil	I-Entity
on	O
large	O
epicardial	O
and	O
small	O
coronary	O
arteries	O
in	O
conscious	O
dogs	O
.	O

bolus	O
administration	O
of	O
cromakalim	I-Entity
(	O
1	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
and	O
pinacidil	I-Entity
(	O
3	O
-	O
100	O
micrograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumflex	O
artery	O
)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	I-Entity
(	O
0.03	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
.	O

Nitroglycerin	I-Entity
,	O
up	O
to	O
0.3	O
micrograms	O
/	O
kg	O
,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(	O
CxAD	O
)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter	O
.	O

In	O
contrast	O
,	O
cromakalim	I-Entity
and	O
pinacidil	I-Entity
at	O
all	O
doses	O
and	O
nitroglycerin	I-Entity
at	O
doses	O
higher	O
than	O
0.3	O
micrograms	O
/	O
kg	O
simultaneously	O
and	O
dose	O
-	O
dependently	O
increased	O
CxAD	O
,	O
coronary	O
blood	O
flow	O
and	O
heart	O
rate	O
and	O
decreased	O
coronary	O
vascular	O
resistance	O
and	O
aortic	O
pressure	O
.	O

Cromakalim	I-Entity
was	O
approximately	O
8-	O
to	O
9.5-fold	O
more	O
potent	O
than	O
pinacidil	I-Entity
in	O
increasing	O
CxAD	O
.	O

Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	I-Entity
induced	O
by	O
cromakalim	I-Entity
and	O
pinacidil	I-Entity
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	B-Entity
adrenergic	I-Entity
and	I-Entity
muscarinic	I-Entity
receptors	I-Entity
blockade	I-Entity
but	O
drug	O
-	O
induced	O
tachycardia	I-Entity
was	O
abolished	O
.	O

When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant	O
,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	I-Entity
(	O
10	O
micrograms	O
/	O
kg	O
)	O
,	O
pinacidil	I-Entity
(	O
30	O
micrograms	O
/	O
kg	O
)	O
and	O
nitroglycerin	I-Entity
(	O
10	O
micrograms	O
/	O
kg	O
)	O
were	O
reduced	O
by	O
68	O
+	O
/-	O

Thus	O
,	O
whereas	O
nitroglycerin	I-Entity
preferentially	O
and	O
flow	O
-	O
independently	O
dilates	O
large	O
coronary	O
arteries	O
,	O
cromakalim	I-Entity
and	O
pinacidil	I-Entity
dilate	O
both	O
large	O
and	O
small	O
coronary	O
arteries	O
and	O
this	O
effect	O
is	O
not	O
dependent	O
upon	O
the	O
simultaneous	O
beta	O
adrenoceptors	O
-	O
mediated	O
rise	O
in	O
myocardial	O
metabolic	O
demand	O
.	O

Finally	O
,	O
two	O
mechanisms	O
at	O
least	O
,	O
direct	O
vasodilation	O
and	O
flow	O
dependency	O
,	O
are	O
involved	O
in	O
the	O
cromakalim-	I-Entity
and	O
pinacidil	I-Entity
-	O
induced	O
increase	O
in	O
CxAD	O
.	O



Mefenamic	B-Entity
acid	I-Entity
-	O
induced	O
neutropenia	I-Entity
and	O
renal	B-Entity
failure	I-Entity
in	O
elderly	O
females	O
with	O
hypothyroidism	I-Entity
.	O

We	O
report	O
mefenamic	B-Entity
acid	I-Entity
-	O
induced	O
non	O
-	O
oliguric	O
renal	B-Entity
failure	I-Entity
and	O
severe	O
neutropenia	I-Entity
occurring	O
simultaneously	O
in	O
two	O
elderly	O
females	O
.	O

The	O
neutropenia	I-Entity
was	O
due	O
to	O
maturation	O
arrest	O
of	O
the	O
myeloid	O
series	O
in	O
one	O
patient	O
.	O

Both	O
patients	O
were	O
also	O
hypothyroid	I-Entity
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposing	O
factor	O
to	O
the	O
development	O
of	O
these	O
adverse	O
reactions	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	B-Entity
acid	I-Entity
in	O
hypothyroid	I-Entity
patients	O
until	O
the	O
hypothyroidism	I-Entity
has	O
been	O
corrected	O
.	O



Etiology	O
of	O
hypercalcemia	I-Entity
in	O
hemodialysis	O
patients	O
on	O
calcium	B-Entity
carbonate	I-Entity
therapy	O
.	O

Fourteen	O
of	O
39	O
dialysis	O
patients	O
(	O
36%	O
)	O
became	O
hypercalcemic	I-Entity
after	O
switching	O
to	O
calcium	B-Entity
carbonate	I-Entity
as	O
their	O
principal	O
phosphate	I-Entity
binder	O
.	O

In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	I-Entity
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	I-Entity
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
length	O
of	O
time	O
on	O
dialysis	O
,	O
and	O
etiology	O
of	O
renal	B-Entity
disease	I-Entity
.	O

In	O
addition	O
to	O
experiencing	O
hypercalcemic	I-Entity
episodes	O
with	O
peak	O
calcium	I-Entity
values	O
of	O
2.7	O
to	O
3.8	O
mmol	O
/	O
L	O
(	O
10.7	O
to	O
15.0	O
mg	O
/	O
dL	O
)	O
,	O
patients	O
in	O
the	O
hypercalcemic	I-Entity
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	I-Entity
concentration	O
obtained	O
during	O
6	O
months	O
before	O
the	O
switch	O
,	O
compared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
months	O
of	O
observation	O
after	O
the	O
switch	O
(	O
2.4	O
+	O
/-	O

In	O
contrast	O
,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	I-Entity
values	O
over	O
the	O
same	O
time	O
period	O
(	O
2.3	O
+	O
/-	O

CaCO3	I-Entity
dosage	O
,	O
calculated	O
dietary	O
calcium	I-Entity
intake	O
,	O
and	O
circulating	O
levels	O
of	O
vitamin	B-Entity
D	I-Entity
metabolites	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Physical	O
activity	O
index	O
and	O
predialysis	O
serum	O
bicarbonate	I-Entity
levels	O
also	O
were	O
similar	O
in	O
both	O
groups	O
.	O



Methyldopa	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near	O
-	O
syncope	I-Entity
.	O

Methyldopa	I-Entity
is	O
an	O
antihypertensive	O
medication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trade	O
name	O
Aldomet	I-Entity
that	O
is	O
widely	O
prescribed	O
in	O
the	O
adult	O
population	O
and	O
infrequently	O
used	O
in	O
children	O
.	O

Methyldopa	I-Entity
causes	O
an	O
autoimmune	B-Entity
hemolytic	I-Entity
anemia	I-Entity
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug	O
.	O

We	O
report	O
a	O
case	O
of	O
methyldopa	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
in	O
a	O
15-year	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	B-Entity
department	I-Entity
with	O
near	O
-	O
syncope	I-Entity
.	O

The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	I-Entity
during	O
a	O
trauma	I-Entity
admission	O
seven	O
weeks	O
prior	O
to	O
presentation	O
.	O

Transfusion	O
and	O
corticosteroid	I-Entity
therapy	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
the	O
patient	O
.	O

A	O
brief	O
review	O
of	O
autoimmune	O
and	O
drug	O
-	O
induced	O
hemolytic	B-Entity
anemias	I-Entity
is	O
provided	O
.	O



The	O
long	O
-	O
term	O
safety	O
of	O
danazol	I-Entity
in	O
women	O
with	O
hereditary	B-Entity
angioedema	I-Entity
.	O

Although	O
the	O
short	O
-	O
term	O
safety	O
(	O
less	O
than	O
or	O
equal	O
to	O
6	O
months	O
)	O
of	O
danazol	I-Entity
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
information	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
safety	O
.	O

We	O
therefore	O
investigated	O
the	O
long	O
-	O
term	O
safety	O
of	O
danazol	I-Entity
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	B-Entity
angioedema	I-Entity
treated	O
with	O
danazol	I-Entity
for	O
a	O
continuous	O
period	O
of	O
6	O
months	O
or	O
longer	O
.	O

Menstrual	B-Entity
abnormalities	I-Entity
(	O
79%	O
)	O
,	O
weight	B-Entity
gain	I-Entity
(	O
60%	O
)	O
,	O
muscle	B-Entity
cramps	I-Entity
/	O
myalgias	I-Entity
(	O
40%	O
)	O
,	O
and	O
transaminase	O
elevations	O
(	O
40%	O
)	O
were	O
the	O
most	O
common	O
adverse	O
reactions	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions	O
,	O
danazol	I-Entity
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
group	O
of	O
patients	O
.	O



Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	B-Entity
diphosphanilate	I-Entity
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	I-Entity
.	O

Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	I-Entity
and	O
mortality	O
in	O
burn	I-Entity
patients	O
.	O

Chlorhexidine	B-Entity
phosphanilate	I-Entity
(	O
CHP	I-Entity
)	O
,	O
a	O
new	O
broad	O
-	O
spectrum	O
antimicrobial	O
agent	O
,	O
has	O
been	O
evaluated	O
as	O
a	O
topical	O
burn	I-Entity
wound	O
dressing	O
in	O
cream	O
form	O
,	O
but	O
preliminary	O
clinical	O
trials	O
reported	O
that	O
it	O
was	O
painful	O
upon	O
application	O
.	O

This	O
study	O
compared	O
various	O
concentrations	O
of	O
CHP	I-Entity
to	O
determine	O
if	O
a	O
tolerable	O
concentration	O
could	O
be	O
identified	O
with	O
retention	O
of	O
antimicrobial	O
efficacy	O
.	O

Twenty	O
-	O
nine	O
burn	I-Entity
patients	O
,	O
each	O
with	O
two	O
similar	O
burns	I-Entity
which	O
could	O
be	O
separately	O
treated	O
,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	O
successive	O
12-h	O
intervals	O
over	O
a	O
3-day	O
period	O
.	O

One	O
burn	I-Entity
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	I-Entity
concentrations	O
,	O
from	O
0.25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicle	O
,	O
and	O
1	O
per	O
cent	O
silver	B-Entity
sulphadiazine	I-Entity
(	O
AgSD	I-Entity
)	O
cream	O
,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	I-Entity
wounds	O
.	O

The	O
other	O
site	O
was	O
always	O
treated	O
with	O
AgSD	I-Entity
cream	O
.	O

There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	I-Entity
concentration	O
and	O
patients	O
'	O
ratings	O
of	O
pain	I-Entity
on	O
an	O
analogue	O
scale	O
.	O

The	O
0.25	O
per	O
cent	O
CHP	I-Entity
cream	O
was	O
closest	O
to	O
AgSD	I-Entity
in	O
pain	I-Entity
tolerance	O
;	O
however	O
,	O
none	O
of	O
the	O
treatments	O
differed	O
statistically	O
from	O
AgSD	I-Entity
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
ease	O
of	O
application	O
of	O
CHP	I-Entity
creams	O
was	O
less	O
satisfactory	O
than	O
that	O
of	O
AgSD	I-Entity
.	O

It	O
was	O
concluded	O
that	O
formulations	O
at	O
or	O
below	O
0.5	O
per	O
cent	O
CHP	I-Entity
may	O
prove	O
acceptable	O
for	O
wound	O
care	O
,	O
but	O
the	O
vehicle	O
system	O
needs	O
pharmaceutical	O
improvement	O
to	O
render	O
it	O
more	O
tolerable	O
and	O
easier	O
to	O
use	O
.	O



Dose	O
-	O
dependent	O
neurotoxicity	I-Entity
of	O
high	O
-	O
dose	O
busulfan	I-Entity
in	O
children	O
:	O
a	O
clinical	O
and	O
pharmacological	O
study	O
.	O

Busulfan	I-Entity
is	O
known	O
to	O
be	O
neurotoxic	I-Entity
in	O
animals	O
and	O
humans	O
,	O
but	O
its	O
acute	O
neurotoxicity	I-Entity
remains	O
poorly	O
characterized	O
in	O
children	O
.	O

We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(	O
median	O
age	O
,	O
6.5	O
years	O
)	O
receiving	O
high	O
-	O
dose	O
busulfan	I-Entity
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	I-Entity
,	O
brain	B-Entity
tumors	I-Entity
excluded	O
.	O

Busulfan	I-Entity
was	O
given	O
p.o	O
.	O

Ninety	O
-	O
six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis	O
;	O
7	O
(	O
7.5%	O
)	O
developed	O
seizures	I-Entity
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	I-Entity
course	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosing	O
.	O

When	O
the	O
total	O
busulfan	I-Entity
dose	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	I-Entity
incidence	O
among	O
patients	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1.7%	O
)	O
and	O
patients	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15.4%	O
)	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Twenty	O
-	O
seven	O
patients	O
were	O
given	O
a	O
600-mg	O
/	O
m2	O
busulfan	I-Entity
total	O
dose	O
with	O
continuous	O
i.v	O
.	O

infusion	O
of	O
clonazepam	I-Entity
;	O
none	O
had	O
any	O
neurological	B-Entity
symptoms	I-Entity
.	O

Busulfan	I-Entity
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	B-Entity
nervous	I-Entity
system	I-Entity
disease	I-Entity
under	O
600	O
mg	O
/	O
m2	O
busulfan	I-Entity
with	O
clonazepam	I-Entity
:	O

busulfan	I-Entity
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
was	O
1.39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0.02	O
)	O
from	O
the	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16-mg	O
/	O
kg	O
total	O
dose	O
of	O
busulfan	I-Entity
.	O

This	O
study	O
shows	O
that	O
busulfan	I-Entity
neurotoxicity	I-Entity
is	O
dose	O
-	O
dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	I-Entity
.	O

A	O
busulfan	I-Entity
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children	O
,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	I-Entity
,	O
close	O
to	O
neurotoxicity	I-Entity
incidence	O
observed	O
in	O
adults	O
.	O

Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	I-Entity
clearance	O
in	O
children	O
than	O
in	O
adults	O
,	O
this	O
new	O
dose	O
may	O
approximate	O
more	O
closely	O
the	O
adult	O
systemic	O
exposure	O
obtained	O
after	O
the	O
usual	O
16-mg	O
/	O
kg	O
total	O
dose	O
,	O
with	O
potential	O
inferences	O
in	O
terms	O
of	O
anticancer	O
or	O
myeloablative	O
effects	O
.	O

The	O
busulfan	I-Entity
dose	O
in	O
children	O
and	O
infants	O
undergoing	O
bone	O
marrow	O
transplantation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pharmacokinetic	O
studies	O
.	O



Histamine	I-Entity
antagonists	O
and	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
cardiac	O
surgical	O
patients	O
.	O

Hemodynamic	O
effects	O
and	O
histamine	I-Entity
release	O
by	O
bolus	O
injection	O
of	O
0.35	O
mg	O
/	O
kg	O
of	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
were	O
studied	O
in	O
24	O
patients	O
.	O

H1-	O
and	O
H2-histamine	I-Entity
antagonists	O
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
in	O
a	O
randomized	O
double	O
-	O
blind	O
fashion	O
to	O
four	O
groups	O
:	O
group	O
1	O
-	O
-placebo	O
;	O
group	O
2	O
-	O
-cimetidine	I-Entity
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
group	O
3	O
-	O
-chlorpheniramine	I-Entity
,	O
0.1	O

mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
and	O
group	O
4	O
-	O
-cimetidine	I-Entity
plus	O
chlorpheniramine	I-Entity
.	O

Histamine	I-Entity
release	O
occurred	O
in	O
most	O
patients	O
,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
dosing	O
.	O

Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	I-Entity
change	O
and	O
systemic	O
vascular	O
resistance	O
(	O
r	O
=	O
0.58	O
;	O
P	O
less	O
than	O
0.05	O
)	O
not	O
present	O
in	O
group	O
4	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	I-Entity
release	O
.	O



Convulsant	O
effect	O
of	O
lindane	I-Entity
and	O
regional	O
brain	O
concentration	O
of	O
GABA	I-Entity
and	O
dopamine	I-Entity
.	O

Lindane	I-Entity
(	O
gamma	B-Entity
-	I-Entity
hexachlorocyclohexane	I-Entity
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	I-Entity
effects	O
.	O

Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	I-Entity
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagonist	O
at	O
the	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA)-A	I-Entity
receptor	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lindane	I-Entity
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	I-Entity
,	O
dopamine	I-Entity
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	O
the	O
onset	O
of	O
seizures	I-Entity
.	O

All	O
animals	O
suffered	O
tonic	O
convulsions	I-Entity
at	O
18.3	O

1.4	O
min	O
after	O
lindane	I-Entity
administration	O
.	O

The	O
concentration	O
of	O
GABA	I-Entity
was	O
only	O
slightly	O
but	O
significantly	O
decreased	O
in	O
the	O
colliculi	O
without	O
modifications	O
in	O
the	O
other	O
areas	O
.	O

The	O
concentration	O
of	O
dopamine	I-Entity
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	I-Entity
was	O
also	O
increased	O
in	O
the	O
mesencephalon	O
and	O
the	O
striatum	O
.	O



Two	O
cases	O
of	O
propylthiouracil	I-Entity
-	O
associated	O
acute	O
hepatitis	I-Entity
,	O
one	O
case	O
of	O
fatal	O
methimazole	I-Entity
-	O
associated	O
hepatocellular	B-Entity
necrosis	I-Entity
and	O
one	O
case	O
of	O
propylthiouracil	I-Entity
-	O
associated	O
lupus	B-Entity
-	I-Entity
like	I-Entity
syndrome	I-Entity
are	O
described	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	I-Entity
.	O



Anticonvulsant	O
actions	O
of	O
MK-801	I-Entity
on	O
the	O
lithium	I-Entity
-	O
pilocarpine	I-Entity
model	O
of	O
status	B-Entity
epilepticus	I-Entity
in	O
rats	O
.	O

MK-801	I-Entity
,	O
a	O
noncompetitive	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptor	O
antagonist	O
,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	I-Entity
models	O
,	O
coadministration	O
of	O
lithium	I-Entity
and	O
pilocarpine	I-Entity
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	I-Entity
alone	O
.	O

First	O
,	O
pretreatment	O
with	O
MK-801	I-Entity
produced	O
an	O
effective	O
and	O
dose	O
-	O
dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium	I-Entity
-	O
pilocarpine	I-Entity
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	I-Entity
alone	O
,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	I-Entity
in	O
these	O
two	O
models	O
.	O

Second	O
,	O
the	O
anticonvulsant	O
effect	O
of	O
MK-801	I-Entity
in	O
the	O
lithium	I-Entity
-	O
pilocarpine	I-Entity
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	I-Entity
activity	O
.	O

This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK-801	I-Entity
binding	O
requires	O
agonist	O
-	O
induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	I-Entity
receptor	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	I-Entity
induced	O
by	O
lithium	I-Entity
and	O
pilocarpine	I-Entity
by	O
administration	O
of	O
anticonvulsants	O
prior	O
to	O
pilocarpine	I-Entity
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	B-Entity
epilepticus	I-Entity
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	I-Entity
.	O

Administration	O
of	O
MK-801	I-Entity
30	O
or	O
60	O
min	O
after	O
pilocarpine	I-Entity
,	O
i.e.	O
,	O
during	O
status	B-Entity
epilepticus	I-Entity
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	I-Entity
activity	O
and	O
greatly	O
enhanced	O
the	O
survival	O
rate	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	I-Entity
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	B-Entity
epilepticus	I-Entity
and	O
brain	B-Entity
damage	I-Entity
in	O
the	O
lithium	I-Entity
-	O
pilocarpine	I-Entity
model	O
.	O

This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	I-Entity
and	O
pilocarpine	I-Entity
were	O
synergistic	O
,	O
resulting	O
in	O
status	B-Entity
epilepticus	I-Entity
and	O
subsequent	O
mortality	O
.	O



Nifedipine	I-Entity
induced	O
bradycardia	I-Entity
in	O
a	O
patient	O
with	O
autonomic	B-Entity
neuropathy	I-Entity
.	O

An	O
80	O
year	O
old	O
diabetic	I-Entity
male	O
with	O
evidence	O
of	O
peripheral	B-Entity
and	I-Entity
autonomic	I-Entity
neuropathy	I-Entity
was	O
admitted	O
with	O
chest	B-Entity
pain	I-Entity
.	O

He	O
was	O
found	O
to	O
have	O
atrial	B-Entity
flutter	I-Entity
at	O
a	O
ventricular	O
rate	O
of	O
70/min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40/min	O
when	O
nifedipine	I-Entity
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doses	O
,	O
during	O
which	O
he	O
was	O
paced	O
at	O
a	O
rate	O
of	O
70/min	O
.	O

This	O
is	O
inconsistent	O
with	O
the	O
well	O
-	O
established	O
finding	O
that	O
nifedipine	I-Entity
induces	O
tachycardia	I-Entity
in	O
normally	O
innervated	O
hearts	O
.	O

However	O
,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycardia	I-Entity
.	O



The	O
effect	O
of	O
haloperidol	I-Entity
in	O
cocaine	I-Entity
and	O
amphetamine	I-Entity
intoxication	O
.	O

The	O
effectiveness	O
of	O
haloperidol	I-Entity
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	I-Entity
and	O
cocaine	I-Entity
was	O
studied	O
in	O
rats	O
.	O

injection	O
of	O
amphetamine	I-Entity
75	O
mg	O
/	O
kg	O
(	O
100%	O
death	O
rate	O
)	O
or	O
cocaine	I-Entity
70	O
mg	O
/	O
kg	O
(	O
82%	O
death	O
rate	O
)	O
.	O

Haloperidol	I-Entity
failed	O
to	O
prevent	O
amphetamine	I-Entity
-	O
induced	O
seizures	I-Entity
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	O
most	O
doses	O
tested	O
.	O

Haloperidol	I-Entity
decreased	O
the	O
incidence	O
of	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
at	O
the	O
two	O
highest	O
doses	O
,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	O
any	O
dose	O
.	O

These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	I-Entity
blocker	O
haloperidol	I-Entity
against	O
death	O
from	O
high	O
-	O
dose	O
amphetamine	I-Entity
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	I-Entity
.	O

In	O
contrast	O
,	O
haloperidol	I-Entity
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
without	O
significantly	O
reducing	O
mortality	O
.	O



Autoradiographic	O
evidence	O
of	O
estrogen	I-Entity
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	I-Entity
induced	O
hamster	O
renal	B-Entity
carcinomas	I-Entity
.	O

Estrogen	I-Entity
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	I-Entity

induced	O
renal	B-Entity
carcinomas	I-Entity
in	O
three	O
hamsters	O
.	O

Radiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H-17	O
beta	O
estradiol	I-Entity
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	I-Entity
cells	O
;	O
stereologic	O
analysis	O
revealed	O
a	O
4.5-	O
to	O
6.7-times	O
higher	O
concentration	O
of	O
reduced	O
silver	I-Entity
grains	O
over	O
nuclei	O
than	O
cytoplasm	O
of	O
these	O
cells	O
.	O

Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	I-Entity
which	O
peaked	O
in	O
less	O
than	O
1	O

This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	I-Entity
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	I-Entity
induced	O
hamster	O
renal	B-Entity
carcinomas	I-Entity
.	O



Bradycardia	I-Entity
due	O
to	O
biperiden	I-Entity
.	O

In	O
a	O
38-year	O
-	O
old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	I-Entity
trigeminal	B-Entity
neuralgia	I-Entity
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	B-Entity
lactate	I-Entity
led	O
to	O
a	O
long	O
-	O
lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	I-Entity
,	O
dysarthria	I-Entity
,	O
and	O
dysphagia	I-Entity
.	O

The	O
heart	O
rate	O
was	O
back	O
to	O
normal	O
within	O
12	O
hours	O
upon	O
administration	O
of	O
orciprenaline	I-Entity
under	O
cardiac	O
monitoring	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

Bradycardia	I-Entity
induced	O
by	O
biperiden	I-Entity
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose	O
-	O
related	O
dual	O
effect	O
of	O
atropine	I-Entity
-	O
like	O
drugs	O
on	O
muscarine	I-Entity
receptors	O
.	O



Deliberate	O
hypotension	I-Entity
induced	O
by	O
labetalol	I-Entity
with	O
halothane	I-Entity
,	O
enflurane	I-Entity
or	O
isoflurane	I-Entity
for	O
middle	O
-	O
ear	O
surgery	O
.	O

The	O
feasibility	O
of	O
using	O
labetalol	I-Entity
,	O
an	O
alpha-	O
and	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
as	O
a	O
hypotensive	I-Entity
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	I-Entity
,	O
enflurane	I-Entity
or	O
isoflurane	I-Entity
)	O
was	O
studied	O
in	O
23	O
adult	O
patients	O
undergoing	O
middle	O
-	O
ear	O
surgery	O
.	O

10	O
min	O
in	O
the	O
halothane	I-Entity
(	O
H	I-Entity
)	O
group	O
,	O
from	O
79	O
+	O
/-	O

11	O
min	O
in	O
the	O
enflurane	I-Entity
(	O
E	I-Entity
)	O
group	O
,	O
and	O
from	O
80	O
+	O
/-	O

15	O
min	O
in	O
the	O
isoflurane	I-Entity
(	O
I	I-Entity
)	O
group	O
.	O

The	O
mean	O
H	I-Entity
concentration	O
during	O
hypotension	I-Entity
in	O
the	O
inspiratory	O
gas	O
was	O
0.7	O
+	O
/-	O

0.1	O
vol%	O
,	O
the	O
mean	O
E	I-Entity
concentration	O
1.6	O
+	O
/-	O

I	I-Entity
concentration	O
1.0	O
+	O
/-	O

In	O
addition	O
,	O
the	O
patients	O
received	O
fentanyl	I-Entity
and	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
.	O

The	O
initial	O
dose	O
of	O
labetalol	I-Entity
for	O
lowering	O
blood	O
pressure	O
was	O
similar	O
,	O
0.52	O
-	O
0.59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
groups	O
.	O

During	O
hypotension	I-Entity
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy-	B-Entity
or	I-Entity
bradycardia	I-Entity
.	O

The	O
operating	O
conditions	O
regarding	O
bleeding	I-Entity
were	O
estimated	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

During	O
hypotension	I-Entity
,	O
the	O
serum	O
creatinine	I-Entity
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	I-Entity
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups	O
,	O
except	O
the	O
isoflurane	I-Entity
group	O
.	O

After	O
hypotension	I-Entity
there	O
was	O
no	O
rebound	O
phenomenon	O
in	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

These	O
results	O
indicate	O
that	O
labetalol	I-Entity
induces	O
easily	O
adjustable	O
hypotension	I-Entity
without	O
compensatory	O
tachycardia	I-Entity
and	O
rebound	O
hypertension	I-Entity
.	O



Convulsion	I-Entity
following	O
intravenous	O
fluorescein	I-Entity
angiography	O
.	O

Tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizures	I-Entity
followed	O
intravenous	O
fluorescein	I-Entity
injection	O
for	O
fundus	O
angiography	O
in	O
a	O
47-year	O
-	O
old	O
male	O
.	O

Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re	O
-	O
exposure	O
to	O
intravenous	O
fluorescein	I-Entity
.	O



Pharmacology	O
of	O
ACC-9653	I-Entity
(	O
phenytoin	I-Entity
prodrug	O
)	O
.	O

ACC-9653	I-Entity
,	O
the	O
disodium	B-Entity
phosphate	I-Entity
ester	I-Entity
of	O
3-hydroxymethyl-5,5-diphenylhydantoin	I-Entity
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	I-Entity
with	O
advantageous	O
physicochemical	O
properties	O
.	O

ACC-9653	I-Entity
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	I-Entity
in	O
vivo	O
.	O

ACC-9653	I-Entity
and	O
phenytoin	B-Entity
sodium	I-Entity

have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	I-Entity
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
in	O
mice	O
following	O
i.p	O
.	O

ACC-9653	I-Entity
and	O
8	O
mg	O
/	O
kg	O
for	O
i.v	O
.	O

phenytoin	B-Entity
sodium	I-Entity
.	O

ACC-9653	I-Entity
and	O
phenytoin	B-Entity
sodium	I-Entity
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	I-Entity
-	O
induced	O
ventricular	B-Entity
tachycardia	I-Entity
in	O
anesthetized	O
dogs	O
.	O

The	O
total	O
doses	O
of	O
ACC-9653	I-Entity
or	O
phenytoin	B-Entity
sodium	I-Entity
necessary	O
to	O
convert	O
the	O
arrhythmia	I-Entity
to	O
a	O
normal	O
sinus	O
rhythm	O
were	O
24	O
+	O
/-	O

Only	O
phenytoin	B-Entity
sodium	I-Entity
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin	I-Entity
-	O
induced	O
arrhythmias	I-Entity
in	O
guinea	O
pig	O
right	O
atria	O
.	O

In	O
anesthetized	O
dogs	O
,	O
a	O
high	O
dose	O
of	O
ACC-9653	I-Entity
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	B-Entity
sodium	I-Entity
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC-9653	I-Entity
and	O
phenytoin	B-Entity
sodium	I-Entity
treatments	O
produced	O
similar	O
marked	O
reductions	O
in	O
diastolic	O
blood	O
pressure	O
and	O
contractile	O
force	O
(	O
LVdP	O
/	O
dt	O
)	O
.	O

The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	O
the	O
time	O
of	O
maximum	O
phenytoin	B-Entity
sodium	I-Entity
levels	O
.	O

Acute	O
toxicity	I-Entity
studies	O
of	O
ACC-9653	I-Entity
and	O
phenytoin	B-Entity
sodium	I-Entity
were	O
carried	O
out	O
in	O
mice	O
,	O
rats	O
,	O
rabbits	O
,	O
and	O
dogs	O
by	O
i.v	O
.	O

Importantly	O
,	O
the	O
local	O
irritation	O
of	O
ACC-9653	I-Entity
was	O
markedly	O
less	O
than	O
phenytoin	B-Entity
sodium	I-Entity
following	O
i.m	O
.	O



Phenytoin	I-Entity
induced	O
fatal	O
hepatic	B-Entity
injury	I-Entity
.	O

A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	B-Entity
failure	I-Entity
after	O
phenytoin	I-Entity
administration	O
.	O

A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	B-Entity
injury	I-Entity
.	O

The	O
hematologic	O
,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	B-Entity
damage	I-Entity
due	O
to	O
drug	B-Entity
hypersensitivity	I-Entity
.	O

In	O
a	O
patient	O
receiving	O
phenytoin	I-Entity
who	O
presents	O
a	O
viral	O
-	O
like	O
illness	O
,	O
early	O
recognition	O
and	O
discontinuation	O
of	O
the	O
drug	O
are	O
mandatory	O
.	O



Treatment	O
of	O
lethal	O
pertussis	B-Entity
vaccine	I-Entity
reaction	O
with	O
histamine	I-Entity
H1	O
antagonists	O
.	O

We	O
studied	O
mortality	O
after	O
pertussis	I-Entity
immunization	O
in	O
the	O
mouse	O
.	O

Without	O
treatment	O
,	O
73	O
of	O
92	O
animals	O
(	O
80%	O
)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	I-Entity
immunization	O
.	O

After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	I-Entity
,	O
2	O
mg	O
mianserin	I-Entity
,	O
or	O
2	O
mg	O
chlorpheniramine	I-Entity
,	O
only	O
5	O
of	O
105	O
animals	O
(	O
5%	O
)	O
died	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Blockade	O
of	O
histamine	I-Entity
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	I-Entity
immunization	O
-	O
induced	O
encephalopathy	I-Entity
in	O
mice	O
.	O



Support	O
for	O
adrenaline	I-Entity
-	O
hypertension	I-Entity
hypothesis	O
:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	I-Entity
infusion	O
.	O

In	O
a	O
double	O
blind	O
,	O
crossover	O
study	O
6	O
h	O
infusions	O
of	O
adrenaline	I-Entity
(	O

15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5.458	O
pmol	O
)	O
,	O
noradrenaline	I-Entity
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5.911	O
pmol	O
)	O
,	O
and	O
a	O
5%	O
dextrose	I-Entity
solution	O
(	O
5.4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healthy	O
volunteers	O
in	O
random	O
order	O
2	O
weeks	O
apart	O
.	O

Adrenaline	I-Entity
,	O
but	O
not	O
noradrenaline	I-Entity
,	O
caused	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

Over	O
the	O
total	O
postinfusion	O
period	O
systolic	O
and	O
diastolic	O
arterial	O
pressure	O
were	O
6	O
(	O
SEM	O
2)%	O
and	O
7	O
(	O
2)%	O
,	O
respectively	O
,	O
higher	O
than	O
after	O
dextrose	I-Entity
infusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Thus	O
,	O
""""	O
stress	O
""""	O
levels	O
of	O
adrenaline	I-Entity
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline	I-Entity
-	O
hypertension	I-Entity
hypothesis	O
in	O
man	O
.	O



Effect	O
of	O
alkylxanthines	I-Entity
on	O
gentamicin	I-Entity
-	O
induced	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
in	O
the	O
rat	O
.	O

Adenosine	I-Entity
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	I-Entity
and	O
nephrotoxic	I-Entity
models	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
(	O
ARF	I-Entity
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	I-Entity
with	O
different	O
potencies	O
as	O
adenosine	I-Entity
antagonists	O
8-phenyltheophylline	I-Entity
,	O
theophylline	I-Entity
and	O
enprofylline	I-Entity
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
after	O
4	O
daily	O
injections	O
of	O
gentamicin	I-Entity
(	O
200	O
mg	O
kg-1	O
)	O
.	O

Renal	O
function	O
was	O
assessed	O
by	O
biochemical	O
(	O
plasma	O
urea	I-Entity
and	O
creatinine	I-Entity
)	O
,	O
functional	O
(	O
urine	O
analysis	O
and	O
[	O
3H]inulin	O
and	O
[	O
14C]p	B-Entity
-	I-Entity
aminohippuric	I-Entity
acid	I-Entity
clearances	O
)	O
and	O
morphological	O
(	O
degree	O
of	O
necrosis	I-Entity
)	O
indices	O
.	O

However	O
,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	B-Entity
glycol	I-Entity
and	O
NaOH	I-Entity
)	O
.	O

The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	I-Entity
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	I-Entity
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiological	O
role	O
in	O
gentamicin	I-Entity
-	O
induced	O
ARF	I-Entity
.	O



Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	I-Entity
.	O

A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	I-Entity
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	I-Entity
.	O

Blepharoconjunctivitis	I-Entity
,	O
subjective	O
complaints	O
of	O
dry	B-Entity
eyes	I-Entity
,	O
blurred	B-Entity
vision	I-Entity
,	O
contact	O
lens	O
intolerance	O
,	O
and	O
photodermatitis	I-Entity
are	O
reversible	O
side	O
effects	O
.	O

More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	I-Entity
,	O
pseudotumor	B-Entity
cerebri	I-Entity
,	O
and	O
white	O
or	O
gray	O
subepithelial	O
corneal	B-Entity
opacities	I-Entity
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drug	O
is	O
discontinued	O
.	O

Isotretinoin	I-Entity
is	O
contraindicated	O
in	O
pregnancy	O
because	O
of	O
the	O
many	O
reported	O
congenital	B-Entity
abnormalities	I-Entity
after	O
maternal	O
use	O
(	O
including	O
microphthalmos	I-Entity
,	O
orbital	O
hypertelorism	I-Entity
,	O
and	O
optic	B-Entity
nerve	I-Entity
hypoplasia	I-Entity
)	O
.	O



Procaterol	I-Entity
and	O
terbutaline	I-Entity
in	O
bronchial	B-Entity
asthma	I-Entity
.	O

Procaterol	I-Entity
,	O
a	O
new	O
beta-2	O
adrenoceptor	O
stimulant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
trial	O
in	O
patients	O
with	O
bronchial	B-Entity
asthma	I-Entity
.	O

Oral	O
procaterol	I-Entity
50	O
micrograms	O
b.d	O
.	O

,	O
procaterol	I-Entity
100	O
micrograms	O
b.d	O
.	O

terbutaline	I-Entity
5	O
mg	O
t.i.d	O
.	O

The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	I-Entity
.	O

Both	O
anti	O
-	O
asthmatic	I-Entity
and	O
tremorgenic	I-Entity
effects	O
of	O
procaterol	I-Entity
were	O
dose	O
-	O
related	O
.	O

Procaterol	I-Entity
appeared	O
effective	O
in	O
the	O
doses	O
tested	O
,	O
and	O
a	O
twice	O
daily	O
regimen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
drug	O
.	O



Subacute	O
effects	O
of	O
propranolol	I-Entity
and	O
B	O
24/76	O
on	O
isoproterenol	I-Entity
-	O
induced	O
rat	O
heart	B-Entity
hypertrophy	I-Entity
in	O
correlation	O
with	O
blood	O
pressure	O
.	O

24/76	O
i.e.	O
1-(2,4-dichlorophenoxy)-3[2	O
-	O
3,4-dimethoxyphenyl)ethanolamino]-prop	O
an-2-ol	O
,	O
which	O
is	O
characterized	O
by	O
beta	O
1-adrenoceptor	O
blocking	O
and	O
beta	O
2-adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	I-Entity
.	O

The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol	I-Entity
-	O
induced	O
heart	B-Entity
hypertrophy	I-Entity
in	O
rats	O
.	O

A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	B-Entity
hypertrophy	I-Entity
with	O
the	O
two	O
beta	O
-	O
receptor	O
blockers	O
.	O

Both	O
beta	O
-	O
blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	I-Entity
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	I-Entity
decarboxylase	O
activity	O
with	O
both	O
beta	O
-	O
blockers	O
in	O
hypertrophied	B-Entity
hearts	I-Entity
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
heart	O
mass	O
.	O

Neither	O
propranolol	I-Entity
nor	O
B	O
24/76	O
could	O
stop	O
the	O
changes	O
in	O
the	O
characteristic	O
myosin	O
isoenzyme	O
pattern	O
of	O
the	O
hypertrophied	I-Entity
rat	O
heart	O
.	O

Thus	O
,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta	O
-	O
receptor	O
blockers	O
propranolol	I-Entity
and	O
B	O
24/76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	I-Entity
from	O
producing	O
heart	B-Entity
hypertrophy	I-Entity
.	O



Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	B-Entity
bromide	I-Entity
and	O
of	O
slow	O
-	O
release	O
theophylline	I-Entity
on	O
nocturnal	O
asthma	I-Entity
.	O

The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug	O
,	O
oxitropium	B-Entity
bromide	I-Entity
,	O
and	O
of	O
a	O
slow	O
-	O
release	O
theophylline	I-Entity
preparation	O
upon	O
nocturnal	O
asthma	I-Entity
were	O
compared	O
in	O
a	O
placebo	O
-	O
controlled	O
double	O
-	O
blind	O
study	O
.	O

Two	O
samples	O
were	O
studied	O
:	O
12	O
patients	O
received	O
oxitropium	I-Entity
at	O
600	O
micrograms	O
(	O
6	O
subjects	O
)	O
or	O
at	O
400	O
micrograms	O
t.i.d	O
.	O

(	O
6	O
subjects	O
)	O
whereas	O
11	O
received	O
theophylline	I-Entity
at	O
300	O
mg	O
b.i.d	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug	O
,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	I-Entity
.	O

No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	I-Entity
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	I-Entity
,	O
vomiting	I-Entity
and	O
tremors	I-Entity
after	O
theophylline	I-Entity
.	O

Oxitropium	I-Entity
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	I-Entity
in	O
nocturnal	O
asthma	I-Entity
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titration	O
of	O
dosage	O
.	O



Penicillin	I-Entity
anaphylaxis	I-Entity
.	O

A	O
case	O
of	O
oral	O
penicillin	I-Entity
anaphylaxis	I-Entity
is	O
described	O
,	O
and	O
the	O
terminology	O
,	O
occurrence	O
,	O
clinical	O
manifestations	O
,	O
pathogenesis	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
anaphylaxis	I-Entity
are	O
reviewed	O
.	O

Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	I-Entity
anaphylaxis	I-Entity
in	O
order	O
to	O
prevent	O
its	O
occurrence	O
by	O
prescribing	O
the	O
antibiotic	O
judiciously	O
and	O
knowledgeably	O
and	O
to	O
offer	O
optimal	O
medical	O
therapy	O
once	O
this	O
life	O
-	O
threatening	O
reaction	O
has	O
begun	O
.	O



Reversible	O
valproic	B-Entity
acid	I-Entity
-	O
induced	O
dementia	I-Entity
:	O
a	O
case	O
report	O
.	O

Reversible	O
valproic	B-Entity
acid	I-Entity
-	O
induced	O
dementia	I-Entity
was	O
documented	O
in	O
a	O
21-year	O
-	O
old	O
man	O
with	O
epilepsy	I-Entity
who	O
had	O
a	O
3-year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
abilities	O
documented	O
by	O
serial	O
neuropsychological	O
studies	O
.	O

Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxic	O
effect	O
of	O
valproic	B-Entity
acid	I-Entity
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	B-Entity
acid	I-Entity
-	O
induced	O
hyperammonemia	I-Entity
.	O



Reversal	O
of	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
of	O
passive	O
avoidance	O
by	O
pre-	O
and	O
post	O
-	O
training	O
naloxone	I-Entity
.	O

In	O
a	O
series	O
of	O
five	O
experiments	O
,	O
the	O
modulating	O
role	O
of	O
naloxone	I-Entity
on	O
a	O
scopolamine	I-Entity
-	O
induced	O
retention	B-Entity
deficit	I-Entity
in	O
a	O
passive	O
avoidance	O
paradigm	O
was	O
investigated	O
in	O
mice	O
.	O

Scopolamine	I-Entity
,	O
but	O
not	O
methyl	B-Entity
scopolamine	I-Entity
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induced	O
an	O
amnesia	I-Entity
as	O
measured	O
by	O
latency	O
and	O
duration	O
parameters	O
.	O

Naloxone	I-Entity
(	O
0.3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	B-Entity
deficit	I-Entity
with	O
a	O
peak	O
of	O
activity	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
effect	O
of	O
naloxone	I-Entity
could	O
be	O
antagonized	O
with	O
morphine	I-Entity
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	I-Entity
effect	O
.	O

Post	O
-	O
training	O
administration	O
of	O
naloxone	I-Entity
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O

Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	I-Entity
sensitivity	O
(	O
pre	O
-	O
training	O
naloxone	I-Entity
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(	O
post	O
-	O
training	O
naloxone	I-Entity
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	I-Entity
on	O
the	O
scopolamine	I-Entity
-	O
induced	O
retention	B-Entity
deficit	I-Entity
.	O



Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide	I-Entity
-	O
induced	O
lesions	B-Entity
of	I-Entity
the	I-Entity
urinary	I-Entity
bladder	I-Entity
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	I-Entity
.	O

Fully	O
developed	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium	O
,	O
severe	O
submucosal	O
edema	I-Entity
owing	O
to	O
damage	O
to	O
the	O
microvascular	O
bed	O
and	O
focal	O
muscle	O
necroses	I-Entity
.	O

The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	I-Entity
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	I-Entity
membrane	O
.	O

Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells	O
,	O
intercellular	O
and	O
intracellular	O
edema	I-Entity
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	O
to	O
progressive	O
degeneration	O
and	O
detachment	O
of	O
the	O
epithelial	O
cells	O
with	O
exposure	O
and	O
splitting	O
of	O
the	O
basal	O
membrane	O
.	O

These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	I-Entity
.	O



Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium	I-Entity
-	O
induced	O
muscle	B-Entity
fasciculations	I-Entity
in	O
children	O
:	O
inhibition	O
by	O
alfentanil	I-Entity
.	O

Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	I-Entity
1.5	O
mg	O
kg-1	O
i.v	O
.	O
were	O
studied	O
in	O
32	O
children	O
(	O
mean	O
age	O
6.9	O
yr	O
)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	I-Entity
50	O
micrograms	O
kg-1	O
.	O

Anaesthesia	O
was	O
induced	O
with	O
thiopentone	I-Entity
5	O
mg	O
kg-1	O
.	O

The	O
incidence	O
and	O
intensity	O
of	O
muscle	B-Entity
fasciculations	I-Entity
caused	O
by	O
suxamethonium	I-Entity
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	I-Entity
group	O
.	O

The	O
intragastric	O
pressure	O
during	O
muscle	B-Entity
fasciculations	I-Entity
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(	O
16	O
+	O
/-	O

0.7	O
(	O
SEM	O
)	O
cm	O
H2O	I-Entity
)	O
than	O
in	O
the	O
alfentanil	I-Entity
group	O
(	O
7.7	O
+	O
/-	O

(	O
SEM	O
)	O
cm	O
H2O	I-Entity
)	O
.	O

The	O
increase	O
in	O
intragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
intensity	O
of	O
muscle	B-Entity
fasciculations	I-Entity
(	O
regression	O
line	O
:	O
y	O
=	O
0.5	O
+	O
4.78x	O
with	O
r	O
of	O
0.78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	B-Entity
fasciculations	I-Entity
caused	O
by	O
suxamethonium	I-Entity
in	O
healthy	O
children	O
.	O

Alfentanil	I-Entity
50	O
micrograms	O
kg-1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium	I-Entity
-	O
induced	O
muscle	B-Entity
fasciculations	I-Entity
;	O
moreover	O
,	O
intragastric	O
pressure	O
remains	O
at	O
its	O
control	O
value	O
.	O



Acute	O
insulin	O
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	I-Entity
effect	O
of	O
isoproterenol	I-Entity
in	O
streptozotocin	I-Entity
diabetic	I-Entity
rats	O
.	O

A	O
morphometric	O
study	O
of	O
isoproterenol	I-Entity
induced	O
myocardial	O
fibrosis	I-Entity
.	O

The	O
acute	O
effect	O
of	O
insulin	O
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	I-Entity
diabetes	I-Entity
against	O
the	O
cardiotoxic	I-Entity
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	I-Entity
(	O
ISO	I-Entity
)	O
was	O
investigated	O
in	O
rats	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	O
,	O
ISO	I-Entity
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	I-Entity
induced	O
fibrosis	I-Entity
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0.83	O
,	O
2	O
p	O
=	O
0.006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	I-Entity
after	O
insulin	O
treatment	O
appeared	O
.	O

The	O
myocardial	O
content	O
of	O
catecholamines	I-Entity
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	I-Entity
rats	O
.	O

The	O
norepinephrine	I-Entity
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	I-Entity
remained	O
unchanged	O
.	O

An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta	O
-	O
adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	I-Entity
resistance	O
.	O

The	O
rapid	O
reversion	O
after	O
insulin	O
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	I-Entity
in	O
itself	O
causes	O
the	O
ISO	I-Entity
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	O
effect	O
on	O
myocardial	O
catecholamine	I-Entity
sensitivity	O
in	O
diabetic	I-Entity
rats	O
.	O

The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	I-Entity
patients	O
.	O



Differential	O
effects	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
in	O
rats	O
.	O

The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	I-Entity
induces	O
in	O
rats	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
followed	O
by	O
widespread	O
damage	O
to	O
the	O
forebrain	O
.	O

anti	O
-	O
inflammatory	O
drugs	O
,	O
sodium	B-Entity
salicylate	I-Entity
,	O
phenylbutazone	I-Entity
,	O
indomethacin	I-Entity
,	O
ibuprofen	I-Entity
and	O
mefenamic	B-Entity
acid	I-Entity
,	O
on	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
.	O

Pretreatment	O
of	O
rats	O
with	O
sodium	B-Entity
salicylate	I-Entity
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutazone	I-Entity
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
convulsant	O
dose	O
of	O
pilocarpine	I-Entity
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsant	O
one	O
.	O

Indomethacin	I-Entity
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuprofen	I-Entity
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modulate	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
.	O

Mefenamic	B-Entity
acid	I-Entity
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seizures	I-Entity
and	O
protected	O
rats	O
from	O
seizure	I-Entity
-	O
related	O
brain	B-Entity
damage	I-Entity
induced	O
by	O
pilocarpine	I-Entity
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O



Acute	B-Entity
neurologic	I-Entity
dysfunction	I-Entity
after	O
high	O
-	O
dose	O
etoposide	I-Entity
therapy	O
for	O
malignant	B-Entity
glioma	I-Entity
.	O

Etoposide	I-Entity
(	O
VP-16	B-Entity
-	I-Entity
213	I-Entity
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	I-Entity
and	O
hematologic	B-Entity
malignancies	I-Entity
.	O

When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment	O
-	O
resistant	O
cancers	I-Entity
including	O
malignant	B-Entity
glioma	I-Entity
.	O

In	O
six	O
of	O
eight	O
patients	O
(	O
75%	O
)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	I-Entity
,	O
sudden	O
severe	O
neurologic	B-Entity
deterioration	I-Entity
occurred	O
.	O

This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
etoposide	I-Entity
therapy	O
.	O

Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	I-Entity
,	O
papilledema	I-Entity
,	O
somnolence	I-Entity
,	O
exacerbation	O
of	O
motor	B-Entity
deficits	I-Entity
,	O
and	O
sharp	O
increase	O
in	O
seizure	I-Entity
activity	O
.	O

These	O
abnormalities	O
resolved	O
rapidly	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
intravenous	O
dexamethasone	I-Entity
therapy	O
.	O

brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	I-Entity
size	O
and	O
peritumor	O
edema	I-Entity
when	O
compared	O
with	O
pretransplant	O
scans	O
.	O

This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	I-Entity
of	O
high	O
-	O
dose	O
etoposide	I-Entity
therapy	O
for	O
malignant	B-Entity
glioma	I-Entity
.	O



Progressive	O
bile	B-Entity
duct	I-Entity
injury	I-Entity
after	O
thiabendazole	I-Entity
administration	O
.	O

A	O
27-yr	O
-	O
old	O
man	O
developed	O
jaundice	I-Entity
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	I-Entity
.	O

Cholestasis	I-Entity
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
time	O
a	O
liver	O
transplant	O
was	O
performed	O
.	O

Prominent	O
fibrosis	I-Entity
and	O
hepatocellular	O
regeneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobular	O
architecture	O
was	O
preserved	O
.	O

This	O
case	O
represents	O
an	O
example	O
of	O
""""	O
idiosyncratic	O
""""	O
drug	B-Entity
-	I-Entity
induced	I-Entity
liver	I-Entity
damage	I-Entity
in	O
which	O
the	O
primary	O
target	O
of	O
injury	O
is	O
the	O
bile	O
duct	O
.	O

An	O
autoimmune	O
pathogenesis	O
of	O
the	O
bile	B-Entity
duct	I-Entity
destruction	I-Entity
is	O
suggested	O
.	O



Differential	O
effects	O
of	O
1,4-dihydropyridine	I-Entity
calcium	B-Entity
channel	I-Entity
blockers	I-Entity
:	O
therapeutic	O
implications	O
.	O

Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	I-Entity
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B-Entity
disease	I-Entity
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	B-Entity
channel	I-Entity
blocking	I-Entity
agents	I-Entity
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	B-Entity
diseases	I-Entity
.	O

Clinical	O
applications	O
of	O
calcium	B-Entity
channel	I-Entity
blockers	I-Entity
parallel	O
their	O
tissue	O
selectivity	O
.	O

In	O
contrast	O
to	O
verapamil	I-Entity
and	O
diltiazem	I-Entity
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle	O
,	O
the	O
dihydropyridine	I-Entity
calcium	B-Entity
channel	I-Entity
blockers	I-Entity
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	O
agents	O
that	O
exert	O
minimal	O
electrophysiologic	O
effects	O
on	O
cardiac	O
nodal	O
or	O
conduction	O
tissue	O
.	O

As	O
the	O
first	O
dihydropyridine	I-Entity
available	O
for	O
use	O
in	O
the	O
United	O
States	O
,	O
nifedipine	I-Entity
controls	O
angina	I-Entity
and	O
hypertension	I-Entity
with	O
minimal	O
depression	O
of	O
cardiac	O
function	O
.	O

Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	B-Entity
channel	I-Entity
blockers	I-Entity
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indications	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therapy	O
.	O

Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	I-Entity
and	O
nisoldipine	I-Entity
offers	O
a	O
convenient	O
administration	O
schedule	O
,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long	O
-	O
term	O
therapy	O
of	O
hypertension	I-Entity
.	O

The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	I-Entity
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	I-Entity
.	O

Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	I-Entity
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	B-Entity
hemorrhage	I-Entity
,	O
migraine	B-Entity
headache	I-Entity
,	O
dementia	I-Entity
,	O
and	O
stroke	I-Entity
.	O

In	O
general	O
,	O
the	O
dihydropyridine	I-Entity
calcium	B-Entity
channel	I-Entity
blockers	I-Entity
are	O
usually	O
well	O
tolerated	O
,	O
with	O
headache	I-Entity
,	O
facial	O
flushing	I-Entity
,	O
palpitations	I-Entity
,	O
edema	I-Entity
,	O
nausea	I-Entity
,	O
anorexia	I-Entity
,	O
and	O
dizziness	I-Entity
being	O
the	O
more	O
common	O
adverse	O
effects	O
.	O



The	O
enhancement	O
of	O
aminonucleoside	I-Entity
nephrosis	I-Entity
by	O
the	O
co	O
-	O
administration	O
of	O
protamine	O
.	O

An	O
experimental	O
model	O
of	O
focal	B-Entity
segmental	I-Entity
glomerular	I-Entity
sclerosis	I-Entity
(	O
FSGS	I-Entity
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin	B-Entity
-	I-Entity
aminonucleoside	I-Entity
(	O
AMNS	I-Entity
)	O
and	O
protamine	B-Entity
sulfate	I-Entity
(	O
PS	I-Entity
)	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
uninephrectomized	O
three	O
weeks	O
before	O
,	O
received	O
daily	O
injections	O
of	O
subcutaneous	O
AMNS	I-Entity
(	O
1	O
mg/100	O
g	O
body	O

wt	O
)	O
and	O
intravenous	O
PS	I-Entity
(	O
2	O
separated	O
doses	O
of	O
2.5	O
mg/100	O
g	O
body	O
wt	O
)	O
for	O
four	O
days	O
.	O

They	O
developed	O
nephrotic	B-Entity
syndrome	I-Entity
and	O
finally	O
renal	B-Entity
failure	I-Entity
.	O

The	O
time	O
-	O
course	O
curve	O
of	O
creatinine	I-Entity
clearance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.01	O
)	O
from	O
that	O
of	O
each	O
control	O
group	O
,	O
such	O
as	O
,	O
AMNS	I-Entity
alone	O
,	O
PS	I-Entity
alone	O
or	O
saline	O
injected	O
.	O

Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	I-Entity
.	O

The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	I-Entity
red	O
on	O
the	O
lamina	O
rara	O
externa	O
and	O
marked	O
changes	O
in	O
epithelial	O
cell	O
cytoplasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	I-Entity
enhances	O
the	O
toxicity	I-Entity
of	O
AMNS	I-Entity
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	I-Entity
in	O
rats	O
resulting	O
in	O
the	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
.	O



Theophylline	I-Entity
neurotoxicity	I-Entity
in	O
pregnant	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	I-Entity
of	O
theophylline	I-Entity
is	O
altered	O
in	O
advanced	O
pregnancy	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	I-Entity
until	O
onset	O
of	O
maximal	O
seizures	I-Entity
which	O
occurred	O
after	O
28	O
and	O
30	O
minutes	O
respectively	O
.	O

Theophylline	I-Entity
concentrations	O
at	O
this	O
endpoint	O
in	O
serum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
serum	O
(	O
free	O
)	O
and	O
brain	O
concentrations	O
were	O
slightly	O
different	O
in	O
pregnant	O
rats	O
.	O

Theophylline	I-Entity
serum	O
protein	O
binding	O
determined	O
by	O
equilibrium	O
dialysis	O
was	O
lower	O
in	O
pregnant	O
rats	O
.	O

Fetal	O
serum	O
concentrations	O
at	O
onset	O
of	O
seizures	I-Entity
in	O
the	O
mother	O
were	O
similar	O
to	O
maternal	O
brain	O
and	O
CSF	O
concentrations	O
and	O
correlated	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	O
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	I-Entity
response	O
to	O
theophylline	I-Entity
in	O
rats	O
.	O



Hyperkalemia	I-Entity
induced	O
by	O
indomethacin	I-Entity
and	O
naproxen	I-Entity
and	O
reversed	O
by	O
fludrocortisone	I-Entity
.	O

We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	B-Entity
arthritis	I-Entity
and	O
a	O
history	O
of	O
mefenamic	B-Entity
acid	I-Entity
nephropathy	I-Entity
in	O
whom	O
hyperkalemia	I-Entity
and	O
inappropriate	O
hypoaldosteronism	I-Entity
were	O
caused	O
by	O
both	O
indomethacin	I-Entity
and	O
naproxen	I-Entity
,	O
without	O
major	O
decline	O
in	O
renal	O
function	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
renal	B-Entity
disease	I-Entity
predisposed	O
this	O
patient	O
to	O
type	B-Entity
IV	I-Entity
renal	I-Entity
tubular	I-Entity
acidosis	I-Entity
with	O
prostaglandin	I-Entity
synthetase	O
inhibitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
,	O
fludrocortisone	I-Entity
was	O
added	O
,	O
correcting	O
the	O
hyperkalemia	I-Entity
and	O
allowing	O
indomethacin	I-Entity
therapy	O
to	O
be	O
continued	O
safely	O
.	O



Hypotension	I-Entity
as	O
a	O
manifestation	O
of	O
cardiotoxicity	I-Entity
in	O
three	O
patients	O
receiving	O
cisplatin	I-Entity
and	O
5-fluorouracil	I-Entity
.	O

Cardiac	O
symptoms	O
,	O
including	O
hypotension	I-Entity
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	B-Entity
carcinoma	I-Entity
while	O
being	O
treated	O
with	O
cisplatin	I-Entity
(	O
CDDP	I-Entity
)	O
and	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
.	O

In	O
two	O
patients	O
,	O
hypotension	I-Entity
was	O
associated	O
with	O
severe	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
.	O

The	O
presentation	O
and	O
cardiac	O
evaluation	O
(	O
hemodynamic	O
,	O
echocardiographic	O
,	O
and	O
scintigraphic	O
)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5-FU	I-Entity
cardiotoxicity	I-Entity
that	O
may	O
be	O
influenced	O
by	O
CDDP	I-Entity
.	O



Fatal	O
aplastic	B-Entity
anemia	I-Entity
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	I-Entity
.	O

A	O
case	O
of	O
fatal	O
aplastic	B-Entity
anemia	I-Entity
due	O
to	O
carbamazepine	I-Entity
treatment	O
in	O
an	O
epileptic	I-Entity
woman	O
is	O
reported	O
.	O

Despite	O
concerns	O
of	O
fatal	O
bone	B-Entity
marrow	I-Entity
toxicity	I-Entity
due	O
to	O
carbamazepine	I-Entity
,	O
this	O
is	O
only	O
the	O
fourth	O
documented	O
and	O
published	O
report	O
.	O

Carbamazepine	I-Entity
is	O
a	O
safe	O
drug	O
,	O
but	O
physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rare	O
but	O
potentially	O
fatal	O
side	O
effects	O
,	O
better	O
prevented	O
by	O
clinical	O
than	O
by	O
laboratory	O
monitoring	O
.	O



Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine	I-Entity
-	O
induced	O
hypotension	I-Entity
and	O
bradycardia	I-Entity
.	O

The	O
effects	O
of	O
microinjection	O
of	O
clonidine	I-Entity
(	O
1	O
-	O
10	O
micrograms	O
in	O
1	O
microliter	O
)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane	I-Entity
-	O
anesthetized	O
rats	O
.	O

Intramedullary	O
administration	O
of	O
clonidine	I-Entity
,	O
but	O
not	O
saline	O
vehicle	O
,	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

The	O
clonidine	I-Entity
-	O
induced	O
hypotension	I-Entity
was	O
antagonized	O
by	O
prior	O
spinal	O
transection	O
,	O
but	O
not	O
bilateral	O
vagotomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clonidine	I-Entity
-	O
induced	O
bradycardia	I-Entity
was	O
antagonized	O
by	O
prior	O
bilateral	O
vagotomy	O
,	O
but	O
not	O
spinal	O
transection	O
.	O

Furthermore	O
,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5-HT	I-Entity
nerves	O
,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5,7-dihydroxytryptamine	I-Entity
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	I-Entity
responses	O
to	O
clonidine	I-Entity
microinjected	O
into	O
the	O
area	O
near	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
in	O
rats	O
.	O

The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine	I-Entity
-	O
induced	O
hypotension	I-Entity
and	O
bradycardia	I-Entity
.	O

The	O
induced	O
hypotension	I-Entity
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity	O
,	O
whereas	O
the	O
induced	O
bradycardia	I-Entity
was	O
due	O
to	O
an	O
increase	O
in	O
vagal	O
efferent	O
activity	O
.	O



Hypertension	I-Entity
in	O
neuroblastoma	I-Entity
induced	O
by	O
imipramine	I-Entity
.	O

Hypertension	I-Entity
is	O
a	O
well	O
-	O
known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	I-Entity
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	I-Entity
.	O

We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	I-Entity
(	O
blood	O
pressure	O
190/160	O
)	O
in	O
a	O
4-year	O
-	O
old	O
girl	O
with	O
neuroblastoma	I-Entity
who	O
was	O
given	O
Imipramine	I-Entity
to	O
control	O
a	O
behavior	B-Entity
disorder	I-Entity
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patient	O
's	O
tumor	I-Entity
was	O
recurring	O
at	O
the	O
time	O
of	O
her	O
hypertensive	I-Entity
episode	O
.	O

Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	I-Entity
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
)	O
,	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	I-Entity
.	O

The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	I-Entity
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	I-Entity
.	O

From	O
this	O
experience	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	O
in	O
children	O
with	O
active	O
neuroblastoma	I-Entity
.	O



Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	B-Entity
candidiasis	I-Entity
or	O
hoarseness	I-Entity
with	O
beclomethasone	B-Entity
dipropionate	I-Entity
.	O

Of	O
158	O
asthmatic	I-Entity
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	I-Entity
,	O
15	O
(	O
9.5%	O
)	O
developed	O
either	O
hoarseness	I-Entity
(	O
8)	O
,	O
oral	O
thrush	I-Entity
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
adverse	O
reactions	O
subsided	O
,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	I-Entity
.	O

These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	I-Entity
and	O
three	O
who	O
developed	O
Candidiasis	I-Entity
.	O

Oral	O
thrush	I-Entity
did	O
not	O
recur	O
,	O
but	O
60%	O
(	O
3/5	O
)	O
of	O
patients	O
with	O
hoarseness	I-Entity
had	O
recurrence	O
.	O

We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	I-Entity
when	O
clinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	O
rate	O
,	O
patients	O
who	O
develop	O
hoarseness	I-Entity
should	O
not	O
be	O
re	O
-	O
challenged	O
.	O

Concomitant	O
use	O
of	O
oral	O
prednisone	I-Entity
and	O
topical	O
beclomethasone	I-Entity
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	I-Entity
or	O
candidiasis	I-Entity
.	O



Cyclophosphamide	I-Entity
cardiotoxicity	I-Entity
:	O
an	O
analysis	O
of	O
dosing	O
as	O
a	O
risk	O
factor	O
.	O

Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	I-Entity
(	O
CYA	I-Entity
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patient	O
's	O
weight	O
.	O

At	O
these	O
high	O
doses	O
of	O
CYA	I-Entity
,	O
serious	O
cardiotoxicity	I-Entity
may	O
occur	O
,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	I-Entity
have	O
not	O
been	O
described	O
.	O

Since	O
chemotherapeutic	O
agent	O
toxicity	I-Entity
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	I-Entity
in	O
patients	O
transplanted	O
at	O
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	I-Entity
cardiotoxicity	I-Entity
correlated	O
with	O
the	O
dose	O
per	O
body	O
surface	O
area	O
.	O

Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	I-Entity
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	B-Entity
anemia	I-Entity
,	O
Wiskott	B-Entity
-	I-Entity
Aldrich	I-Entity
syndrome	I-Entity
,	O
or	O
severe	B-Entity
combined	I-Entity
immunodeficiency	I-Entity
syndrome	I-Entity
.	O

Fourteen	O
of	O
84	O
(	O
17%	O
)	O
patients	O
had	O
symptoms	O
and	O
signs	O
consistent	O
with	O
CYA	I-Entity
cardiotoxicity	I-Entity
within	O
ten	O
days	O
of	O
receiving	O
1	O
to	O
4	O
doses	O
of	O
CYA	I-Entity
.	O

Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
.	O

The	O
dose	O
of	O
CYA	I-Entity
per	O
body	O
surface	O
area	O
was	O
calculated	O
for	O
all	O
patients	O
and	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
daily	O
CYA	I-Entity
dose	O
:	O
Group	O
1	O
,	O
CYA	I-Entity
less	O
than	O
or	O
equal	O
to	O
1.55	O
g	O
/	O
m2/d	O
;	O
Group	O
2	O
,	O
CYA	I-Entity
greater	O
than	O
1.55	O

Cardiotoxicity	I-Entity
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	I-Entity
occurred	O
in	O
1/32	O
(	O
3%	O
)	O
of	O
patients	O
in	O
Group	O
1	O
and	O
in	O
13/52	O
(	O
25%	O
)	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Congestive	B-Entity
heart	I-Entity
failure	I-Entity
caused	O
or	O
contributed	O
to	O
death	O
in	O
0/32	O
patients	O
in	O
Group	O
1	O
v	O
6/52	O
(	O
12%	O
)	O
of	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.25	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	I-Entity
cardiotoxicity	I-Entity
correlates	O
with	O
CYA	I-Entity
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area	O
,	O
and	O
that	O
patients	O
with	O
aplastic	B-Entity
anemia	I-Entity
and	O
immunodeficiencies	I-Entity
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	O
a	O
CYA	I-Entity
dose	O
of	O
1.55	O
g	O
/	O
m2/d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	I-Entity
than	O
patients	O
whose	O
CYA	I-Entity
dosage	O
is	O
calculated	O
based	O
on	O
weight	O
.	O

This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	I-Entity
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
.	O



Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	I-Entity
nephrotoxicity	I-Entity
.	O

The	O
epidemiology	O
of	O
aminoglycoside	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
is	O
not	O
fully	O
understood	O
.	O

Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	I-Entity
cause	O
proximal	O
tubular	O
damage	O
in	O
most	O
patients	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glomerular	B-Entity
or	I-Entity
tubular	I-Entity
dysfunction	I-Entity
.	O

Clinical	O
trials	O
of	O
aminoglycosides	I-Entity
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
during	O
therapy	O
ranges	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
risk	O
is	O
70%	O
to	O
80%	O
.	O

Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy	O
,	O
plasma	O
aminoglycoside	I-Entity
levels	O
,	O
liver	B-Entity
disease	I-Entity
,	O
advanced	O
age	O
,	O
high	O
initial	O
estimated	O
creatinine	I-Entity
clearance	O
and	O
,	O
possibly	O
,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	I-Entity
.	O

Other	O
causes	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
,	O
such	O
as	O
shock	I-Entity
,	O
appear	O
to	O
have	O
an	O
additive	O
effect	O
.	O

These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
.	O



Flurothyl	I-Entity
seizure	I-Entity
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	B-Entity
glutamate	I-Entity
(	O
MSG	I-Entity
)	O
:	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	I-Entity
seizure	I-Entity
testing	O
.	O

Monosodium	B-Entity
glutamate	I-Entity
(	O
MSG	I-Entity
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	I-Entity
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits	O
.	O

These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	I-Entity
produced	O
permanent	O
alterations	O
in	O
seizure	I-Entity
susceptibility	O
,	O
since	O
previous	O
investigations	O
were	O
inconclusive	O
.	O

A	O
flurothyl	I-Entity
ether	I-Entity
seizure	I-Entity
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	I-Entity
susceptibility	O
in	O
adult	O
mice	O
that	O
received	O
neonatal	O
injections	O
of	O
MSG	I-Entity
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	I-Entity
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	I-Entity
threshold	O
.	O

A	O
naloxone	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	I-Entity
thresholds	O
of	O
either	O
control	O
of	O
MSG	I-Entity
-	O
treated	O
mice	O
.	O

Flurothyl	I-Entity
ether	I-Entity
produced	O
hypothermia	I-Entity
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	I-Entity
exposure	O
;	O
however	O
,	O
the	O
relationship	O
of	O
hypothermia	I-Entity
to	O
seizure	I-Entity
induction	O
was	O
unclear	O
.	O

Flurothyl	I-Entity
seizure	I-Entity
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	I-Entity
susceptibility	O
.	O



Susceptibility	O
to	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	I-Entity
or	O
gamma	B-Entity
-	I-Entity
vinyl	I-Entity
-	I-Entity
GABA	I-Entity
into	O
the	O
substantia	O
nigra	O
.	O

Pilocarpine	I-Entity
,	O
given	O
intraperitoneally	O
to	O
rats	O
,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	I-Entity
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	I-Entity
within	O
the	O
forebrain	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA)-mediated	I-Entity
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
in	O
rats	O
,	O
were	O
investigated	O
.	O

In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	I-Entity
,	O
150	O
micrograms	O
,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA	I-Entity
-	O
synthesizing	O
enzyme	O
,	O
L	B-Entity
-	I-Entity
glutamic	I-Entity
acid	I-Entity
decarboxylase	O
,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(	O
SNR	O
)	O
,	O
bilaterally	O
,	O
non	O
-	O
convulsant	O
doses	O
of	O
pilocarpine	I-Entity
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
.	O

Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O

Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure	I-Entity
-	O
related	O
damage	O
to	O
the	O
hippocampal	O
formation	O
,	O
thalamus	O
,	O
amygdala	O
,	O
olfactory	O
cortex	O
,	O
substantia	O
nigra	O
and	O
neocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	I-Entity
in	O
doses	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	I-Entity
did	O
not	O
augment	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
,	O
200	O
mg	O
/	O
kg	O
.	O

Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	I-Entity
transaminase	O
,	O
gamma	B-Entity
-	I-Entity
vinyl	I-Entity
-	I-Entity
GABA	I-Entity
(	O
D	B-Entity
,	I-Entity
L-4-amino	I-Entity
-	I-Entity
hex-5-enoic	I-Entity
acid	I-Entity
)	O
,	O
5	O
micrograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	I-Entity
produced	O
by	O
pilocarpine	I-Entity
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	B-Entity
damage	I-Entity
.	O

Microinjections	O
of	O
gamma	B-Entity
-	I-Entity
vinyl	I-Entity
-	I-Entity
GABA	I-Entity
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	I-Entity
produced	O
by	O
pilocarpine	I-Entity
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA	I-Entity
-	O
mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
.	O



Non	O
-	O
invasive	O
detection	O
of	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	I-Entity
infusion	O
.	O

Electrocardiographic	O
changes	O
after	O
dipyridamole	I-Entity
infusion	O
(	O
0.568	O
mg	O
/	O
kg/4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
;	O
19	O
patients	O
without	O
myocardial	B-Entity
infarction	I-Entity
(	O
non	O
-	O
MI	I-Entity
group	O
)	O
,	O
14	O
with	O
anterior	B-Entity
infarction	I-Entity
(	O
ANT	B-Entity
-	I-Entity
MI	I-Entity
)	O
and	O
eight	O
with	O
inferior	B-Entity
infarction	I-Entity
(	O
INF	B-Entity
-	I-Entity
MI	I-Entity
)	O
.	O

After	O
dipyridamole	I-Entity
,	O
ischemic	I-Entity
ST	O
-	O
segment	O
depression	I-Entity
(	O
0.05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84%	O
of	O
the	O
non	O
-	O
MI	I-Entity
group	O
,	O
29%	O
of	O
the	O
ANT	B-Entity
-	I-Entity
MI	I-Entity
group	O
,	O
63%	O
of	O
the	O
INF	B-Entity
-	I-Entity
MI	I-Entity
group	O
and	O
61%	O
of	O
the	O
total	O
population	O
.	O

Exercise	O
-	O
induced	O
ST	O
depression	I-Entity
was	O
observed	O
in	O
84%	O
of	O
the	O
non	O
-	O
MI	I-Entity
group	O
,	O
43%	O
of	O
the	O
ANT	B-Entity
-	I-Entity
MI	I-Entity
group	O
,	O
38%	O
of	O
the	O
INF	B-Entity
-	I-Entity
MI	I-Entity
group	O
and	O
61%	O
of	O
the	O
total	O
.	O

For	O
individual	O
patients	O
,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	I-Entity
in	O
both	O
tests	O
.	O

The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	I-Entity
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmill	O
exercise	O
.	O

The	O
data	O
suggest	O
that	O
the	O
dipyridamole	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
is	O
caused	O
by	O
the	O
inhomogenous	O
distribution	O
of	O
myocardial	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
the	O
dipyridamole	I-Entity
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O



Bradycardia	I-Entity
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	I-Entity
therapy	O
.	O

In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
who	O
received	O
intravenous	O
high	O
-	O
dose	O
methylprednisolone	I-Entity
(	O
MP	I-Entity
)	O
therapy	O
(	O
1	O
g	O
daily	O
for	O
2	O
or	O
3	O
consecutive	O
days	O
)	O
,	O
a	O
decline	O
in	O
pulse	O
rate	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	I-Entity
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure	O
.	O

Electrocardiographic	O
registrations	O
showed	O
sinus	B-Entity
bradycardia	I-Entity
in	O
all	O
cases	O
.	O

Careful	O
observation	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
MP	I-Entity
is	O
recommended	O
.	O

High	O
-	O
dose	O
MP	I-Entity
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	B-Entity
disease	I-Entity
.	O



Two	O
cases	O
of	O
downbeat	B-Entity
nystagmus	I-Entity
and	O
oscillopsia	I-Entity
associated	O
with	O
carbamazepine	I-Entity
.	O

Downbeat	B-Entity
nystagmus	I-Entity
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	O
the	O
craniocervical	O
junction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestation	O
of	O
metabolic	O
imbalance	O
or	O
drug	O
intoxication	O
.	O

We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	B-Entity
nystagmus	I-Entity
related	O
to	O
carbamazepine	I-Entity
therapy	O
.	O

The	O
nystagmus	I-Entity
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	I-Entity
levels	O
.	O

In	O
patients	O
with	O
downbeat	B-Entity
nystagmus	I-Entity
who	O
are	O
taking	O
anticonvulsant	O
medications	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
in	O
dose	O
before	O
further	O
investigation	O
is	O
undertaken	O
.	O



Improvement	O
by	O
denopamine	I-Entity
(	O
TA-064	I-Entity
)	O
of	O
pentobarbital	I-Entity
-	O
induced	O
cardiac	B-Entity
failure	I-Entity
in	O
the	O
dog	O
heart	O
-	O
lung	O
preparation	O
.	O

The	O
efficacy	O
of	O
denopamine	I-Entity
,	O
an	O
orally	O
active	O
beta	O
1-adrenoceptor	O
agonist	O
,	O
in	O
improving	O
cardiac	B-Entity
failure	I-Entity
was	O
assessed	O
in	O
dog	O
heart	O
-	O
lung	O
preparations	O
.	O

Cardiac	O
functions	O
depressed	O
by	O
pentobarbital	I-Entity
(	O
118	O
+	O
/-	O

SD	O
)	O
such	O
that	O
cardiac	O
output	O
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
reduced	O
by	O
about	O
35%	O
and	O
26%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	I-Entity
(	O
10	O
-	O
300	O
micrograms	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

With	O
100	O
micrograms	O
denopamine	I-Entity
,	O
almost	O
complete	O
restoration	O
of	O
cardiac	O
performance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
increase	O
in	O
heart	O
rate	O
.	O

No	O
arrhythmias	I-Entity
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	I-Entity
.	O

The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	I-Entity
in	O
the	O
treatment	O
of	O
cardiac	B-Entity
failure	I-Entity
.	O



Clonazepam	I-Entity
monotherapy	O
for	O
epilepsy	I-Entity
in	O
childhood	O
.	O

Sixty	O
patients	O
(	O
age	O
-	O
range	O
one	O
month	O
to	O
14	O
years	O
)	O
with	O
other	O
types	O
of	O
epilepsy	I-Entity
than	O
infantile	B-Entity
spasms	I-Entity
were	O
treated	O
with	O
clonazepam	I-Entity
.	O

Disappearance	O
of	O
seizures	I-Entity
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	I-Entity
were	O
recognized	O
in	O
77%	O
and	O
50%	O
,	O
respectively	O
.	O

Seizures	I-Entity
disappeared	O
in	O
71%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	I-Entity
and	O
89%	O
of	O
partial	O
seizures	I-Entity
.	O

The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	I-Entity
and	O
ataxia	I-Entity
was	O
only	O
5%	O
.	O



Postmarketing	O
study	O
of	O
timolol	I-Entity
-	O
hydrochlorothiazide	I-Entity
antihypertensive	O
therapy	O
.	O

A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed	O
-	O
ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	B-Entity
maleate	I-Entity
and	O
25	O
mg	O
of	O
hydrochlorothiazide	I-Entity
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	I-Entity
patients	O
.	O

Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	I-Entity
-	O
hydrochlorothiazide	I-Entity
therapy	O
(	O
P	O
less	O
than	O
0.01	O
,	O
both	O
comparisons	O
)	O
.	O

The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	I-Entity
.	O

Overall	O
,	O
1,453	O
patients	O
experienced	O
a	O
total	O
of	O
2,658	O
adverse	O
events	O
,	O
the	O
most	O
common	O
being	O
fatigue	I-Entity
,	O
dizziness	I-Entity
,	O
and	O
weakness	I-Entity
.	O



Salicylate	I-Entity
nephropathy	I-Entity
in	O
the	O
Gunn	O
rat	O
:	O
potential	O
role	O
of	O
prostaglandins	I-Entity
.	O

We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	I-Entity
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	I-Entity
in	O
the	O
Gunn	O
strain	O
of	O
rat	O
.	O

The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	I-Entity
due	O
to	O
the	O
absence	O
of	O
glucuronyl	I-Entity
transferase	O
,	O
leading	O
to	O
marked	O
bilirubin	I-Entity
deposition	O
in	O
renal	O
medulla	O
and	O
papilla	O
.	O

These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	B-Entity
necrosis	I-Entity
with	O
analgesic	O
administration	O
.	O

Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	I-Entity
300	O
mg	O
/	O
kg	O
every	O
other	O
day	O
or	O
sham	O
-	O
treated	O
.	O

After	O
one	O
week	O
,	O
slices	O
of	O
cortex	O
,	O
outer	O
and	O
inner	O
medulla	O
from	O
one	O
kidney	O
were	O
incubated	O
in	O
buffer	O
and	O
prostaglandin	I-Entity
synthesis	O
was	O
determined	O
by	O
radioimmunoassay	O
.	O

A	O
marked	O
corticomedullary	O
gradient	O
of	O
prostaglandin	I-Entity
synthesis	O
was	O
observed	O
in	O
all	O
groups	O
.	O

PGE2	I-Entity
synthesis	O
was	O
significantly	O
higher	O
in	O
outer	O
medulla	O
,	O
but	O
not	O
cortex	O
or	O
inner	O
medulla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/-	O

Aspirin	I-Entity
treatment	O
reduced	O
PGE2	I-Entity
synthesis	O
in	O
all	O
regions	O
,	O
but	O
outer	O
medullary	O
PGE2	I-Entity
remained	O
higher	O
in	O
jj	O
(	O
18	O
+	O
/-	O

PGF2	B-Entity
alpha	I-Entity
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	I-Entity
administration	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
changes	O
in	O
renal	O
prostaglandin	I-Entity
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	B-Entity
damage	I-Entity
in	O
aspirin	I-Entity
-	O
treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by	O
:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	I-Entity
(	O
p	O
less	O
than	O
0.01	O
)	O
;	O
increased	O
serum	O
creatinine	I-Entity
(	O
p	O
less	O
than	O
0.05	O
)	O
;	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(	O
p	O
less	O
than	O
0.005	O
compared	O
to	O
either	O
sham	O
-	O
treated	O
jj	O
or	O
aspirin	I-Entity
-	O
treated	O
jJ	O
)	O
.	O

These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	I-Entity
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	O
function	O
and	O
morphological	O
integrity	O
,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	I-Entity
synthesis	O
may	O
lead	O
to	O
pathological	B-Entity
renal	I-Entity
medullary	I-Entity
lesions	I-Entity
and	O
deterioration	B-Entity
of	I-Entity
renal	I-Entity
function	I-Entity
.	O



Prophylactic	O
lidocaine	I-Entity
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	B-Entity
infarction	I-Entity
.	O

Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	B-Entity
infarction	I-Entity
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double	O
-	O
blind	O
randomized	O
trial	O
of	O
lidocaine	I-Entity
vs	O
placebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	B-Entity
fibrillation	I-Entity
or	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
among	O
the	O
204	O
patients	O
with	O
acute	O
myocardial	B-Entity
infarction	I-Entity
was	O
low	O
,	O
1.5%	O
.	O

Lidocaine	I-Entity
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously	O
,	O
did	O
not	O
prevent	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	I-Entity
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	I-Entity
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
average	O
plasma	O
lidocaine	I-Entity
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	B-Entity
infarction	I-Entity
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	I-Entity
.	O

The	O
mean	O
plasma	O
lidocaine	I-Entity
level	O
of	O
patients	O
on	O
beta	O
-	O
blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents	O
.	O

During	O
the	O
1-hour	O
study	O
period	O
,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	I-Entity
group	O
,	O
hypotension	I-Entity
occurred	O
in	O
11	O
patients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	I-Entity
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	I-Entity
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	I-Entity
.	O

We	O
can	O
not	O
advocate	O
the	O
administration	O
of	O
lidocaine	I-Entity
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	B-Entity
infarction	I-Entity
.	O



Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	I-Entity
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

Large	O
doses	O
of	O
the	O
cholinomimetic	O
,	O
pilocarpine	I-Entity
,	O
could	O
induce	O
catalepsy	I-Entity
when	O
peripheral	O
cholinergic	O
receptors	O
were	O
blocked	O
.	O

Low	O
doses	O
of	O
pilocarpine	I-Entity
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	I-Entity
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker	O
,	O
haloperidol	I-Entity
.	O

A	O
muscarinic	O
receptor	O
blocker	O
,	O
atropine	I-Entity
,	O
disrupted	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

Intracranial	O
injection	O
of	O
an	O
acetylcholine	I-Entity
-	O
synthesis	O
inhibitor	O
,	O
hemicholinium	I-Entity
,	O
prevented	O
the	O
catalepsy	I-Entity
that	O
is	O
usually	O
induced	O
by	O
haloperidol	I-Entity
.	O

These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	I-Entity
that	O
is	O
produced	O
by	O
neuroleptics	I-Entity
such	O
as	O
haloperidol	I-Entity
is	O
actually	O
mediated	O
by	O
intrinsic	O
central	O
cholinergic	O
systems	O
.	O

Alternatively	O
,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	I-Entity
by	O
suppression	O
of	O
dopaminergic	O
systems	O
.	O



Cardiovascular	B-Entity
dysfunction	I-Entity
and	O
hypersensitivity	I-Entity
to	O
sodium	B-Entity
pentobarbital	I-Entity
induced	O
by	O
chronic	O
barium	B-Entity
chloride	I-Entity
ingestion	O
.	O

Barium	I-Entity
-	O
supplemented	O
Long	O
-	O
Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	I-Entity
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	I-Entity
(	O
100	O
micrograms	O
/	O
ml	O
mineral	O
fortified	O
water	O
)	O
treatment	O
.	O

myocardial	O
excitability	O
,	O
contractility	O
,	O
and	O
metabolic	O
characteristics	O
at	O
16	O
months	O
revealed	O
other	O
significant	O
barium	I-Entity
-	O
induced	O
disturbances	B-Entity
within	I-Entity
the	I-Entity
cardiovascular	I-Entity
system	I-Entity
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	I-Entity
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	I-Entity
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-Entity
pentobarbital	I-Entity
.	O

Under	O
barbiturate	I-Entity
anesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	O
significantly	O
in	O
barium	I-Entity
-	O
exposed	O
rats	O
relative	O
to	O
the	O
corresponding	O
control	O
-	O
fed	O
rats	O
.	O

The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	I-Entity
and	O
xylazine	I-Entity
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	B-Entity
pentobarbital	I-Entity
in	O
barium	I-Entity
-	O
treated	O
rats	O
were	O
linked	O
specifically	O
to	O
this	O
anesthetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalized	O
anesthetic	O
response	O
.	O

Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	I-Entity
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
employed	O
.	O

The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium	I-Entity
-	O
treated	O
rats	O
relative	O
to	O
the	O
control	O
groups	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
regimen	O
.	O

Similarly	O
,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	O
were	O
detected	O
in	O
the	O
barium	I-Entity
-	O
exposed	O
rats	O
which	O
were	O
consistent	O
with	O
the	O
reduced	O
contractile	O
element	O
shortening	O
velocity	O
.	O

In	O
addition	O
,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	O
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium	I-Entity
-	O
exposed	O
rats	O
.	O

Overall	O
,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics	O
,	O
the	O
myocardial	O
metabolic	B-Entity
disturbances	I-Entity
,	O
and	O
the	O
hypersensitivity	I-Entity
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-Entity
pentobarbital	I-Entity
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	B-Entity
disorder	I-Entity
induced	O
by	O
chronic	O
barium	I-Entity
exposure	O
.	O

These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life	O
-	O
long	O
barium	I-Entity
ingestion	O
may	O
have	O
significant	O
adverse	O
effects	O
on	O
the	O
mammalian	O
cardiovascular	O
system	O
.	O



Propranolol	I-Entity
antagonism	O
of	O
phenylpropanolamine	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

Phenylpropanolamine	I-Entity
(	O
PPA	I-Entity
)	O
overdose	I-Entity
can	O
cause	O
severe	O
hypertension	I-Entity
,	O
intracerebral	B-Entity
hemorrhage	I-Entity
,	O
and	O
death	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	I-Entity
in	O
the	O
treatment	O
of	O
PPA	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

Subjects	O
received	O
propranolol	I-Entity
either	O
by	O
mouth	O
for	O
48	O
hours	O
before	O
PPA	I-Entity
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	I-Entity
.	O

PPA	I-Entity
,	O
75	O
mg	O
alone	O
,	O
increased	O
blood	O
pressure	O
(	O
31	O
+	O
/-	O

5	O
mm	O
Hg	O
diastolic	O
)	O
,	O
and	O
propranolol	I-Entity
pretreatment	O
antagonized	O
this	O
increase	O
(	O
12	O
+	O
/-	O

Intravenous	O
propranolol	I-Entity
after	O
PPA	I-Entity
also	O
decreased	O
blood	O
pressure	O
.	O

Left	O
ventricular	O
function	O
(	O
assessed	O
by	O
echocardiography	O
)	O
showed	O
that	O
PPA	I-Entity
increased	O
the	O
stroke	I-Entity
volume	O
30%	O
(	O
from	O
62.5	O
+	O
/-	O

Intravenous	O
propranolol	I-Entity
reversed	O
these	O
effects	O
.	O

Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	I-Entity
28%	O
(	O
from	O
1710	O
+	O
/-	O

sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	I-Entity
22%	O
(	O
to	O
2660	O
+	O
/-	O

We	O
conclude	O
that	O
PPA	I-Entity
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
,	O
and	O
that	O
propranolol	I-Entity
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	I-Entity
on	O
cardiac	O
output	O
.	O

That	O
propranolol	I-Entity
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	I-Entity
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	I-Entity
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	I-Entity
.	O

This	O
is	O
probably	O
because	O
PPA	I-Entity
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	I-Entity
.	O



Mesangial	O
function	O
and	O
glomerular	B-Entity
sclerosis	I-Entity
in	O
rats	O
with	O
aminonucleoside	I-Entity
nephrosis	I-Entity
.	O

The	O
possible	O
relationship	O
between	O
mesangial	B-Entity
dysfunction	I-Entity
and	O
development	O
of	O
glomerular	B-Entity
sclerosis	I-Entity
was	O
studied	O
in	O
the	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
)	O
model	O
.	O

Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	I-Entity
injections	O
;	O
five	O
controls	O
received	O
saline	O
only	O
.	O

After	O
4	O
weeks	O
the	O
PAN	I-Entity
rats	O
were	O
severely	O
proteinuric	I-Entity
(	O
190	O
+	O
/-	O

80	O
mg/24	O
hr	O
)	O
,	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	I-Entity
(	O
CC	O
)	O
intravenously	O
.	O

At	O
5	O
months	O
glomerular	B-Entity
sclerosis	I-Entity
was	O
found	O
in	O
7.6	O
+	O
/-	O

3.4%	O
of	O
the	O
glomeruli	O
of	O
PAN	I-Entity
rats	O
;	O
glomeruli	O
of	O
the	O
controls	O
were	O
normal	O
.	O

Glomeruli	O
of	O
PAN	I-Entity
rats	O
contained	O
significantly	O
more	O
CC	O
than	O
glomeruli	O
of	O
controls	O
.	O

Glomeruli	O
with	O
sclerosis	I-Entity
contained	O
significantly	O
more	O
CC	O
than	O
non	O
-	O
sclerotic	O
glomeruli	O
in	O
the	O
same	O
kidneys	O
.	O

Since	O
mesangial	O
CC	O
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	I-Entity
treatment	O
,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	O
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	O
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	I-Entity
will	O
develop	O
subsequently	O
.	O

Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	I-Entity
glomeruli	O
in	O
concordance	O
with	O
the	O
random	O
localization	O
of	O
mesangial	O
areas	O
with	O
dysfunction	O
in	O
this	O
model	O
.	O

Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	I-Entity
nephrosis	I-Entity
the	O
development	O
of	O
glomerular	B-Entity
sclerosis	I-Entity
may	O
be	O
related	O
to	O
""""	O
mesangial	O
overloading	O
.	O
""""	O



Relationship	O
between	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
hippocampal	O
nicotinic	O
receptors	O
.	O

Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design	O
,	O
a	O
relationship	O
between	O
nicotine	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
alpha	O
-	O
bungarotoxin	O
nicotinic	O
receptor	O
concentration	O
was	O
found	O
.	O

Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	I-Entity
had	O
greater	O
alpha	O
-	O
bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	I-Entity
insensitive	O
mice	O
.	O

The	O
binding	O
sites	O
from	O
seizure	I-Entity
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	I-Entity
,	O
trypsin	O
or	O
heat	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	I-Entity
sensitive	O
and	O
insensitive	O
animals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocampal	O
nicotinic	O
receptor	O
concentration	O
as	O
measured	O
with	O
alpha	O
-	O
bungarotoxin	O
binding	O
.	O



The	O
role	O
of	O
p	B-Entity
-	I-Entity
aminophenol	I-Entity
in	O
acetaminophen	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
:	O
effect	O
of	O
bis(p	B-Entity
-	I-Entity
nitrophenyl	I-Entity
)	I-Entity
phosphate	I-Entity
on	O
acetaminophen	I-Entity
and	O
p	B-Entity
-	I-Entity
aminophenol	I-Entity
nephrotoxicity	I-Entity
and	O
metabolism	O
in	O
Fischer	O
344	O
rats	O
.	O

Acetaminophen	I-Entity
(	O
APAP	I-Entity
)	O
produces	O
proximal	O
tubular	B-Entity
necrosis	I-Entity
in	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
.	O

Recently	O
,	O
p	B-Entity
-	I-Entity
aminophenol	I-Entity
(	O
PAP	I-Entity
)	O
,	O
a	O
known	O
potent	O
nephrotoxicant	O
,	O
was	O
identified	O
as	O
a	O
metabolite	O
of	O
APAP	I-Entity
in	O
F344	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	I-Entity
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
.	O

Therefore	O
,	O
the	O
effect	O
of	O
bis(p	B-Entity
-	I-Entity
nitrophenyl	I-Entity
)	I-Entity
phosphate	I-Entity
(	O
BNPP	I-Entity
)	O
,	O
an	O
acylamidase	O
inhibitor	O
,	O
on	O
APAP	I-Entity
and	O
PAP	I-Entity
nephrotoxicity	I-Entity
and	O
metabolism	O
was	O
determined	O
.	O

BNPP	I-Entity
(	O
1	O
to	O
8	O
mM	O
)	O
reduced	O
APAP	I-Entity
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	O
cortical	O
homogenates	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Pretreatment	O
of	O
animals	O
with	O
BNPP	I-Entity
prior	O
to	O
APAP	I-Entity
or	O
PAP	I-Entity
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	I-Entity
(	O
900	O
mg	O
/	O
kg	O
)	O

nephrotoxicity	I-Entity
but	O
not	O
PAP	I-Entity
nephrotoxicity	I-Entity
.	O

This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	I-Entity
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	O
cortical	O
and	O
hepatic	O
tissue	O
.	O

Rather	O
,	O
BNPP	I-Entity
pretreatment	O
reduced	O
the	O
fraction	O
of	O
APAP	I-Entity
excreted	O
as	O
PAP	I-Entity
by	O
64	O
and	O
75%	O
after	O
APAP	I-Entity
doses	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BNPP	I-Entity
did	O
not	O
alter	O
the	O
excretion	O
of	O
APAP	I-Entity
or	O
any	O
of	O
its	O
non	O
-	O
deacetylated	O
metabolites	O
nor	O
did	O
BNPP	I-Entity
alter	O
excretion	O
of	O
PAP	I-Entity
or	O
its	O
metabolites	O
after	O
PAP	I-Entity
doses	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BNPP	I-Entity
-	O
induced	O
reduction	O
in	O
APAP	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
appears	O
to	O
be	O
due	O
to	O
inhibition	O
of	O
APAP	I-Entity
deacetylation	O
.	O

It	O
is	O
concluded	O
that	O
PAP	I-Entity
formation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP	I-Entity
-	O
induced	O
renal	B-Entity
tubular	I-Entity
necrosis	I-Entity
.	O



Morphine	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
newborn	O
infants	O
.	O

Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	I-Entity
during	O
the	O
course	O
of	O
intravenous	O
morphine	B-Entity
sulfate	I-Entity
for	O
post	O
-	O
operative	O
analgesia	O
.	O

They	O
received	O
morphine	I-Entity
in	O
doses	O
of	O
32	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micrograms	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6	O
-	O
24	O
micrograms	O
/	O
kg	O

/	O
hr	O
and	O
had	O
no	O
seizures	I-Entity
.	O

Plasma	O
concentrations	O
of	O
morphine	I-Entity
in	O
these	O
neonates	O
was	O
excessive	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
reasons	O
for	O
seizures	I-Entity
were	O
ruled	O
out	O
and	O
the	O
convulsions	I-Entity
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	I-Entity
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months	O
.	O

It	O
is	O
suggested	O
that	O
post	O
-	O
operative	O
intravenous	O
morphine	I-Entity
should	O
not	O
exceed	O
20	O
micrograms	O
/	O
kg	O
/	O
ml	O
in	O
neonates	O
.	O



Effect	O
of	O
vincristine	B-Entity
sulfate	I-Entity
on	O
Pseudomonas	B-Entity
infections	I-Entity
in	O
monkeys	O
.	O

Leukocytosis	I-Entity
was	O
observed	O
in	O
all	O
monkeys	O
.	O

Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2.0	O
to	O
2.5	O
mg	O
of	O
vincristine	B-Entity
sulfate	I-Entity
was	O
followed	O
by	O
leukopenia	I-Entity
in	O
4	O
to	O
5	O
days	O
.	O

Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	B-Entity
sulfate	I-Entity
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	I-Entity
in	O
11	O
of	O
14	O
monkeys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseudomonas	O
alone	O
died	O
.	O

These	O
studies	O
suggest	O
that	O
an	O
antimetabolite	O
-	O
induced	O
leukopenia	I-Entity
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	I-Entity
and	O
that	O
such	O
monkeys	O
may	O
serve	O
as	O
a	O
biological	O
model	O
for	O
study	O
of	O
comparative	O
efficacy	O
of	O
antimicrobial	O
agents	O
.	O



Central	O
excitatory	O
actions	O
of	O
flurazepam	I-Entity
.	O

Toxic	O
actions	O
of	O
flurazepam	I-Entity
(	O
FZP	I-Entity
)	O
were	O
studied	O
in	O
cats	O
,	O
mice	O
and	O
rats	O
.	O

High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	I-Entity
,	O
superimposed	O
on	O
general	O
depression	I-Entity
.	O

Following	O
a	O
lethal	O
dose	O
,	O
death	O
was	O
always	O
associated	O
with	O
convulsions	I-Entity
.	O

Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	I-Entity
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	I-Entity
at	O
doses	O
that	O
did	O
not	O
first	O
cause	O
loss	B-Entity
of	I-Entity
consciousness	I-Entity
,	O
while	O
cats	O
most	O
clearly	O
showed	O
marked	O
central	O
excitatory	O
actions	O
.	O

Signs	O
of	O
FZP	I-Entity
toxocity	I-Entity
in	O
cats	O
included	O
excessive	O
salivation	I-Entity
,	O
extreme	O
apprehensive	O
behavior	O
,	O
retching	O
,	O
muscle	B-Entity
tremors	I-Entity
and	O
convulsions	I-Entity
.	O

An	O
interaction	O
between	O
FZP	I-Entity
and	O
pentylenetetrazol	I-Entity
(	O
PTZ	I-Entity
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	I-Entity
before	O
PTZ	I-Entity
challenge	O
.	O

As	O
a	O
function	O
of	O
dose	O
,	O
FZP	I-Entity
first	O
protected	O
against	O
convulsions	I-Entity
and	O
death	O
.	O

At	O
higher	O
doses	O
,	O
however	O
,	O
convulsions	I-Entity
again	O
emerged	O
.	O

These	O
doses	O
of	O
FZP	I-Entity
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	I-Entity
.	O

These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	I-Entity
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability	O
,	O
such	O
as	O
epilepsy	I-Entity
or	O
sedative	O
-	O
hypnotic	O
drug	O
withdrawal	O
.	O



We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	I-Entity
(	O
cardioselective	O
)	O
,	O
40	O
mg	O
propranolol	I-Entity
(	O
nonselective	O
)	O
,	O
and	O
placebo	O
on	O
both	O
exercise-	O
and	O
isoproterenol	I-Entity
-	O
induced	O
tachycardia	I-Entity
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects	O
.	O

7	O
bpm	O
after	O
atenolol	I-Entity
and	O
138	O
+	O
/-	O

6	O
bpm	O
after	O
propranolol	I-Entity
,	O

The	O
effects	O
on	O
isoproterenol	I-Entity
tachycardia	I-Entity
were	O
determined	O
before	O
and	O
after	O
atropine	I-Entity
(	O
0.04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Isoproterenol	I-Entity
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
increased	O
from	O
1.8	O
+	O
/-	O

8.3	O
micrograms	O
after	O
propranolol	I-Entity
and	O
8.3	O
+	O
/-	O

1.7	O
micrograms	O
after	O
atenolol	I-Entity
.	O

After	O
atropine	I-Entity
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(	O
2.3	O
+	O
/-	O

0.3	O
micrograms	O
)	O
and	O
atenolol	I-Entity
(	O
7.7	O
+	O
/-	O

1.3	O
micrograms	O
)	O
;	O
it	O
was	O
reduced	O
after	O
propranolol	I-Entity
(	O
24.8	O
+	O
/-	O

5.0	O
micrograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenolol	I-Entity
.	O

This	O
change	O
with	O
propranolol	I-Entity
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka	O
,	O
this	O
was	O
unchanged	O
by	O
atropine	I-Entity
(	O
11.7	O
+	O
/-	O

These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise	O
-	O
induced	O
tachycardia	I-Entity
results	O
largely	O
from	O
beta	O
1-receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	I-Entity
activates	O
both	O
beta	O
1-	O
and	O
beta	O
2-receptors	O
so	O
that	O
after	O
cardioselective	O
blockade	O
there	O
remains	O
a	O
beta	O
2-component	O
that	O
can	O
be	O
blocked	O
with	O
a	O
nonselective	O
drug	O
.	O



Hormones	O
and	O
risk	O
of	O
breast	B-Entity
cancer	I-Entity
.	O

It	O
was	O
hypothesized	O
that	O
progestins	I-Entity
could	O
equilibrate	O
the	O
effects	O
of	O
the	O
estrogenic	O
stimulation	O
on	O
the	O
mammary	O
and	O
endometrial	O
target	O
tissues	O
of	O
women	O
on	O
hormonal	O
replacement	O
therapy	O
.	O

The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	B-Entity
estrogens	I-Entity
(	O
Premarin	I-Entity
)	O
1.25	O
mg	O

/	O
day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	B-Entity
acetate	I-Entity
10	O
mg	O
/	O
day	O
for	O
10	O
days	O
in	O
each	O
month	O
.	O

Mastodynia	I-Entity
was	O
reported	O
by	O
21	O
patients	O
,	O
and	O
physical	O
examination	O
revealed	O
a	O
light	O
increase	O
in	O
breast	O
firmness	O
in	O
12	O
women	O
and	O
a	O
moderate	O
increase	O
in	O
breast	O
nodularity	O
in	O
2	O
women	O
.	O

Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	I-Entity
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	I-Entity
.	O

Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	I-Entity
dose	O
.	O



Early	O
infections	I-Entity
in	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
transplant	O
recipients	O
on	O
cyclosporine	I-Entity
.	O

Eighty	O
-	O
one	O
renal	O
,	O
seventeen	O
heart	O
,	O
and	O
twenty	O
-	O
four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	I-Entity
.	O

Seventeen	O
renal	O
patients	O
received	O
azathioprine	I-Entity
(	O
Aza	I-Entity
)	O
and	O
prednisone	I-Entity
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine	I-Entity
-	O
and	O
-	O
prednisone	I-Entity
-	O
treated	O
renal	O
transplant	O
patients	O
.	O

All	O
others	O
received	O
cyclosporine	I-Entity
and	O
prednisone	I-Entity
.	O

The	O
randomized	O
Aza	I-Entity
patients	O
had	O
more	O
overall	O
infections	I-Entity
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
more	O
nonviral	O
infections	I-Entity
(	O
P	O
less	O
than	O
0.02	O
)	O
than	O
the	O
randomized	O
cyclosporine	I-Entity
patients	O
.	O

Heart	O
and	O
liver	O
patients	O
had	O
more	O
infections	I-Entity
than	O
cyclosporine	I-Entity
renal	O
patients	O
but	O
fewer	O
infections	I-Entity
than	O
the	O
Aza	I-Entity
renal	O
patients	O
.	O

There	O
were	O
no	O
infectious	O
deaths	O
in	O
renal	O
transplant	O
patients	O
on	O
cyclosporine	I-Entity
or	O
Aza	I-Entity
,	O
but	O
infection	I-Entity
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	O
and	O
in	O
8	O
out	O
of	O
9	O
liver	O
transplant	O
deaths	O
.	O

Renal	O
patients	O
on	O
cyclosporine	I-Entity
had	O
the	O
fewest	O
bacteremias	I-Entity
.	O

Analysis	O
of	O
site	O
of	O
infection	I-Entity
showed	O
a	O
preponderance	O
of	O
abdominal	B-Entity
infections	I-Entity
in	O
liver	O
patients	O
,	O
intrathoracic	O
infections	I-Entity
in	O
heart	O
patients	O
,	O
and	O
urinary	B-Entity
tract	I-Entity
infections	I-Entity
in	O
renal	O
patients	O
.	O

Pulmonary	O
infections	I-Entity
were	O
less	O
common	O
in	O
cyclosporine	I-Entity
-	O
treated	O
renal	O
patients	O
than	O
in	O
Aza	I-Entity
-	O
treated	O
patients	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Aza	I-Entity
patients	O
had	O
significantly	O
more	O
staphylococcal	B-Entity
infections	I-Entity
than	O
all	O
other	O
transplant	O
groups	O
(	O
P	O
less	O
than	O
0.005	O
)	O
,	O
and	O
systemic	O
fungal	B-Entity
infections	I-Entity
occurred	O
only	O
in	O
the	O
liver	O
transplant	O
group	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer	O
,	O
or	O
both	O
occurred	O
in	O
78%	O
of	O
cyclosporine	I-Entity
patients	O
and	O
76%	O
of	O
Aza	I-Entity
patients	O
.	O

Of	O
the	O
cyclosporine	I-Entity
patients	O
,	O
15%	O
had	O
symptoms	O
related	O
to	O
CMV	B-Entity
infection	I-Entity
.	O

Serological	O
evidence	O
for	O
Epstein	B-Entity
Barr	I-Entity
Virus	I-Entity
infection	I-Entity
was	O
found	O
in	O
20%	O
of	O
65	O
cyclosporine	I-Entity
patients	O
studied	O
.	O

Three	O
had	O
associated	O
symptoms	O
,	O
and	O
one	O
developed	O
a	O
lymphoma	I-Entity
.	O



Structure	O
-	O
activity	O
and	O
dose	O
-	O
effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin	I-Entity
-	O
induced	O
seizures	I-Entity
by	O
cholecystokinin	I-Entity
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	I-Entity
in	O
mice	O
.	O

Intraperitoneal	O
administration	O
of	O
cholecystokinin	B-Entity
octapeptide	I-Entity
sulphate	O
ester	O
(	O
CCK-8-SE	I-Entity
)	O
and	O
nonsulphated	O
cholecystokinin	B-Entity
octapeptide	I-Entity
(	O
CCK-8-NS	I-Entity
)	O
enhanced	O
the	O
latency	O
of	O
seizures	I-Entity
induced	O
by	O
picrotoxin	I-Entity
in	O
mice	O
.	O

The	O
analogues	O
CCK-8-SE	I-Entity
and	O
CCK-8-NS	I-Entity
(	O
dose	O
range	O
0.2	O
-	O
6.4	O
mumol	O
/	O
kg	O
)	O
and	O
caerulein	I-Entity
dose	O
range	O
0.1	O
-	O
0.8	O
mumol	O
/	O
kg	O
)	O
showed	O
bell	O
-	O
shaped	O
dose	O
-	O
effect	O
curves	O
,	O
with	O
the	O
greatest	O
maximum	O
inhibition	O
for	O
CCK-8-NS	I-Entity
.	O

The	O
peptide	O
CCK-5	O
-	O
8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides	O
,	O
3.2	O
mumol	O
/	O
kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug	O
,	O
diazepam	I-Entity
,	O
totally	O
prevented	O
picrotoxin	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
mortality	O
.	O

The	O
maximum	O
effect	O
of	O
the	O
peptides	O
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	I-Entity
.	O

Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta	O
-	O
alanyl	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK-8-SE	I-Entity
.	O

Of	O
the	O
CCK-2	O
-	O
8	O
analogues	O
,	O
Ser(SO3H)7-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
and	O
Thr(SO3H)7-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
and	O
Hyp(SO3H)-Ac	O
-	O
CCK-2	O
-	O
8-SE	O
were	O
slightly	O
more	O
active	O
than	O
CCK-8-SE	I-Entity
.	O



Vasopressin	I-Entity
as	O
a	O
possible	O
contributor	O
to	O
hypertension	I-Entity
.	O

The	O
role	O
of	O
vasopressin	I-Entity
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	I-Entity
process	O
was	O
examined	O
.	O

Vasopressin	I-Entity
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA	I-Entity
-	O
salt	O
hypertension	I-Entity
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium	I-Entity
-	O
treated	O
diabetes	B-Entity
insipidus	I-Entity
after	O
DOCA	I-Entity
-	O
salt	O
treatment	O
.	O

Administration	O
of	O
DDAVP	I-Entity
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
pressor	O
action	O
of	O
vasopressin	I-Entity
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	I-Entity
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	I-Entity
.	O

Increased	O
secretion	O
of	O
vasopressin	I-Entity
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	I-Entity
.	O

An	O
unproportional	O
release	O
of	O
vasopressin	I-Entity
compared	O
to	O
plasma	O
osmolality	O
may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	I-Entity
II	O
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	I-Entity
balance	O
in	O
the	O
brain	O
.	O

However	O
,	O
the	O
role	O
of	O
vasopressin	I-Entity
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	O
hypertension	I-Entity
.	O



Toxic	B-Entity
hepatitis	I-Entity
induced	O
by	O
disulfiram	I-Entity
in	O
a	O
non	O
-	O
alcoholic	O
.	O

A	O
reversible	O
toxic	B-Entity
liver	I-Entity
damage	I-Entity
was	O
observed	O
in	O
a	O
non	O
-	O
alcoholic	O
woman	O
treated	O
with	O
disulfiram	I-Entity
.	O



Atrial	B-Entity
thrombosis	I-Entity
involving	O
the	O
heart	O
of	O
F-344	O
rats	O
ingesting	O
quinacrine	B-Entity
hydrochloride	I-Entity
.	O

Quinacrine	B-Entity
hydrochloride	I-Entity
is	O
toxic	O
for	O
the	O
heart	O
of	O
F-344	O
rats	O
.	O

Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	B-Entity
hydrochloride	I-Entity
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	B-Entity
thrombosis	I-Entity
.	O

The	O
lesion	O
was	O
associated	O
with	O
cardiac	B-Entity
hypertrophy	I-Entity
and	O
dilatation	O
and	O
focal	O
myocardial	B-Entity
degeneration	I-Entity
.	O

Rats	O
died	O
from	O
cardiac	B-Entity
hypertrophy	I-Entity
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs	O
,	O
liver	O
,	O
and	O
other	O
organs	O
.	O

Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	B-Entity
hydrochloride	I-Entity
and	O
1,000	O
ppm	O
sodium	B-Entity
nitrite	I-Entity
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	I-Entity
of	O
the	O
atria	O
of	O
the	O
heart	O
,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	B-Entity
thrombosis	I-Entity
.	O

Sodium	B-Entity
nitrite	I-Entity
in	O
combination	O
with	O
quinacrine	B-Entity
hydrochloride	I-Entity
appeared	O
to	O
have	O
no	O
additional	O
effect	O
.	O



Alternating	B-Entity
sinus	I-Entity
rhythm	I-Entity
and	O
intermittent	O
sinoatrial	B-Entity
block	I-Entity
induced	O
by	O
propranolol	I-Entity
.	O

Alternating	B-Entity
sinus	I-Entity
rhythm	I-Entity
and	O
intermittent	O
sinoatrial	B-Entity
(	I-Entity
S	I-Entity
-	I-Entity
A	I-Entity
)	I-Entity
block	I-Entity
was	O
observed	O
in	O
a	O
57-year	O
-	O
old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	I-Entity
with	O
80	O
mg	O
propranolol	I-Entity
daily	O
.	O

Following	O
these	O
basic	O
sinus	O
cycles	O
,	O
alternating	B-Entity
rhythm	I-Entity
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
interval	O
.	O

In	O
one	O
recording	O
a	O
short	O
period	O
of	O
regular	O
sinus	O
rhythm	O
with	O
intermittent	O
2/1	O
S	B-Entity
-	I-Entity
A	I-Entity
block	I-Entity
was	O
observed	O
.	O

Atropine	I-Entity
1	O
mg	O
given	O
intravenously	O
resulted	O
in	O
shortening	O
of	O
all	O
P	O
-	O
P	O
intervals	O
without	O
changing	O
the	O
rhythm	O
.	O

The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	I-Entity
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2/1	O
S	B-Entity
-	I-Entity
A	I-Entity
block	I-Entity
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	I-Entity
being	O
the	O
cause	O
of	O
this	O
conduction	B-Entity
disorder	I-Entity
.	O



Antitumor	O
effect	O
,	O
cardiotoxicity	I-Entity
,	O
and	O
nephrotoxicity	I-Entity
of	O
doxorubicin	I-Entity
in	O
the	O
IgM	O
solid	O
immunocytoma	I-Entity
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Antitumor	O
activity	O
,	O
cardiotoxicity	I-Entity
,	O
and	O
nephrotoxicity	I-Entity
induced	O
by	O
doxorubicin	I-Entity
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inbred	O
rats	O
each	O
bearing	O
a	O
transplantable	O
solid	O
IgM	O
immunocytoma	I-Entity
.	O

Animals	O
with	O
a	O
tumor	I-Entity
(	O
diameter	O
,	O
15.8	O
+	O
/-	O

3.3	O
mm	O
)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	I-Entity
on	O
5	O
consecutive	O
days	O
,	O
followed	O
by	O
1	O
weekly	O
injection	O
for	O
7	O
weeks	O
(	O
dose	O
range	O
,	O
0.015	O
-	O
4.0	O

Tumor	I-Entity
regression	O
was	O
observed	O
with	O
0.5	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
.	O

Complete	O
disappearance	O
of	O
the	O
tumor	I-Entity
was	O
induced	O
with	O
1.0	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
.	O

Histologic	O
evidence	O
of	O
cardiotoxicity	I-Entity
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dose	O
of	O
1.0	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
.	O

Light	O
microscopic	O
evidence	O
of	O
renal	B-Entity
damage	I-Entity
was	O
seen	O
above	O
a	O
dose	O
of	O
0.5	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuria	I-Entity
and	O
very	O
low	O
serum	O
albumin	O
levels	O
.	O

In	O
the	O
group	O
that	O
received	O
1.0	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
,	O
the	O
serum	O
albumin	O
level	O
decreased	O
from	O
33.6	O
+	O
/-	O

Ascites	I-Entity
and	O
hydrothorax	I-Entity
were	O
observed	O
simultaneously	O
.	O

The	O
same	O
experiments	O
were	O
performed	O
with	O
non	O
-	O
tumor	I-Entity
-	O
bearing	O
rats	O
,	O
in	O
which	O
no	O
major	O
differences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	I-Entity
,	O
and	O
nephrotoxicity	I-Entity
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Albuminuria	I-Entity
due	O
to	O
renal	B-Entity
damage	I-Entity
led	O
to	O
extremely	O
low	O
serum	O
albumin	O
levels	O
,	O
so	O
ascites	I-Entity
and	O
hydrothorax	I-Entity
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	I-Entity
.	O



Intraoperative	O
bradycardia	I-Entity
and	O
hypotension	I-Entity
associated	O
with	O
timolol	I-Entity
and	O
pilocarpine	I-Entity
eye	O
drops	O
.	O

A	O
69-yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	B-Entity
nitrate	I-Entity
and	O
timolol	B-Entity
maleate	I-Entity
eye	O
drops	O
,	O
developed	O
a	O
bradycardia	I-Entity
and	O
became	O
hypotensive	I-Entity
during	O
halothane	I-Entity
anaesthesia	O
.	O

Both	O
timolol	I-Entity
and	O
pilocarpine	I-Entity
were	O
subsequently	O
identified	O
in	O
a	O
24-h	O
collection	O
of	O
urine	O
.	O

Timolol	I-Entity
(	O
but	O
not	O
pilocarpine	I-Entity
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery	O
;	O
the	O
plasma	O
concentration	O
of	O
timolol	I-Entity
(	O
2.6	O
ng	O
ml-1	O
)	O
was	O
consistent	O
with	O
partial	O
beta	O
-	O
adrenoceptor	O
blockade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	I-Entity
anaesthesia	O
with	O
resultant	O
bradycardia	I-Entity
and	O
hypotension	I-Entity
.	O

Pilocarpine	I-Entity
may	O
have	O
had	O
a	O
contributory	O
effect	O
.	O



Succinylcholine	I-Entity
apnoea	I-Entity
:	O
attempted	O
reversal	O
with	O
anticholinesterases	O
.	O

Anticholinesterases	O
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	B-Entity
blockade	I-Entity
following	O
the	O
administration	O
of	O
succinylcholine	I-Entity
in	O
a	O
patient	O
later	O
found	O
to	O
be	O
homozygous	O
for	O
atypical	O
plasma	O
cholinesterase	O
.	O

Edrophonium	I-Entity
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcholine	I-Entity
,	O
when	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
was	O
characteristic	O
of	O
phase	O
II	O
block	O
,	O
produced	O
partial	O
antagonism	O
which	O
was	O
not	O
sustained	O
.	O

Repeated	O
doses	O
of	O
edrophonium	I-Entity
to	O
70	O
mg	O
and	O
neostigmine	I-Entity
to	O
2.5	O
mg	O
did	O
not	O
antagonize	O
or	O
augment	O
the	O
block	O
.	O

Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	I-Entity
administration	O
.	O

It	O
is	O
concluded	O
that	O
anticholinesterases	O
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	I-Entity
apnoea	I-Entity
despite	O
muscle	O
twitch	O
activity	O
typical	O
of	O
phase	O
II	O
block	O
.	O



Effect	O
of	O
doxorubicin	I-Entity
on	O
[	B-Entity
omega	I-Entity
-	I-Entity
I-131]heptadecanoic	I-Entity
acid	I-Entity
myocardial	O
scintigraphy	O
and	O
echocardiography	O
in	O
dogs	O
.	O

The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	I-Entity
on	O
dynamic	O
myocardial	O
scintigraphy	O
with	O
[	B-Entity
omega	I-Entity
-	I-Entity
I-131]heptadecanoic	I-Entity
acid	I-Entity
(	O
I-131	B-Entity
HA	I-Entity
)	O
,	O
and	O
on	O
global	O
left	O
-	O
ventricular	O
function	O
determined	O
echocardiographically	O
,	O
were	O
studied	O
in	O
a	O
group	O
of	O
nine	O
mongrel	O
dogs	O
.	O

Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin	I-Entity
-	O
treated	O
dogs	O
.	O

A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	O
a	O
cumulative	O
doxorubicin	I-Entity
dose	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1/2	O
of	O
the	O
I-131	B-Entity
HA	I-Entity
was	O
observed	O
only	O
at	O
a	O
higher	O
cumulative	O
dose	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	O
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	I-Entity
.	O

Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I-131	B-Entity
HA	I-Entity
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	I-Entity
cardiotoxicity	I-Entity
.	O



Hemodynamics	O
and	O
myocardial	O
metabolism	O
under	O
deliberate	O
hypotension	I-Entity
.	O

Coronary	O
blood	O
flow	O
,	O
cardiac	O
work	O
and	O
metabolism	O
were	O
studied	O
in	O
dogs	O
under	O
sodium	B-Entity
nitroprusside	I-Entity
(	O
SNP	I-Entity
)	O
and	O
trimetaphan	I-Entity
(	O
TMP	I-Entity
)	O
deliberate	O
hypotension	I-Entity
(	O
20%	O
and	O

Regarding	O
the	O
effects	O
of	O
drug	O
-	O
induced	O
hypotension	I-Entity
on	O
coronary	O
blood	O
flow	O
,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusside	I-Entity
hypotension	I-Entity
could	O
be	O
safely	O
used	O
to	O
30%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control	O
,	O
trimetaphan	I-Entity
hypotension	I-Entity
to	O
20%	O
mean	O
blood	O
pressure	O
decrease	O
.	O

Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	I-Entity
hypotension	I-Entity
.	O

Myocardial	O
O2	I-Entity
consumption	O
and	O
O2	I-Entity
availability	O
were	O
directly	O
dependent	O
on	O
the	O
coronary	O
perfusion	O
.	O



Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	I-Entity
in	O
the	O
rat	O
.	O

Male	O
rats	O
received	O
the	O
noradrenaline	I-Entity
neurotoxin	O
DSP4	I-Entity
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D	B-Entity
-	I-Entity
amphetamine	I-Entity
(	O
10	O
or	O
40	O
mumol	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

The	O
hyperactivity	I-Entity
induced	O
by	O
D	B-Entity
-	I-Entity
amphetamine	I-Entity
(	O
10	O
mumol	O
/	O
kg	O
)	O
was	O
significantly	O
reduced	O
by	O
DSP4	I-Entity
pretreatment	O
.	O

However	O
,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine	I-Entity
-	O
induced	O
stereotypies	I-Entity
were	O
not	O
blocked	O
by	O
pretreatment	O
with	O
DSP4	I-Entity
.	O

The	O
reduction	O
of	O
amphetamine	I-Entity
hyperactivity	I-Entity
induced	O
by	O
DSP4	I-Entity
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline	I-Entity
-	O
uptake	O
blocking	O
agent	O
,	O
desipramine	I-Entity
,	O
which	O
prevents	O
the	O
neurotoxic	I-Entity
action	O
of	O
DSP4	I-Entity
.	O

The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	I-Entity
in	O
the	O
rat	O
.	O



Accelerated	B-Entity
junctional	I-Entity
rhythms	I-Entity
during	O
oral	O
verapamil	I-Entity
therapy	O
.	O

This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	B-Entity
junctional	I-Entity
rhythms	I-Entity
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	I-Entity
.	O

Accelerated	B-Entity
junctional	I-Entity
rhythms	I-Entity
and	O
AV	O
dissociation	O
were	O
frequent	O
in	O
patients	O
with	O
supraventricular	B-Entity
tachyarrhythmias	I-Entity
,	O
particularly	O
AV	O
nodal	O
reentry	O
.	O

Verapamil	I-Entity
administration	O
to	O
these	O
patients	O
led	O
to	O
an	O
asymptomatic	O
increase	O
in	O
activity	O
of	O
these	O
junctional	O
pacemakers	O
.	O

In	O
patients	O
with	O
various	O
chest	B-Entity
pain	I-Entity
syndromes	O
,	O
verapamil	I-Entity
neither	O
increased	O
the	O
frequency	O
of	O
junctional	O
rhythms	O
nor	O
suppressed	O
their	O
role	O
as	O
escape	O
rhythms	O
under	O
physiologically	O
appropriate	O
circumstances	O
.	O



Treatment	O
of	O
ovarian	B-Entity
cancer	I-Entity
with	O
a	O
combination	O
of	O
cis	B-Entity
-	I-Entity
platinum	I-Entity
,	O
adriamycin	I-Entity
,	O
cyclophosphamide	I-Entity
and	O
hexamethylmelamine	I-Entity
.	O

During	O
the	O
last	O
2	O
1/2	O
years	O
,	O
38	O
patients	O
with	O
ovarian	B-Entity
cancer	I-Entity
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	I-Entity
(	O
CPDD	I-Entity
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adriamycin	I-Entity
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphamide	I-Entity
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hexamethylmelamine	I-Entity
(	O
HMM	I-Entity
)	O
,	O
6	O
mg	O
/	O
kg	O
daily	O
,	O
for	O
14	O
days	O
.	O

14	O
of	O
the	O
38	O
patients	O
were	O
previously	O
treated	O
with	O
chemotherapy	O
,	O
1	O
with	O
radiation	O
,	O
6	O
with	O
both	O
chemotherapy	O
and	O
radiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatment	O
before	O
CPDD	I-Entity
combination	O
.	O

Hematologic	B-Entity
toxicity	I-Entity
was	O
moderate	O
and	O
with	O
reversible	O
anemia	I-Entity
developing	O
in	O
71%	O
of	O
patients	O
.	O

Gastrointestinal	O
side	O
effects	O
from	O
CPDD	I-Entity
were	O
universal	O
.	O

HMM	I-Entity
gastrointestinal	B-Entity
toxicity	I-Entity
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients	O
.	O

Severe	O
nephrotoxicity	I-Entity
was	O
observed	O
in	O
2	O
patients	O
but	O
was	O
reversible	O
.	O



Nontraumatic	O
dissecting	B-Entity
aneurysm	I-Entity
of	O
the	O
basilar	O
artery	O
.	O

A	O
case	O
of	O
nontraumatic	O
dissecting	B-Entity
aneurysm	I-Entity
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	I-Entity
,	O
smoke	O
,	O
and	O
oral	B-Entity
contraceptives	I-Entity
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked	B-Entity
-	I-Entity
in	I-Entity
syndrome	I-Entity
.	O



Propylthiouracil	I-Entity
-	O
induced	O
hepatic	B-Entity
damage	I-Entity
.	O

Two	O
cases	O
of	O
propylthiouracil	I-Entity
-	O
induced	O
liver	B-Entity
damage	I-Entity
have	O
been	O
observed	O
.	O

The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	B-Entity
active	I-Entity
hepatitis	I-Entity
,	O
with	O
spontaneous	O
remission	O
.	O



Studies	O
on	O
the	O
bradycardia	I-Entity
induced	O
by	O
bepridil	I-Entity
.	O

Bepridil	I-Entity
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	B-Entity
attacks	I-Entity
,	O
induced	O
persistent	O
bradycardia	I-Entity
and	O
a	O
non	O
-	O
specific	O
anti	O
-	O
tachycardial	I-Entity
effect	O
,	O
the	O
mechanisms	O
of	O
which	O
were	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perfusion	O
of	O
bepridil	I-Entity
in	O
the	O
life	O
-	O
support	O
medium	O
for	O
isolated	O
sino	O
-	O
atrial	O
tissue	O
from	O
rabbit	O
heart	O
,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(	O
AP	O
)	O
spike	O
frequency	O
(	O
recorded	O
by	O
KCl	I-Entity
microelectrodes	O
)	O
starting	O
at	O
doses	O
of	O
5	O
X	O
10(-6	O
)	O
M.	O

Bepridil	I-Entity
at	O
a	O
dose	O
of	O
5	O
X	O
10(-6	O
)	O

In	O
vivo	O
injection	O
of	O
bepridil	I-Entity
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i.v	O
.	O
)	O

It	O
is	O
concluded	O
that	O
bepridil	I-Entity
reduces	O
heart	O
rate	O
by	O
acting	O
directly	O
on	O
the	O
sinus	O
node	O
.	O

This	O
effect	O
,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
duration	O
,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	I-Entity
current	O
(	O
Ip	O
)	O
.	O



Hepatitis	I-Entity
and	O
renal	B-Entity
tubular	I-Entity
acidosis	I-Entity
after	O
anesthesia	O
with	O
methoxyflurane	I-Entity
.	O

A	O
69-year	O
-	O
old	O
man	O
operated	O
for	O
acute	B-Entity
cholecystitis	I-Entity
under	O
methoxyflurane	I-Entity
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	B-Entity
insufficiency	I-Entity
syndrome	I-Entity
and	O
renal	B-Entity
tubular	I-Entity
acidosis	I-Entity
.	O

Massive	O
bleeding	I-Entity
appeared	O
during	O
surgery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O



Pituitary	O
response	O
to	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
during	O
haloperidol	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
.	O

The	O
effects	O
of	O
a	O
6-hour	O
infusion	O
with	O
haloperidol	I-Entity
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O

Control	O
patients	O
received	O
infusions	O
of	O
0.9%	O
NaCl	I-Entity
solution	O
.	O

During	O
the	O
course	O
of	O
haloperidol	I-Entity
infusions	O
,	O
significant	O
hyperprolactinemia	I-Entity
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O



Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin	I-Entity
-	O
associated	O
renal	B-Entity
failure	I-Entity
.	O

5	O
patients	O
with	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
(	O
3	O
with	O
thrombopenia	I-Entity
and	O
hemolysis	I-Entity
)	O
induced	O
by	O
the	O
reintroduction	O
of	O
rifampicin	I-Entity
are	O
described	O
.	O

Antibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
class	O
were	O
detected	O
in	O
all	O
3	O
patients	O
with	O
hematological	B-Entity
disorders	I-Entity
.	O

The	O
pattern	O
of	O
non	O
-	O
specific	O
acute	B-Entity
tubular	I-Entity
necrosis	I-Entity
found	O
in	O
the	O
2	O
biopsied	O
patients	O
,	O
indistinguishable	O
from	O
that	O
of	O
ischemic	O
origin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascular	O
-	O
mediated	O
damage	O
.	O



Cardiovascular	O
effects	O
of	O
hypotension	I-Entity
induced	O
by	O
adenosine	B-Entity
triphosphate	I-Entity
and	O
sodium	B-Entity
nitroprusside	I-Entity
on	O
dogs	O
with	O
denervated	O
hearts	O
.	O

Adenosine	B-Entity
triphosphate	I-Entity
(	O
ATP	I-Entity
)	O
and	O
sodium	B-Entity
nitroprusside	I-Entity
(	O
SNP	I-Entity
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	I-Entity
during	O
anesthesia	O
.	O

SNP	I-Entity
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	I-Entity
is	O
clinically	O
used	O
in	O
other	O
countries	O
such	O
as	O
Japan	O
.	O

ATP	I-Entity
(	O
10	O
dogs	O
)	O
or	O
SNP	I-Entity
(	O
10	O
dogs	O
)	O
was	O
administered	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
by	O
30%	O
to	O
70%	O
of	O
control	O
.	O

Before	O
,	O
during	O
and	O
after	O
induced	O
hypotension	I-Entity
,	O
we	O
measured	O
major	O
cardiovascular	O
parameters	O
.	O

Hypotension	I-Entity
induced	O
by	O
ATP	I-Entity
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
body	O
oxygen	I-Entity
consumption	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
;	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	I-Entity
was	O
stopped	O
.	O

During	O
hypotension	I-Entity
produced	O
by	O
SNP	I-Entity
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
oxygen	I-Entity
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
cardiac	O
output	O
(	O
p	O
less	O
than	O
0.05	O
)	O
were	O
increased	O
.	O

Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	I-Entity
had	O
been	O
stopped	O
.	O

Both	O
ATP	I-Entity
and	O
SNP	I-Entity
should	O
act	O
on	O
the	O
pacemaker	O
tissue	O
of	O
the	O
heart	O
.	O



Comparative	O
study	O
:	O
Endografine	I-Entity
(	O
diatrizoate	I-Entity
)	O
,	O
Vasurix	B-Entity
polyvidone	I-Entity
(	O
acetrizoate	I-Entity
)	O
,	O
Dimer	B-Entity
-	I-Entity
X	I-Entity
(	O
iocarmate	I-Entity
)	O
and	O
Hexabrix	I-Entity
(	O
ioxaglate	I-Entity
)	O
in	O
hysterosalpingography	O
.	O

Side	O
effects	O
of	O
hysterosalpingography	O
with	O
Dimer	B-Entity
-	I-Entity
X	I-Entity
,	O
Hexabrix	I-Entity
,	O
Vasurix	B-Entity
polyvidone	I-Entity
and	O
Endografine	I-Entity
in	O
142	O
consecutive	O
patients	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tested	O
media	O
were	O
evaluated	O
from	O
replies	O
to	O
postal	O
questionnaires	O
.	O

The	O
Dimer	B-Entity
-	I-Entity
X	I-Entity
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	I-Entity
and	O
dizziness	I-Entity
.	O

The	O
Endografine	I-Entity
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	B-Entity
pain	I-Entity
.	O

Hexabrix	I-Entity
and	O
Vasurix	B-Entity
polyvidone	I-Entity
are	O
considered	O
the	O
best	O
contrast	B-Entity
media	I-Entity
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	I-Entity
Hexabrix	I-Entity
should	O
be	O
preferred	O
.	O



Post	O
-	O
suxamethonium	I-Entity
pains	I-Entity
in	O
Nigerian	O
surgical	O
patients	O
.	O

Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon	O
,	O
scoline	I-Entity
pain	I-Entity
occurs	O
in	O
African	O
negroes	O
.	O

About	O
62%	O
of	O
the	O
out	O
-	O
patients	O
developed	O
scoline	I-Entity
pain	I-Entity
as	O
compared	O
with	O
about	O
26%	O
among	O
the	O
in	O
-	O
patients	O
.	O

The	O
abolition	O
of	O
muscle	O
fasciculations	I-Entity
(	O
by	O
0.075mg	O
/	O
kg	O
dose	O
of	O
Fazadinium	I-Entity
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	I-Entity
pain	I-Entity
.	O

Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	I-Entity
or	O
Thiopentone	I-Entity
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	I-Entity
used	O
(	O
chloride	I-Entity
or	O
bromide	I-Entity
)	O
,	O
affected	O
the	O
incidence	O
of	O
scoline	I-Entity
pain	I-Entity
.	O



Medial	O
changes	O
in	O
arterial	O
spasm	I-Entity
induced	O
by	O
L	B-Entity
-	I-Entity
norepinephrine	I-Entity
.	O

In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch	O
,	O
vasoconstriction	O
induced	O
by	O
L	B-Entity
-	I-Entity
norepinephrine	I-Entity
produced	O
many	O
cell	O
-	O
to	O
-	O
cell	O
hernias	I-Entity
within	O
15	O
minutes	O
.	O

The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	I-Entity
.	O



Abnormalities	O
of	O
the	O
pupil	O
and	O
visual	O
-	O
evoked	O
potential	O
in	O
quinine	I-Entity
amblyopia	I-Entity
.	O

Total	O
blindness	I-Entity
with	O
a	O
transient	O
tonic	B-Entity
pupillary	I-Entity
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
developed	O
in	O
a	O
54-year	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-Entity
sulfate	I-Entity
for	O
leg	B-Entity
cramps	I-Entity
.	O

A	O
transient	O
tonic	B-Entity
pupillary	I-Entity
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
in	O
quinine	I-Entity
toxicity	I-Entity
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O



Suxamethonium	I-Entity
-	O
induced	O
jaw	B-Entity
stiffness	I-Entity
and	O
myalgia	I-Entity
associated	O
with	O
atypical	O
cholinesterase	O
:	O
case	O
report	O
.	O

An	O
11-year	O
-	O
old	O
boy	O
was	O
given	O
halothane	I-Entity
,	O
nitrous	B-Entity
oxide	I-Entity
and	O
oxygen	I-Entity
,	O
pancuronium	I-Entity
0.4	O
mg	O
and	O
suxamethonium	I-Entity
100	O
mg	O
for	O
induction	O
of	O
anaesthesia	O
.	O

In	O
response	O
to	O
this	O
a	O
marked	O
jaw	B-Entity
stiffness	I-Entity
occurred	O
which	O
lasted	O
for	O
two	O
minutes	O
and	O
the	O
anaesthesia	O
were	O
terminated	O
.	O

Four	O
hours	O
of	O
apnoea	I-Entity
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	I-Entity
lasting	O
for	O
one	O
week	O
.	O

He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	I-Entity
number	O
of	O
12	O
,	O
indicating	O
homozygocity	O
.	O

The	O
case	O
shows	O
that	O
prolonged	B-Entity
jaw	I-Entity
rigidity	I-Entity
and	O
myalgia	I-Entity
may	O
occur	O
after	O
suxamethonium	I-Entity
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	I-Entity
.	O



Indomethacin	I-Entity
-	O
induced	O
hyperkalemia	I-Entity
in	O
three	O
patients	O
with	O
gouty	B-Entity
arthritis	I-Entity
.	O

We	O
describe	O
three	O
patients	O
in	O
whom	O
severe	O
,	O
life	O
-	O
threatening	O
hyperkalemia	I-Entity
and	O
renal	B-Entity
insufficiency	I-Entity
developed	O
after	O
treatment	O
of	O
acute	O
gouty	B-Entity
arthritis	I-Entity
with	O
indomethacin	I-Entity
.	O

This	O
complication	O
may	O
result	O
from	O
an	O
inhibition	O
of	O
prostaglandin	I-Entity
synthesis	O
and	O
consequent	O
hyporeninemic	B-Entity
hypoaidosteronism	I-Entity
.	O

Careful	O
attention	O
to	O
renal	O
function	O
and	O
potassium	I-Entity
balance	O
in	O
patients	O
receiving	O
indomethacin	I-Entity
or	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	B-Entity
mellitus	I-Entity
or	O
preexisting	O
renal	B-Entity
disease	I-Entity
,	O
will	O
help	O
prevent	O
this	O
potentially	O
serious	O
complication	O
.	O



Etomidate	I-Entity
:	O
a	O
foreshortened	O
clinical	O
trial	O
.	O

A	O
clinical	O
evaluation	O
of	O
etomidate	I-Entity
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon	O
.	O

Unpremedicated	O
patients	O
were	O
given	O
fentanyl	I-Entity
1	O
microgram	O
/	O
kg	O
followed	O
by	O
etomidate	I-Entity
0.3	O
mg	O
/	O
kg	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	I-Entity
in	O
2	O
-	O
4	O
mg	O
doses	O
.	O

Venous	O
pain	I-Entity
occurred	O
in	O
68%	O
of	O
patients	O
and	O
50%	O
had	O
redness	O
,	O
pain	I-Entity
or	O
swelling	I-Entity
related	O
to	O
the	O
injection	O
site	O
,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia	O
.	O

Skeletal	O
movements	O
occurred	O
in	O
50%	O
of	O
patients	O
;	O
30%	O
experienced	O
respiratory	B-Entity
upset	I-Entity
,	O
one	O
sufficiently	O
severe	O
to	O
necessitate	O
abandoning	O
the	O
technique	O
.	O

Nausea	I-Entity
and	O
vomiting	I-Entity
occurred	O
in	O
40%	O
and	O
25%	O
had	O
disturbing	O
emergence	O
psychoses	I-Entity
.	O



Levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
are	O
improved	O
by	O
fluoxetine	I-Entity
.	O

We	O
evaluated	O
the	O
severity	O
of	O
motor	B-Entity
disability	I-Entity
and	O
dyskinesias	I-Entity
in	O
seven	O
levodopa	I-Entity
-	O
responsive	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	I-Entity
agonist	O
,	O
apomorphine	I-Entity
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	I-Entity
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/-	O

After	O
fluoxetine	I-Entity
treatment	O
,	O
there	O
was	O
a	O
significant	O
47%	O
improvement	O
(	O
p	O
<	O
0.05	O
)	O
of	O
apomorphine	I-Entity
-	O
induced	O
dyskinesias	I-Entity
without	O
modification	O
of	O
parkinsonian	I-Entity
motor	B-Entity
disability	I-Entity
.	O

The	O
dyskinesias	I-Entity
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	B-Entity
dyskinesias	I-Entity
(	O
onset-	O
and	O
end	O
-	O
of	O
-	O
dose	O
dyskinesias	I-Entity
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	B-Entity
mid	I-Entity
-	I-Entity
dose	I-Entity
dyskinesias	I-Entity
.	O

The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	I-Entity
may	O
reduce	O
levodopa-	I-Entity
or	O
dopamine	I-Entity
agonist	O
-	O
induced	O
dyskinesias	I-Entity
without	O
aggravating	O
parkinsonian	I-Entity
motor	B-Entity
disability	I-Entity
.	O



A	O
large	O
population	O
-	O
based	O
follow	O
-	O
up	O
study	O
of	O
trimethoprim	B-Entity
-	I-Entity
sulfamethoxazole	I-Entity
,	O
trimethoprim	I-Entity
,	O
and	O
cephalexin	I-Entity
for	O
uncommon	O
serious	O
drug	B-Entity
toxicity	I-Entity
.	O

We	O
conducted	O
a	O
population	O
-	O
based	O
45-day	O
follow	O
-	O
up	O
study	O
of	O
232,390	O
people	O
who	O
were	O
prescribed	O
trimethoprim	B-Entity
-	I-Entity
sulfamethoxazole	I-Entity
(	O
TMP	B-Entity
-	I-Entity
SMZ	I-Entity
)	O
,	O
266,951	O
prescribed	O
trimethoprim	I-Entity
alone	O
,	O
and	O
196,397	O
prescribed	O
cephalexin	I-Entity
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver	B-Entity
,	I-Entity
blood	I-Entity
,	I-Entity
skin	I-Entity
,	I-Entity
and	I-Entity
renal	I-Entity
disorders	I-Entity
resulting	O
in	O
referral	O
or	O
hospitalization	O
associated	O
with	O
these	O
drugs	O
.	O

The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	B-Entity
disease	I-Entity
was	O
similar	O
for	O
persons	O
prescribed	O
TMP	B-Entity
-	I-Entity
SMZ	I-Entity
(	O
5.2/100,000	O
)	O
and	O
those	O
prescribed	O
trimethoprim	I-Entity
alone	O
(	O
3.8/100,000	O
)	O
.	O

The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	I-Entity
was	O
somewhat	O
lower	O
(	O
2.0/100,000	O
)	O
.	O

Only	O
five	O
patients	O
experienced	O
blood	O
disorders	O
,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP	B-Entity
-	I-Entity
SMZ	I-Entity
;	O
of	O
seven	O
with	O
erythema	B-Entity
multiforme	I-Entity
and	O
Stevens	B-Entity
-	I-Entity
Johnson	I-Entity
syndrome	I-Entity
,	O
four	O
were	O
exposed	O
to	O
TMP	B-Entity
-	I-Entity
SMZ	I-Entity
.	O

The	O
one	O
case	O
of	O
toxic	B-Entity
epidermal	I-Entity
necrolysis	I-Entity
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	I-Entity
.	O

Finally	O
,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	B-Entity
disease	I-Entity
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
study	O
drug	O
.	O



Clinical	O
safety	O
of	O
lidocaine	I-Entity
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
myocardial	B-Entity
infarction	I-Entity
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	I-Entity
in	O
the	O
setting	O
of	O
cocaine	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
.	O

Patients	O
with	O
cocaine	I-Entity
-	O
associated	O
MI	I-Entity
who	O
received	O
lidocaine	I-Entity
in	O
the	O
emergency	O
department	O
.	O

Of	O
29	O
patients	O
who	O
received	O
lidocaine	I-Entity
in	O
the	O
setting	O
of	O
cocaine	I-Entity
-	O
associated	O
MI	I-Entity
,	O
no	O
patient	O
died	O
;	O
exhibited	O
bradydysrhythmias	I-Entity
,	O
ventricular	B-Entity
tachycardia	I-Entity
,	O
or	O
ventricular	B-Entity
fibrillation	I-Entity
;	O
or	O
experienced	O
seizures	I-Entity
after	O
administration	O
of	O
lidocaine	I-Entity
(	O
95%	O
confidence	O
interval	O
,	O
0%	O
to	O
11%	O
)	O
.	O

CONCLUSION	O
:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	I-Entity
may	O
enhance	O
cocaine	I-Entity
toxicity	I-Entity
,	O
the	O
use	O
of	O
lidocaine	I-Entity
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
MI	I-Entity
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	B-Entity
or	I-Entity
central	I-Entity
nervous	I-Entity
system	I-Entity
toxicity	I-Entity
.	O



Paclitaxel	I-Entity
3-hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	I-Entity
:	O
preliminary	O
results	O
of	O
dose	O
-	O
escalation	O
trials	O
.	O

Paclitaxel	I-Entity
(	O
Taxol	I-Entity
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
by	O
3-hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	I-Entity
in	O
a	O
phase	O
I	O
/	O
II	O
study	O
directed	O
to	O
patients	O
with	O
non	B-Entity
-	I-Entity
small	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
.	O

Carboplatin	I-Entity
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
of	O
6.0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	I-Entity
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	I-Entity
(	O
arthralgia	I-Entity
and	O
sensory	B-Entity
neuropathy	I-Entity
)	O
.	O

Toxicities	I-Entity
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	I-Entity
alone	O
at	O
identical	O
dose	O
levels	O
.	O

Carboplatin	I-Entity
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	B-Entity
toxicities	I-Entity
observed	O
,	O
and	O

the	O
paclitaxel	I-Entity
/	O
carboplatin	I-Entity
combination	O
could	O
be	O
dosed	O
every	O
3	O
weeks	O
.	O



The	O
dose	O
-	O
dependent	O
effect	O
of	O
misoprostol	I-Entity
on	O
indomethacin	I-Entity
-	O
induced	O
renal	B-Entity
dysfunction	I-Entity
in	O
well	O
compensated	O
cirrhosis	I-Entity
.	O

Misoprostol	I-Entity
(	O
200	O
micrograms	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin	I-Entity
-	O
induced	O
renal	B-Entity
dysfunction	I-Entity
in	O
well	O
compensated	O
cirrhotic	I-Entity
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	I-Entity
was	O
dose	O
-	O
dependent	O
.	O

Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	I-Entity
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	I-Entity
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	I-Entity
and	O
various	O
doses	O
of	O
misoprostol	I-Entity
.	O

The	O
200-micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	O
effects	O
of	O
indomethacin	I-Entity
,	O
whereas	O
the	O
800-micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	O
hemodynamics	O
and	O
sodium	I-Entity
retention	O
.	O

These	O
results	O
suggest	O
that	O
the	O
renal	O
protective	O
effects	O
of	O
misoprostol	I-Entity
is	O
dose	O
-	O
dependent	O
.	O

However	O
,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	I-Entity
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	I-Entity
on	O
renal	O
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	I-Entity
.	O



Increased	O
frequency	O
and	O
severity	O
of	O
angio	B-Entity
-	I-Entity
oedema	I-Entity
related	O
to	O
long	O
-	O
term	O
therapy	O
with	O
angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
inhibitor	I-Entity
in	O
two	O
patients	O
.	O

Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	O
urticaria	I-Entity
,	O
and	O
angio	B-Entity
-	I-Entity
oedema	I-Entity
.	O

Angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
(	I-Entity
ACE	I-Entity
)	I-Entity
inhibitors	I-Entity
,	O
used	O
to	O
treat	O
hypertension	I-Entity
and	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
,	O
were	O
introduced	O
in	O
Europe	O
in	O
the	O
middle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
drugs	O
has	O
increased	O
progressively	O
.	O

Soon	O
after	O
the	O
introduction	O
of	O
ACE	B-Entity
inhibitors	I-Entity
,	O
acute	O
bouts	O
of	O
angio	B-Entity
-	I-Entity
oedema	I-Entity
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs	O
.	O

We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
adverse	O
reactions	O
to	O
ACE	B-Entity
inhibitors	I-Entity
after	O
long	O
-	O
term	O
use	O
and	O
in	O
patients	O
with	O
pre	O
-	O
existing	O
angio	B-Entity
-	I-Entity
oedema	I-Entity
.	O



Myoclonus	I-Entity
associated	O
with	O
lorazepam	I-Entity
therapy	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
infants	O
.	O

Lorazepam	I-Entity
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant	O
.	O

Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	I-Entity
in	O
this	O
age	O
group	O
,	O
especially	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
(	O
VLBW	O
;	O
<	O
1,500	O
g	O
)	O
infants	O
.	O

Three	O
young	O
infants	O
,	O
all	O
of	O
birth	O
weight	O
<	O
1,500	O
g	O
,	O
experienced	O
myoclonus	I-Entity
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	I-Entity
.	O

The	O
potential	O
neurotoxic	I-Entity
effects	O
of	O
the	O
drug	O
(	O
and	O
its	O
vehicle	O
)	O
in	O
this	O
population	O
are	O
discussed	O
.	O

Injectable	O
lorazepam	I-Entity
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infants	O
.	O



right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	I-Entity
.	O

We	O
describe	O
the	O
cardiopulmonary	O
resuscitation	O
efforts	O
on	O
five	O
patients	O
who	O
presented	O
in	O
acute	O
circulatory	B-Entity
failure	I-Entity
from	O
myocardial	B-Entity
dysfunction	I-Entity
.	O

Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	I-Entity
,	O
one	O
had	O
a	O
carbamazepine	I-Entity
-	O
induced	O
acute	O
eosinophilic	B-Entity
myocarditis	I-Entity
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	O
resulting	O
in	O
acute	O
cardiogenic	B-Entity
shock	I-Entity
.	O

An	O
introducer	O
sheath	O
,	O
a	O
pacemaker	O
,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	I-Entity
.	O

All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	I-Entity
and	O
dysrhythmias	I-Entity
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admission	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
.	O

These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	B-Entity
arrest	I-Entity
,	O
resulting	O
in	O
death	O
,	O
within	O
10	O
to	O
60	O
minutes	O
.	O

We	O
conclude	O
that	O
cardiac	O
pacing	O
during	O
resuscitative	O
efforts	O
in	O
pediatric	O
patients	O
suffering	O
from	O
acute	O
myocardial	B-Entity
dysfunction	I-Entity
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temporary	O
hemodynamic	O
stability	O
is	O
achieved	O
by	O
this	O
procedure	O
,	O
it	O
may	O
provide	O
additional	O
time	O
needed	O
to	O
institute	O
other	O
therapeutic	O
modalities	O
.	O



Efficacy	O
and	O
safety	O
of	O
granisetron	I-Entity
,	O
a	O
selective	O
5-hydroxytryptamine-3	I-Entity
receptor	O
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	I-Entity
and	O
vomiting	I-Entity
induced	O
by	O
high	O
-	O
dose	O
cisplatin	I-Entity
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	I-Entity
(	O
Kytril	I-Entity
;	O
SmithKline	O
Beecham	O
Pharmaceuticals	O
,	O
Philadelphia	O
,	O
PA	O
)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin	I-Entity
-	O
induced	O
nausea	I-Entity
and	O
vomiting	I-Entity
.	O

One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	I-Entity
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	I-Entity
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
signs	O
,	O
nausea	I-Entity
,	O
vomiting	I-Entity
,	O
retching	O
,	O
and	O
appetite	O
were	O
assessed	O
.	O

After	O
granisetron	I-Entity
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrograms	O
/	O
kg	O
,	O
a	O
major	O
response	O
(	O
<	O
or	O
=	O
two	O
vomiting	I-Entity
or	O
retching	O
episodes	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23%	O
,	O
57%	O
,	O
58%	O
,	O
and	O
60%	O
of	O
patients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
response	O
(	O
no	O
vomiting	I-Entity
or	O
retching	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
in	O
18%	O
,	O
41%	O
,	O
40%	O
,	O
and	O
47%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	I-Entity
(	O
P	O
=	O
.0015	O
)	O
and	O
vomiting	I-Entity
(	O
P	O
=	O
.0001	O
)	O
,	O
and	O
fewer	O
patients	O
were	O
administered	O
additional	O
antiemetic	O
medication	O
in	O
the	O
10-micrograms	O
/	O
kg	O
dosing	O
groups	O
than	O
in	O
the	O
5-micrograms	O
/	O
kg	O
dosing	O
group	O
.	O

As	O
granisetron	I-Entity
dose	O
increased	O
,	O
appetite	O
return	O
increased	O
(	O
P	O
=	O
.040	O
)	O
.	O

Headache	I-Entity
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
(	O
20%	O
)	O
.	O

A	O
single	O
10-	O
,	O
20-	O
,	O
or	O
40-micrograms	O
/	O
kg	O
dose	O
of	O
granisetron	I-Entity
was	O
effective	O
in	O
controlling	O
vomiting	I-Entity
in	O
57%	O
to	O
60%	O
of	O
patients	O
who	O
received	O
cisplatin	I-Entity
at	O
doses	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomiting	I-Entity
in	O
40%	O
to	O
47%	O
of	O
patients	O
.	O

Granisetron	I-Entity
was	O
well	O
tolerated	O
at	O
all	O
doses	O
.	O



Adverse	O
interaction	O
between	O
clonidine	I-Entity
and	O
verapamil	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	I-Entity
and	O
verapamil	I-Entity
resulting	O
in	O
atrioventricular	B-Entity
(	I-Entity
AV	I-Entity
)	I-Entity
block	I-Entity
in	O
both	O
patients	O
and	O
severe	O
hypotension	I-Entity
in	O
one	O
patient	O
.	O

A	O
54-year	O
-	O
old	O
woman	O
with	O
hyperaldosteronism	I-Entity
was	O
treated	O
with	O
verapamil	I-Entity
480	O
mg	O
/	O
d	O
and	O
spironolactone	I-Entity
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	I-Entity
(	O
0.15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	B-Entity
block	I-Entity
and	O
severe	O
hypotension	I-Entity
,	O
which	O
resolved	O
upon	O
cessation	O
of	O
all	O
medications	O
.	O

A	O
65-year	O
-	O
old	O
woman	O
was	O
treated	O
with	O
extended	O
-	O
release	O
verapamil	I-Entity
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clonidine	I-Entity
0.15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B-Entity
block	I-Entity
,	O
which	O
resolved	O
after	O
all	O
therapy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
adverse	O
interaction	O
between	O
clonidine	I-Entity
and	O
verapamil	I-Entity
has	O
not	O
been	O
reported	O
previously	O
.	O

Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	I-Entity
and	O
verapamil	I-Entity
therapy	O
,	O
even	O
in	O
patients	O
who	O
do	O
not	O
have	O
sinus	O
or	O
AV	O
node	O
dysfunction	O
.	O



Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	B-Entity
calcium	I-Entity
antagonist	O
,	O
S-312-d	I-Entity
.	O

S-312	I-Entity
,	O
S-312-d	I-Entity
,	O
but	O
not	O
S-312-l	I-Entity
,	O
L	O
-	O
type	O
calcium	I-Entity
channel	O
antagonists	O
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	B-Entity
tonic	I-Entity
convulsions	I-Entity
in	O
DBA/2	O
mice	O
;	O
and	O
their	O
ED50	O
values	O
were	O
18.4	O
(	O
12.8	O
-	O
27.1	O
)	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O

and	O
15.0	O
(	O
10.2	O
-	O
23.7	O
)	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	I-Entity
was	O
34.0	O
(	O
26.0	O
-	O
44.8	O

Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S-312-d	I-Entity
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	I-Entity
induced	O
by	O
pentylenetetrazole	I-Entity
(	O
85	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
or	O
bemegride	I-Entity
(	O
40	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
,	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	I-Entity
induced	O
by	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
,	O
picrotoxin	I-Entity
,	O
or	O
electroshock	O
in	O
Slc	O
:	O
ddY	O
mice	O
.	O

S-312-d	I-Entity
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	I-Entity
.	O



Transmural	O
myocardial	B-Entity
infarction	I-Entity
with	O
sumatriptan	I-Entity
.	O

For	O
sumatriptan	I-Entity
,	O
tightness	O
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5%	O
of	O
users	O
.	O

We	O
describe	O
a	O
47-year	O
-	O
old	O
woman	O
with	O
an	O
acute	O
myocardial	B-Entity
infarction	I-Entity
after	O
administration	O
of	O
sumatriptan	I-Entity
6	O
mg	O
subcutaneously	O
for	O
cluster	B-Entity
headache	I-Entity
.	O

The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	B-Entity
heart	I-Entity
disease	I-Entity
or	O
Prinzmetal	B-Entity
's	I-Entity
angina	I-Entity
.	O



Flumazenil	I-Entity
induces	O
seizures	I-Entity
and	O
death	O
in	O
mixed	O
cocaine	I-Entity
-	O
diazepam	I-Entity
intoxications	O
.	O

Administration	O
of	O
the	O
benzodiazepine	I-Entity
antagonist	O
flumazenil	I-Entity
may	O
unmask	O
seizures	I-Entity
in	O
mixed	O
cocaine	I-Entity
-	O
benzodiazepine	I-Entity
intoxication	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
100	O
mg	O
/	O
kg	O
cocaine	I-Entity
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazepam	I-Entity
alone	O
,	O
or	O
a	O
combination	O
of	O
diazepam	I-Entity
and	O
cocaine	I-Entity
.	O

Three	O
minutes	O
later	O
,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	I-Entity
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Animal	O
behavior	O
,	O
seizures	I-Entity
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
death	O
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
and	O
cortical	O
EEG	O
tracings	O
were	O
recorded	O
.	O

Administration	O
of	O
flumazenil	I-Entity
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	I-Entity
and	O
diazepam	I-Entity
.	O

In	O
group	O
1	O
,	O
animals	O
received	O
cocaine	I-Entity
followed	O
by	O
vehicle	O
.	O

This	O
resulted	O
in	O
100%	O
developing	O
seizures	I-Entity
and	O
death	O
.	O

Group	O
2	O
received	O
diazepam	I-Entity
alone	O
followed	O
by	O
vehicle	O
.	O

Group	O
3	O
received	O
diazepam	I-Entity
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	I-Entity
.	O

Animals	O
became	O
somnolent	O
after	O
diazepam	I-Entity
and	O
then	O
active	O
after	O
flumazenil	I-Entity
administration	O
.	O

In	O
group	O
4	O
,	O
a	O
combination	O
of	O
cocaine	I-Entity
and	O
diazepam	I-Entity
was	O
administered	O
simultaneously	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectable	O
seizures	I-Entity
and	O
a	O
50%	O
incidence	O
of	O
death	O
.	O

Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	I-Entity
and	O
diazepam	I-Entity
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	I-Entity
.	O

This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	I-Entity
,	O
90%	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
death	O
,	O
100%	O

Group	O
6	O
received	O
cocaine	I-Entity
and	O
diazepam	I-Entity
followed	O
by	O
10	O
mg	O

/	O
kg	O
flumazenil	I-Entity
.	O

This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	I-Entity
,	O
90%	O

CONCLUSION	O
:	O
Flumazenil	I-Entity
can	O
unmask	O
seizures	I-Entity
and	O
increase	O
the	O
incidence	O
of	O
death	O
in	O
a	O
model	O
of	O
combined	O
cocaine	I-Entity
-	O
diazepam	I-Entity
intoxications	O
.	O



Mechanisms	O
for	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	I-Entity
-	O
mediated	O
nephropathy	I-Entity
in	O
rats	O
.	O

Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	I-Entity
(	O
GM)-mediated	I-Entity
nephropathy	I-Entity
.	O

Administration	O
of	O
GM	I-Entity
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
inulin	O
clearance	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tubular	B-Entity
damage	I-Entity
.	O

A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	B-Entity
3',5'-cyclic	I-Entity
monophosphate	I-Entity
(	O
cGMP	I-Entity
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin-1	O
contents	O
were	O
also	O
observed	O
in	O
GM	I-Entity
-	O
mediated	O
nephropathy	I-Entity
.	O

Superoxide	I-Entity
dismutase	O
(	O
SOD	O
)	O
or	O
dimethylthiourea	I-Entity
(	O
DMTU	I-Entity
)	O
significantly	O
lessened	O
the	O
GM	I-Entity
-	O
induced	O
decrement	O
in	O
CIn	O
.	O

The	O
SOD	O
-	O
induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF	O
,	O
an	O
increase	O
in	O
urinary	O
cGMP	I-Entity
excretion	O
,	O
and	O
a	O
decrease	O
in	O
renal	O
renin	O
and	O
endothelin-1	O
content	O
.	O

SOD	O
did	O
not	O
attenuate	O
the	O
tubular	B-Entity
damage	I-Entity
.	O

In	O
contrast	O
,	O
DMTU	I-Entity
significantly	O
reduced	O
the	O
tubular	B-Entity
damage	I-Entity
and	O
lipid	O
peroxidation	O
,	O
but	O
it	O
did	O
not	O
affect	O
renal	O
hemodynamics	O
and	O
vasoactive	O
substances	O
.	O

Neither	O
SOD	O
nor	O
DMTU	I-Entity
affected	O
the	O
renal	O
cortical	O
GM	I-Entity
content	O
in	O
GM	I-Entity
-	O
treated	O
rats	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	I-Entity
have	O
protective	O
effects	O
on	O
GM	I-Entity
-	O
mediated	O
nephropathy	I-Entity
,	O
2	O
)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	I-Entity
,	O
and	O
3	O
)	O
superoxide	I-Entity
anions	O
play	O
a	O
critical	O
role	O
in	O
GM	I-Entity
-	O
induced	O
renal	O
vasoconstriction	O
.	O



Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	I-Entity
in	O
adult	O
mice	O
.	O

The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	B-Entity
hypertrophy	I-Entity
was	O
assessed	O
in	O
adult	O
mice	O
.	O

Isoproterenol	I-Entity
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb	O
/	O
FeJ	O
mice	O
resulted	O
in	O
a	O
46%	O
increase	O
in	O
heart	O
weight	O
and	O
a	O
19.3%	O
increase	O
in	O
cardiomyocyte	O
area	O
.	O

No	O
DNA	O
synthesis	O
,	O
as	O
assessed	O
by	O
autoradiographic	O
analysis	O
of	O
isolated	O
cardiomyocytes	O
,	O
was	O
observed	O
in	O
control	O
or	O
hypertrophic	B-Entity
hearts	I-Entity
.	O

To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B-Entity
hypertrophy	I-Entity
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey	O
.	O

These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol	I-Entity
-	O
induced	O
cardiac	B-Entity
hypertrophy	I-Entity
.	O



Central	O
cardiovascular	O
effects	O
of	O
AVP	I-Entity
and	O
ANP	O
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	B-Entity
vasopressin	I-Entity
(	O
AVP	I-Entity
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
in	O
normotensive	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	I-Entity
(	O
SHR	O
)	O
rats	O
.	O

injections	O
of	O
either	O
vehicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	I-Entity
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(	O
CCB	O
)	O
,	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
period	O
(	O
HRp	O
)	O
during	O
phenylephrine	I-Entity
(	O
Phe)-induced	I-Entity
hypertension	I-Entity
and	O
sodium	B-Entity
nitroprusside	I-Entity
(	O
SN)-induced	I-Entity
hypotension	I-Entity
.	O

CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle	O
,	O
AVP	I-Entity
,	O
ANP	O
,	O
or	O
both	O
peptides	O
together	O
.	O

Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	I-Entity
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle	O
,	O
but	O
it	O
abolished	O
AVP	I-Entity
-	O
induced	O
MAP	O
increase	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	I-Entity
during	O
SN	I-Entity
-	O
induced	O
hypotension	I-Entity
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP	O
,	O
AVP	I-Entity
and	O
ANP	O
+	O
AVP	I-Entity
decreased	O
CCB	O
during	O
Phe	I-Entity
-	O
induced	O
MAP	O
elevation	O
.	O

The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	I-Entity
and	O
ANP	O
exert	O
differential	O
effects	O
on	O
blood	O
pressure	O
and	O
baroreflex	O
control	O
of	O
heart	O
rate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interaction	O
of	O
these	O
two	O
peptides	O
in	O
blood	O
pressure	O
regulation	O
at	O
the	O
level	O
of	O
central	O
nervous	O
system	O
.	O



Cutaneous	O
exposure	O
to	O
warfarin	I-Entity
-	O
like	O
anticoagulant	O
causing	O
an	O
intracerebral	B-Entity
hemorrhage	I-Entity
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
intercerebral	O
hematoma	I-Entity
due	O
to	O
warfarin	I-Entity
-	O
induced	O
coagulopathy	I-Entity
is	O
presented	O
.	O

The	O
39-year	O
-	O
old	O
woman	O
had	O
spread	O
a	O
warfarin	I-Entity
-	O
type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands	O
,	O
with	O
no	O
washing	O
post	O
application	O
.	O

Percutaneous	O
absorption	O
of	O
warfarin	I-Entity
causing	O
coagulopathy	I-Entity
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
risk	O
if	O
protective	O
measures	O
,	O
such	O
as	O
gloves	O
,	O
are	O
not	O
used	O
.	O

An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	I-Entity
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	I-Entity
.	O



Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	I-Entity
.	O

Indications	O
for	O
transplantation	O
were	O
idiopathic	B-Entity
cardiomyopathy	I-Entity
(	O
52%	O
)	O
,	O
congenital	B-Entity
heart	I-Entity
disease	I-Entity
(	O
35%	O
)	O
with	O
and	O
without	O
prior	O
repair	O
(	O
71%	O
and	O
29%	O
,	O
respectively	O
)	O
,	O
hypertrophic	B-Entity
cardiomyopathy	I-Entity
(	O
5%	O
)	O
,	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
(	O
3%	O
)	O
,	O
and	O
doxorubicin	I-Entity
cardiomyopathy	I-Entity
(	O
5%	O
)	O
.	O

Patients	O
were	O
managed	O
with	O
cyclosporine	I-Entity
and	O
azathioprine	I-Entity
.	O

Steroids	I-Entity
were	O
given	O
to	O
39%	O
of	O
patients	O
for	O
refractory	O
rejection	O
,	O
but	O
weaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64%	O
)	O
.	O

Five	O
patients	O
(	O
14%	O
)	O
received	O
maintenance	O
steroids	I-Entity
.	O

There	O
have	O
been	O
no	O
deaths	O
related	O
to	O
rejection	O
or	O
infection	I-Entity
.	O

Freedom	O
from	O
serious	O
infections	I-Entity
was	O
83%	O
at	O
1	O
month	O
and	O
65%	O
at	O
1	O
year	O
.	O

Cytomegalovirus	B-Entity
infections	I-Entity
were	O
treated	O
successfully	O
with	O
ganciclovir	I-Entity
in	O
11	O
patients	O
.	O

Twenty	O
-	O
one	O
patients	O
(	O
60%	O
)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	I-Entity
has	O
been	O
observed	O
.	O

Seizures	I-Entity
occurred	O
in	O
five	O
patients	O
(	O
14%	O
)	O
and	O
hypertension	I-Entity
was	O
treated	O
in	O
10	O
patients	O
(	O
28%	O
)	O
.	O

No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	B-Entity
disorder	I-Entity
was	O
observed.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Delirium	I-Entity
during	O
fluoxetine	I-Entity
treatment	O
.	O

Only	O
a	O
few	O
reports	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
toxic	O
effects	O
.	O

In	O
some	O
cases	O
,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	I-Entity
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	I-Entity
and	O
movement	B-Entity
difficulties	I-Entity
.	O

Widespread	O
cognitive	B-Entity
disorders	I-Entity
,	O
such	O
as	O
delirium	I-Entity
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
blood	O
levels	O
of	O
SSRIs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	I-Entity
delirium	I-Entity
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	I-Entity
(	O
fluoxetine	I-Entity
plus	O
desmethylfluoxetine	I-Entity
)	O
concentration	O
.	O



Pulmonary	B-Entity
edema	I-Entity
and	O
shock	I-Entity
after	O
high	O
-	O
dose	O
aracytine	B-Entity
-	I-Entity
C	I-Entity
for	O
lymphoma	I-Entity
;	O
possible	O
role	O
of	O
TNF	O
-	O
alpha	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
Ara	B-Entity
-	I-Entity
C	I-Entity
for	O
lymphomas	I-Entity
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	O
during	O
the	O
perfusion	O
.	O

It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	I-Entity
,	O
diarrhea	I-Entity
,	O
shock	I-Entity
,	O
pulmonary	B-Entity
edema	I-Entity
,	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
,	O
metabolic	B-Entity
acidosis	I-Entity
,	O
weight	B-Entity
gain	I-Entity
and	O
leukocytosis	I-Entity
.	O

Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	I-Entity
.	O

Sequential	O
biological	O
assays	O
of	O
IL-1	O
,	O
IL-2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	B-Entity
-	I-Entity
C	I-Entity
infusion	O
to	O
ten	O
patients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	I-Entity
and	O
adult	B-Entity
respiratory	I-Entity
distress	I-Entity
syndrome	I-Entity
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dose	O
Ara	B-Entity
-	I-Entity
C	I-Entity
may	O
be	O
associated	O
with	O
cytokine	O
release	O
.	O



Protective	O
effect	O
of	O
clentiazem	I-Entity
against	O
epinephrine	I-Entity
-	O
induced	O
cardiac	B-Entity
injury	I-Entity
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
clentiazem	I-Entity
,	O
a	O
1,5-benzothiazepine	I-Entity
calcium	I-Entity
antagonist	O
,	O
on	O
epinephrine	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
in	O
rats	O
.	O

With	O
2-week	O
chronic	O
epinephrine	I-Entity
infusion	O
,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days	O
,	O
and	O
severe	O
ischemic	B-Entity
lesions	I-Entity
and	O
fibrosis	I-Entity
of	O
the	O
left	O
ventricles	O
were	O
observed	O
.	O

In	O
epinephrine	I-Entity
-	O
treated	O
rats	O
,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	I-Entity
were	O
reduced	O
,	O
but	O
responses	O
to	O
calcium	I-Entity
were	O
normal	O
or	O
enhanced	O
compared	O
to	O
controls	O
.	O

Treatment	O
with	O
clentiazem	I-Entity
prevented	O
epinephrine	I-Entity
-	O
induced	O
death	O
(	O
P	O
<	O

.05	O
)	O
,	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	B-Entity
lesions	I-Entity
and	O
fibrosis	I-Entity
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	I-Entity
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	I-Entity
alone	O
,	O
but	O
combined	O
with	O
epinephrine	I-Entity
,	O
clentiazem	I-Entity
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	I-Entity
.	O

On	O
the	O
other	O
hand	O
clentiazem	I-Entity
did	O
not	O
prevent	O
epinephrine	I-Entity
-	O
induced	O
down	O
-	O
regulation	O
of	O
alpha	O
and	O
beta	O
adrenoceptors	O
.	O

Interestingly	O
,	O
clentiazem	I-Entity
,	O
infused	O
alone	O
,	O
resulted	O
in	O
decreased	O
adrenergic	O
receptor	O
densities	O
in	O
the	O
left	O
ventricle	O
.	O

Clentiazem	I-Entity
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	I-Entity
seen	O
in	O
the	O
epinephrine	I-Entity
-	O
treated	O
animals	O
,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	I-Entity
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	I-Entity
compared	O
to	O
epinephrine	I-Entity
-	O
treated	O
animals	O
.	O

In	O
conclusion	O
,	O
clentiazem	I-Entity
attenuated	O
epinephrine	I-Entity
-	O
induced	O
cardiac	B-Entity
injury	I-Entity
,	O
possibly	O
through	O
its	O
effect	O
on	O
the	O
adrenergic	O
pathway	O
.	O



Cocaine	I-Entity
induced	O
myocardial	B-Entity
ischemia	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
myocardial	B-Entity
ischemia	I-Entity
induced	O
by	O
cocaine	I-Entity
.	O

The	O
ischemia	I-Entity
probably	O
induced	O
by	O
coronary	B-Entity
artery	I-Entity
spasm	I-Entity
was	O
reversed	O
by	O
nitroglycerin	I-Entity
and	O
calcium	I-Entity
blocking	O
agents	O
.	O



Doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
monitored	O
by	O
ECG	O
in	O
freely	O
moving	O
mice	O
.	O

In	O
laboratory	O
animals	O
,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	I-Entity
administration	O
on	O
the	O
ECG	O
of	O
freely	O
moving	O
BALB	O
/	O
c	O
mice	O
and	O
the	O
efficacy	O
of	O
ICRF-187	I-Entity
as	O
a	O
protective	O
agent	O
.	O

11.8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	I-Entity
given	O
i.v	O
.	O

After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin	I-Entity
-	O
treated	O
animals	O
were	O
enlarged	O
and	O
the	O
atria	O
were	O
hypertrophic	I-Entity
.	O

As	O
this	O
schedule	O
exerted	O
more	O
toxicity	I-Entity
than	O
needed	O
to	O
investigate	O
protective	O
agents	O
,	O
the	O
protection	O
of	O
ICRF-187	I-Entity
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	I-Entity
(	O
6	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	I-Entity
given	O
i.v	O
.	O

On	O
this	O
schedule	O
,	O
the	O
animals	O
'	O
hearts	O
appeared	O
normal	O
after	O
sacrifice	O
and	O
ICRF-187	I-Entity
(	O
50	O
mg	O
/	O
kg	O
given	O
i.p	O
.	O

1	O
h	O
before	O
doxorubicin	I-Entity
)	O
provided	O
almost	O
full	O
protection	O
.	O

The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	I-Entity
with	O
time	O
.	O

These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
as	O
demonstrated	O
by	O
the	O
protection	O
provided	O
by	O
ICRF-187	I-Entity
.	O



Epinephrine	I-Entity
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	I-Entity
in	O
dogs	O
.	O

Since	O
bupivacaine	I-Entity
and	O
epinephrine	I-Entity
may	O
both	O
precipitate	O
dysrhythmias	I-Entity
,	O
circulating	O
bupivacaine	I-Entity
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	I-Entity
.	O

We	O
therefore	O
examined	O
whether	O
bupivacaine	I-Entity
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	I-Entity
in	O
conscious	O
,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	B-Entity
infarction	I-Entity
.	O

Forty	O
-	O
one	O
conscious	O
dogs	O
received	O
10	O
micrograms.kg-1.min-1	O
epinephrine	I-Entity
.	O

Seventeen	O
animals	O
responded	O
with	O
ventricular	B-Entity
tachycardia	I-Entity
(	O
VT	I-Entity
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupivacaine	I-Entity
or	O
saline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micrograms.kg-1.min-1	O
epinephrine	I-Entity
.	O

In	O
the	O
bupivacaine	I-Entity
groups	O
,	O
epinephrine	I-Entity
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	I-Entity
.	O

VT	I-Entity
appeared	O
in	O
fewer	O
dogs	O
and	O
at	O
a	O
later	O
time	O
,	O
and	O
there	O
were	O
more	O
sinoatrial	O
beats	O
and	O
less	O
ectopies	O
.	O

Epinephrine	I-Entity
shortened	O
QT	O
less	O
after	O
bupivacaine	I-Entity
than	O
in	O
control	O
animals	O
.	O

One	O
day	O
after	O
experimental	O
myocardial	B-Entity
infarction	I-Entity
,	O
six	O
additional	O
halothane	I-Entity
-	O
anesthetized	O
dogs	O
received	O
4	O
micrograms.kg-1.min-1	O
epinephrine	I-Entity
until	O
VT	I-Entity
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivacaine	I-Entity
was	O
injected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
micrograms.kg-1.min-1	O
epinephrine	I-Entity
.	O

In	O
these	O
dogs	O
,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	I-Entity
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	I-Entity
.	O

Bupivacaine	I-Entity
antagonizes	O
epinephrine	I-Entity
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	I-Entity
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	I-Entity
.	O

There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	I-Entity
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	I-Entity
.	O



Milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
induced	O
by	O
1,25(OH)2D	I-Entity
in	O
a	O
patient	O
with	O
hypoparathyroidism	I-Entity
.	O

Milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	B-Entity
ulcer	I-Entity
disease	I-Entity
with	O
large	O
amounts	O
of	O
calcium	I-Entity
and	O
alkali	I-Entity
.	O

Although	O
with	O
current	O
ulcer	I-Entity
therapy	O
(	O
H-2	O
blockers	O
,	O
omeprazole	I-Entity
,	O
and	O
sucralfate	I-Entity
)	O
,	O
the	O
frequency	O
of	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
has	O
decreased	O
significantly	O
,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	I-Entity
,	O
alkalosis	I-Entity
,	O
and	O
renal	B-Entity
impairment	I-Entity
remains	O
the	O
hallmark	O
of	O
the	O
syndrome	O
.	O

Milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
can	O
present	O
serious	O
and	O
occasionally	O
life	O
-	O
threatening	O
illness	O
unless	O
diagnosed	O
and	O
treated	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	I-Entity
who	O
was	O
treated	O
with	O
calcium	B-Entity
carbonate	I-Entity
and	O
calcitriol	I-Entity
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	I-Entity
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	I-Entity
on	O
the	O
second	O
.	O

This	O
illustrates	O
intravenous	O
pamidronate	I-Entity
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
presents	O
as	O
hypercalcemic	B-Entity
emergency	I-Entity
.	O



Encephalopathy	I-Entity
during	O
amitriptyline	I-Entity
therapy	O
:	O
are	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
and	O
serotonin	B-Entity
syndrome	I-Entity
spectrum	O
disorders	O
?	O

This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	I-Entity
developed	O
in	O
the	O
course	O
of	O
amitriptyline	I-Entity
therapy	O
,	O
during	O
a	O
remission	O
of	O
unipolar	B-Entity
depression	I-Entity
.	O

This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
(	O
NMS	I-Entity
)	O
or	O
serotonin	B-Entity
syndrome	I-Entity
(	O
SS	I-Entity
)	O
.	O

The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine	I-Entity
/	O
serotonin	I-Entity
imbalance	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
NMS	I-Entity
-	O
like	O
encephalopathy	I-Entity
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	O
indicates	O
that	O
NMS	I-Entity
and	O
SS	I-Entity
are	O
spectrum	O
disorders	O
induced	O
by	O
drugs	O
with	O
both	O
antidopaminergic	O
and	O
serotonergic	O
effects	O
.	O



Genetic	O
separation	O
of	O
tumor	I-Entity
growth	O
and	O
hemorrhagic	I-Entity
phenotypes	O
in	O
an	O
estrogen	I-Entity
-	O
induced	O
tumor	I-Entity
.	O

Chronic	O
administration	O
of	O
estrogen	I-Entity
to	O
the	O
Fischer	O
344	O
(	O
F344	O
)	O
rat	O
induces	O
growth	O
of	O
large	O
,	O
hemorrhagic	I-Entity
pituitary	B-Entity
tumors	I-Entity
.	O

Ten	O
weeks	O
of	O
diethylstilbestrol	I-Entity
(	O
DES	I-Entity
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109.2	O
+	O
/-	O

1.4	O
mg	O
for	O
untreated	O
rats	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagic	I-Entity
.	O

The	O
same	O
DES	I-Entity
treatment	O
produced	O
no	O
significant	O
growth	O
(	O
8.9	O
+	O
/-	O

An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	I-Entity
treatment	O
with	O
an	O
average	O
mass	O
of	O
26.3	O
+	O
/-	O

Surprisingly	O
,	O
the	O
F1	O
hybrid	O
tumors	I-Entity
were	O
not	O
hemorrhagic	I-Entity
and	O
had	O
hemoglobin	O
content	O
and	O
outward	O
appearance	O
identical	O
to	O
that	O
of	O
BN	O
.	O

However	O
,	O
while	O
DES	I-Entity
-	O
induced	O
pituitary	O
growth	O
exhibited	O
quantitative	O
,	O
additive	O
inheritance	O
,	O
the	O
hemorrhagic	I-Entity
phenotype	O
exhibited	O
recessive	O
,	O
epistatic	O
inheritance	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	I-Entity
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	I-Entity
,	O
indicating	O
that	O
the	O
hemorrhagic	I-Entity
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth	O
.	O

The	O
hemorrhagic	I-Entity
F2	O
pituitaries	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
genes	O
regulate	O
both	O
phenotypes	O
.	O



Increased	O
expression	O
of	O
neuronal	O
nitric	B-Entity
oxide	I-Entity
synthase	O
in	O
bladder	O
afferent	O
pathways	O
following	O
chronic	O
bladder	B-Entity
irritation	I-Entity
.	O

Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	B-Entity
oxide	I-Entity
synthase	O
(	O
NOS	O
)	O
in	O
bladder	O
pathways	O
following	O
acute	O
and	O
chronic	O
irritation	B-Entity
of	I-Entity
the	I-Entity
urinary	I-Entity
tract	I-Entity
of	O
the	O
rat	O
.	O

Chemical	O
cystitis	I-Entity
was	O
induced	O
by	O
cyclophosphamide	I-Entity
(	O
CYP	I-Entity
)	O
which	O
is	O
metabolized	O
to	O
acrolein	I-Entity
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine	O
.	O

Injection	O
of	O
CYP	I-Entity
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O

Fos	O
-	O
IR	O
in	O
the	O
spinal	O
cord	O
was	O
not	O
changed	O
in	O
rats	O
receiving	O
chronic	O
CYP	I-Entity
treatment	O
(	O

In	O
control	O
animals	O
and	O
in	O
animals	O
treated	O
acutely	O
with	O
CYP	I-Entity
,	O
only	O
small	O
numbers	O
of	O
NOS	O
-	O
IR	O
cells	O
(	O
0.5	O
-	O
0.7	O
cell	O
profiles	O
/	O
sections	O
)	O
were	O
detected	O
in	O
the	O
L6-S1	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O

Chronic	O
CYP	I-Entity
administration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.002	O
)	O
increased	O
bladder	O
weight	O
by	O
60%	O
and	O
increased	O
(	O
7-	O
to	O
11-fold	O
)	O
the	O
numbers	O
of	O
NOS	O
-	O
immunoreactive	O
(	O
IR	O
)	O
afferent	O
neurons	O
in	O
the	O
L6-S1	O
DRG	O
.	O

Bladder	O
afferent	O
cells	O
in	O
the	O
L6-S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(	O
40	O
microliters	O
)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
control	O
animals	O
;	O
however	O
,	O
following	O
chronic	O
CYP	I-Entity
administration	O
,	O
a	O
significant	O
percentage	O
of	O
bladder	O
afferent	O
neurons	O
were	O
NOS	O
-	O
IR	O
:	O



Effects	O
of	O
a	O
new	O
calcium	I-Entity
antagonist	O
,	O
CD-832	I-Entity
,	O
on	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
in	O
dogs	O
with	O
partial	O
coronary	B-Entity
stenosis	I-Entity
.	O

Effects	O
of	O
CD-832	I-Entity
on	O
isoproterenol	I-Entity
(	O
ISO)-induced	I-Entity
myocardial	B-Entity
ischemia	I-Entity
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	B-Entity
stenosis	I-Entity
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	I-Entity
or	O
diltiazem	I-Entity
.	O

In	O
the	O
presence	O
of	O
coronary	B-Entity
artery	I-Entity
stenosis	I-Entity
,	O
3-min	O
periods	O
of	O
intracoronary	O
ISO	I-Entity
infusion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
increased	O
heart	O
rate	O
and	O
maximal	O
rate	O
of	O
left	O
ventricular	O
pressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
and	O
ST	O
-	O
segment	O
elevation	O
of	O
the	O
epicardial	O
electrocardiogram	O
.	O

After	O
the	O
control	O
ISO	I-Entity
infusion	O
with	O
stenosis	I-Entity
was	O
performed	O
,	O
equihypotensive	O
doses	O
of	O
CD-832	I-Entity
(	O
3	O
and	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifedipine	I-Entity

(	O
1	O
and	O
3	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiazem	I-Entity
(	O
10	O
and	O

30	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	I-Entity
infusion	O
.	O

Both	O
CD-832	I-Entity
and	O
diltiazem	I-Entity
,	O
but	O
not	O
nifedipine	I-Entity
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	I-Entity
infusion	O
.	O

In	O
contrast	O
to	O
nifedipine	I-Entity
,	O
CD-832	I-Entity
(	O
10	O
micrograms	O
/	O

<	O
.01	O
)	O
at	O
3	O
min	O
after	O
ISO	I-Entity
infusion	O
with	O
stenosis	I-Entity
.	O

Diltiazem	I-Entity
(	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+	O
/-	O

.01	O
)	O
at	O
3	O
min	O
after	O
ISO	I-Entity
infusion	O
with	O
stenosis	I-Entity
.	O

These	O
data	O
show	O
that	O
CD-832	I-Entity
improves	O
myocardial	B-Entity
ischemia	I-Entity
during	O
ISO	I-Entity
infusion	O
with	O
stenosis	I-Entity
and	O
suggest	O
that	O
the	O
negative	O
chronotropic	O
property	O
of	O
CD-832	I-Entity
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD-832	I-Entity
.	O



The	O
effect	O
of	O
recombinant	O
human	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
on	O
chronic	O
puromycin	B-Entity
aminonucleoside	I-Entity
nephropathy	I-Entity
in	O
rats	O
.	O

We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
)	O

nephropathy	I-Entity
,	O
an	O
experimental	O
model	O
of	O
glomerular	B-Entity
disease	I-Entity
.	O

IGF	O
-	O
I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	B-Entity
failure	I-Entity
in	O
rats	O
with	O
chronic	O
PAN	I-Entity
nephropathy	I-Entity
.	O

The	O
glomerulopathy	I-Entity
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	I-Entity
over	O
12	O
wk	O
.	O

rhIGF	O
-	O
I	O
improved	O
weight	O
gain	O
by	O
14%	O
(	O
p	O
<	O
0.05	O
)	O
,	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	B-Entity
disease	I-Entity
.	O

I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	I-Entity
nephropathy	I-Entity
.	O

0.06	O
mL	O
/	O
min/100	O
g	O
of	O
body	O
weight	O
in	O
untreated	O
PAN	I-Entity
nephropathy	I-Entity
animals	O
,	O
p	O

The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	B-Entity
hypertrophy	I-Entity
or	O
increased	O
segmental	O
glomerulosclerosis	I-Entity
,	O
tubulointerstitial	B-Entity
injury	I-Entity
,	O
or	O
renal	O
cortical	O
malondialdehyde	I-Entity
content	O
.	O

In	O
rats	O
with	O
PAN	I-Entity
nephropathy	I-Entity
,	O
administration	O
of	O
rhIGF	O
-	O
I	O
increased	O
IGF	O
-	O
I	O
and	O
GH	O
receptor	O
gene	O
expression	O
,	O
without	O
altering	O
the	O
steady	O
state	O
level	O
of	O
IGF	O
-	O
I	O
receptor	O
mRNA	O
.	O

In	O
normal	O
rats	O
with	O
intact	O
kidneys	O
,	O
rhIGF	O
-	O
I	O
administration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
weight	O
gain	O
,	O
blood	O
pressure	O
,	O
proteinuria	I-Entity
,	O
GFR	O
,	O
glomerular	O
planar	O
area	O
,	O
renal	O
cortical	O
malondialdehyde	I-Entity
content	O
,	O
or	O
glomerular	O
or	O
tubulointerstitial	B-Entity
damage	I-Entity
,	O
compared	O
with	O
untreated	O
animals	O
(	O
n	O
=	O
4	O
)	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF	O
-	O
I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	I-Entity
nephropathy	I-Entity
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worsen	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	O
model	O
.	O



Nefiracetam	I-Entity
(	O
DM-9384	I-Entity
)	O
reverses	O
apomorphine	I-Entity
-	O
induced	O
amnesia	I-Entity
of	O
a	O
passive	O
avoidance	O
response	O
:	O

Nefiracetam	I-Entity
is	O
a	O
novel	O
pyrrolidone	I-Entity
derivative	O
which	O
attenuates	O
scopolamine	I-Entity
-	O
induced	O
learning	B-Entity
and	I-Entity
post	I-Entity
-	I-Entity
training	I-Entity
consolidation	I-Entity
deficits	I-Entity
.	O

Given	O
that	O
apomorphine	I-Entity
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	I-Entity
to	O
attenuate	O
amnesia	I-Entity
induced	O
by	O
dopaminergic	O
agonism	O
.	O

A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	I-Entity
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	I-Entity
(	O
0.5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O

Co	O
-	O
administration	O
of	O
nefiracetam	I-Entity
and	O
apomorphine	I-Entity
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	O
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	I-Entity
during	O
training	O
completely	O
reversed	O
the	O
amnesia	I-Entity
induced	O
by	O
apomorphine	I-Entity
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	I-Entity
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H]SCH	B-Entity
23390	I-Entity
or	O
[	O
3H]spiperone	I-Entity
binding	O
from	O
D1	O
or	O
D2	O
dopamine	I-Entity
receptor	O
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	I-Entity
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O



Human	O
corticotropin	I-Entity
-	O
releasing	O
hormone	O
and	O
thyrotropin	I-Entity
-	O
releasing	O
hormone	O
modulate	O
the	O
hypercapnic	I-Entity
ventilatory	O
response	O
in	O
humans	O
.	O

Human	O
corticotropin	I-Entity
-	O
releasing	O
hormone	O
(	O
hCRH	O
)	O
and	O
thyrotropin	I-Entity
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stimulate	O
ventilation	O
after	O
i.v	O
.	O

Two	O
subsequent	O
CO2-rebreathing	I-Entity
tests	O
were	O
performed	O
in	O
healthy	O
young	O
volunteers	O
.	O

During	O
the	O
first	O
test	O
0.9%	O
NaCl	I-Entity
was	O
given	O
i.v	O
.	O

Nine	O
subjects	O
received	O
0.9%	O
NaCl	I-Entity
i.v	O
.	O

The	O
CO2-response	I-Entity
curves	O
for	O
the	O
two	O
tests	O
were	O
compared	O
within	O
the	O
same	O
subject	O
.	O

In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2-response	I-Entity
curve	O
to	O
the	O
left	O
was	O
observed	O
after	O
hCRH	O
(	O
P	O
<	O
0.01	O
)	O
.	O

hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	I-Entity
threshold	O
.	O

The	O
CO2-response	I-Entity
curves	O
in	O
the	O
control	O
group	O
were	O
nearly	O
identical	O
.	O

The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	O
on	O
the	O
hypercapnic	I-Entity
ventilatory	O
response	O
in	O
humans	O
,	O
presumably	O
independent	O
of	O
central	O
chemosensitivity	O
.	O



Lamivudine	I-Entity
is	O
effective	O
in	O
suppressing	O
hepatitis	B-Entity
B	I-Entity
virus	O
DNA	O
in	O
Chinese	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
carriers	O
:	O
a	O
placebo	O
-	O
controlled	O
trial	O
.	O

Lamivudine	I-Entity
is	O
a	O
novel	O
2',3'-dideoxy	B-Entity
cytosine	I-Entity
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	B-Entity
B	I-Entity
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
(	O
HBsAg	I-Entity
)	O
carriers	O
.	O

Forty	O
-	O
two	O
Chinese	O
HBsAg	I-Entity
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
6	O
patients	O
)	O
or	O
lamivudine	I-Entity
orally	O
in	O
dosages	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
daily	O
(	O
12	O
patients	O
for	O
each	O
dosage	O
)	O
.	O

All	O
36	O
patients	O
receiving	O
lamivudine	I-Entity
had	O
a	O
decrease	O
in	O
hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
DNA	O
values	O
of	O
>	O
90%	O
(	O
P	O
<	O
.001	O
compared	O
with	O
placebo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lamivudine	I-Entity
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(	O
P	O
=	O
.011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.005	O
)	O
,	O
it	O
still	O
induced	O
94%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
therapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	B-Entity
B	I-Entity
e	O
antigen	O
status	O
or	O
in	O
aminotransferase	O
levels	O
.	O

In	O
conclusion	O
,	O
a	O
4-week	O
course	O
of	O
lamivudine	I-Entity
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	I-Entity
carriers	O
.	O

Studies	O
with	O
long	O
-	O
term	O
lamivudine	I-Entity
administration	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prolonged	O
suppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O



Population	O
-	O
based	O
study	O
of	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
associated	O
with	O
various	O
oral	B-Entity
contraceptives	I-Entity
.	O

BACKGROUND	O
:	O
Four	O
studies	O
published	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	B-Entity
thromboembolism	I-Entity
(	O
VTE	I-Entity
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	B-Entity
contraceptives	I-Entity
(	O
OCs	I-Entity
)	O
containing	O
the	O
third	O
-	O
generation	O
progestagens	I-Entity
gestodene	I-Entity
or	O
desogestrel	I-Entity
than	O
in	O
users	O
of	O
OCs	I-Entity
containing	O
second	O
-	O
generation	O
progestagens	I-Entity
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re	O
-	O
examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	I-Entity
and	O
OC	I-Entity
use	O
with	O
a	O
different	O
study	O
design	O
and	O
analysis	O
to	O
avoid	O
some	O
of	O
the	O
bias	O
and	O
confounding	O
of	O
the	O
earlier	O
studies	O
.	O

All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep	B-Entity
-	I-Entity
vein	I-Entity
thrombosis	I-Entity
,	O
venous	B-Entity
thrombosis	I-Entity
not	O
otherwise	O
specified	O
,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period	O
,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	I-Entity
.	O

We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	I-Entity
in	O
users	O
of	O
the	O
main	O
OC	I-Entity
preparations	O
,	O
and	O
a	O
nested	O
case	O
-	O
control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	I-Entity
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	I-Entity
,	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
.	O

In	O
the	O
case	O
-	O
control	O
study	O
,	O
we	O
matched	O
cases	O
to	O
controls	O
by	O
exact	O
year	O
of	O
birth	O
,	O
practice	O
,	O
and	O
current	O
use	O
of	O
OCs	I-Entity
.	O

We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body	O
-	O
mass	O
index	O
,	O
number	O
of	O
cycles	O
,	O
change	O
in	O
type	O
of	O
OC	I-Entity
prescribed	O
within	O
3	O
months	O
of	O
the	O
event	O
,	O
previous	O
pregnancy	O
,	O
and	O
concurrent	O
disease	O
.	O

FINDINGS	O
:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	I-Entity
,	O
two	O
of	O
whom	O
were	O
users	O
of	O
progestagen	I-Entity
-	O
only	O
OCs	I-Entity
.	O

Of	O
the	O
83	O
cases	O
of	O
VTE	I-Entity
associated	O
with	O
use	O
of	O
combined	O
OCs	I-Entity
,	O
43	O
were	O
recorded	O
as	O
deep	B-Entity
-	I-Entity
vein	I-Entity
thrombosis	I-Entity
,	O
35	O
as	O
pulmonary	O
thrombosis	I-Entity
,	O
and	O
five	O
as	O
venous	B-Entity
thrombosis	I-Entity
not	O
otherwise	O
specified	O
.	O

The	O
crude	O
rate	O
of	O
VTE	I-Entity
per	O
10,000	O
woman	O
-	O
years	O
was	O
4.10	O
in	O
current	O
users	O
of	O
any	O
OC	I-Entity
,	O
3.10	O
in	O
users	O
of	O
second	O
-	O
generation	O
OCs	I-Entity
,	O
and	O
4.96	O
in	O
users	O
of	O
third	O
-	O
generation	O
preparations	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
the	O
rate	O
ratio	O
of	O
VTE	I-Entity
in	O
users	O
of	O
third	O
-	O
generation	O
relative	O
to	O
second	O
-	O
generation	O
OCs	I-Entity
was	O
1.68	O
(	O
95%	O
CI	O
1.04	O
-	O
2.75	O
)	O
.	O

Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	I-Entity
between	O
users	O
of	O
third	O
-	O
generation	O
and	O
second	O
-	O
generation	O
OCs	I-Entity
.	O

Among	O
users	O
of	O
third	O
-	O
generation	O
progestagens	I-Entity
,	O
the	O
risk	O
of	O
VTE	I-Entity
was	O
higher	O
in	O
users	O
of	O
desogestrel	I-Entity
with	O
20	O
g	O
ethinyloestradiol	I-Entity
than	O
in	O
users	O
of	O
gestodene	I-Entity
or	O
desogestrel	I-Entity
with	O
30	O
g	O
ethinyloestradiol	I-Entity
.	O

With	O
all	O
second	O
-	O
generation	O
OCs	I-Entity
as	O
the	O
reference	O
,	O
the	O
odds	O
ratios	O
for	O
VTE	I-Entity
were	O
3.49	O
(	O
1.21	O
-	O
10.12	O
)	O
for	O
desogestrel	I-Entity
plus	O
20	O
g	O
ethinyloestradiol	I-Entity
and	O
1.18	O
(	O
0.66	O
-	O
2.17	O
)	O
for	O
the	O
other	O
third	O
-	O
generation	O
progestagens	I-Entity
.	O

The	O
previously	O
reported	O
increase	O
in	O
odds	O
ratio	O
associated	O
with	O
third	O
-	O
generation	O
OCs	I-Entity
when	O
compared	O
with	O
second	O
-	O
generation	O
products	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residual	O
confounding	O
by	O
age	O
.	O

The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	I-Entity
and	O
desogestrel	I-Entity
compared	O
with	O
the	O
30	O
micrograms	O
product	O
is	O
biologically	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferential	O
prescribing	O
and	O
,	O
thus	O
,	O
confounding	O
.	O



MK-801	I-Entity
augments	O
pilocarpine	I-Entity
-	O
induced	O
electrographic	O
seizure	I-Entity
but	O
protects	O
against	O
brain	B-Entity
damage	I-Entity
in	O
rats	O

The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK-801	I-Entity
on	O
the	O
pilocarpine	I-Entity
-	O
induced	O
seizure	I-Entity
model	O
.	O

Intraperitoneal	O
injection	O
of	O
pilocarpine	I-Entity
(	O
400	O
mg	O
/	O
kg	O
)	O
induced	O
tonic	B-Entity
and	I-Entity
clonic	I-Entity
seizure	I-Entity
.	O

Scopolamine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pentobarbital	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
development	O
of	O
pilocarpine	I-Entity
-	O
induced	O
behavioral	O
seizure	I-Entity
but	O
MK-801	I-Entity
(	O
0.5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

An	O
electrical	O
seizure	I-Entity
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine	I-Entity
-	O
treated	O
group	O
.	O

Scopolamine	I-Entity
and	O
pentobarbital	I-Entity
blocked	O
the	O
pilocarpine	I-Entity
-	O
induced	O
electrographic	O
seizure	I-Entity
,	O
MK-801	I-Entity
treatment	O
augmented	O
the	O
electrographic	O
seizure	I-Entity
induced	O
by	O
pilocarpine	I-Entity
.	O

Brain	B-Entity
damage	I-Entity
was	O
assessed	O
by	O
examining	O
the	O
hippocampus	O
microscopically	O
.	O

Pilocarpine	I-Entity
produced	O
neuronal	B-Entity
death	I-Entity
in	O
the	O
hippocampus	O
,	O
which	O
showed	O
pyknotic	O
changes	O
.	O

Pentobarbital	I-Entity
,	O
scopolamine	I-Entity
and	O
MK-801	I-Entity
protected	O
the	O
brain	B-Entity
damage	I-Entity
by	O
pilocarpine	I-Entity
,	O
though	O
in	O
the	O
MK-801-treated	I-Entity
group	O
,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal	O
.	O

These	O
results	O
indicate	O
that	O
status	B-Entity
epilepticus	I-Entity
induced	O
by	O
pilocarpine	I-Entity
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission	O
,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	B-Entity
damage	I-Entity
through	O
an	O
excitatory	O
NMDA	I-Entity
receptor	O
-	O
mediated	O
mechanism	O
.	O



Paclitaxel	I-Entity
,	O
5-fluorouracil	I-Entity
,	O
and	O
folinic	B-Entity
acid	I-Entity
in	O
metastatic	O
breast	B-Entity
cancer	I-Entity
:	O

5-Fluorouracil	I-Entity
plus	O
folinic	B-Entity
acid	I-Entity
and	O
paclitaxel	I-Entity

(	O
Taxol	I-Entity
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	B-Entity
cancer	I-Entity
patients	O
.	O

Paclitaxel	I-Entity
and	O
5-fluorouracil	I-Entity
have	O
additive	O
cytotoxicity	I-Entity
in	O
MCF-7	O
cell	O
lines	O
.	O

We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	I-Entity
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	B-Entity
acid	I-Entity
300	O
mg	O
over	O
1	O
hour	O
before	O
5-fluorouracil	I-Entity
350	O
mg	O
/	O
m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(	O
TFL	O
)	O
in	O
women	O
with	O
metastatic	O
breast	B-Entity
cancer	I-Entity
.	O

Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL	O
:	O
nine	O
cycles	O
(	O
5%	O
)	O
were	O
associated	O
with	O
grade	O
3/4	O
neutropenia	I-Entity
requiring	O
hospitalization	O
;	O
seven	O
(	O
4%	O
)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	B-Entity
colony	I-Entity
-	I-Entity
stimulating	I-Entity
factor	I-Entity
due	O
to	O
neutropenia	I-Entity
;	O
no	O
patient	O
required	O
platelet	O
transfusions	O
.	O

Grade	O
3/4	O
nonhematologic	O
toxicities	I-Entity
were	O
uncommon	O
.	O

Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	I-Entity
exposure	O
,	O
11	O
(	O
58%	O
)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(	O
60%	O
)	O
without	O
prior	O
doxorubicin	I-Entity
.	O

Plasma	O
paclitaxel	I-Entity
concentrations	O
were	O
measured	O
at	O
the	O
completion	O
of	O
paclitaxel	I-Entity
infusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patients	O
.	O

TFL	O
is	O
an	O
active	O
,	O
well	O
-	O
tolerated	O
regimen	O
in	O
metastatic	O
breast	B-Entity
cancer	I-Entity
.	O



Efficacy	O
and	O
proarrhythmia	I-Entity
with	O
the	O
use	O
of	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
for	O
sustained	O
ventricular	B-Entity
tachyarrhythmias	I-Entity
.	O

This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy	O
,	O
the	O
incidence	O
of	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
in	O
patients	O
treated	O
with	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
for	O
sustained	O
ventricular	B-Entity
tachyarrhythmias	I-Entity
.	O

Eighty	O
-	O
one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
and	O
20	O
with	O
dilated	B-Entity
cardiomyopathy	I-Entity
)	O
with	O
inducible	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
or	O
ventricular	B-Entity
fibrillation	I-Entity
received	O
oral	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
to	O
prevent	O
induction	O
of	O
the	O
ventricular	B-Entity
tachyarrhythmia	I-Entity
.	O

During	O
oral	O
loading	O
with	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
,	O
continuous	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
was	O
performed	O
.	O

Those	O
patients	O
in	O
whom	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
prevented	O
induction	O
of	O
ventricular	B-Entity
tachycardia	I-Entity
or	O
ventricular	B-Entity
fibrillation	I-Entity
were	O
discharged	O
with	O
the	O
drug	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
for	O
21	O
+	O
/-	O

Induction	O
of	O
the	O
ventricular	B-Entity
tachyarrhythmia	I-Entity
was	O
prevented	O
by	O
oral	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
in	O
35	O
(	O
43%	O
)	O
patients	O
;	O
the	O
ventricular	B-Entity
tachyarrhythmia	I-Entity
remained	O
inducible	O
in	O
40	O
(	O
49%	O
)	O
patients	O
;	O
and	O
two	O
(	O
2.5%	O
)	O

patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
once	O
daily	O
.	O

Four	O
(	O
5%	O
)	O
patients	O
had	O
from	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
.	O

Neither	O
ECG	O
[	O
sinus	O
-	O
cycle	O
length	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
.	O

However	O
,	O
the	O
oral	O
dose	O
of	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
(	O
200	O
+	O
/-	O

Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(	O
p	O
=	O
0.049	O
)	O
,	O
female	O
gender	O
(	O
p	O
=	O
0.015	O
)	O
,	O
and	O
significant	O
dose	O
-	O
corrected	O
changes	O
of	O
SCL	O
,	O
QT	O
interval	O
,	O
and	O
QTc	O
interval	O
(	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20%	O
)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	B-Entity
tachycardia	I-Entity
recurrence	O
,	O
and	O
two	O
(	O
6%	O
)	O

One	O
female	O
patient	O
with	O
stable	O
cardiac	B-Entity
disease	I-Entity
had	O
recurrent	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
.	O

Torsades	B-Entity
de	I-Entity
pointes	I-Entity
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
.	O

Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(	O
cycle	O
length	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
.	O

Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
did	O
not	O
identify	O
patients	O
at	O
increased	O
risk	O
for	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
.	O

Recurrence	O
rates	O
of	O
ventricular	B-Entity
tachyarrhythmias	I-Entity
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	I-Entity
during	O
programmed	O
stimulation	O
.	O

Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d	B-Entity
,	I-Entity
l	I-Entity
-	I-Entity
sotalol	I-Entity
seems	O
to	O
be	O
of	O
limited	O
prognostic	O
value	O
.	O



Chronic	O
hyperprolactinemia	I-Entity
and	O
changes	O
in	O
dopamine	I-Entity
neurons	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	I-Entity
in	O
rats	O
for	O
extended	O
periods	O
of	O
time	O
and	O
examine	O
its	O
effects	O
on	O
dopaminergic	O
systems	O
in	O
the	O
brain	O
.	O

Hyperprolactinemia	I-Entity
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	I-Entity
,	O
a	O
dopamine	I-Entity
receptor	O
antagonist	O
,	O
and	O
Palkovits	O
'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain	O
.	O

After	O
6	O
months	O
of	O
hyperprolactinemia	I-Entity
,	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
concentrations	O
in	O
the	O
median	O
eminence	O
(	O
ME	O
)	O
increased	O
by	O
84%	O
over	O
the	O
control	O
group	O
.	O

Nine	O
months	O
of	O
hyperprolactinemia	I-Entity
produced	O
a	O
50%	O
increase	O
in	O
DA	I-Entity
concentrations	O
in	O
the	O
ME	O
over	O
the	O
control	O
group	O
.	O

However	O
,	O
DA	I-Entity
response	O
was	O
lost	O
if	O
a	O
9-month	O
long	O
haloperidol	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
was	O
followed	O
by	O
a	O
1	O
1/2	O
month	O
-	O
long	O
extremely	O
high	O
increase	O
in	O
serum	O
PRL	O
levels	O
produced	O
by	O
implantation	O
of	O
MMQ	O
cells	O
under	O
the	O
kidney	O
capsule	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	I-Entity
,	O
norepinephrine	I-Entity
(	O
NE	I-Entity
)	O
,	O
serotonin	I-Entity
(	O
5-HT	I-Entity
)	O
,	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(	O
AN	O
)	O
,	O
medial	O
preoptic	O
area	O
(	O
MPA	O
)	O
,	O
caudate	O
putamen	O
(	O
CP	O
)	O
,	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
and	O
zona	O
incerta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrease	O
in	O
5-hydroxyindoleacetic	B-Entity
acid	I-Entity
(	O
5-HIAA	I-Entity
)	O
in	O
the	O
AN	O
after	O
6-months	O
of	O
hyperprolactinemia	I-Entity
and	O
an	O
increase	O
in	O
DA	I-Entity
concentrations	O
in	O
the	O
AN	O
after	O
9-months	O
of	O
hyperprolactinemia	I-Entity
.	O

These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	I-Entity
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary	O
,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	I-Entity
.	O

The	O
age	O
-	O
related	O
decrease	O
in	O
hypothalamic	O
dopamine	I-Entity
function	O
may	O
be	O
associated	O
with	O
increases	O
in	O
PRL	O
secretion	O
.	O



Treatment	O
-	O
related	O
disseminated	O
necrotizing	O
leukoencephalopathy	I-Entity
with	O
characteristic	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
.	O

This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1-weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	I-Entity
,	O
which	O
developed	O
from	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
treated	O
with	O
high	O
-	O
dose	O
methotrexate	I-Entity
.	O

Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	B-Entity
of	I-Entity
myelination	I-Entity
and	O
necrosis	I-Entity
of	O
the	O
white	O
matter	O
.	O

Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	I-Entity
are	O
discussed	O
.	O



Thrombotic	I-Entity
complications	O
in	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
during	O
all	B-Entity
-	I-Entity
trans	I-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
therapy	O
.	O

A	O
case	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
,	O
due	O
to	O
occlusion	B-Entity
of	I-Entity
renal	I-Entity
vessels	I-Entity
in	O
a	O
patient	O
with	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
(	O
APL	I-Entity
)	O
treated	O
with	O
all	B-Entity
-	I-Entity
trans	I-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
(	O
ATRA	I-Entity
)	O
and	O
tranexamic	B-Entity
acid	I-Entity
has	O
been	O
described	O
recently	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
in	O
an	O
APL	I-Entity
patient	O
treated	O
with	O
ATRA	I-Entity
alone	O
.	O

This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	I-Entity
complications	O
associated	O
with	O
ATRA	I-Entity
therapy	O
in	O
APL	I-Entity
patients	O
.	O

The	O
patients	O
,	O
a	O
43-year	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
signs	O
and	O
symptoms	O
of	O
APL	I-Entity
and	O
was	O
included	O
in	O
a	O
treatment	O
protocol	O
with	O
ATRA	I-Entity
.	O

After	O
10	O
days	O
of	O
treatment	O
,	O
he	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	O
of	O
APL	I-Entity
was	O
achieved	O
and	O
therapy	O
discontinued	O
.	O

We	O
conclude	O
that	O
ATRA	I-Entity
is	O
a	O
valid	O
therapeutic	O
choice	O
for	O
patients	O
with	O
APL	I-Entity
,	O
although	O
the	O
procoagulant	O
tendency	O
is	O
not	O
completely	O
corrected	O
.	O

Thrombotic	I-Entity
events	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dose	O
heparin	I-Entity
.	O



Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant	O
-	O
induced	O
mania	I-Entity
:	O
a	O
case	O
report	O
.	O

A	O
30-year	O
-	O
old	O
cocaine	I-Entity
-	O
dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	I-Entity
(	O
DEP	I-Entity
)	O
became	O
manic	I-Entity
during	O
his	O
second	O
week	O
on	O
the	O
study	O
drug	O
.	O

Pupillometric	O
changes	O
while	O
on	O
DEP	I-Entity
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B-Entity
oscillation	I-Entity
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	I-Entity
.	O

The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	B-Entity
oscillation	I-Entity
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	I-Entity
.	O

Such	O
medication	O
-	O
associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B-Entity
oscillation	I-Entity
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	O
risk	O
for	O
manic	I-Entity
-	O
like	O
adverse	O
effects	O
during	O
the	O
medical	O
use	O
of	O
psychomotor	O
stimulants	O
or	O
sympathomimetic	O
agents	O
.	O



OBJECTIVE	O
:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain	I-Entity
-	O
related	O
signal	O
(	O
chemo	O
-	O
somatosensory	O
evoked	O
potential	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripheral	O
signal	O
(	O
negative	O
mucosal	O
potential	O
,	O
NMP	O
)	O
allows	O
for	O
separation	O
of	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
.	O

For	O
this	O
purpose	O
,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	O
pain	I-Entity
by	O
either	O
central	O
or	O
peripheral	O
mechanisms	O
.	O

According	O
to	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
controlled	O
,	O
threefold	O
cross	O
-	O
over	O
design	O
,	O
18	O
healthy	O
subjects	O
(	O
11	O
males	O
,	O
7	O
females	O
;	O
mean	O
age	O
26	O
years	O
)	O
received	O
either	O
placebo	O
,	O
400	O
mg	O
ibuprofen	I-Entity
,	O
or	O
800	O
mg	O
ibuprofen	I-Entity
.	O

Phasic	O
pain	I-Entity
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	I-Entity
to	O
the	O
nasal	O
mucosa	O
(	O
stimulus	O
duration	O
500	O
ms	O
,	O
interval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
tonic	O
pain	I-Entity
was	O
induced	O
in	O
the	O
nasal	O
cavity	O
by	O
means	O
of	O
dry	O
air	O
of	O
controlled	O
temperature	O
,	O
humidity	O
and	O
flow	O
rate	O
(	O
22	O
degrees	O
C	O
,	O
0%	O
relative	O
humidity	O
,	O
145	O
ml.s-1	O
)	O
.	O

Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	I-Entity
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	I-Entity
stimuli	O
.	O

Additionally	O
,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	O
pain	I-Entity
by	O
means	O
of	O
visual	O
analogue	O
scales	O
.	O

As	O
described	O
earlier	O
,	O
administration	O
of	O
ibuprofen	I-Entity
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	O
pain	I-Entity
but	O
-	O
relative	O
to	O
placebo	O
-	O
an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	I-Entity
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	I-Entity
on	O
the	O
interaction	O
between	O
the	O
pain	I-Entity
stimuli	O
under	O
these	O
special	O
experimental	O
conditions	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pain	I-Entity
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain	I-Entity
-	O
related	O
activity	O
directly	O
using	O
a	O
non	O
-	O
invasive	O
technique	O
in	O
humans	O
.	O



Acute	O
severe	O
depression	I-Entity
following	O
peri	O
-	O
operative	O
ondansetron	I-Entity
.	O

A	O
41-year	O
-	O
old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	B-Entity
nausea	I-Entity
and	I-Entity
vomiting	I-Entity
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	I-Entity
prophylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
severe	O
acute	O
major	B-Entity
depression	I-Entity
disorder	I-Entity
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	I-Entity
antagonist	O
.	O

Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self	O
-	O
limited	O
puerperal	O
depressive	B-Entity
episode	I-Entity
.	O

Anaesthesia	O
with	O
a	O
propofol	I-Entity
infusion	O
and	O
avoidance	O
of	O
serotonin	I-Entity
antagonists	O
provided	O
a	O
nausea	I-Entity
-	O
free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	B-Entity
disorder	I-Entity
.	O



Hypertensive	I-Entity
response	O
during	O
dobutamine	I-Entity
stress	O
echocardiography	O
.	O

Among	O
3,129	O
dobutamine	I-Entity
stress	O
echocardiographic	O
studies	O
,	O
a	O
hypertensive	I-Entity
response	O
,	O
defined	O
as	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patients	O
(	O
1%	O
)	O
.	O

Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	I-Entity
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O

BP	O
before	O
dobutamine	I-Entity
infusion	O
.	O



Continuously	O
nebulized	O
albuterol	I-Entity
in	O
severe	O
exacerbations	O
of	O
asthma	I-Entity
in	O
adults	O
:	O
a	O
case	O
-	O
controlled	O
study	O
.	O

A	O
retrospective	O
,	O
case	O
-	O
controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	I-Entity
who	O
received	O
continuously	O
nebulized	O
albuterol	I-Entity
(	O
CNA	O
)	O
versus	O
intermittent	O
albuterol	I-Entity
(	O
INA	O
)	O
treatments	O
is	O
reported	O
.	O

Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	I-Entity
are	O
compared	O
.	O

The	O
incidence	O
of	O
cardiac	B-Entity
dysrhythmias	I-Entity
was	O
similar	O
between	O
groups	O
.	O

Symptomatic	O
hypokalemia	I-Entity
did	O
not	O
occur	O
.	O



Hyperosmolar	B-Entity
nonketotic	I-Entity
coma	I-Entity
precipitated	O
by	O
lithium	I-Entity
-	O
induced	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
.	O

A	O
45-year	O
-	O
old	O
man	O
,	O
with	O
a	O
10-year	O
history	O
of	O
manic	B-Entity
depression	I-Entity
treated	O
with	O
lithium	I-Entity
,	O
was	O
admitted	O
with	O
hyperosmolar	B-Entity
,	I-Entity
nonketotic	I-Entity
coma	I-Entity
.	O

He	O
gave	O
a	O
five	O
-	O
year	O
history	O
of	O
polyuria	I-Entity
and	O
polydipsia	I-Entity
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	I-Entity
.	O

After	O
recovery	O
from	O
hyperglycaemia	I-Entity
,	O
he	O
remained	O
polyuric	I-Entity
despite	O
normal	O
blood	O
glucose	I-Entity
concentrations	O
;	O
water	O
deprivation	O
testing	O
indicated	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
,	O
likely	O
to	O
be	O
lithium	I-Entity
-	O
induced	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	B-Entity
2	I-Entity
diabetes	I-Entity
,	O
chronic	O
polyuria	I-Entity
due	O
to	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	I-Entity
.	O



Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	I-Entity
on	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	I-Entity
causes	O
a	O
profound	O
deterioration	B-Entity
of	I-Entity
left	I-Entity
ventricular	I-Entity
(	I-Entity
LV	I-Entity
)	I-Entity
systolic	I-Entity
function	I-Entity
and	O
an	O
increase	O
in	O
LV	O
end	O
-	O
diastolic	O
pressure	O
.	O

This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	I-Entity
concentration	O
on	O
LV	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patients	O
(	O
14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years	O
)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	B-Entity
pain	I-Entity
,	O
we	O
measured	O
heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15-minute	O
intracoronary	O
infusion	O
of	O
saline	O
(	O
n=10	O
,	O
control	O
subjects	O
)	O
or	O
cocaine	B-Entity
hydrochloride	I-Entity
1	O
mg	O
/	O
min	O
(	O
n=10	O
)	O
.	O

With	O
cocaine	I-Entity
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3.0+/-0.4	O
(	O
mean+/-SD	O
)	O

/	O
L	O
,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	I-Entity
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	I-Entity
intoxication	O
.	O

Cocaine	I-Entity
induced	O
no	O
significant	O
change	O
in	O
heart	O
rate	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
positive	O
or	O
negative	O
)	O
,	O
or	O
LV	O
end	O
-	O
diastolic	O
volume	O
,	O
but	O
it	O
caused	O
an	O
increase	O
in	O
systolic	O
and	O
mean	O
arterial	O
pressures	O
,	O
LV	O
end	O
-	O
diastolic	O
pressure	O
,	O
and	O
LV	O
end	O
-	O
systolic	O
volume	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LV	O
ejection	O
fraction	O
.	O

In	O
humans	O
,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	I-Entity
sufficient	O
in	O
amount	O
to	O
achieve	O
a	O
high	O
drug	O
concentration	O
in	O
coronary	O
sinus	O
blood	O
causes	O
a	O
deterioration	B-Entity
of	I-Entity
LV	I-Entity
systolic	I-Entity
and	I-Entity
diastolic	I-Entity
performance	I-Entity
.	O



Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
,	O
paradoxical	O
thromboembolism	I-Entity
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	I-Entity
therapy	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	I-Entity
remains	O
the	O
drug	O
of	O
choice	O
for	O
most	O
anticoagulation	O
needs	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	I-Entity
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Important	O
untoward	O
effects	O
of	O
heparin	I-Entity
therapy	O
including	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
,	O
heparin	I-Entity
-	O
associated	O
osteoporosis	I-Entity
,	O
eosinophilia	I-Entity
,	O
skin	B-Entity
reactions	I-Entity
,	O
allergic	B-Entity
reactions	I-Entity
other	O
than	O
thrombocytopenia	I-Entity
and	O
alopecia	I-Entity
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O



Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	B-Entity
obstruction	I-Entity
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	I-Entity
therapy	O
.	O

We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	B-Entity
calculi	I-Entity
in	O
six	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
patients	O
receiving	O
indinavir	I-Entity
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	I-Entity
.	O

CONCLUSION	O
:	O
Ureteric	B-Entity
obstruction	I-Entity
caused	O
by	O
precipitated	O
indinavir	I-Entity
crystals	O
may	O
be	O
difficult	O
to	O
diagnose	O
with	O
unenhanced	O
CT	O
.	O

contrast	O
material	O
to	O
enable	O
diagnosis	O
of	O
ureteric	B-Entity
stones	I-Entity
or	I-Entity
obstruction	I-Entity
in	O
patients	O
with	O
HIV	B-Entity
infection	I-Entity
who	O
receive	O
indinavir	I-Entity
therapy	O
.	O



Ischemic	B-Entity
colitis	I-Entity
and	O
sumatriptan	I-Entity
use	O
.	O

Sumatriptan	B-Entity
succinate	I-Entity
,	O
a	O
serotonin-1	I-Entity
(	O
5-hydroxytryptamine-1	I-Entity
)	O
receptor	O
agonist	O
,	O
is	O
an	O
antimigraine	O
drug	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constricting	O
intracranial	O
arteries	O
.	O

Cases	O
have	O
been	O
published	O
of	O
coronary	B-Entity
vasospasm	I-Entity
,	O
myocardial	B-Entity
ischemia	I-Entity
,	O
and	O
myocardial	B-Entity
infarction	I-Entity
occurring	O
after	O
sumatriptan	I-Entity
use	O
.	O

We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	B-Entity
colitis	I-Entity
in	O
patients	O
with	O
migraine	I-Entity
treated	O
with	O
sumatriptan	I-Entity
.	O



51	O
patients	O
with	O
medically	O
refractory	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	I-Entity
,	O
rigidity	I-Entity
,	O
and	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O

Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
(	O
UPDRS	O
)	O

85	O
percent	O
of	O
patients	O
with	O
dyskinesias	I-Entity
were	O
relieved	O
of	O
symptoms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Gamma	O
Knife	O
or	O
radiofrequency	O
methods	O
.	O

About	O
2/3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	I-Entity
and	O
rigidity	I-Entity
,	O
although	O
when	O
considered	O
as	O
a	O
group	O
neither	O
the	O
Gamma	O
Knife	O
nor	O
the	O
radiofrequency	O
group	O
showed	O
statistically	O
significant	O
improvements	O
in	O
UPDRS	O
scores	O
.	O

One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(	O
3.4%	O
)	O
developed	O
a	O
homonymous	B-Entity
hemianopsia	I-Entity
9	O
months	O
following	O
treatment	O
and	O
5	O
patients	O
(	O
27.7%	O
)	O
in	O
the	O
radiofrequency	O
group	O
became	O
transiently	O
confused	O
postoperatively	O
.	O

Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants	O
,	O
have	O
bleeding	I-Entity
diatheses	O
or	O
serious	O
systemic	O
medical	O
illnesses	O
.	O



Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
and	O
methylphenidate	I-Entity
.	O

A	O
1-year	O
-	O
old	O
female	O
presented	O
with	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
probably	O
caused	O
by	O
methylphenidate	I-Entity
.	O

She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	B-Entity
encephalomalacia	I-Entity
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic	B-Entity
-	I-Entity
ischemic	I-Entity
encephalopathy	I-Entity
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
.	O

However	O
,	O
methylphenidate	I-Entity
is	O
a	O
dopamine	I-Entity
agonist	O
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	I-Entity
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(	O
mainly	O
the	O
midbrain	O
)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome	O
.	O

A	O
relative	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
-	O
ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	I-Entity
,	O
a	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
-	O
mimetic	O
agent	O
,	O
was	O
strikingly	O
effective	O
.	O

This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
probably	O
caused	O
by	O
methylphenidate	I-Entity
.	O



Differential	O
effects	O
of	O
17alpha	B-Entity
-	I-Entity
ethinylestradiol	I-Entity
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	B-Entity
salt	I-Entity
synthesis	O
in	O
the	O
rat	O
.	O

Effects	O
of	O
17alpha	B-Entity
-	I-Entity
ethinylestradiol	I-Entity
(	O
EE	I-Entity
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	B-Entity
salt	I-Entity
(	O
BS	I-Entity
)	O
synthesis	O
were	O
evaluated	O
in	O
rats	O
with	O
an	O
intact	O
enterohepatic	O
circulation	O
and	O
in	O
rats	O
with	O
long	O
-	O
term	O
bile	O
diversion	O
to	O
induce	O
BS	I-Entity
synthesis	O
.	O

For	O
this	O
purpose	O
,	O
bile	B-Entity
salt	I-Entity
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	I-Entity
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	I-Entity
7alpha	O
-	O
hydroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
sterol	I-Entity
27-hydroxylase	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	I-Entity
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	I-Entity
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
days	O
)	O
or	O
its	O
vehicle	O
.	O

BS	I-Entity
pool	O
size	O
was	O
decreased	O
by	O
27%	O
but	O
total	O
BS	I-Entity
synthesis	O
was	O
not	O
affected	O
by	O
EE	I-Entity
in	O
intact	O
rats	O
.	O

Synthesis	O
of	O
cholate	I-Entity
was	O
reduced	O
by	O
68%	O
in	O
EE	I-Entity
-	O
treated	O
rats	O
,	O
while	O
that	O
of	O
chenodeoxycholate	I-Entity
was	O
increased	O
by	O
60%	O
.	O

The	O
recently	O
identified	O
Delta22-isomer	O
of	O
beta	O
-	O
muricholate	O
contributed	O
for	O
5.4%	O
and	O
18.3	O
%	O
(	O
P	O
<	O
0.01	O
)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE	I-Entity
-	O
treated	O
rats	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detected	O
in	O
bile	O
after	O
exhaustion	O
of	O
the	O
pool	O
.	O

A	O
clear	O
reduction	O
of	O
BS	I-Entity
synthesis	O
was	O
found	O
in	O
bile	O
-	O
diverted	O
rats	O
treated	O
with	O
EE	I-Entity
,	O
yet	O
biliary	O
BS	I-Entity
composition	O
was	O
only	O
minimally	O
affected	O
.	O

Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	I-Entity
in	O
both	O
intact	O
and	O
bile	O
-	O
diverted	O
rats	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
CYP27	O
was	O
not	O
affected	O
.	O

Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	I-Entity
in	O
bile	O
-	O
diverted	O
rats	O
only	O
;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	I-Entity
.	O

In	O
addition	O
,	O
mRNA	O
levels	O
of	O
sterol	I-Entity
12alpha	O
-	O
hydroxylase	O
and	O
lithocholate	O

6beta	O
-	O
hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	I-Entity
.	O

This	O
study	O
shows	O
that	O
17alpha	B-Entity
-	I-Entity
ethinylestradiol	I-Entity
(	O
EE)-induced	I-Entity
intrahepatic	B-Entity
cholestasis	I-Entity
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	B-Entity
salt	I-Entity
(	O
BS	I-Entity
)	O
synthesis	O
.	O

Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	I-Entity
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	I-Entity
on	O
BS	I-Entity
synthesis	O
.	O



Glibenclamide	I-Entity
-	O
sensitive	O
hypotension	I-Entity
produced	O
by	O
helodermin	I-Entity
assessed	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
helodermin	I-Entity
,	O
a	O
basic	O
35-amino	B-Entity
acid	I-Entity
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland	O
,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	I-Entity
sensitive	O
K+	I-Entity
(	O
K(ATP	I-Entity
)	O
)	O
channels	O
is	O
involved	O
in	O
the	O
responses	O
.	O

Helodermin	I-Entity
produced	O
hypotension	I-Entity
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
approximately	O
similar	O
potency	O
and	O
duration	O
to	O
VIP	O
.	O

Hypotension	I-Entity
induced	O
by	O
both	O
peptides	O
was	O
significantly	O
attenuated	O
by	O
glibenclamide	I-Entity
,	O
which	O
abolished	O
a	O
levcromakalim	I-Entity
-	O
produced	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
.	O

Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin	I-Entity
-	O
induced	O
hypotension	I-Entity
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	I-Entity
(	O
ACh)-produced	I-Entity
hypotension	I-Entity
.	O

These	O
findings	O
suggest	O
that	O
helodermin	I-Entity
-	O
produced	O
hypotension	I-Entity
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide	I-Entity
-	O
sensitive	O
K+	I-Entity
channels	O
(	O
K(ATP	I-Entity
)	O
channels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
arterial	O
smooth	O
muscle	O
cells	O
.	O

EDRF	O
(	O
endothelium	O
-	O
derived	O
relaxing	O
factor)/nitric	B-Entity
oxide	I-Entity
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide	O
-	O
produced	O
hypotension	I-Entity
.	O



Long	O
-	O
term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	I-Entity
sustained	O
-	O
release	O
tablets	O
for	O
cyclosporin	B-Entity
A	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
patients	O
with	O
psoriasis	I-Entity
.	O

Thirteen	O
psoriatic	I-Entity
patients	O
with	O
hypertension	I-Entity
during	O
the	O
course	O
of	O
cyclosporin	B-Entity
A	I-Entity
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	I-Entity
channel	O
blocker	O
,	O
sustained	O
-	O
release	O
nifedipine	I-Entity
,	O
to	O
study	O
the	O
clinical	O
antihypertensive	O
effects	O
and	O
adverse	O
events	O
during	O
treatment	O
with	O
both	O
drugs	O
.	O

Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	I-Entity
state	O
before	O
cyclosporin	B-Entity
A	I-Entity
therapy	O
.	O

Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	I-Entity
therapy	O
,	O
and	O
blood	O
pressure	O
was	O
maintained	O
within	O
the	O
normal	O
range	O
thereafter	O
for	O
25	O
months	O
.	O

The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	B-Entity
A	I-Entity
and	O
nifedipine	I-Entity
included	O
an	O
increase	O
in	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	B-Entity
hyperplasia	I-Entity
in	O
2	O
of	O
the	O
13	O
patients	O
.	O

Our	O
findings	O
indicate	O
that	O
sustained	O
-	O
release	O
nifedipine	I-Entity
is	O
useful	O
for	O
hypertensive	I-Entity
psoriatic	I-Entity
patients	O
under	O
long	O
-	O
term	O
treatment	O
with	O
cyclosporin	B-Entity
A	I-Entity
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	B-Entity
hyperplasia	I-Entity
.	O



Torsade	B-Entity
de	I-Entity
pointes	I-Entity
ventricular	B-Entity
tachycardia	I-Entity
during	O
low	O
dose	O
intermittent	O
dobutamine	I-Entity
treatment	O
in	O
a	O
patient	O
with	O
dilated	B-Entity
cardiomyopathy	I-Entity
and	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
.	O

The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56-year	O
-	O
old	O
woman	O
with	O
chronic	O
,	O
severe	O
heart	B-Entity
failure	I-Entity
secondary	O
to	O
dilated	B-Entity
cardiomyopathy	I-Entity
and	O
absence	O
of	O
significant	O
ventricular	B-Entity
arrhythmias	I-Entity
who	O
developed	O
QT	B-Entity
prolongation	I-Entity
and	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
ventricular	B-Entity
tachycardia	I-Entity
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(	O
2.5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O

dobutamine	I-Entity
.	O

This	O
report	O
of	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
ventricular	B-Entity
tachycardia	I-Entity
during	O
intermittent	O
dobutamine	I-Entity
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	I-Entity
may	O
occur	O
even	O
with	O
low	O
doses	O
and	O
in	O
patients	O
with	O
no	O
history	O
of	O
significant	O
rhythm	O
disturbances	O
.	O

The	O
mechanisms	O
of	O
proarrhythmic	O
effects	O
of	O
Dubutamine	I-Entity
are	O
discussed	O
.	O



Positive	O
skin	O
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	B-Entity
media	I-Entity
.	O

In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	B-Entity
materials	I-Entity
(	O
PRC	I-Entity
)	O
have	O
been	O
described	O
with	O
increasing	O
frequency	O
.	O

The	O
authors	O
report	O
two	O
observations	O
on	O
patients	O
with	O
delayed	O
reactions	O
in	O
whom	O
intradermoreactions	O
(	O
IDR	O
)	O
and	O
patch	O
tests	O
to	O
a	O
series	O
of	O
ionic	O
and	O
non	O
ionic	O
PRC	I-Entity
were	O
studied	O
.	O

After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	I-Entity
,	O
loss	B-Entity
of	I-Entity
consciousness	I-Entity
)	O
and	O
delayed	O
macro	B-Entity
-	I-Entity
papular	I-Entity
rash	I-Entity
appeared	O
,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat	O
,	O
persistent	O
pain	I-Entity
at	O
the	O
site	O
of	O
injection	O
immediately	O
and	O
a	O
generalised	O
macro	O
-	O
papular	O
reaction	O
after	O
24	O
hours	O
.	O

The	O
skin	O
tests	O
revealed	O
positive	O
delayed	O
reactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patch	O
tests	O
to	O
only	O
some	O
PRC	I-Entity
with	O
common	O
chains	O
in	O
their	O
structures	O
.	O

The	O
positive	O
skin	O
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	I-Entity
in	O
the	O
patients	O
.	O



Risk	O
of	O
transient	O
hyperammonemic	B-Entity
encephalopathy	I-Entity
in	O
cancer	I-Entity
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5-fluorouracil	I-Entity
with	O
the	O
complication	O
of	O
dehydration	I-Entity
and	O
infection	I-Entity
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cancer	I-Entity
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	B-Entity
encephalopathy	I-Entity
related	O
to	O
continuous	O
infusion	O
of	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
were	O
identified	O
.	O

None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	B-Entity
disease	I-Entity
.	O

Onset	O
of	O
hyperammonemic	B-Entity
encephalopathy	I-Entity
varied	O
from	O
0.5	O
to	O
5	O
days	O
(	O
mean	O
:	O
2.6	O
+	O
/-	O

Plasma	O
ammonium	I-Entity
level	O
ranged	O
from	O
248	O
to	O
2387	O
microg%	O
(	O
mean	O
:	O
626	O
+	O
/-	O

Among	O
the	O
32	O
episodes	O
,	O
26	O
(	O
81%	O
)	O
had	O
various	O
degrees	O
of	O
azotemia	I-Entity
,	O
18	O
(	O
56%	O
)	O
occurred	O
during	O
bacterial	B-Entity
infections	I-Entity
and	O
14	O
(	O
44%	O
)	O
without	O
infection	I-Entity
occurred	O
during	O
periods	O
of	O
dehydration	I-Entity
.	O

Higher	O
plasma	O
ammonium	I-Entity
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	I-Entity
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	B-Entity
infections	I-Entity
(	O
p=0.003	O
and	O
0.0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5-FU	I-Entity
(	O
p=0.0001	O
and	O

In	O
25	O
out	O
of	O
32	O
episodes	O
(	O
78%	O
)	O
,	O
plasma	O
ammonium	I-Entity
levels	O
and	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
2	O
days	O
after	O
adequate	O
management	O
.	O

In	O
conclusion	O
,	O
hyperammonemic	B-Entity
encephalopathy	I-Entity
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	I-Entity
.	O

Azotemia	I-Entity
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	B-Entity
infections	I-Entity
were	O
frequently	O
found	O
in	O
these	O
patients	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	I-Entity
.	O



The	O
effects	O
of	O
quinine	I-Entity
and	O
4-aminopyridine	I-Entity
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	I-Entity
in	O
rats	O

The	O
effects	O
of	O
two	O
unselective	O
potassium	I-Entity
(	O
K(+)-	I-Entity
)	O
channel	O
blockers	O
,	O
quinine	I-Entity
(	O
12.5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4-aminopyridine	I-Entity
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tested	O
in	O
Wistar	O
rats	O
.	O

Quinine	I-Entity
is	O
known	O
to	O
block	O
voltage-	O
,	O
calcium-	I-Entity
and	O
ATP	I-Entity
-	O
sensitive	O
K(+)-channels	I-Entity
while	O
4-aminopyridine	I-Entity
is	O
known	O
to	O
block	O
voltage	O
-	O
sensitive	O
K(+)-channels	I-Entity
.	O

In	O
the	O
counterbalanced	O
method	O
,	O
quinine	I-Entity
attenuated	O
morphine	I-Entity
-	O
induced	O
place	O
preference	O
,	O
whereas	O
4-aminopyridine	I-Entity
was	O
ineffective	O
.	O

In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex	O
-	O
activity	O
meter	O
neither	O
of	O
the	O
K(+)-channel	I-Entity
blockers	O
affected	O
morphine	I-Entity
-	O
induced	O
hypoactivity	I-Entity
,	O
but	O
both	O
K(+)-channel	I-Entity
blockers	O
prevented	O
morphine	I-Entity
-	O
induced	O
secondary	O
hyperactivity	I-Entity
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine	I-Entity
-	O
sensitive	O
but	O
not	O
4-aminopyridine	I-Entity
-	O
sensitive	O
K(+)-channels	I-Entity
in	O
morphine	I-Entity
reward	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K(+)-channels	I-Entity
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine	I-Entity
-	O
induced	O
hypoactivity	I-Entity
whereas	O
morphine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine-	I-Entity
and	O
4-aminopyridine	I-Entity
-	O
sensitive	O
K(+)-channels	I-Entity
.	O



Nociceptin	I-Entity
/	O
orphanin	B-Entity
FQ	I-Entity
and	O
nocistatin	I-Entity
on	O
learning	B-Entity
and	I-Entity
memory	I-Entity
impairment	I-Entity
induced	O
by	O
scopolamine	I-Entity
in	O
mice	O

Nociceptin	I-Entity
,	O
also	O
known	O
as	O
orphanin	B-Entity
FQ	I-Entity
,	O
is	O
an	O
endogenous	O
ligand	O
for	O
the	O
orphan	O
opioid	O
receptor	O
-	O
like	O
receptor	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functions	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistatin	I-Entity
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	I-Entity
and	O
blocks	O
nociceptin	I-Entity
-	O
induced	O
allodynia	I-Entity
and	O
hyperalgesia	I-Entity
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin	I-Entity
/	O
orphanin	B-Entity
FQ	I-Entity
and	O
nocistatin	I-Entity
could	O
modulate	O
impairment	B-Entity
of	I-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
induced	O
by	O
scopolamine	I-Entity
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
antagonist	O
,	O
using	O
spontaneous	O
alternation	O
of	O
Y	O
-	O
maze	O
and	O
step	O
-	O
down	O
type	O
passive	O
avoidance	O
tasks	O
in	O
mice	O
.	O

While	O
nocistatin	I-Entity
(	O
0.5	O
-	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O

administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours	O
,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step	O
-	O
down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	I-Entity
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O

Administration	O
of	O
nocistatin	I-Entity
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
attenuated	O
the	O
scopolamine	I-Entity
-	O
induced	O
impairment	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
behaviours	O
.	O

These	O
results	O
indicated	O
that	O
nocistatin	I-Entity
,	O
a	O
new	O
biologically	O
active	O
peptide	O
,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	I-Entity
,	O
and	O
suggested	O
that	O
these	O
peptides	O
play	O
opposite	O
roles	O
in	O
learning	O
and	O
memory	O
.	O



Meloxicam	I-Entity
-	O
induced	O
liver	B-Entity
toxicity	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
who	O
developed	O
acute	O
cytolytic	O
hepatitis	I-Entity
due	O
to	O
meloxicam	I-Entity
.	O

Recently	O
introduced	O
in	O
Belgium	O
,	O
meloxicam	I-Entity
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	O
2	O
.	O

The	O
acute	O
cytolytic	O
hepatitis	I-Entity
occurred	O
rapidly	O
after	O
meloxicam	I-Entity
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	I-Entity
mechanism	O
.	O

This	O
first	O
case	O
of	O
meloxicam	I-Entity
related	O
liver	B-Entity
toxicity	I-Entity
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	B-Entity
damage	I-Entity
.	O



Induction	O
of	O
apoptosis	O
by	O
remoxipride	I-Entity
metabolites	O
in	O
HL60	O
and	O
CD34+/CD19-	O
human	O
bone	O
marrow	O
progenitor	O
cells	O
:	O
potential	O
relevance	O
to	O
remoxipride	I-Entity
-	O
induced	O
aplastic	B-Entity
anemia	I-Entity
.	O

The	O
antipsychotic	O
agent	O
,	O
remoxipride	I-Entity
[	O
(	B-Entity
S)-(-)-3-bromo	I-Entity
-	I-Entity
N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	I-Entity
amide	I-Entity
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	B-Entity
anemia	I-Entity
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	I-Entity
,	O
three	O
pyrrolidine	I-Entity
ring	O
metabolites	O
and	O
five	O
aromatic	O
ring	O
metabolites	O
of	O
the	O
parent	O
compound	O
to	O
induce	O
apoptosis	O
in	O
HL60	O
cells	O
and	O
human	O
bone	O
marrow	O
progenitor	O
(	O
HBMP	O
)	O
cells	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	B-Entity
33342-	I-Entity
and	O
propidium	B-Entity
iodide	I-Entity
stained	O
cell	O
samples	O
.	O

The	O
catechol	I-Entity
and	O
hydroquinone	I-Entity
metabolites	O
,	O
NCQ436	I-Entity
and	O
NCQ344	I-Entity
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time-	O
and	O
concentration	O
dependent	O
manner	O
,	O
while	O
the	O
phenols	I-Entity
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	I-Entity
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	I-Entity
ring	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
effect	O
.	O

No	O
necrosis	I-Entity
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	I-Entity
but	O
NCQ344	I-Entity
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types	O
,	O
inducing	O
apoptosis	O
at	O
lower	O
concentrations	O
and	O
necrosis	I-Entity
at	O
higher	O
concentrations	O
.	O

These	O
data	O
show	O
that	O
the	O
catechol	I-Entity
and	O
hydroquinone	I-Entity
metabolites	O
of	O
remoxipride	I-Entity
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells	O
,	O
leading	O
to	O
apoptosis	O
,	O
while	O
the	O
phenol	I-Entity
metabolites	O
were	O
inactive	O
.	O

Similarly	O
,	O
benzene	I-Entity
-	O
derived	O
catechol	I-Entity
and	O
hydroquinone	I-Entity
,	O
but	O
not	O
phenol	I-Entity
,	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O

We	O
propose	O
that	O
remoxipride	I-Entity
and	O
benzene	I-Entity
may	O
induce	O
aplastic	B-Entity
anemia	I-Entity
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	I-Entity
and	O
NCQ344	I-Entity
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B-Entity
anemia	I-Entity
that	O
has	O
been	O
associated	O
with	O
remoxipride	I-Entity
.	O



Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	I-Entity
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	O
agents	O
in	O
mice	O
.	O

The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	O
agents	O
based	O
on	O
the	O
structure	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	I-Entity
(	O
7	O
)	O
is	O
described	O
.	O

Compound	O
7e	O
,	O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	B-Entity
dro-1H-	I-Entity
indol-2-one	I-Entity
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5-HT1A	O
and	O
5-HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	O
the	O
D2	O
receptor	O
.	O

7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	I-Entity
induced	O
by	O
haloperidol	I-Entity
indicating	O
its	O
atypical	O
antipsychotic	O
nature	O
.	O



Sub	O
-	O
chronic	O
inhibition	O
of	O
nitric	B-Entity
-	I-Entity
oxide	I-Entity
synthesis	O
modifies	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
and	O
the	O
number	O
of	O
NADPH	I-Entity
-	O
diaphorase	O
neurons	O
in	O
mice	O
.	O

NG	B-Entity
-	I-Entity
nitro	I-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
(	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
)	O
,	O
an	O
inhibitor	O
of	O
nitric	B-Entity
-	I-Entity
oxide	I-Entity
synthase	O
(	O
NOS	O
)	O
,	O
induces	O
catalepsy	I-Entity
in	O
mice	O
.	O

This	O
effect	O
undergoes	O
rapid	O
tolerance	O
,	O
showing	O
a	O
significant	O
decrease	O
after	O
2	O
days	O
of	O
sub	O
-	O
chronic	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
treatment	O
.	O

Nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
has	O
been	O
shown	O
to	O
influence	O
dopaminergic	O
neurotransmission	O
in	O
the	O
striatum	O
.	O

Neuroleptic	O
drugs	O
such	O
as	O
haloperidol	I-Entity
,	O
which	O
block	O
dopamine	I-Entity
receptors	O
,	O
also	O
cause	O
catalepsy	I-Entity
in	O
rodents	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
treatment	O
in	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
and	O
the	O
number	O
of	O
NOS	O
neurons	O
in	O
areas	O
related	O
to	O
motor	O
control	O
.	O

Male	O
albino	O
Swiss	O
mice	O
were	O
treated	O
sub	O
-	O
chronically	O
(	O
twice	O
a	O
day	O
for	O
4	O
days	O
)	O
with	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
(	O
40	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

or	O
haloperidol	I-Entity
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

Catalepsy	I-Entity
was	O
evaluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatments	O
.	O

Reduced	O
nicotinamide	B-Entity
adenine	I-Entity
dinucleotide	I-Entity
phosphate	I-Entity
-	O
diaphorase	O
(	O
NADPH	I-Entity
-	O
d	O
)	O

L	B-Entity
-	I-Entity
NOARG	I-Entity
sub	O
-	O
chronic	O
administration	O
produced	O
tolerance	O
of	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
and	O
of	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH	I-Entity
-	O
d	O
-	O
positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	I-Entity
and	O
in	O
the	O
pedunculopontine	O
tegmental	O
nucleus	O
compared	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH	I-Entity
-	O
d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra	O
,	O
pars	O
compacta	O
in	O
both	O
haloperidol	I-Entity
-	O
treated	O
and	O
L	B-Entity
-	I-Entity
NOARG	I-Entity
-	O
treated	O
animals	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
give	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
NO	I-Entity
plays	O
a	O
role	O
in	O
motor	O
behavior	O
control	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
synaptic	O
changes	O
produced	O
by	O
antipsychotic	O
treatment	O
.	O



Prolonged	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
occurs	O
in	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
after	O
both	O
dobutamine	I-Entity
and	O
exercise	O
induced	O
myocardial	B-Entity
ischaemia	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
in	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	I-Entity
induced	O
ischaemia	I-Entity
.	O

SUBJECTS	O
:	O
10	O
patients	O
with	O
stable	B-Entity
angina	I-Entity
,	O
angiographically	O
proven	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
and	O
normal	O
left	O
ventricular	O
function	O
.	O

INTERVENTIONS	O
:	O
Treadmill	O
exercise	O
and	O
dobutamine	I-Entity
stress	O
were	O
performed	O
on	O
different	O
days	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(	O
p	O
=	O
0.53	O
)	O
or	O
ST	O
depression	I-Entity
(	O
p	O
=	O
0.63	O
)	O
with	O
either	O
form	O
of	O
stress	O
.	O

After	O
exercise	O
,	O
ejection	O
fraction	O
was	O
reduced	O
at	O
15	O
and	O
30	O
minutes	O
compared	O
with	O
baseline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-5.6	O
(	O
1.5)%	O
,	O
p	O
<	O
0.05	O
;	O
and	O
-6.1	O
(	O
2.2)%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
minutes	O
after	O
dobutamine	I-Entity
(	O
-10.8	O
(	O
1.8)%	O
and	O
-5	O
.	O

Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(	O
-27.9	O
(	O
7.2)%	O
and	O
-28.6	O
(	O
5.7)%	O
,	O
both	O
p	O
<	O
0.01	O
)	O
,	O
and	O
at	O
30	O
minutes	O
after	O
dobutamine	I-Entity

In	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
dobutamine	I-Entity
induced	O
ischaemia	I-Entity
results	O
in	O
prolonged	O
reversible	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
,	O
presumed	O
to	O
be	O
myocardial	B-Entity
stunning	I-Entity
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

Dobutamine	I-Entity
induced	O
ischaemia	I-Entity
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O



Anorexigens	O
and	O
pulmonary	B-Entity
hypertension	I-Entity
in	O
the	O
United	O
States	O
:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	B-Entity
hypertension	I-Entity
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
appetite	O
suppressants	O
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
(	O
PPH	I-Entity
)	O
.	O

Recently	O
,	O
fenfluramine	I-Entity
appetite	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
United	O
States	O
but	O
were	O
withdrawn	O
in	O
September	O
1997	O
because	O
of	O
concerns	O
over	O
adverse	O
effects	O
.	O

:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	B-Entity
hypertension	I-Entity
at	O
12	O
large	O
referral	O
centers	O
in	O
North	O
America	O
.	O

Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B-Entity
hypertension	I-Entity
and	O
its	O
severity	O
.	O

Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	B-Entity
hypertension	I-Entity
were	O
classed	O
as	O
PPH	I-Entity
.	O

A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants	O
,	O
anorexigens	O
,	O
and	O
amphetamines	I-Entity
.	O

Five	O
hundred	O
seventy	O
-	O
nine	O
patients	O
were	O
studied	O
,	O
205	O
with	O
PPH	I-Entity
and	O
374	O
with	O
pulmonary	B-Entity
hypertension	I-Entity
from	O
other	O
causes	O
(	O
secondary	O
pulmonary	B-Entity
hypertension	I-Entity
[	O
SPH	O
]	O
)	O
.	O

However	O
,	O
of	O
the	O
medications	O
surveyed	O
,	O
only	O
the	O
fenfluramines	I-Entity
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	I-Entity
as	O
compared	O
with	O
SPH	O
(	O
adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months	O
,	O
7.5	O
;	O
95%	O
confidence	O
interval	O
,	O
1.7	O
to	O
32.4	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
association	O
with	O
PPH	I-Entity
,	O
the	O
increase	O
of	O
association	O
with	O
increasing	O
duration	O
of	O
use	O
,	O
and	O
the	O
specificity	O
for	O
fenfluramines	I-Entity
are	O
consistent	O
with	O
previous	O
studies	O
indicating	O
that	O
fenfluramines	I-Entity
are	O
causally	O
related	O
to	O
PPH	I-Entity
.	O

The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	B-Entity
hypertension	I-Entity
in	O
patients	O
with	O
underlying	O
conditions	O
associated	O
with	O
SPH	O
.	O



Clinical	O
aspects	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
and	O
thrombosis	I-Entity
and	O
other	O
side	O
effects	O
of	O
heparin	I-Entity
therapy	O
.	O

Heparin	I-Entity
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	I-Entity
for	O
more	O
than	O
50	O
years	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	I-Entity
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	I-Entity
episodes	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	I-Entity
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Bleeding	I-Entity
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	I-Entity
.	O

Major	O
bleeding	I-Entity
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	I-Entity
therapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	I-Entity
therapy	O
include	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
,	O
heparin	I-Entity
-	O
associated	O
osteoporosis	I-Entity
,	O
eosinophilia	I-Entity
,	O
skin	B-Entity
reactions	I-Entity
,	O
allergic	B-Entity
reactions	I-Entity
other	O
than	O
thrombocytopenia	I-Entity
,	O
alopecia	I-Entity
,	O
transaminasemia	O
,	O
hyperkalemia	I-Entity
,	O
hypoaldosteronism	I-Entity
,	O
and	O
priapism	I-Entity
.	O

These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	I-Entity
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	I-Entity
and	O
osteoporosis	I-Entity
.	O

Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
""""	O
softly	O
""""	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	I-Entity
,	O
at	O
present	O
the	O
incidences	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
molecular	O
weight	O
heparins	I-Entity
appear	O
to	O
be	O
much	O
less	O
common	O
.	O



A	O
case	O
of	O
bilateral	O
optic	B-Entity
neuropathy	I-Entity
in	O
a	O
patient	O
on	O
tacrolimus	I-Entity
(	O
FK506	I-Entity
)	O
therapy	O
after	O
liver	O
transplantation	O
.	O

PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B-Entity
neuropathy	I-Entity
in	O
a	O
patient	O
receiving	O
tacrolimus	I-Entity
(	O
FK	B-Entity
506	I-Entity
,	O
Prograf	O
;	O
Fujisawa	O
USA	O
,	O
Inc	O
,	O
Deerfield	O
,	O
Illinois	O
)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	O
transplantation	O
.	O

In	O
a	O
58-year	O
-	O
old	O
man	O
receiving	O
tacrolimus	I-Entity
after	O
orthotropic	O
liver	O
transplantation	O
,	O
serial	O
neuro	O
-	O
ophthalmologic	O
examinations	O
and	O
laboratory	O
studies	O
were	O
performed	O
.	O

The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	O
in	O
both	O
eyes	O
,	O
with	O
clinical	O
features	O
resembling	O
ischemic	B-Entity
optic	I-Entity
neuropathies	I-Entity
.	O

Deterioration	B-Entity
of	I-Entity
vision	I-Entity
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	I-Entity
.	O

Tacrolimus	I-Entity
and	O
other	O
immunosuppressive	O
agents	O
may	O
be	O
associated	O
with	O
optic	B-Entity
nerve	I-Entity
toxicity	I-Entity
.	O



Hypercalcemia	I-Entity
,	O
arrhythmia	I-Entity
,	O
and	O
mood	O
stabilizers	O
.	O

Recent	O
findings	O
in	O
a	O
bipolar	I-Entity
patient	O
receiving	O
maintenance	O
lithium	I-Entity
therapy	O
who	O
developed	O
hypercalcemia	I-Entity
and	O
severe	O
bradyarrhythmia	I-Entity
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	I-Entity
patients	O
with	O
lithium	I-Entity
-	O
associated	O
hypercalcemia	I-Entity
.	O

A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	I-Entity
that	O
presented	O
during	O
a	O
1-year	O
period	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercalcemias	I-Entity
or	O
those	O
associated	O
with	O
intravenous	O
fluids	O
,	O
the	O
authors	O
identified	O
18	O
non	O
-	O
lithium	I-Entity
-	O
treated	O
patients	O
with	O
hypercalcemias	I-Entity
related	O
to	O
malignancies	I-Entity
and	O
other	O
medical	O
conditions	O
(	O
group	O
A	O
)	O
and	O
12	O
patients	O
with	O
lithium	I-Entity
-	O
associated	O
hypercalcemia	I-Entity
(	O
group	O
B	O
)	O
.	O

Thus	O
,	O
two	O
control	O
groups	O
were	O
generated	O
:	O
group	O
C1	O
,	O
which	O
included	O
age-	O
and	O
sex	O
-	O
comparable	O
lithium	I-Entity
-	O
treated	O
bipolar	I-Entity
normocalcemic	O
patients	O
,	O
and	O
group	O
C2	O
,	O
which	O
included	O
bipolar	I-Entity
normocalcemic	O
patients	O
treated	O
with	O
anticonvulsant	O
mood	O
stabilizers	O
.	O

Patients	O
with	O
hypercalcemia	I-Entity
resulting	O
from	O
medical	O
diseases	O
and	O
bipolar	I-Entity
patients	O
with	O
lithium	I-Entity
-	O
associated	O
hypercalcemia	I-Entity
had	O
significantly	O
higher	O
frequencies	O
of	O
conduction	O
defects	O
.	O



Attenuation	O
of	O
nephrotoxicity	I-Entity
by	O
a	O
novel	O
lipid	O
nanosphere	O
(	O
NS-718	O
)	O
incorporating	O
amphotericin	B-Entity
B.	I-Entity
NS-718	O
,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	B-Entity
B	I-Entity
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	I-Entity
.	O

We	O
compared	O
the	O
toxicity	I-Entity
of	O
NS-718	O
with	O
that	O
of	O
Fungizone	I-Entity
(	O
amphotericin	B-Entity
B	I-Entity
-	I-Entity
sodium	I-Entity
deoxycholate	I-Entity
;	O
D	B-Entity
-	I-Entity
AmB	I-Entity
)	O
in	O
vitro	O
using	O
renal	O
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis	O
,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	B-Entity
B	I-Entity
following	O
intravenous	O
infusion	O
of	O
the	O
formulation	O
in	O
rats	O
.	O

Incubation	O
with	O
NS-718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D	B-Entity
-	I-Entity
AmB.	I-Entity
Serum	O
blood	O
urea	I-Entity
and	O
creatinine	I-Entity
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D	B-Entity
-	I-Entity
AmB	I-Entity
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS-718	O
.	O

Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	B-Entity
necrosis	I-Entity
in	O
D	B-Entity
-	I-Entity
AmB	I-Entity
-	O
treated	O
rats	O
but	O
no	O
change	O
in	O
NS-718-treated	O
rats	O
.	O

Amphotericin	B-Entity
B	I-Entity
concentrations	O
in	O
the	O
kidney	O
in	O
NS-718-treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D	B-Entity
-	I-Entity
AmB	I-Entity
-	O
treated	O
rats	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	B-Entity
B	I-Entity
into	O
lipid	O
nanospheres	O
of	O
NS-718	O
attenuates	O
the	O
nephrotoxicity	I-Entity
of	O
amphotericin	B-Entity
B.	I-Entity



Patterns	O
of	O
sulfadiazine	I-Entity
acute	B-Entity
nephrotoxicity	I-Entity
.	O

Sulfadiazine	I-Entity
acute	B-Entity
nephrotoxicity	I-Entity
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	I-Entity
in	O
HIV	O
-	O
positive	O
patients	O
.	O

Under	O
treatment	O
with	O
sulfadiazine	I-Entity
they	O
developed	O
oliguria	I-Entity
,	O
abdominal	B-Entity
pain	I-Entity
,	O
renal	B-Entity
failure	I-Entity
and	O
showed	O
multiple	O
radiolucent	O
renal	B-Entity
calculi	I-Entity
in	O
echography	O
.	O

A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	B-Entity
lithiasis	I-Entity
in	O
a	O
single	O
functional	O
kidney	O
.	O

Treatment	O
with	O
sulfadiazine	I-Entity
requires	O
exquisite	O
control	O
of	O
renal	O
function	O
,	O
an	O
increase	O
in	O
water	O
ingestion	O
and	O
possibly	O
the	O
alcalinization	O
of	O
the	O
urine	O
.	O



Downbeat	B-Entity
nystagmus	I-Entity
associated	O
with	O
intravenous	O
patient	O
-	O
controlled	O
administration	O
of	O
morphine	I-Entity
.	O

This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	I-Entity
with	O
downbeating	B-Entity
nystagmus	I-Entity
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient	O
-	O
controlled	O
analgesia	O
morphine	I-Entity
.	O

Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	I-Entity
with	O
these	O
symptoms	O
and	O
signs	O
,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient	O
-	O
controlled	O
analgesia	O
morphine	I-Entity
.	O



Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	I-Entity
and	O
amiodarone	I-Entity
in	O
animals	O
with	O
a	O
healed	O
myocardial	B-Entity
infarction	I-Entity
.	O

The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	I-Entity
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	I-Entity
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	I-Entity
after	O
prolonged	O
oral	O
administration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	B-Entity
infarction	I-Entity
.	O

All	O
dogs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
dronedarone	I-Entity
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amiodarone	I-Entity
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
placebo	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
a	O
3-week	O
washout	O
between	O
consecutive	O
treatments	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
MBP	O
)	O
,	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(	O
+	O
LVdP	O
/	O
dt	O
)	O
,	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
and	O
fractional	O
shortening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	I-Entity
and	O
exercise	O
-	O
induced	O
sympathetic	O
stimulation	O
were	O
evaluated	O
under	O
baseline	O
and	O
posttreatment	O
conditions	O
.	O

Resting	O
values	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen	O
,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose	O
-	O
dependently	O
lowered	O
after	O
dronedarone	I-Entity
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	I-Entity
.	O

Both	O
dronedarone	I-Entity
and	O
amiodarone	I-Entity
significantly	O
reduced	O
the	O
exercise	O
-	O
induced	O
tachycardia	I-Entity
and	O
,	O
at	O
the	O
highest	O
dose	O
,	O
decreased	O
the	O
isoproterenol	I-Entity
-	O
induced	O
tachycardia	I-Entity
.	O

Thus	O
,	O
dronedarone	I-Entity
and	O
amiodarone	I-Entity
displayed	O
a	O
similar	O
level	O
of	O
antiadrenergic	O
effect	O
and	O
did	O
not	O
impair	O
the	O
resting	O
left	O
ventricular	O
function	O
.	O

Consequently	O
,	O
dronedarone	I-Entity
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	I-Entity
,	O
without	O
compromising	O
the	O
left	O
ventricular	O
function	O
.	O



Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	I-Entity
(	O
40	O
mg	O
/	O
m(2	O
)	O
)	O
in	O
platinum	I-Entity
/	O
paclitaxel	I-Entity
-	O
refractory	O
ovarian	B-Entity
and	I-Entity
fallopian	I-Entity
tube	I-Entity
cancers	I-Entity
and	O
primary	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
peritoneum	I-Entity
.	O

Several	O
studies	O
have	O
demonstrated	O
liposomal	O
doxorubicin	I-Entity
(	O
Doxil	I-Entity
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum	I-Entity
-	O
resistant	O
ovarian	B-Entity
cancer	I-Entity
,	O
with	O
dose	O
limiting	O
toxicity	I-Entity
of	O
the	O
standard	O
dosing	O
regimen	O
(	O
50	O
mg	O
/	O
m(2	O
)	O

q	O
4	O
weeks	O
)	O
being	O
severe	O
erythrodysesthesia	I-Entity
(	O
""""	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
""""	O
)	O
and	O
stomatitis	I-Entity
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	O
doxorubicin	I-Entity
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well	O
-	O
defined	O
patient	O
population	O
with	O
platinum	I-Entity
/	O
paclitaxel	I-Entity
-	O
refractory	O
disease	O
.	O

Patients	O
with	O
ovarian	B-Entity
or	I-Entity
fallopian	I-Entity
tube	I-Entity
cancers	I-Entity
or	O
primary	O
peritoneal	B-Entity
carcinoma	I-Entity
with	O
platinum	I-Entity
/	O
paclitaxel	I-Entity
-	O
refractory	O
disease	O
(	O
stable	O
or	O
progressive	O
disease	O
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<3	O
months	O
in	O
duration	O
)	O
were	O
treated	O
with	O
liposomal	O
doxorubicin	I-Entity
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m(2	O
)	O
q	O
4	O
weeks	O
.	O

Six	O
(	O
12%	O
)	O
and	O
4	O
(	O
8%	O
)	O
patients	O
experienced	O
grade	O
2	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
and	O
stomatitis	I-Entity
,	O
respectively	O
(	O
no	O
episodes	O
of	O
grade	O
3	O
)	O
.	O

One	O
patient	O
developed	O
grade	O
3	O
diarrhea	I-Entity
requiring	O
hospitalization	O
for	O
hydration	O
.	O

The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	O
doxorubicin	I-Entity
administered	O
on	O
this	O
protocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

This	O
modified	O
liposomal	O
doxorubicin	I-Entity
regimen	O
results	O
in	O
less	O
toxicity	I-Entity
(	O
stomatitis	I-Entity
,	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
)	O
than	O
the	O
standard	O
FDA	O
-	O
approved	O
dose	O
schedule	O
.	O

Definite	O
,	O
although	O
limited	O
,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well	O
-	O
defined	O
platinum-	I-Entity
and	O
paclitaxel	I-Entity
-	O
refractory	O
ovarian	B-Entity
cancer	I-Entity
.	O



Efficacy	O
of	O
olanzapine	I-Entity
in	O
acute	O
bipolar	B-Entity
mania	I-Entity
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

The	O
Olanzipine	I-Entity
HGGW	O
Study	O
Group	O
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	I-Entity
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	B-Entity
mania	I-Entity
.	O

A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
bipolar	B-Entity
disorder	I-Entity
,	O
manic	I-Entity
or	O
mixed	O
,	O
were	O
randomized	O
to	O
olanzapine	I-Entity
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young	O
-	O
Mania	I-Entity
Rating	O
Scale	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
score	O
.	O

Safety	O
was	O
assessed	O
using	O
adverse	O
events	O
,	O
Extrapyramidal	B-Entity
Symptom	I-Entity
(	O
EPS	I-Entity
)	O
rating	O
scales	O
,	O
laboratory	O
values	O
,	O
electrocardiograms	O
,	O
vital	O
signs	O
,	O
and	O
weight	O
change	O
.	O

Olanzapine	I-Entity
-	O
treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O

Olanzapine	I-Entity
-	O
treated	O
patients	O
demonstrated	O
a	O
higher	O
rate	O
of	O
response	O
(	O
65%	O
vs	O
43%	O
,	O
respectively	O
;	O
P	O
=	O
.02	O
)	O
and	O
euthymia	O
(	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
EPSs	I-Entity
between	O
groups	O
.	O

However	O
,	O
olanzapine	I-Entity
-	O
treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O

SD	O
)	O
weight	B-Entity
gain	I-Entity
than	O
placebo	O
-	O
treated	O
patients	O
(	O
2.1	O
+	O
/-	O

2.3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatment	O
-	O
emergent	O
somnolence	I-Entity
(	O
21	O
patients	O
[	O
38.2%	O
]	O
vs	O
5	O
[	O
8.3%	O
]	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
Olanzapine	I-Entity
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	B-Entity
mania	I-Entity
and	O
was	O
generally	O
well	O
tolerated	O
.	O



The	O
effect	O
of	O
pupil	B-Entity
dilation	I-Entity
with	O
tropicamide	I-Entity
on	O
vision	O
and	O
driving	O
simulator	O
performance	O
.	O

To	O
assess	O
the	O
effect	O
of	O
pupil	B-Entity
dilation	I-Entity
on	O
vision	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers	O
,	O
before	O
and	O
after	O
pupil	B-Entity
dilation	I-Entity
using	O
guttae	O
tropicamide	I-Entity
1%	O
.	O

RESULTS	O
:	O
Pupillary	B-Entity
dilation	I-Entity
resulted	O
in	O
a	O
statistically	O
significant	O
deterioration	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O

Pupillary	B-Entity
dilation	I-Entity
may	O
lead	O
to	O
a	O
decrease	O
in	O
vision	O
and	O
daylight	O
driving	O
performance	O
in	O
young	O
people	O
.	O



A	O
case	O
of	O
isotretinoin	B-Entity
embryopathy	I-Entity
with	O
bilateral	O
anotia	I-Entity
and	O
Taussig	B-Entity
-	I-Entity
Bing	I-Entity
malformation	I-Entity
.	O

We	O
report	O
a	O
newborn	O
infant	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
anotia	I-Entity
and	O
Taussig	B-Entity
-	I-Entity
Bing	I-Entity
malformation	I-Entity
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	I-Entity
within	O
the	O
first	O
trimester	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	B-Entity
A	I-Entity
-	O
containing	O
drugs	O
to	O
women	O
of	O
childbearing	O
years	O
.	O



Effect	O
of	O
methoxamine	I-Entity
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	B-Entity
incontinence	I-Entity
:	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
study	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1-adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	B-Entity
stress	I-Entity
incontinence	I-Entity
.	O

Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	I-Entity
or	O
placebo	O
(	O
saline	O
)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	B-Entity
incontinence	I-Entity
while	O
measuring	O
maximum	O
urethral	O
pressure	O
(	O
MUP	O
)	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
symptomatic	O
side	O
effects	O
.	O

Methoxamine	I-Entity
evoked	O
non	O
-	O
significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	B-Entity
significant	I-Entity
rise	I-Entity
in	I-Entity
systolic	I-Entity
blood	I-Entity
pressure	I-Entity
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	O
maximum	O
dosage	O
.	O

Systemic	O
side	O
effects	O
including	O
piloerection	O
,	O
headache	I-Entity
,	O
and	O
cold	O
extremities	O
were	O
experienced	O
in	O
all	O
subjects	O
.	O

The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub	O
-	O
type	O
-	O
selective	O
alpha1-adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	B-Entity
incontinence	I-Entity
may	O
be	O
limited	O
by	O
associated	O
piloerection	O
and	O
cardiovascular	O
side	O
effects	O
.	O



Toleration	O
of	O
high	O
doses	O
of	O
angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
inhibitors	I-Entity
in	O
patients	O
with	O
chronic	O
heart	B-Entity
failure	I-Entity
:	O
results	O
from	O
the	O
ATLAS	O
trial	O
.	O

The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	I-Entity
and	O
Survival	O
.	O

BACKGROUND	O
:	O
Treatment	O
with	O
angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
(	I-Entity
ACE	I-Entity
)	I-Entity
inhibitors	I-Entity
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	B-Entity
failure	I-Entity
(	O
CHF	I-Entity
)	O
,	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials	O
,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents	O
,	O
especially	O
at	O
the	O
recommended	O
doses	O
.	O

The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high-	O
compared	O
with	O
low	O
-	O
dose	O
lisinopril	I-Entity
in	O
CHF	I-Entity
.	O

The	O
Assessment	O
of	O
Lisinopril	I-Entity
and	O
Survival	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	B-Entity
inhibitor	I-Entity
treatment	O
were	O
stabilized	O
receiving	O
medium	O
-	O
dose	O
lisinopril	I-Entity
(	O
12.5	O
or	O
15.0	O
mg	O
once	O
daily	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomized	O
to	O
high-	O
(	O
35.0	O
or	O
32.5	O
mg	O
OD	O
)	O
or	O
low	O
-	O
dose	O
(	O
5.0	O
or	O
2.5	O
mg	O
OD	O
)	O
groups	O
.	O

Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	I-Entity
and	O
left	O
ventricular	O
ejection	O
fractions	O
of	O
no	O
greater	O
than	O
0.30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
a	O
median	O
of	O
46	O
months	O
.	O

We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment	O
,	O
with	O
a	O
focus	O
on	O
hypotension	I-Entity
and	O
renal	B-Entity
dysfunction	I-Entity
.	O

Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	B-Entity
inhibitor	I-Entity
,	O
doses	O
in	O
only	O
4.2%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	I-Entity
(	O
2.0%	O
)	O
or	O
because	O
of	O
renal	B-Entity
dysfunction	I-Entity
or	O
hyperkalemia	I-Entity
(	O
2.3%	O
)	O
.	O

Subgroups	O
presumed	O
to	O
be	O
at	O
higher	O
risk	O
for	O
ACE	B-Entity
inhibitor	I-Entity
intolerance	O
(	O
blood	O
pressure	O
,	O
<	O

creatinine	I-Entity
,	O
>	O
or	O
=	O
132.6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1.5	O
mg	O
/	O
dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
years	O
;	O
and	O
patients	O
with	O
diabetes	I-Entity
)	O
generally	O
tolerated	O
the	O
high	O
-	O
dose	O
strategy	O
.	O

These	O
findings	O
demonstrate	O
that	O
ACE	B-Entity
inhibitor	I-Entity
therapy	O
in	O
most	O
patients	O
with	O
CHF	I-Entity
can	O
be	O
successfully	O
titrated	O
to	O
and	O
maintained	O
at	O
high	O
doses	O
,	O
and	O
that	O
more	O
aggressive	O
use	O
of	O
these	O
agents	O
is	O
warranted	O
.	O



Cocaine	I-Entity
,	O
ethanol	I-Entity
,	O
and	O
cocaethylene	I-Entity
cardiotoxity	I-Entity
in	O
an	O
animal	O
model	O
of	O
cocaine	B-Entity
and	I-Entity
ethanol	I-Entity
abuse	I-Entity
.	O

Simultaneous	O
abuse	B-Entity
of	I-Entity
cocaine	I-Entity
and	I-Entity
ethanol	I-Entity
affects	O
12	O
million	O
Americans	O
annually	O
.	O

Their	O
combined	O
cardiac	B-Entity
toxicity	I-Entity
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	I-Entity
(	O
CE	I-Entity
)	O
,	O
a	O
cocaine	I-Entity
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	I-Entity
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	I-Entity
in	O
the	O
combined	O
cardiotoxicity	I-Entity
of	O
cocaine	I-Entity
and	O
ethanol	I-Entity
in	O
a	O
model	O
simulating	O
their	O
abuse	O
.	O

Twenty	O
-	O
three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	I-Entity
7.5	O
mg	O
/	O
kg	O
with	O
ethanol	I-Entity
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C+E	O
,	O

n	O
=	O
8)	O
,	O
2	O
)	O
three	O
cocaine	I-Entity
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethanol	I-Entity
infusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebo	O
boluses	O
and	O
infusion	O
(	O
n	O
=	O
4	O
)	O
.	O

Two	O
of	O
eight	O
dogs	O
in	O
the	O
C+E	O
group	O
experienced	O
cardiovascular	B-Entity
collapse	I-Entity
.	O

The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	I-Entity
bolus	O
in	O
the	O
C+E	O
and	O
C	O
only	O
groups	O
;	O
however	O
,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C+E	O
group	O
.	O

Peak	O
CE	I-Entity
levels	O
were	O
associated	O
with	O
a	O
45%	O
(	O
SD	O
+	O
/-	O

22%	O
to	O
69%	O
)	O
decrease	B-Entity
in	I-Entity
cardiac	I-Entity
output	I-Entity
(	O
p	O
<	O
0.05	O
)	O
,	O
a	O
56%	O
(	O
SD	O
+	O
/-	O

Ventricular	B-Entity
arrhythmias	I-Entity
were	O
primarily	O
observed	O
in	O
the	O
C+E	O
group	O
,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

Cocaine	I-Entity
and	O
ethanol	I-Entity
in	O
combination	O
were	O
more	O
toxic	O
than	O
either	O
substance	O
alone	O
.	O

Co	O
-	O
administration	O
resulted	O
in	O
prolonged	O
cardiac	B-Entity
toxicity	I-Entity
and	O
was	O
dysrhythmogenic	O
.	O

Peak	O
serum	O
cocaethylene	I-Entity
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	B-Entity
depression	I-Entity
.	O



Worsening	O
of	O
Parkinsonism	I-Entity
after	O
the	O
use	O
of	O
veralipride	I-Entity
for	O
treatment	O
of	O
menopause	O
:	O
case	O
report	O
.	O

We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	O
related	O
symptoms	O
with	O
veralipride	I-Entity
,	O
as	O
well	O
as	O
the	O
improvement	O
of	O
her	O
symptoms	O
back	O
to	O
baseline	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

We	O
emphasize	O
the	O
anti	O
-	O
dopaminergic	O
effect	O
of	O
veralipride	I-Entity
.	O



Viracept	I-Entity
and	O
irregular	B-Entity
heartbeat	I-Entity
warning	O
.	O

A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	O
inhibitor	O
Viracept	I-Entity
may	O
cause	O
an	O
irregular	B-Entity
heart	I-Entity
beat	I-Entity
,	O
known	O
as	O
bradycardia	I-Entity
,	O
in	O
people	O
with	O
HIV	O
.	O

Bradycardia	I-Entity
occurred	O
in	O
a	O
45-year	O
-	O
old	O
male	O
patient	O
who	O
was	O
Viracept	I-Entity
in	O
combination	O
with	O
other	O
anti	O
-	O
HIV	O
drugs	O
.	O



Frequency	O
of	O
appearance	O
of	O
myeloperoxidase	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
patients	O
treated	O
with	O
propylthiouracil	I-Entity
and	O
the	O
relationship	O
between	O
MPO	O
-	O
ANCA	O
and	O
clinical	O
manifestations	O
.	O

OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA)-positive	O
vasculitis	I-Entity
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
who	O
were	O
treated	O
with	O
propylthiouracil	I-Entity
(	O
PTU	I-Entity
)	O
.	O

The	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
in	O
these	O
cases	O
was	O
suspected	O
of	O
being	O
related	O
to	O
PTU	I-Entity
because	O
the	O
titres	O
of	O
MPO	O
-	O
ANCA	O
decreased	O
when	O
PTU	I-Entity
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasculitis	I-Entity
during	O
PTU	I-Entity
therapy	O
,	O
or	O
on	O
the	O
incidence	O
of	O
MPO	O
-	O
ANCA	O
in	O
untreated	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
patients	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
.	O

We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	I-Entity
due	O
to	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
for	O
the	O
presence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
development	O
vasculitis	I-Entity
after	O
starting	O
PTU	I-Entity
therapy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
adverse	O
effects	O
of	O
PTU	I-Entity
or	O
because	O
the	O
observation	O
period	O
was	O
less	O
than	O
3	O
months	O
.	O

Before	O
treatment	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
patients	O
were	O
within	O
the	O
reference	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4.1%	O
)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO	O
-	O
ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	I-Entity
therapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
transiently	O
increased	O
to	O
12.8	O
and	O
15.0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	I-Entity
therapy	O
,	O
but	O
no	O
vasculitic	B-Entity
disorders	I-Entity
developed	O
.	O

In	O
the	O
third	O
patient	O
,	O
the	O
MPO	O
-	O
ANCA	O
titre	O
increased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	I-Entity
,	O
oral	B-Entity
ulcers	I-Entity
and	O
polyarthralgia	I-Entity
,	O
but	O
the	O
symptoms	O
resolved	O
2	O
weeks	O
after	O
stopping	O
PTU	I-Entity
therapy	O
,	O
and	O
the	O
MPO	O
-	O
ANCA	O
titre	O
decreased	O
to	O
20.7	O

U	O
/	O
ml	O
by	O
4	O
months	O
after	O
discontinuing	O
PTU	I-Entity
.	O

PTU	I-Entity
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	I-Entity
.	O



Prevalence	O
of	O
heart	B-Entity
disease	I-Entity
in	O
asymptomatic	O
chronic	O
cocaine	I-Entity
users	O
.	O

To	O
determine	O
the	O
prevalence	O
of	O
heart	B-Entity
disease	I-Entity
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	I-Entity
users	O
,	O
35	O
cocaine	I-Entity
users	O
and	O
32	O
age	O
-	O
matched	O
controls	O
underwent	O
resting	O
and	O
exercise	O
electrocardiography	O
(	O
ECG	O
)	O
and	O
Doppler	O
echocardiography	O
.	O

Findings	O
consistent	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
were	O
detected	O
in	O
12	O
(	O
34%	O
)	O
patients	O
and	O
3	O
(	O
9%	O
)	O
controls	O
(	O
p	O
=	O
0.01	O
)	O
.	O

Finally	O
,	O
resting	O
and	O
peak	O
exercise	O
abnormal	B-Entity
left	I-Entity
ventricular	I-Entity
filling	I-Entity
was	O
detected	O
in	O
38	O
and	O
35%	O
of	O
patients	O
as	O
compared	O
to	O
19	O
and	O
9%	O
of	O
controls	O
,	O
respectively	O
(	O
p	O
=	O
0.11	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronary	B-Entity
artery	I-Entity
or	I-Entity
myocardial	I-Entity
disease	I-Entity
is	O
common	O
(	O
38%	O
)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	I-Entity
users	O
.	O



Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	O
stress	O
in	O
rats	O
.	O

The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	I-Entity
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
with	O
respect	O
to	O
lipid	O
metabolism	O
in	O
serum	O
and	O
heart	O
tissue	O
has	O
been	O
investigated	O
.	O

day(-1	O
)	O
for	O
15	O
days	O
)	O
significantly	O
prevented	O
the	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
and	O
maintained	O
the	O
rats	O
at	O
near	O
normal	O
status	O
.	O



Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	B-Entity
tachycardia	I-Entity
in	O
acquired	O
long	B-Entity
-	I-Entity
QT	I-Entity
syndrome	I-Entity
:	O
direct	O
evidence	O
from	O
intracellular	O
recordings	O
in	O
the	O
intact	O
left	O
ventricular	O
wall	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TdP	I-Entity
)	O
with	O
QT	B-Entity
prolongation	I-Entity
induced	O
by	O
dl	O
-	O
sotalol	I-Entity
and	O
azimilide	I-Entity
.	O

The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	I-Entity
was	O
also	O
evaluated	O
.	O

-	O
Sotalol	I-Entity
preferentially	O
prolonged	O
action	O
potential	O
duration	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dose	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	B-Entity
prolongation	I-Entity
and	O
an	O
increase	O
in	O
TDR	O
.	O

Azimilide	I-Entity
,	O
however	O
,	O
significantly	O
prolonged	O
APD	O
and	O
QT	O
interval	O
at	O
concentrations	O
from	O
0.1	O
to	O
10	O

Unlike	O
dl	O
-	O
sotalol	I-Entity
,	O
azimilide	I-Entity
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
increased	O
epicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
sotalol	I-Entity
and	O
azimilide	I-Entity
rarely	O
induced	O
EADs	O
in	O
canine	O
left	O
ventricles	O
,	O
they	O
produced	O
frequent	O
EADs	O
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B-Entity
prolongation	I-Entity
was	O
seen	O
.	O

An	O
increase	O
in	O
TDR	O
by	O
dl	O
-	O
sotalol	I-Entity
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	I-Entity
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles	O
.	O

Of	O
note	O
,	O
although	O
azimilide	I-Entity
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
increased	O
APD	O
more	O
than	O
dl	O
-	O
sotalol	I-Entity
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagate	O
transmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	I-Entity
under	O
QT	B-Entity
prolongation	I-Entity
.	O



Prenatal	O
cocaine	I-Entity
exposure	O
and	O
cranial	O
sonographic	O
findings	O
in	O
preterm	B-Entity
infants	I-Entity
.	O

Prenatal	O
cocaine	I-Entity
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	I-Entity
and	O
the	O
formation	O
of	O
cysts	I-Entity
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	I-Entity
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	B-Entity
cysts	I-Entity
in	O
preterm	B-Entity
infants	I-Entity
.	O

METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
and	O
cranial	O
sonograms	O
obtained	O
during	O
a	O
1-year	O
period	O
on	O
122	O
premature	B-Entity
(	I-Entity
<	I-Entity
36	I-Entity
weeks	I-Entity
of	I-Entity
gestation	I-Entity
)	I-Entity
infants	I-Entity
.	O

Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups	O
:	O
those	O
exposed	O
to	O
cocaine	I-Entity
and	O
those	O
not	O
exposed	O
to	O
cocaine	I-Entity
.	O

Infants	O
were	O
assigned	O
to	O
the	O
cocaine	I-Entity
-	O
exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	B-Entity
abuse	I-Entity
during	O
pregnancy	O
or	O
if	O
maternal	O
or	O
neonatal	O
urine	O
toxicology	O
results	O
were	O
positive	O
at	O
the	O
time	O
of	O
delivery	O
.	O

The	O
incidence	O
of	O
subependymal	B-Entity
cysts	I-Entity
in	O
the	O
117	O
remaining	O
infants	O
was	O
14%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
incidence	O
of	O
subependymal	B-Entity
cysts	I-Entity
in	O
infants	O
exposed	O
to	O
cocaine	I-Entity
prenatally	O
was	O
44%	O
(	O
8	O
of	O
18	O
)	O
compared	O
with	O
8%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexposed	O
group	O
(	O
p	O

We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	B-Entity
cyst	I-Entity
formation	O
in	O
preterm	B-Entity
infants	I-Entity
who	O
were	O
exposed	O
to	O
cocaine	I-Entity
prenatally	O
.	O



Thalidomide	I-Entity
neuropathy	I-Entity
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	B-Entity
cancer	I-Entity
.	O

We	O
prospectively	O
evaluated	O
thalidomide	I-Entity
-	O
induced	O
neuropathy	I-Entity
using	O
electrodiagnostic	O
studies	O
.	O

Sixty	O
-	O
seven	O
men	O
with	O
metastatic	O
androgen	I-Entity
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
in	O
an	O
open	O
-	O
label	O
trial	O
of	O
oral	O
thalidomide	I-Entity
underwent	O
neurologic	O
examinations	O
and	O
nerve	O
conduction	O
studies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3-month	O
intervals	O
during	O
treatment	O
.	O

Thalidomide	I-Entity
was	O
discontinued	O
in	O
55	O
patients	O
for	O
lack	O
of	O
therapeutic	O
response	O
.	O

Of	O
67	O
patients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidomide	I-Entity
for	O
3	O
months	O
,	O
8	O
remained	O
at	O
6	O
months	O
,	O
and	O
3	O
remained	O
at	O
9	O
months	O
.	O

Six	O
patients	O
developed	O
neuropathy	I-Entity
.	O

Neuropathy	I-Entity
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	I-Entity
in	O
older	O
patients	O
.	O

The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	B-Entity
neuropathy	I-Entity
,	O
but	O
not	O
for	O
early	O
detection	O
.	O



Overexpression	O
of	O
copper	I-Entity
/	O
zinc	I-Entity
-	O
superoxide	I-Entity
dismutase	O
protects	O
from	O
kanamycin	I-Entity
-	O
induced	O
hearing	B-Entity
loss	I-Entity
.	O

The	O
participation	O
of	O
reactive	O
oxygen	I-Entity
species	O
in	O
aminoglycoside	I-Entity
-	O
induced	O
ototoxicity	I-Entity
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside	I-Entity
-	O
iron	I-Entity
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	I-Entity
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	O
attenuate	O
ototoxicity	I-Entity
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu	I-Entity
/	O
Zn	I-Entity
-	O
superoxide	I-Entity
dismutase	O
(	O
h	O
-	O
SOD1	O
)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	I-Entity
.	O

Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	I-Entity
(	O
400	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
for	O
10	O
days	O
beginning	O
on	O
day	O
10	O
after	O
birth	O
.	O

In	O
nontransgenic	O
animals	O
,	O
the	O
threshold	O
in	O
the	O
kanamycin	I-Entity
-	O
treated	O
group	O
was	O
45	O
-	O
50	O
dB	O
higher	O
than	O
in	O
saline	O
-	O
injected	O
controls	O
.	O

In	O
the	O
transgenic	O
group	O
,	O
kanamycin	I-Entity
increased	O
the	O
threshold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
controls	O
.	O

The	O
protection	O
by	O
overexpression	O
of	O
superoxide	I-Entity
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	I-Entity
-	O
induced	O
ototoxicity	I-Entity
.	O



Prednisone	I-Entity
induces	O
anxiety	I-Entity
and	O
glial	O
cerebral	O
changes	O
in	O
rats	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisone	I-Entity
(	O
PDN	I-Entity
)	O
produces	O
anxiety	I-Entity
and/or	O
cerebral	O
glial	O
changes	O
in	O
rats	O
.	O

The	O
moderate	O
-	O
dose	O
group	O
received	O
5	O
mg	O
/	O
kg	O
/	O
day	O
PDN	I-Entity
released	O
from	O
a	O
subcutaneous	O
implant	O
.	O

In	O
the	O
high	O
-	O
dose	O
group	O
,	O
implants	O
containing	O
PDN	I-Entity
equivalent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
day	O
were	O
applied	O
.	O

In	O
the	O
control	O
group	O
implants	O
contained	O
no	O
PDN	I-Entity
.	O

Anxiety	I-Entity
was	O
assessed	O
using	O
an	O
open	O
field	O
and	O
elevated	O
plus	O
-	O
maze	O
devices	O
.	O

Anxiety	I-Entity
was	O
documented	O
in	O
both	O
groups	O
of	O
PDN	I-Entity
treated	O
rats	O
compared	O
with	O
controls	O
.	O

The	O
magnitude	O
of	O
transformation	O
of	O
the	O
microglia	O
assessed	O
by	O
the	O
number	O
of	O
intersections	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	I-Entity
groups	O
than	O
in	O
controls	O
in	O
the	O
prefrontal	O
cortex	O
(	O
moderate	O
-	O
dose	O
,	O
24.1	O
;	O
high	O
-	O
dose	O
,	O
23.6	O
;	O
controls	O
18.7	O
;	O

The	O
number	O
of	O
stained	O
microglia	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	I-Entity
treated	O
groups	O
in	O
the	O
prefrontal	O
cortex	O
than	O
in	O
controls	O
(	O
moderate	O
-	O
dose	O
,	O
29.1	O
;	O
high	O
-	O
dose	O
,	O
28.4	O
;	O
control	O
,	O
17.7	O
cells	O
per	O
field	O
;	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
:	O
Subacute	O
exposure	O
to	O
PDN	I-Entity
induced	O
anxiety	I-Entity
and	O
reactivity	O
of	O
microglia	O
.	O

The	O
relevance	O
of	O
these	O
features	O
for	O
patients	O
using	O
PDN	I-Entity
remains	O
to	O
be	O
elucidated	O
.	O



Phase	O
II	O
study	O
of	O
carboplatin	I-Entity
and	O
liposomal	O

doxorubicin	I-Entity
in	O
patients	O
with	O
recurrent	O
squamous	B-Entity
cell	I-Entity
carcinoma	I-Entity
of	I-Entity
the	I-Entity
cervix	I-Entity
.	O

The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	I-Entity
and	O
liposomal	O
doxorubicin	I-Entity
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	B-Entity
carcinoma	I-Entity
.	O

METHODS	O
:	O
The	O
combination	O
of	O
carboplatin	I-Entity
(	O
area	O
under	O
the	O
concentration	O
curve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
liposomal	O
doxorubicin	I-Entity
(	O
Doxil	I-Entity
;	O
starting	O
dose	O
,	O
40	O
mg	O
/	O
m(2	O
)	O
)	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	B-Entity
cell	I-Entity
cervical	I-Entity
carcinoma	I-Entity
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	I-Entity
profile	O
.	O

Twenty	O
-	O
nine	O
patients	O
were	O
assessable	O
for	O
response	O
,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	I-Entity
.	O

The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	I-Entity
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	I-Entity
in	O
16	O
patients	O
,	O
anemia	I-Entity
in	O
12	O
patients	O
,	O
thrombocytopenia	I-Entity
in	O
11	O
patients	O
,	O
and	O
neutropenic	B-Entity
fever	I-Entity
in	O
3	O
patients	O
.	O

Four	O
patients	O
had	O
five	O
infusion	O
-	O
related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	O
doxorubicin	I-Entity
,	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
three	O
patients	O
.	O

Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	I-Entity
included	O
nausea	I-Entity
in	O
17	O
patients	O
,	O
emesis	I-Entity
in	O
14	O
patients	O
,	O
fatigue	I-Entity
in	O
9	O
patients	O
,	O
mucositis	I-Entity
and/or	O
stomatitis	I-Entity
in	O
8	O
patients	O
,	O
constipation	I-Entity
in	O
6	O
patients	O
,	O
weight	B-Entity
loss	I-Entity
in	O
5	O
patients	O
,	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
in	O
2	O
patients	O
,	O
and	O
skin	B-Entity
reactions	I-Entity
in	O
3	O
patients	O
.	O

The	O
combination	O
of	O
carboplatin	I-Entity
and	O
liposomal	O

doxorubicin	I-Entity
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	B-Entity
carcinoma	I-Entity
.	O



Antimicrobial	O
-	O
induced	O
mania	I-Entity
(	O
antibiomania	I-Entity
)	O
:	O
a	O
review	O
of	O
spontaneous	O
reports	O
.	O

The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic	O
-	O
induced	O
manic	I-Entity
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic	O
-	O
induced	O
mania	I-Entity
.	O

Twenty	O
-	O
one	O
reports	O
of	O
antimicrobial	O
-	O
induced	O
mania	I-Entity
were	O
found	O
in	O
the	O
literature	O
.	O

There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	I-Entity
,	O
13	O
implicating	O
isoniazid	I-Entity
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	I-Entity
and	O
amoxicillin	I-Entity
.	O

Of	O
these	O
,	O
clarithromycin	I-Entity
was	O
implicated	O
in	O
23	O
(	O
27.6%	O
)	O
cases	O
,	O
ciprofloxacin	I-Entity
in	O
12	O
(	O
14.4%	O
)	O
cases	O
,	O
and	O
ofloxacin	I-Entity
in	O
10	O
(	O
12%	O
)	O
cases	O
.	O

Cotrimoxazole	I-Entity
,	O
metronidazole	I-Entity
,	O
and	O
erythromycin	I-Entity
were	O
involved	O
in	O
15	O
reported	O
manic	I-Entity
episodes	O
.	O

Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	I-Entity
and	O
ciprofloxacin	I-Entity
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	I-Entity
.	O

Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	I-Entity
while	O
being	O
treated	O
with	O
antimicrobials	O
.	O

Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial	O
-	O
induced	O
mania	I-Entity
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial	O
-	O
induced	O
manic	I-Entity
episode	O
among	O
various	O
demographic	O
populations	O
,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	O
disorders	O
once	O
the	O
initial	O
episode	O
,	O
which	O
occurs	O
while	O
the	O
patient	O
is	O
taking	O
antibiotics	O
,	O
subsides	O
.	O

The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	O
""""	O
antibiomania	I-Entity
.	O
""""	O



Levodopa	I-Entity
-	O
induced	O
ocular	B-Entity
dyskinesias	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Levodopa	I-Entity
-	O
induced	O
ocular	B-Entity
dyskinesias	I-Entity
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak	O
-	O
dose	O
choreatic	B-Entity
dyskinesias	I-Entity
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	I-Entity
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa	I-Entity
-	O
induce	O
ocular	B-Entity
dyskinesias	I-Entity
.	O



A	O
comparison	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
with	O
diclofenac	I-Entity
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	I-Entity
:	O
an	O
open	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
.	O

Primary	O
dysmenorrhea	I-Entity
is	O
a	O
syndrome	O
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	I-Entity
;	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatment	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
(	O
GTN	I-Entity
)	O
,	O
an	O
NO	I-Entity
donor	O
,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	I-Entity
in	O
comparison	O
with	O
diclofenac	I-Entity
(	O
DCF	I-Entity
)	O
.	O

A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	I-Entity
were	O
studied	O
during	O
two	O
consecutive	O
menstrual	O
cycles	O
.	O

cross	O
-	O
over	O
,	O
controlled	O
design	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	I-Entity
per	O
os	O
or	O
GTN	I-Entity
patches	O
the	O
first	O
days	O
of	O
menses	O
,	O
when	O
menstrual	O
cramps	O
became	O
unendurable	O
.	O

Patients	O
received	O
up	O
to	O
3	O
doses	O
/	O
day	O
of	O
50	O
mg	O
DCF	I-Entity
or	O
2.5	O
mg/24	O

h	O
transdermal	O
GTN	I-Entity
for	O
the	O
first	O
3	O
days	O
of	O
the	O
cycle	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
difference	O
in	O
pain	I-Entity
intensity	O
score	O
(	O
DPI	O
)	O
was	O
the	O
main	O
outcome	O
variable	O
.	O

Both	O
treatments	O
significantly	O
reduced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	I-Entity
,	O
-12.8	O

DCF	I-Entity
,	O
-18.9	O

However	O
,	O
DCF	I-Entity
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	B-Entity
pain	I-Entity
for	O
two	O
hours	O
,	O
whereas	O
GTN	I-Entity
scores	O
remained	O
more	O
or	O
less	O
stable	O
after	O
30	O
min	O
and	O
significantly	O
higher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O

GTN	I-Entity
,	O
-12.8	O

16.6	O
and	O
after	O
two	O
hours	O
:	O
GTN	I-Entity
,	O
-23.7	O

Low	B-Entity
back	I-Entity
pain	I-Entity
was	O
also	O
relieved	O
by	O
both	O
drugs	O
.	O

Headache	I-Entity
was	O
significantly	O
increased	O
by	O
GTN	I-Entity
but	O
not	O
by	O
DCF	I-Entity
.	O

Eight	O
patients	O
stopped	O
using	O
GTN	I-Entity
because	O
headache	I-Entity
--	O
attributed	O
to	O
its	O
use	O
--	O
became	O
intolerable	O
.	O

These	O
findings	O
indicate	O
that	O
GTN	I-Entity
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	I-Entity
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	I-Entity
.	O



Temocapril	I-Entity
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	I-Entity
converting	O
enzyme	O
inhibitor	O
,	O
modulates	O
glomerular	B-Entity
injury	I-Entity
in	O
chronic	O
puromycin	B-Entity
aminonucleoside	I-Entity
nephrosis	I-Entity
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	I-Entity
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	I-Entity
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
reduced	O
proteinuria	I-Entity
,	O
inhibited	O
glomerular	O
hypertrophy	I-Entity
and	O
prevented	O
glomerulosclerosis	I-Entity
in	O
chronic	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
)	O
-	O
induced	O
nephrotic	I-Entity
rats	O
.	O

Nephrosis	I-Entity
was	O
induced	O
by	O
injection	O
of	O
PAN	I-Entity
(	O
15mg/100	O
g	O
body	O
weight	O
)	O
in	O
male	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

Four	O
groups	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	I-Entity
group	O
(	O
14	O
)	O
,	O
ii	O
)	O

PAN	I-Entity
/	O
temocapril	I-Entity
(	O
13	O
)	O
,	O
iii	O
)	O
temocapril	I-Entity
(	O
14	O
)	O
and	O
iv	O
)	O
untreated	O
controls	O
(	O
15	O
)	O
.	O

Temocapril	I-Entity
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O

Systolic	O
BP	O
in	O
the	O
PAN	I-Entity
group	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN	I-Entity
/	O
temocapril	I-Entity
group	O
.	O

Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	I-Entity
group	O
increased	O
significantly	O
,	O
peaking	O
at	O
8	O
days	O
,	O
then	O
decreased	O
at	O
4	O
weeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weeks	O
.	O

Temocapril	I-Entity
did	O
not	O
attenuate	O
proteinuria	I-Entity
at	O
8	O
days	O
,	O
but	O
it	O
did	O
markedly	O
lower	O
it	O
from	O
weeks	O
4	O
to	O
20	O
.	O

The	O
glomerulosclerosis	I-Entity
index	O
(	O
GSI	O
)	O
was	O
6.21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25.35	O
%	O
and	O
30.49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	I-Entity
group	O
.	O

The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
's	O
capsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	I-Entity
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	I-Entity
/	O
temocapril	I-Entity
group	O
.	O

It	O
appears	O
that	O
temocapril	I-Entity
was	O
effective	O
in	O
retarding	O
renal	O
progression	O
and	O
protected	O
renal	O
function	O
in	O
PAN	I-Entity
neprotic	I-Entity
rats	O
.	O



Pulmonary	B-Entity
hypertension	I-Entity
after	O
ibuprofen	I-Entity
prophylaxis	O
in	O
very	O
preterm	O
infants	O
.	O

We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	I-Entity
after	O
ibuprofen	I-Entity
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	B-Entity
ductus	I-Entity
arteriosus	I-Entity
with	O
ibuprofen	I-Entity
in	O
premature	O
infants	O
born	O
at	O
less	O
than	O
28	O
weeks	O
of	O
gestation	O
.	O

Hypoxaemia	I-Entity
resolved	O
quickly	O
on	O
inhaled	O
nitric	B-Entity
oxide	I-Entity
therapy	O
.	O

We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	I-Entity
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	I-Entity
.	O



Hyponatremia	I-Entity
and	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
anti	I-Entity
-	I-Entity
diuretic	I-Entity
hormone	I-Entity
reported	O
with	O
the	O
use	O
of	O
Vincristine	I-Entity
:	O
an	O
over	O
-	O
representation	O
of	O
Asians	O
?	O

This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company	O
's	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	I-Entity
and/or	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
secretion	I-Entity
of	I-Entity
anti	I-Entity
-	I-Entity
diuretic	I-Entity
hormone	I-Entity
(	O
SIADH	I-Entity
)	O
among	O
vincristine	I-Entity
-	O
treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
risk	O
population	O
subgroups	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
's	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	I-Entity
and/or	O
SIADH	I-Entity
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	I-Entity
.	O

A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	I-Entity
and/or	O
SIADH	I-Entity
associated	O
with	O
vincristine	I-Entity
use	O
were	O
identified	O
.	O

Approximately	O
75%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	I-Entity
or	O
lymphoma	I-Entity
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
hyponatremia	I-Entity
and/or	O
SIADH	I-Entity
associated	O
with	O
vincristine	I-Entity
use	O
.	O

Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	I-Entity
associated	O
with	O
vincristine	I-Entity
is	O
very	O
low	O
,	O
physicians	O
caring	O
for	O
Asian	O
oncology	O
patients	O
should	O
be	O
aware	O
of	O
this	O
potential	O
serious	O
but	O
reversible	O
adverse	O
event	O
.	O



Delayed	O
toxicity	I-Entity
of	O
cyclophosphamide	I-Entity
on	O
the	O
bladder	O
of	O
DBA/2	O
and	O
C57BL/6	O
female	O
mouse	O
.	O

The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA/2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL/6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dose	O
of	O
cyclophosphamide	I-Entity
(	O
CY	I-Entity
)	O
.	O

Inbred	O
DBA/2	O
and	O
C57BL/6	O
female	O
mice	O
were	O
injected	O
with	O
CY	I-Entity
,	O
and	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
bladder	O
was	O
assessed	O
during	O
100	O
days	O
by	O
light	O
microscopy	O
using	O
different	O
staining	O
procedures	O
,	O
and	O
after	O
30	O
days	O
by	O
conventional	O
electron	O
microscopy	O
.	O

Early	O
CY	I-Entity
toxicity	I-Entity
caused	O
a	O
typical	O
haemorrhagic	I-Entity
cystitis	I-Entity
in	O
both	O
strains	O
that	O
was	O
completely	O
repaired	O
in	O
about	O
7	O
-	O
10	O
days	O
.	O

After	O
30	O
days	O
of	O
CY	I-Entity
injection	O
ulcerous	O
and	O
non	O
-	O
ulcerous	O
forms	O
of	O
chronic	O
cystitis	I-Entity
appeared	O
in	O
86%	O
of	O
DBA/2	O
mice	O
but	O
only	O
in	O
4%	O
of	O
C57BL/6	O
mice	O
.	O

Delayed	O
cystitis	I-Entity
was	O
characterized	O
by	O
infiltration	O
and	O
transepithelial	O
passage	O
into	O
the	O
lumen	O
of	O
inflammatory	O
cells	O
and	O
by	O
frequent	O
exfoliation	O
of	O
the	O
urothelium	O
.	O

Delayed	O
cystitis	I-Entity
still	O
persisted	O
in	O
DBA/2	O
mice	O
100	O
days	O
after	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
delayed	O
toxicity	I-Entity
of	O
CY	I-Entity
in	O
female	O
DBA/2	O
mice	O
causes	O
a	O
bladder	O
pathology	O
that	O
is	O
not	O
observed	O
in	O
C57BL/6	O
mice	O
.	O

This	O
pathology	O
resembles	O
interstitial	B-Entity
cystitis	I-Entity
in	O
humans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animal	O
model	O
for	O
studies	O
on	O
the	O
disease	O
.	O



High	O
-	O
dose	O
5-fluorouracil	I-Entity
/	O
folinic	B-Entity
acid	I-Entity
in	O
combination	O
with	O
three	O
-	O
weekly	O
mitomycin	B-Entity
C	I-Entity
in	O
the	O
treatment	O
of	O
advanced	O
gastric	B-Entity
cancer	I-Entity
.	O

BACKGROUND	O
:	O
The	O
24-hour	O
continuous	O
infusion	O
of	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
and	O
folinic	B-Entity
acid	I-Entity
(	O
FA	I-Entity
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	B-Entity
cancer	I-Entity
(	O
AGC	I-Entity
)	O
has	O
shown	O
to	O
be	O
effective	O
,	O
with	O
low	O
toxicity	I-Entity
.	O

In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3-weekly	O
bolus	O
5-FU	I-Entity
,	O
FA	I-Entity
and	O
mitomycin	B-Entity
C	I-Entity
(	O
MMC	I-Entity
)	O
we	O
found	O
a	O
low	O
toxicity	I-Entity
rate	O
and	O
response	O
rates	O
comparable	O
to	O
those	O
of	O
regimens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
median	O
overall	O
survival	O
.	O

In	O
order	O
to	O
improve	O
this	O
MMC	I-Entity
-	O
dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high	O
-	O
dose	O
5-FU	I-Entity
/	O
FA	I-Entity
and	O
3-weekly	O
bolus	O
MMC	I-Entity
.	O

From	O
February	O
,	O
1998	O
to	O
September	O
,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	I-Entity
to	O
receive	O
weekly	O
24-hour	O
5-FU	I-Entity
2,600	O
mg	O
/	O
m(2	O
)	O
preceded	O
by	O
2-hour	O
FA	I-Entity
500	O
mg	O
/	O
m(2	O
)	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
.	O

MMC	I-Entity
10	O
mg	O
/	O
m(2	O
)	O
was	O
added	O
in	O
3-weekly	O
intervals	O
.	O

18	O
patients	O
had	O
a	O
primary	O
AGC	I-Entity
,	O
and	O
15	O
showed	O
a	O
relapsed	O
AGC	I-Entity
.	O

The	O
worst	O
toxicities	I-Entity
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1/2/3	O
)	O
:	O

leukopenia	I-Entity
45.5/18.2/6.1	O
,	O
thrombocytopenia	I-Entity
33.3/9.1/6.1	O
,	O
vomitus	I-Entity
24.2/9.1/0	O
,	O
diarrhea	I-Entity
36.4/6.1/3.0	O
,	O
stomatitis	I-Entity
18.2/9.1/0	O
,	O
hand	B-Entity
-	I-Entity
foot	I-Entity
syndrome	I-Entity
12.1/0/0	O
.	O

Two	O
patients	O
developed	O
hemolytic	B-Entity
-	I-Entity
uremic	I-Entity
syndrome	I-Entity
(	O
HUS	I-Entity
)	O
.	O

High	O
-	O
dose	O
5-FU	I-Entity
/	O
FA	I-Entity
/	O
MMC	I-Entity
is	O
an	O
effective	O
and	O
well	O
-	O
tolerated	O
outpatient	O
regimen	O
for	O
AGC	I-Entity
(	O
objective	O
response	O
rate	O
54.6%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	I-Entity
-	O
containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	I-Entity
may	O
occur	O
.	O



Persistent	O
sterile	O
leukocyturia	I-Entity
is	O
associated	O
with	O
impaired	B-Entity
renal	I-Entity
function	I-Entity
in	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
type	I-Entity
1-infected	I-Entity
children	O
treated	O
with	O
indinavir	I-Entity
.	O

BACKGROUND	O
:	O
Prolonged	O
administration	O
of	O
indinavir	I-Entity
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	O
complications	O
in	O
adults	O
.	O

A	O
prospective	O
study	O
to	O
monitor	O
indinavir	I-Entity
-	O
related	O
nephrotoxicity	I-Entity
in	O
a	O
cohort	O
of	O
30	O
human	B-Entity
immunodeficiency	I-Entity
virus	I-Entity
type	I-Entity
1-infected	I-Entity
children	O
treated	O
with	O
indinavir	I-Entity
.	O

METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	I-Entity
,	O
the	O
presence	O
of	O
erythrocytes	O
,	O
leukocytes	O
,	O
bacteria	O
and	O
crystals	O
,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks	O
.	O

Serum	O
creatinine	I-Entity
levels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
time	O
points	O
.	O

Steady	O
-	O
state	O
pharmacokinetics	O
of	O
indinavir	I-Entity
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	I-Entity
.	O

The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	I-Entity
(	O
>	O
or	O
=	O
75	O
cells/	O
micro	O
L	O
in	O
at	O
least	O
2	O
consecutive	O
visits	O
)	O
after	O
96	O
weeks	O
was	O
53%	O
.	O

Persistent	O
sterile	O
leukocyturia	I-Entity
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	O
albumin	O
/	O
creatinine	I-Entity
ratio	O
and	O
by	O
microscopic	O
hematuria	I-Entity
.	O

The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	I-Entity
levels	O
>	O
50%	O
above	O
normal	O
was	O
33%	O
after	O
96	O
weeks	O
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	I-Entity
more	O
frequently	O
had	O
serum	O
creatinine	I-Entity
levels	O
of	O
50%	O
above	O
normal	O
than	O
those	O
children	O
without	O
persistent	O
sterile	O
leukocyturia	I-Entity
.	O

In	O
children	O
younger	O
than	O
5.6	O
years	O
,	O
persistent	O
sterile	O
leukocyturia	I-Entity
was	O
significantly	O
more	O
frequent	O
than	O
in	O
older	O
children	O
.	O

A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	I-Entity
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	I-Entity
>	O
12	O
mg	O

In	O
4	O
children	O
,	O
indinavir	I-Entity
was	O
discontinued	O
because	O
of	O
nephrotoxicity	I-Entity
.	O

Subsequently	O
,	O
the	O
serum	O
creatinine	I-Entity
levels	O
decreased	O
,	O
the	O
urine	O
albumin	O
/	O
creatinine	I-Entity
ratios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyturia	I-Entity
disappeared	O
within	O
3	O
months	O
.	O

Children	O
treated	O
with	O
indinavir	I-Entity
have	O
a	O
high	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	I-Entity
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	I-Entity
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	I-Entity
levels	O
of	O
>	O
50%	O
above	O
normal	O
.	O

The	O
impairment	B-Entity
of	I-Entity
the	I-Entity
renal	I-Entity
function	I-Entity
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	I-Entity
.	O

Indinavir	I-Entity
-	O
associated	O
nephrotoxicity	I-Entity
must	O
be	O
monitored	O
closely	O
,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	I-Entity
,	O
age	O

<	O
5.6	O
years	O
,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	I-Entity
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C(max	O
)	O



Utility	O
of	O
troponin	O
I	O
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
.	O

Baseline	O
electrocardiogram	O
abnormalities	O
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	B-Entity
necrosis	I-Entity
make	O
accurate	O
diagnosis	O
of	O
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
difficult	O
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	I-Entity
chest	B-Entity
pain	I-Entity
admitted	O
for	O
exclusion	O
of	O
MI	I-Entity
.	O

Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	I-Entity
after	O
cocaine	I-Entity
use	O
.	O

All	O
patients	O
underwent	O
a	O
rapid	O
rule	O
-	O
in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	I-Entity
kinase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O

Outcomes	O
included	O
CK	O
-	O
MB	O
MI	I-Entity
(	O
CK	O
-	O
MB	O

>	O
or=	O
4	O
,	O
cardiac	B-Entity
death	I-Entity
,	O
and	O
significant	O
coronary	B-Entity
disease	I-Entity
(	O
>	O
or=50%	O
)	O
.	O

Of	O
the	O
246	O
admitted	O
patients	O
,	O
34	O
(	O
14%	O
)	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	I-Entity
and	O
38	O
(	O
16%	O
)	O

Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	O
who	O
had	O
cTnI	O
elevations	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	I-Entity
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
level	O
of	O
13	O
ng	O
/	O
mL.	O
Sensitivities	O
,	O
specificities	O
,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	B-Entity
death	I-Entity
or	O
significant	O
disease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	I-Entity
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	I-Entity
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease	O
.	O

Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK	O
-	O
MB	O
for	O
diagnosing	O
necrosis	I-Entity
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
and	O
suspected	O
MI	I-Entity
.	O



Acute	O
interstitial	B-Entity
nephritis	I-Entity
due	O
to	O
nicergoline	I-Entity
(	O
Sermion	I-Entity
)	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
(	O
AIN	I-Entity
)	O
due	O
to	O
nicergoline	I-Entity
(	O
Sermion	I-Entity
)	O
.	O

A	O
50-year	O
-	O
old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	I-Entity
and	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	I-Entity
and	O
bendazac	B-Entity
lysine	I-Entity
due	O
to	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
at	O
ophthalmologic	O
department	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fever	I-Entity
and	O
skin	B-Entity
rash	I-Entity
.	O

On	O
admission	O
,	O
clinical	O
symptoms	O
(	O
i.e.	O
arthralgia	I-Entity
and	O
fever	I-Entity
)	O
and	O
laboratory	O
findings	O
(	O
i.e.	O
eosinophilia	I-Entity
and	O
renal	B-Entity
failure	I-Entity
)	O
suggested	O
AIN	I-Entity
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy	O
.	O

A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	I-Entity
.	O

Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	I-Entity
and	O
intravenous	O
methylprednisolone	I-Entity
,	O
and	O
his	O
renal	O
function	O
was	O
completely	O
recovered	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline	I-Entity
-	O
associated	O
AIN	I-Entity
.	O



Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
complicated	O
by	O
massive	O
intestinal	O
bleeding	I-Entity
in	O
a	O
patient	O
with	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
.	O

A	O
patient	O
with	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
(	O
CRF	I-Entity
)	O
developed	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
(	O
NMS	I-Entity
)	O
after	O
administration	O
of	O
risperidone	I-Entity
and	O
levomepromazine	I-Entity
.	O

In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	I-Entity
,	O
massive	O
intestinal	O
bleeding	I-Entity
was	O
observed	O
during	O
the	O
episode	O
.	O

This	O
report	O
suggests	O
that	O
NMS	I-Entity
in	O
a	O
patient	O
with	O
CRF	I-Entity
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	I-Entity
and	O
needs	O
special	O
caution	O
for	O
this	O
complication	O
.	O



Adrenaline	I-Entity
-	O
induced	O
hypertension	I-Entity
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	I-Entity
(	O
TTC	I-Entity
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	I-Entity
for	O
30	O
s.	O

In	O
normal	O
rats	O
,	O
the	O
whole	O
brain	O
sections	O
exhibited	O
complete	O
staining	O
with	O
TTC	I-Entity
.	O

After	O
adrenaline	I-Entity
infusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstained	O
areas	O
in	O
the	O
left	O
brain	O
in	O
right	O
-	O
pawed	O
animals	O
,	O
and	O
vice	O
versa	O
in	O
left	O
-	O
pawed	O
animals	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
seizure	I-Entity
-	O
induced	O
breakdown	O
of	O
BBB	O
.	O



Carvedilol	I-Entity
protects	O
against	O
doxorubicin	I-Entity
-	O
induced	O
mitochondrial	O
cardiomyopathy	I-Entity
.	O

Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose	O
-	O
limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	I-Entity
caused	O
by	O
doxorubicin	I-Entity
.	O

Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	B-Entity
dysfunction	I-Entity
are	O
key	O
factors	O
in	O
the	O
pathogenic	O
process	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	I-Entity
,	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties	O
,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	I-Entity
toxicity	I-Entity
.	O

Heart	O
and	O
liver	O
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	I-Entity
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
)	O
,	O
carvedilol	I-Entity
(	O
1	O
mg	O
/	O
kg	O
ip	O
/	O
week	O
)	O
,	O
or	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
.	O

Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin	I-Entity
-	O
treated	O
rats	O
exhibited	O
depressed	O
rates	O
for	O
state	O
3	O
respiration	O
(	O
336	O
+	O
/-	O

Mitochondrial	O
calcium	I-Entity
-	O
loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH	O
-	O
dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin	I-Entity
-	O
treated	O
rats	O
.	O

Doxorubicin	I-Entity
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	O
mitochondria	O
(	O
3.9	O
+	O
/-	O

Coadministration	O
of	O
carvedilol	I-Entity
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	I-Entity
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Carvedilol	I-Entity
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca(2	I-Entity
+	O
)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	I-Entity
.	O

Carvedilol	I-Entity
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	O
mitochondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	I-Entity
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose	O
-	O
limiting	O
mitochondrial	B-Entity
dysfunction	I-Entity
and	O
cardiomyopathy	I-Entity
that	O
accompanies	O
long	O
-	O
term	O
doxorubicin	I-Entity
therapy	O
in	O
cancer	I-Entity
patients	O
.	O



Cocaine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
is	O
more	O
influenced	O
by	O
adenosine	I-Entity
receptor	O
agonists	O
than	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O

The	O
influence	O
of	O
adenosine	I-Entity
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine	I-Entity
-	O
and	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
was	O
examined	O
in	O
mice	O
.	O

All	O
adenosine	I-Entity
receptor	O
agonists	O
significantly	O
decreased	B-Entity
the	I-Entity
locomotor	I-Entity
activity	I-Entity
in	O
mice	O
,	O
and	O
the	O
effects	O
were	O
dose	O
-	O
dependent	O
.	O

It	O
seems	O
that	O
adenosine	I-Entity
A1	O
and	O
A2	O
receptors	O
might	O
be	O
involved	O
in	O
this	O
reaction	O
.	O

Moreover	O
,	O
all	O
adenosine	I-Entity
receptor	O
agonists	O
:	O
2-p-(2-carboxyethyl)phenethylamino-5'-N	B-Entity
-	I-Entity
ethylcarboxamidoadenosine	I-Entity
(	O
CGS	B-Entity
21680	I-Entity
)	O
,	O

A2A	O
receptor	O
agonist	O
,	O
N6-cyclopentyladenosine	I-Entity
(	O
CPA	I-Entity
)	O
,	O
A1	O
receptor	O
agonist	O
,	O
and	O
5'-N	B-Entity
-	I-Entity
ethylcarboxamidoadenosine	I-Entity
(	O
NECA	I-Entity
)	O
,	O
A2/A1	O
receptor	O
agonist	O
significantly	O
and	O
dose	O
-	O
dependently	O
decreased	O
cocaine	I-Entity
-	O
induced	O
locomotor	O
activity	O
.	O

CPA	I-Entity
reduced	O
cocaine	I-Entity
action	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	B-Entity
21680	I-Entity
and	O
NECA	I-Entity
decreased	O
the	O
action	O
of	O
cocaine	I-Entity
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
decreased	O
locomotor	O
activity	O
in	O
animals	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	I-Entity
receptors	O
in	O
the	O
action	O
of	O
cocaine	I-Entity
although	O
agonists	O
of	O
A1	O
receptors	O
seem	O
to	O
have	O
stronger	O
influence	O
on	O
it	O
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	I-Entity
receptor	O
by	O
DMPX	I-Entity
(	O
3,7-dimethyl-1-propargylxanthine	I-Entity
)	O
significantly	O
enhanced	O
cocaine	I-Entity
-	O
induced	O
locomotor	O
activity	O
of	O
animals	O
.	O

Caffeine	I-Entity
had	O
similar	O
action	O
but	O
the	O
effect	O
was	O
not	O
significant	O
.	O

CPT	I-Entity
(	O
8-cyclopentyltheophylline)--A1	I-Entity
receptor	O
antagonist	O
,	O
did	O
not	O
show	O
any	O
influence	O
in	O
this	O
test	O
.	O

Similarly	O
,	O
all	O
adenosine	I-Entity
receptor	O
agonists	O
decreased	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
,	O
but	O
at	O
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	I-Entity
receptors	O
(	O
DMPX	I-Entity
)	O
and	O
non	O
-	O
selective	O
blockade	O
of	O
adenosine	I-Entity
receptors	O
(	O
caffeine	I-Entity
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	I-Entity
in	O
the	O
locomotor	O
activity	O
test	O
.	O

Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	I-Entity
receptor	O
agonists	O
(	O
A1	O
and	O
A2	O
)	O
reduce	O
cocaine-	I-Entity
and	O
amphetamine	I-Entity
-	O
induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
is	O
more	O
influenced	O
by	O
adenosine	I-Entity
receptor	O
agonists	O
(	O
particularly	O
A1	O
receptors	O
)	O
than	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O



Amiodarone	I-Entity
and	O
the	O
risk	O
of	O
bradyarrhythmia	I-Entity
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	B-Entity
fibrillation	I-Entity
and	O
prior	O
myocardial	B-Entity
infarction	I-Entity
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	I-Entity
in	O
patients	O
with	O
atrial	B-Entity
fibrillation	I-Entity
(	O
AF	I-Entity
)	O
increases	O
the	O
risk	O
of	O
bradyarrhythmia	I-Entity
requiring	O
a	O
permanent	O
pacemaker	O
.	O

Reports	O
of	O
severe	O
bradyarrhythmia	I-Entity
during	O
amiodarone	I-Entity
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy	O
's	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	B-Entity
arrhythmias	I-Entity
.	O

METHODS	O
:	O
A	O
study	O
cohort	O
of	O
8,770	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	I-Entity
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
nested	O
case	O
-	O
control	O
design	O
,	O
477	O
cases	O
of	O
bradyarrhythmia	I-Entity
requiring	O
a	O
permanent	O
pacemaker	O
were	O
matched	O
(	O
1:4	O
)	O
to	O
1,908	O
controls	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	I-Entity
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	I-Entity
,	O

Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	I-Entity
channel	O
blockers	O
,	O
and	O
digoxin	I-Entity
.	O

RESULTS	O
:	O
amiodarone	I-Entity
use	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
2.14	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.30	O
to	O
3.54	O
)	O
.	O

Digoxin	I-Entity
was	O
the	O
only	O
other	O
medication	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
1.78	O
,	O
95%	O
CI	O
:	O
1.37	O
to	O
2.31	O
)	O
.	O

This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	I-Entity
in	O
elderly	O
patients	O
with	O
AF	I-Entity
and	O
a	O
previous	O
MI	I-Entity
increases	O
the	O
risk	O
of	O
bradyarrhythmia	I-Entity
requiring	O
a	O
permanent	O
pacemaker	O
.	O

The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	I-Entity
requires	O
further	O
investigation	O
.	O



Indomethacin	I-Entity
-	O
induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	O
bladder	O
epithelium	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	I-Entity
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	I-Entity
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
condition	O
.	O

In	O
addition	O
to	O
tiaprofenic	B-Entity
acid	I-Entity
,	O
indomethacin	I-Entity
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
condition	O
.	O

Three	O
groups	O
were	O
established	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	I-Entity
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oral	O
indomethacin	I-Entity
was	O
administered	O
3.25	O
mg	O
/	O
kg	O
body	O
weight	O
daily	O
for	O
3	O
weeks	O
.	O

When	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
indomethacin	I-Entity
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
penetration	O
of	O
lanthanum	B-Entity
nitrate	I-Entity
through	O
intercellular	O
areas	O
of	O
the	O
epithelium	O
.	O

Indomethacin	I-Entity
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	B-Entity
cystitis	I-Entity
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	I-Entity
.	O

The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	I-Entity
in	O
humans	O
must	O
be	O
clarified	O
by	O
prospective	O
clinical	O
trials	O
.	O



An	O
open	O
-	O
label	O
phase	O
II	O
study	O
of	O
low	O
-	O
dose	O
thalidomide	I-Entity
in	O
androgen	I-Entity
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
.	O

The	O
antiangiogenic	O
effects	O
of	O
thalidomide	I-Entity
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	B-Entity
malignancies	I-Entity
.	O

Thalidomide	I-Entity
blocks	O
the	O
activity	O
of	O
angiogenic	O
agents	O
including	O
bFGF	O
,	O
VEGF	O
and	O
IL-6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
label	O
study	O
using	O
thalidomide	I-Entity
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen	I-Entity
-	O
independent	O
prostate	B-Entity
cancer	I-Entity
.	O

Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
,	O
urea	I-Entity
and	O
electrolytes	O
,	O
serum	O
bFGF	O
and	O
VEGF	O
.	O

Adverse	O
effects	O
included	O
constipation	I-Entity
,	O
morning	O
drowsiness	I-Entity
,	O
dizziness	I-Entity
and	O
rash	I-Entity
,	O
and	O
resulted	O
in	O
withdrawal	O
from	O
the	O
study	O
by	O
three	O
men	O
.	O

Evidence	O
of	O
peripheral	B-Entity
sensory	I-Entity
neuropathy	I-Entity
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treatment	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	I-Entity
,	O
subclinical	O
evidence	O
of	O
peripheral	B-Entity
neuropathy	I-Entity
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing	O
.	O

The	O
findings	O
indicate	O
that	O
thalidomide	I-Entity
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	B-Entity
neuropathy	I-Entity
.	O



Central	B-Entity
nervous	I-Entity
system	I-Entity
toxicity	I-Entity
following	O
the	O
administration	O
of	O
levobupivacaine	I-Entity
for	O
lumbar	O
plexus	O
block	O
:	O

Central	B-Entity
nervous	I-Entity
system	I-Entity
and	I-Entity
cardiac	I-Entity
toxicity	I-Entity
following	O
the	O
administration	O
of	O
local	O
anesthetics	O
is	O
a	O
recognized	O
complication	O
of	O
regional	O
anesthesia	O
.	O

Levobupivacaine	I-Entity
,	O
the	O
pure	O
S(-	O
)	O

enantiomer	O
of	O
bupivacaine	I-Entity
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	I-Entity
.	O

We	O
describe	O
2	O
cases	O
of	O
grand	B-Entity
mal	I-Entity
seizures	I-Entity
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	I-Entity
.	O

Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	I-Entity
0.5%	O
with	O
epinephrine	I-Entity
2.5	O
microgram	O
/	O
mL	O
,	O
the	O
patients	O
developed	O
grand	B-Entity
mal	I-Entity
seizures	I-Entity
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	I-Entity
administration	O
.	O

The	O
seizures	I-Entity
were	O
successfully	O
treated	O
with	O
sodium	B-Entity
thiopental	I-Entity
in	O
addition	O
to	O
succinylcholine	I-Entity
in	O
1	O
patient	O
.	O

Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	B-Entity
toxicity	I-Entity
.	O

Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta	O
-	O
adrenergic	O
antagonist	O
medications	O
,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	I-Entity
with	O
epinephrine	I-Entity
.	O

Although	O
levobupivacaine	I-Entity
may	O
have	O
a	O
safer	O
cardiac	B-Entity
toxicity	I-Entity
profile	O
than	O
racemic	O
bupivacaine	I-Entity
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	I-Entity
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	I-Entity
.	O

Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	B-Entity
nervous	I-Entity
system	I-Entity
toxicity	I-Entity
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	B-Entity
toxicity	I-Entity
in	O
these	O
2	O
patients	O
.	O



Anaesthetic	O
complications	O
associated	O
with	O
myotonia	B-Entity
congenita	I-Entity
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	B-Entity
disorders	I-Entity
.	O

Myotonia	B-Entity
congenita	I-Entity
(	O
MC	I-Entity
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	I-Entity
channel	O
function	O
,	O
which	O
may	O
cause	O
sustained	B-Entity
membrane	I-Entity
depolarisation	I-Entity
.	O

We	O
describe	O
a	O
previously	O
healthy	O
32-year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
life	O
-	O
threatening	O
muscle	B-Entity
spasm	I-Entity
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	I-Entity
.	O

The	O
muscle	B-Entity
spasms	I-Entity
disappeared	O
spontaneously	O
and	O
the	O
surgery	O
proceeded	O
without	O
further	O
problems	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symptoms	O
suggesting	O
a	O
myotonic	B-Entity
condition	I-Entity
.	O

Myotonia	I-Entity
was	O
found	O
on	O
clinical	O
examination	O
and	O
EMG	O
.	O

The	O
diagnosis	O
MC	I-Entity
was	O
confirmed	O
genetically	O
.	O

We	O
give	O
a	O
brief	O
overview	O
of	O
ion	B-Entity
channel	I-Entity
disorders	I-Entity
including	O
malignant	B-Entity
hyperthermia	I-Entity
and	O
their	O
anaesthetic	O
considerations	O
.	O



Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	I-Entity
.	O

Apnea	I-Entity
is	O
known	O
to	O
occur	O
during	O
seizures	I-Entity
,	O
but	O
systematic	O
studies	O
of	O
ictal	O
respiratory	O
changes	O
in	O
adults	O
are	O
few	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine	I-Entity
-	O
induced	O
epilepsy	I-Entity
.	O

METHODS	O
:	O
Twelve	O
rats	O
(	O
six	O
chronically	O
epileptic	I-Entity
animals	O
and	O
six	O
controls	O
)	O
were	O
anesthetized	O
,	O
given	O
tracheotomies	O
,	O
and	O
subjected	O
to	O
hyperventilation	I-Entity
or	O
hypoventilation	O
conditions	O
.	O

The	O
hyperventilation	I-Entity
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine	I-Entity
-	O
treated	O
and	O
control	O
rats	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups	O
,	O
in	O
the	O
epileptic	I-Entity
group	O
,	O
the	O
decrease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
increase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
control	O
animals	O
.	O

In	O
the	O
epileptic	I-Entity
group	O
,	O
the	O
increase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decrease	O
in	O
TE	O
peak	O
compared	O
with	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
indicate	O
that	O
pilocarpine	I-Entity
-	O
treated	O
animals	O
have	O
an	O
altered	O
ability	O
to	O
react	O
to	O
(	O
or	O
compensate	O
for	O
)	O
blood	O
gas	O
changes	O
with	O
changes	O
in	O
ventilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy	I-Entity
-	O
associated	O
conditions	O
.	O



Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
due	O
to	O
paracetamol	I-Entity
overdose	I-Entity
.	O

Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas	O
/	O
Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

METHODOLOGY	O
:	O
Serum	O
levels	O
of	O
sFas	O
(	O
soluble	O
Fas	O
)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
and	O
10	O
normal	O
control	O
subjects	O
.	O

Serum	O
levels	O
of	O
tumor	I-Entity
necrosis	I-Entity
factor	O
-	O
alpha	O
and	O
interferon	O
-	O
gamma	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O

Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
(	O
median	O
,	O
26.8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.9	O
-	O
52.7	O
U	O
/	O
mL	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
median	O
,	O
8.6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.5	O
-	O
12.0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
due	O
to	O
paracetamol	I-Entity
overdose	I-Entity
(	O
median	O
,	O
28.7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12.8	O
-	O
52.7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepatitis	I-Entity
(	O
median	O
,	O
12.5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6.9	O
-	O
46.0	O
U	O
/	O
mL	O
,	O

A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	I-Entity
aminotransferase	O
(	O
r	O
=	O
0.613	O
,	O
P	O
<	O
0.01	O
)	O
.	O

The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
may	O
reflect	O
activation	O
of	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
liver	O
and	O
this	O
together	O
with	O
increased	O
tumor	I-Entity
necrosis	I-Entity
factor	O
-	O
alpha	O
may	O
be	O
an	O
important	O
factor	O
in	O
liver	O
cell	O
loss	O
.	O



Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	O
and	O
symptoms	O
of	O
advanced	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
patients	O
suffering	O
from	O
severe	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity

(	O
Stages	O
III	O
-	O
V	O
on	O
Hoehn	O
and	O
Yahr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinesia	I-Entity
,	O
rigidity	I-Entity
,	O
and	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
underwent	O
bilateral	O
implantation	O
of	O
electrodes	O
in	O
the	O
STN	O
.	O

Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
follow	O
-	O
up	O
,	O
in	O
""""	O
on	O
""""	O
and	O
""""	O
off	O
""""	O
drug	O
conditions	O
,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
,	O
Hoehn	O
and	O
Yahr	O
staging	O
,	O
England	O
activities	O
of	O
daily	O
living	O
score	O
and	O
video	O
recordings	O
.	O

(	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
parts	O
II	O
and	O
III	O
)	O
off	O
medication	O
improved	O
by	O
62%	O
and	O
61%	O
respectively	O
(	O
p<0.0005	O
)	O
.	O

The	O
subscores	O
for	O
the	O
akinesia	I-Entity
,	O
rigidity	I-Entity
,	O
tremor	I-Entity
and	O
gait	O
also	O
improved	O
.	O

The	O
average	O
levodopa	I-Entity
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

It	O
reduces	O
the	O
severity	O
of	O
""""	O
off	O
""""	O
phase	O
symptoms	O
,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	I-Entity
requirements	O
.	O

The	O
reduction	O
in	O
the	O
levodopa	I-Entity
dose	O
is	O
useful	O
in	O
controlling	O
drug	B-Entity
-	I-Entity
induced	I-Entity
dyskinesias	I-Entity
.	O



Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	I-Entity
chemotherapy	O
for	O
retinoblastoma	I-Entity
.	O

Focal	O
subtenon	O
carboplatin	I-Entity
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity	I-Entity
-	O
free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	B-Entity
ocular	I-Entity
motility	I-Entity
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	I-Entity
chemotherapy	O
.	O

:	O
We	O
noted	O
abnormal	B-Entity
ocular	I-Entity
motility	I-Entity
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	I-Entity
who	O
had	O
received	O
subtenon	O
carboplatin	I-Entity
.	O

During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia	O
,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing	O
,	O
comparing	O
ocular	O
motility	O
after	O
tumor	I-Entity
control	O
with	O
ocular	O
motility	O
at	O
diagnosis	O
.	O

Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	I-Entity
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	I-Entity
as	O
part	O
of	O
multimodality	O
therapy	O
.	O

Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye	O
,	O
indicative	O
of	O
phagocytosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necrosis	I-Entity
.	O

The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	I-Entity
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	O
adhesions	O
.	O

Subtenon	O
carboplatin	I-Entity
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	I-Entity
of	O
orbital	O
soft	O
tissues	O
,	O
leading	O
to	O
mechanical	O
restriction	O
of	O
eye	O
movements	O
and	O
making	O
subsequent	O
enucleation	O
difficult	O
.	O

Subtenon	O
carboplatin	I-Entity
is	O
not	O
free	O
of	O
toxicity	I-Entity
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indications	O
.	O



Ethambutol	I-Entity
and	O
optic	B-Entity
neuropathy	I-Entity
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	I-Entity
and	O
optic	B-Entity
neuropathy	I-Entity
.	O

METHOD	O
:	O
Thirteen	O
patients	O
who	O
developed	O
optic	B-Entity
neuropathy	I-Entity
after	O
being	O
treated	O
with	O
ethambutol	I-Entity
for	O
tuberculosis	B-Entity
of	I-Entity
the	I-Entity
lung	I-Entity
or	I-Entity
lymph	I-Entity
node	I-Entity
at	O
Siriraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospectively	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
optic	B-Entity
neuropathy	I-Entity
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2.9	O
months	O
)	O
after	O
starting	O
ethambutol	I-Entity
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Of	O
6	O
patients	O
with	O
irreversible	O
visual	B-Entity
impairment	I-Entity
,	O
4	O
patients	O
had	O
diabetes	B-Entity
mellitus	I-Entity
,	O
glaucoma	I-Entity
and	O
a	O
history	O
of	O
heavy	O
smoking	O
.	O

CONCLUSION	O
:	O
Early	O
recognition	O
of	O
optic	B-Entity
neuropathy	I-Entity
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	I-Entity
therapy	O
.	O

A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B-Entity
mellitus	I-Entity
,	O
glaucoma	I-Entity
or	O
who	O
are	O
heavy	O
smokers	O
.	O



Treatment	O
of	O
compensatory	O
gustatory	B-Entity
hyperhidrosis	I-Entity
with	O
topical	O
glycopyrrolate	I-Entity
.	O

Gustatory	B-Entity
hyperhidrosis	I-Entity
is	O
facial	O
sweating	I-Entity
usually	O
associated	O
with	O
the	O
eating	O
of	O
hot	O
spicy	O
food	O
or	O
even	O
smelling	O
this	O
food	O
.	O

Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	B-Entity
chloride	I-Entity
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin	O
.	O

Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1.5%	O
or	O
2%	O
topical	O
glycopyrrolate	I-Entity
.	O

All	O
patients	O
had	O
gustatory	B-Entity
hyperhidrosis	I-Entity
,	O
which	O
interfered	O
with	O
their	O
social	O
activities	O
,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	I-Entity
.	O

After	O
applying	O
topical	O
glycopyrrolate	I-Entity
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	I-Entity
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	I-Entity
)	O
in	O
3	O
patients	O
(	O
23%	O
)	O
.	O

Adverse	O
effects	O
included	O
a	O
mildly	O
dry	B-Entity
mouth	I-Entity
and	O
a	O
sore	B-Entity
throat	I-Entity
in	O
2	O
patients	O
(	O
2%	O
glycopyrrolate	I-Entity
)	O
,	O
a	O
light	O
headache	I-Entity
in	O
1	O
patient	O
(	O
1.5%	O
glycopyrrolate	I-Entity
)	O
.	O

The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	I-Entity
pad	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
well	O
tolerated	O
,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	B-Entity
hyperhidrosis	I-Entity
in	O
post	O
transthoracic	O
endoscopic	O
sympathectomy	O
or	O
sympathicotomy	O
patients	O
,	O
with	O
few	O
side	O
effects	O
.	O



Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	I-Entity
without	O
soyabean	O
oil	O
.	O

We	O
compared	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	I-Entity
(	O
AM149	O
1%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soyabean	O
oil	O
,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	I-Entity
(	O
Disoprivan	I-Entity
1%	O
)	O
.	O

In	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg.kg-1	O
propofol	I-Entity
.	O

Plasma	O
propofol	I-Entity
levels	O
were	O
measured	O
for	O
48	O
h	O
following	O
drug	O
administration	O
and	O
evaluated	O
according	O
to	O
a	O
three	O
-	O
compartment	O
model	O
.	O

The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
effects	O
,	O
and	O
pain	I-Entity
on	O
injection	O
.	O

Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	I-Entity
,	O
the	O
study	O
was	O
terminated	O
prematurely	O
and	O
only	O
the	O
data	O
of	O
the	O
two	O
parallel	O
treatment	O
groups	O
(	O
15	O
patients	O
in	O
each	O
group	O
)	O
were	O
analysed	O
.	O

Pain	I-Entity
on	O
injection	O
(	O
80	O
vs.	O
20%	O
,	O
p	O
<	O
0.01	O
)	O
and	O
thrombophlebitis	I-Entity
(	O
93.3	O
vs.	O
6.6%	O
,	O
p	O

<	O
0.001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	I-Entity
.	O

Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	I-Entity
produced	O
.	O



Vinorelbine	I-Entity
-	O
related	O
cardiac	O
events	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
clinical	O
trials	O
.	O

Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	I-Entity
(	O
VNR	I-Entity
)	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	I-Entity
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	I-Entity
.	O

Randomized	O
clinical	O
trials	O
comparing	O
VNR	I-Entity
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	I-Entity
were	O
searched	O
in	O
Medline	O
,	O
Embase	O
,	O
Evidence	O
-	O
based	O
Medicine	O
Reviews	O
databases	O
and	O
the	O
Cochrane	O
library	O
from	O
1987	O
to	O
2002	O
.	O

We	O
found	O
19	O
trials	O
,	O
involving	O
2441	O
patients	O
treated	O
by	O
VNR	I-Entity
and	O
2050	O
control	O
patients	O
.	O

The	O
incidence	O
of	O
cardiac	O
events	O
with	O
VNR	I-Entity
was	O
1.19%	O
[	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0.75	O
;	O
1.67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	O
events	O
between	O
VNR	I-Entity
and	O
other	O
drugs	O
[	O
odds	O
ratio	O
:	O
0.92	O
,	O
95%	O
CI	O
(	O
0.54	O
;	O
1.55	O
)	O
]	O
.	O

The	O
risk	O
of	O
VNR	I-Entity
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	I-Entity
(	O
VDS	I-Entity
)	O
and	O
other	O
cardiotoxic	I-Entity
drugs	O
[	O
fluorouracil	I-Entity
,	O
anthracyclines	I-Entity
,	O
gemcitabine	I-Entity
(	O
GEM	I-Entity
)	O
em	O
leader	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases	O
,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history	O
,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre	O
-	O
existing	O
cardiac	B-Entity
diseases	I-Entity
.	O

Vinorelbine	I-Entity
-	O
related	O
cardiac	O
events	O
concern	O
about	O
1%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
risk	O
associated	O
with	O
VNR	I-Entity
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
same	O
indications	O
.	O



MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	I-Entity
in	O
a	O
child	O
with	O
hemolytic	B-Entity
anemia	I-Entity
crisis	O
.	O

We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	B-Entity
anemia	I-Entity
crisis	O
induced	O
by	O
trimethoprim	B-Entity
-	I-Entity
sulfomethoxazole	I-Entity
,	O
resulting	O
in	O
cerebral	B-Entity
anoxia	I-Entity
leading	O
to	O
permanent	O
damage	O
.	O

Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	I-Entity
in	O
arterial	O
border	O
zones	O
in	O
both	O
cerebral	O
hemispheres	O
,	O
ischemic	O
changes	O
in	O
subcortical	O
white	O
matter	O
of	O
left	O
cerebral	O
hemisphere	O
,	O
and	O
in	O
the	O
left	O
putamen	O
.	O

Although	O
cortical	O
laminar	O
necrosis	I-Entity
is	O
a	O
classic	O
entity	O
in	O
adulthood	O
related	O
to	O
conditions	O
of	O
energy	O
depletions	O
,	O
there	O
are	O
few	O
reports	O
available	O
in	O
children	O
.	O



The	O
natural	O
history	O
of	O
Vigabatrin	I-Entity
associated	O
visual	B-Entity
field	I-Entity
defects	I-Entity
in	O
patients	O
electing	O
to	O
continue	O
their	O
medication	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	B-Entity
field	I-Entity
defects	I-Entity
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin	I-Entity
-	O
associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	I-Entity
control	O
.	O

All	O
patients	O
taking	O
Vigabatrin	I-Entity
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(	O
range	O
5	O
-	O
12	O
years	O
)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme	O
.	O

Following	O
already	O
published	O
methodology	O
(	O
Eye	O
2002	O
;	O
16;567	O
-	O
571	O
)	O
monocular	O
mean	O
radial	O
degrees	O
(	O
MRDs	O
)	O
to	O
the	O
I/4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	O
the	O
time	O
of	O
discovery	O
of	O
a	O
visual	B-Entity
field	I-Entity
defect	I-Entity
and	O
again	O
after	O
not	O
less	O
than	O
18	O
months	O
follow	O
-	O
up	O
.	O

Only	O
one	O
patient	O
demonstrated	O
a	O
deterioration	B-Entity
in	I-Entity
visual	I-Entity
field	I-Entity
during	O
the	O
study	O
period	O
and	O
discontinued	O
treatment	O
.	O

Established	O
visual	B-Entity
field	I-Entity
defects	I-Entity
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	I-Entity
therapy	O
did	O
not	O
usually	O
progress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medication	O
.	O

These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin	I-Entity
-	O
associated	O
visual	B-Entity
field	I-Entity
defects	I-Entity
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose	O
-	O
dependent	O
toxicity	I-Entity
.	O



Induction	O
of	O
rosaceiform	O
dermatitis	I-Entity
during	O
treatment	O
of	O
facial	B-Entity
inflammatory	I-Entity
dermatoses	I-Entity
with	O
tacrolimus	I-Entity
ointment	O
.	O

Tacrolimus	I-Entity
ointment	O
is	O
increasingly	O
used	O
for	O
anti	O
-	O
inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face	O
,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid	I-Entity
-	O
aggravated	O
rosacea	I-Entity
and	O
perioral	B-Entity
dermatitis	I-Entity
.	O

We	O
report	O
on	O
rosaceiform	O
dermatitis	I-Entity
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	I-Entity
ointment	O
.	O

Six	O
adult	O
patients	O
with	O
inflammatory	B-Entity
facial	I-Entity
dermatoses	I-Entity
were	O
treated	O
with	O
tacrolimus	I-Entity
ointment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
standard	O
treatments	O
.	O

Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well	O
-	O
tolerated	O
treatment	O
,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	I-Entity
and	O
1	O
with	O
a	O
history	O
of	O
acne	I-Entity
experienced	O
sudden	O
worsening	O
with	O
pustular	O
rosaceiform	O
lesions	O
.	O

In	O
1	O
patient	O
with	O
eyelid	O
eczema	I-Entity
,	O
rosaceiform	O
periocular	B-Entity
dermatitis	I-Entity
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

In	O
1	O
patient	O
with	O
atopic	B-Entity
dermatitis	I-Entity
,	O
telangiectatic	O
and	O
papular	B-Entity
rosacea	I-Entity
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment	O
.	O

Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	I-Entity
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	I-Entity
ointment	O
is	O
heterogeneous	O
.	O

A	O
variety	O
of	O
factors	O
,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	I-Entity
,	O
proliferation	O
of	O
Demodex	O
due	O
to	O
local	O
immunosuppression	O
,	O
and	O
the	O
occlusive	O
properties	O
of	O
the	O
ointment	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomena	O
.	O



Structural	O
abnormalities	O
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	I-Entity
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
profile	O
of	O
structural	B-Entity
deficits	I-Entity
in	I-Entity
the	I-Entity
human	I-Entity
brain	I-Entity
associated	O
with	O
chronic	O
methamphetamine	I-Entity
(	O
MA	I-Entity
)	O
abuse	O
.	O

Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	I-Entity
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	B-Entity
abnormalities	I-Entity
.	O

Using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
new	O
computational	O
brain	O
-	O
mapping	O
techniques	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	I-Entity
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	B-Entity
impairment	I-Entity
.	O

We	O
used	O
high	O
-	O
resolution	O
MRI	O
and	O
surface	O
-	O
based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	B-Entity
in	I-Entity
the	I-Entity
cortex	I-Entity
,	I-Entity
hippocampus	I-Entity
,	I-Entity
white	I-Entity
matter	I-Entity
,	I-Entity
and	I-Entity
ventricles	I-Entity
in	O
22	O
human	O
subjects	O
who	O
used	O
MA	I-Entity
and	O
21	O
age	O
-	O
matched	O
,	O
healthy	O
controls	O
.	O

Cortical	O
maps	O
revealed	O
severe	O
gray	O
-	O
matter	O
deficits	O
in	O
the	O
cingulate	O
,	O
limbic	O
,	O
and	O
paralimbic	O
cortices	O
of	O
MA	I-Entity
abusers	O
(	O
averaging	O
11.3%	O
below	O
control	O
;	O

On	O
average	O
,	O
MA	I-Entity
abusers	O
had	O
7.8%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(	O
p	O
<	O
0.01	O
;	O
left	O
,	O
p	O
=	O
0.01	O
;	O
right	O
,	O
p	O
<	O
0.05	O
)	O
and	O
significant	O
white	O
-	O
matter	O
hypertrophy	I-Entity
(	O
7.0%	O
;	O

MRI	O
-	O
based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	I-Entity
abuse	O
causes	O
a	O
selective	O
pattern	O
of	O
cerebral	O
deterioration	O
that	O
contributes	O
to	O
impaired	B-Entity
memory	I-Entity
performance	I-Entity
.	O

MA	I-Entity
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and	O
,	O
consistent	O
with	O
metabolic	O
studies	O
,	O
the	O
cingulate	O
-	O
limbic	O
cortex	O
,	O
inducing	O
neuroadaptation	O
,	O
neuropil	O
reduction	O
,	O
or	O
cell	O
death	O
.	O

Prominent	O
white	O
-	O
matter	O
hypertrophy	I-Entity
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes	O
,	O
including	O
gliosis	I-Entity
secondary	O
to	O
neuronal	B-Entity
damage	I-Entity
.	O

These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	I-Entity
abuse	O
,	O
providing	O
therapeutic	O
targets	O
for	O
drug	O
-	O
induced	O
brain	B-Entity
injury	I-Entity
.	O



Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	I-Entity
treatment	O
is	O
associated	O
with	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
target	O
gene	O
activation	O
.	O

Amiodarone	I-Entity
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	I-Entity
in	O
some	O
patients	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	I-Entity
and	O
examined	O
for	O
changes	O
in	O
hepatic	O
histology	O
and	O
gene	O
regulation	O
.	O

Amiodarone	I-Entity
induced	O
hepatomegaly	I-Entity
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	I-Entity
and	O
glucose	I-Entity
.	O

Northern	O
blot	O
analysis	O
of	O
hepatic	O
RNA	O
revealed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
critical	O
for	O
fatty	B-Entity
acid	I-Entity
oxidation	O
,	O
lipoprotein	O
assembly	O
,	O
and	O
lipid	O
transport	O
.	O

The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	I-Entity
in	O
PPARalpha	O
knockout	O
[	O
PPARalpha-/-	O
]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	I-Entity
were	O
dependent	O
upon	O
the	O
presence	O
of	O
a	O
functional	O
PPARalpha	O
gene	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
treatment	O
of	O
PPARalpha-/-	O
mice	O
with	O
amiodarone	I-Entity
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	O
weight	B-Entity
loss	I-Entity
.	O

The	O
inability	O
of	O
amiodarone	I-Entity
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	I-Entity
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	I-Entity
on	O
the	O
function	O
of	O
this	O
receptor	O
were	O
indirect	O
.	O

Based	O
upon	O
these	O
results	O
,	O
we	O
conclude	O
that	O
amiodarone	I-Entity
disrupts	O
hepatic	O
lipid	O
homeostasis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
PPARalpha	O
target	O
genes	O
is	O
secondary	O
to	O
this	O
toxic	O
effect	O
.	O

These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	I-Entity
effects	O
of	O
amiodarone	I-Entity
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone	I-Entity
-	O
induced	O
hepatotoxicity	I-Entity
.	O



Safety	O
and	O
compliance	O
with	O
once	O
-	O
daily	O
niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
as	O
initial	O
therapy	O
in	O
the	O
Impact	O
of	O
Medical	O
Subspecialty	O
on	O
Patient	O
Compliance	O
to	O
Treatment	O
(	O
IMPACT	O
)	O
study	O
.	O

Niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	I-Entity
and	O
mixed	O
dyslipidemia	I-Entity
.	O

This	O
open	O
-	O
labeled	O
,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
when	O
dosed	O
as	O
initial	O
therapy	O
and	O
patient	O
compliance	O
to	O
treatment	O
in	O
various	O
clinical	O
practice	O
settings	O
.	O

A	O
total	O
of	O
4,499	O
patients	O
with	O
dyslipidemia	I-Entity
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	O
1,081	O
sites	O
.	O

Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(	O
500	O
mg	O
of	O
niacin	I-Entity
extended	O
-	O
release/20	O
mg	O
of	O
lovastatin	I-Entity
)	O
once	O
nightly	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tablets	O
for	O
8	O
weeks	O
.	O

Patients	O
also	O
received	O
dietary	O
counseling	O
,	O
educational	O
materials	O
,	O
and	O
reminders	O
to	O
call	O
a	O
toll	O
-	O
free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	I-Entity
and	O
niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
.	O

Primary	O
end	O
points	O
were	O
study	O
compliance	O
,	O
increases	O
in	O
liver	O
transaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
clinical	O
myopathy	I-Entity
.	O

Compliance	O
to	O
niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
was	O
77%	O
,	O
with	O
3,245	O
patients	O
completing	O
the	O
study	O
.	O

Flushing	I-Entity
was	O
the	O
most	O
common	O
adverse	O
event	O
,	O
reported	O
by	O
18%	O
of	O
patients	O
and	O
leading	O
to	O
discontinuation	O
by	O
6%	O
.	O

Incidence	O
of	O
increased	O
aspartate	I-Entity
aminotransferase	O
and/or	O
alanine	I-Entity
aminotransferase	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
was	O
<	O
0.3%	O
.	O

An	O
increase	O
of	O
creatine	I-Entity
phosphokinase	O
to	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.24%	O
of	O
patients	O
,	O
and	O
no	O
cases	O
of	O
drug	O
-	O
induced	O
myopathy	I-Entity
were	O
observed	O
.	O

Niacin	B-Entity
extended	I-Entity
-	I-Entity
release	I-Entity
/	I-Entity
lovastatin	I-Entity
1,000/40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	O
and	O
muscle	O
enzymes	O
.	O



Protective	O
effect	O
of	O
Terminalia	B-Entity
chebula	I-Entity
against	O
experimental	O
myocardial	B-Entity
injury	I-Entity
induced	O
by	O
isoproterenol	I-Entity
.	O

Cardioprotective	O
effect	O
of	O
ethanolic	B-Entity
extract	I-Entity
of	I-Entity
Terminalia	I-Entity
chebula	I-Entity
fruits	I-Entity
(	O
500	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
was	O
examined	O
in	O
isoproterenol	I-Entity
(	O
200	O
mg	O
/	O
kg	O
body	O

wt	O
)	O
induced	O
myocardial	B-Entity
damage	I-Entity
in	O
rats	O
.	O

In	O
isoproterenol	I-Entity
administered	O
rats	O
,	O
the	O
level	O
of	O
lipid	O
peroxides	I-Entity
increased	O
significantly	O
in	O
the	O
serum	O
and	O
heart	O
.	O

Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	I-Entity
.	O

T.	B-Entity
chebula	I-Entity
extract	I-Entity
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	I-Entity
on	O
lipid	O
peroxide	I-Entity
formation	O
and	O
retained	O
the	O
activities	O
of	O
the	O
diagnostic	O
marker	O
enzymes	O
.	O



A	O
case	O
of	O
postoperative	O
anxiety	I-Entity
due	O
to	O
low	O
dose	O
droperidol	I-Entity
used	O
with	O
patient	O
-	O
controlled	O
analgesia	O
.	O

Postoperatively	O
,	O
she	O
was	O
given	O
a	O
patient	O
-	O
controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	I-Entity
0.5	O
mg	O
and	O
droperidol	I-Entity
0.025	O
mg	O
.	O

The	O
diagnosis	O
of	O
droperidol	I-Entity
-	O
induced	O
psychological	B-Entity
disturbance	I-Entity
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questioning	O
the	O
patient	O
gave	O
a	O
very	O
clear	O
history	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0.9	O
mg	O
droperidol	I-Entity
,	O
a	O
syringe	O
containing	O
diamorphine	I-Entity
only	O
was	O
substituted	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O



Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	B-Entity
insipidus	I-Entity
:	O
a	O
case	O
study	O
.	O

The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
(	O
DI	I-Entity
)	O
secondary	O
to	O
a	O
traumatic	B-Entity
brain	I-Entity
injury	I-Entity
.	O

The	O
nursing	O
staff	O
,	O
by	O
reviewing	O
the	O
patient	O
's	O
health	O
history	O
with	O
his	O
family	O
,	O
discovered	O
a	O
history	O
of	O
polydipsia	I-Entity
and	O
long	O
-	O
standing	O
lithium	I-Entity
use	O
.	O

Lithium	I-Entity
is	O
implicated	O
in	O
drug	O
-	O
induced	O
nephrogenic	B-Entity
DI	I-Entity
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	I-Entity
since	O
being	O
admitted	O
to	O
the	O
hospital	O
,	O
his	O
treatment	O
changed	O
to	O
focus	O
on	O
nephrogenic	B-Entity
DI	I-Entity
.	O

By	O
combining	O
information	O
from	O
the	O
patient	O
history	O
,	O
the	O
physical	O
examination	O
,	O
and	O
radiologic	O
and	O
laboratory	O
studies	O
,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self	O
-	O
treating	O
his	O
lithium	I-Entity
-	O
induced	O
nephrogenic	B-Entity
DI	I-Entity
and	O
developed	O
neurogenic	B-Entity
DI	I-Entity
secondary	O
to	O
brain	B-Entity
trauma	I-Entity
.	O

Thus	O
successful	O
treatment	O
required	O
that	O
nephrogenic	O
and	O
neurogenic	B-Entity
DI	I-Entity
be	O
treated	O
concomitantly	O
.	O



Factors	O
contributing	O
to	O
ribavirin	I-Entity
-	O
induced	O
anemia	I-Entity
.	O

Interferon	I-Entity
and	O
ribavirin	I-Entity
combination	O
therapy	O
for	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
produces	O
hemolytic	B-Entity
anemia	I-Entity
.	O

This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin	I-Entity
-	O
induced	O
anemia	I-Entity
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
patients	O
with	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
who	O
received	O
interferon	B-Entity
-	I-Entity
alpha-2b	I-Entity
at	O
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	I-Entity
administered	O
orally	O
at	O
a	O
dose	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
study	O
.	O

A	O
hemoglobin	O
concentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribavirin	I-Entity
-	O
induced	O
anemia	I-Entity
.	O

Ribavirin	I-Entity
-	O
induced	O
anemia	I-Entity
occurred	O
in	O
18	O
(	O
20.5%	O
)	O
patients	O
during	O
treatment	O
.	O

A	O
2	O
g	O
/	O
dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	I-Entity
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
.	O

A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	O
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	I-Entity
(	O
P	O
<	O
0.01	O
)	O
.	O

Such	O
factors	O
as	O
sex	O
(	O
female	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
years	O
old	O
)	O
,	O
and	O
the	O
ribavirin	I-Entity
dose	O
by	O
body	O
weight	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univariate	O
analysis	O
.	O

Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=	O
60	O
years	O
old	O
,	O
in	O
female	O
patients	O
,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	I-Entity
dose	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O



Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin	I-Entity
-	O
induced	O
cardiac	O
mitochondrial	B-Entity
injury	I-Entity
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	I-Entity
(	O
ROS)/nitrogen	I-Entity
species	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	I-Entity
(	O
ADR)-induced	I-Entity
cardiotoxicity	I-Entity
actually	O
resulted	O
in	O
cardiomyocyte	O

B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg	O
/	O
kg	O
ADR	I-Entity
.	O

Ultrastructural	O
damage	O
and	O
levels	O
of	O
4-hydroxy-2-nonenal	I-Entity
(	O
4HNE)-protein	I-Entity
adducts	O
and	O
3-nitrotyrosine	I-Entity
(	O
3NT	I-Entity
)	O
were	O
analyzed	O
.	O

Analysis	O
of	O
4HNE	I-Entity
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	I-Entity
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
decline	O
at	O
24	O
hours	O
.	O

3NT	I-Entity
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	O
6	O
hours	O
and	O
subsequently	O
declined	O
at	O
24	O
hours	O
.	O

Our	O
data	O
showed	O
ADR	I-Entity
induced	O
4HNE	I-Entity
-	O
protein	O
adducts	O
in	O
mitochondria	O
at	O
the	O
same	O
time	O
point	O
as	O
when	O
mitochondrial	B-Entity
injury	I-Entity
initially	O
appeared	O
.	O

These	O
results	O
document	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
mitochondrial	B-Entity
oxidative	I-Entity
damage	I-Entity
precedes	O
nitrative	O
damage	O
.	O

The	O
progressive	O
nature	O
of	O
mitochondrial	B-Entity
injury	I-Entity
suggests	O
that	O
mitochondria	O
,	O
not	O
other	O
subcellular	O
organelles	O
,	O
are	O
the	O
major	O
site	O
of	O
intracellular	O
injury	O
.	O



Sotalol	I-Entity
-	O
induced	O
coronary	B-Entity
spasm	I-Entity
in	O
a	O
patient	O
with	O
dilated	B-Entity
cardiomyopathy	I-Entity
associated	O
with	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

A	O
54-year	O
-	O
old	O
man	O
with	O
severe	O
left	O
ventricular	B-Entity
dysfunction	I-Entity
due	O
to	O
dilated	B-Entity
cardiomyopathy	I-Entity
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	B-Entity
tachycardia	I-Entity
(	O
VT	I-Entity
)	O
.	O

After	O
the	O
administration	O
of	O
nifekalant	B-Entity
hydrochloride	I-Entity
,	O
sustained	O
VT	I-Entity
was	O
terminated	O
.	O

An	O
alternate	O
class	O
III	O
agent	O
,	O
sotalol	I-Entity
,	O
was	O
also	O
effective	O
for	O
the	O
prevention	O
of	O
VT	I-Entity
.	O

However	O
,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	I-Entity
to	O
sotalol	I-Entity
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	O
almost	O
the	O
same	O
time	O
for	O
three	O
consecutive	O
days	O
.	O

ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiazem	I-Entity
.	O

Coronary	B-Entity
vasospasm	I-Entity
may	O
be	O
induced	O
by	O
the	O
non	O
-	O
selective	O
beta	O
-	O
blocking	O
properties	O
of	O
sotalol	I-Entity
.	O



Effects	O
of	O
the	O
antidepressant	O
trazodone	I-Entity
,	O
a	O
5-HT	I-Entity
2A/2C	O
receptor	O
antagonist	O
,	O
on	O
dopamine	I-Entity
-	O
dependent	O
behaviors	O
in	O
rats	O
.	O

RATIONALE	O
:	O
5-Hydroxytryptamine	I-Entity
,	O
via	O
stimulation	O
of	O
5-HT	I-Entity
2C	O
receptors	O
,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5-HT	I-Entity
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O

The	O
antidepressant	O
trazodone	I-Entity
is	O
a	O
5-HT	I-Entity
2A/2C	O
receptor	O
antagonist	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	I-Entity
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O

The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	I-Entity
on	O
dexamphetamine-	I-Entity
and	O
apomorphine	I-Entity
-	O
induced	O
oral	B-Entity
stereotypies	I-Entity
,	O
on	O
catalepsy	I-Entity
induced	O
by	O
haloperidol	I-Entity
and	O
apomorphine	I-Entity
(	O
0.05	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
on	O
ergometrine	I-Entity
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	I-Entity
-	O
induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	O
.	O

We	O
also	O
investigated	O
whether	O
trazodone	I-Entity
induces	O
catalepsy	I-Entity
in	O
rats	O
.	O

Trazodone	I-Entity
at	O
2.5	O
-	O
20	O
mg	O

did	O
not	O
induce	O
catalepsy	I-Entity
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	I-Entity
(	O
1.5	O
and	O
3	O
mg	O
/	O
kg	O
)	O

stereotypy	O
and	O
apomorphine	I-Entity
(	O
0.05	O
mg	O

/	O
kg)-induced	O
catalepsy	I-Entity
.	O

trazodone	I-Entity
enhanced	O
dexamphetamine	I-Entity
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	I-Entity
catalepsy	I-Entity
,	O
ergometrine	I-Entity
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	I-Entity
-	O
induced	O
penile	O
erections	O
.	O

Trazodone	I-Entity
at	O
30	O
,	O
40	O
and	O
50	O
mg	O

induced	O
catalepsy	I-Entity
and	O
antagonized	O
apomorphine	I-Entity
and	O
dexamphetamine	I-Entity
stereotypies	O
.	O

Our	O
results	O
indicate	O
that	O
trazodone	I-Entity
at	O
2.5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodone	I-Entity
blocks	O
5-HT	I-Entity
2A	O
and	O
5-HT	I-Entity
2C	O
receptors	O
.	O

We	O
suggest	O
that	O
trazodone	I-Entity
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blocking	O
the	O
5-HT	I-Entity
2C	O
receptors	O
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5-HT	I-Entity
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	I-Entity
stereotypy	O
and	O
antagonizes	O
haloperidol	I-Entity
catalepsy	I-Entity
.	O



Swallowing	B-Entity
abnormalities	I-Entity
and	O
dyskinesia	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Gastrointestinal	B-Entity
abnormalities	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	I-Entity
patients	O
with	O
and	O
without	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
.	O

Fifteen	O
dyskinetic	I-Entity
,	O
12	O
nondyskinetic	O
patients	O
,	O
and	O
a	O
control	O
group	O
were	O
included	O
.	O

Patients	O
were	O
asked	O
about	O
dysphagia	I-Entity
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehn	O
and	O
Yahr	O
scale	O
.	O

Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	I-Entity
swallow	O
with	O
videofluoroscopy	O
.	O

Nondyskinetic	O
patients	O
,	O
but	O
not	O
the	O
dyskinetic	I-Entity
ones	O
,	O
showed	O
less	O
oropharyngeal	O
swallowing	O
efficiency	O
(	O
OPSE	O
)	O
for	O
liquid	O
food	O
than	O
controls	O
(	O
Dunnett	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Dyskinetic	I-Entity
patients	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondyskinetic	O
(	O
Dunnett	O
,	O
P	O
=	O
0.06	O
)	O
.	O

Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	I-Entity
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oral	O
transit	O
time	O
(	O
Pearson	O
's	O
correlation	O
,	O
P	O
=	O
0.01	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
report	O
of	O
dysphagia	I-Entity
nor	O
any	O
of	O
the	O
PD	I-Entity
severity	O
parameters	O
correlated	O
to	O
the	O
videofluoroscopic	O
variables	O
.	O

In	O
the	O
current	O
study	O
,	O
dyskinetic	I-Entity
patients	O
performed	O
better	O
in	O
swallowing	O
function	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	I-Entity
dose	O
.	O

Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	I-Entity
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	I-Entity
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	I-Entity
.	O



Inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B-Entity
nephritis	I-Entity
induced	O
by	O
gentamicin	I-Entity
.	O

:	O
Animals	O
treated	O
with	O
gentamicin	I-Entity
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	I-Entity
in	O
the	O
renal	O
cortex	O
.	O

kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	I-Entity
or	O
gentamicin	I-Entity
+	O
pyrrolidine	B-Entity
dithiocarbamate	I-Entity
(	O
PDTC	I-Entity
)	O
,	O
an	O
NF	O
-	O
kappaB	O
inhibitor	O
.	O

METHODS	O
:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	I-Entity
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
days	O
,	O
38	O
with	O
gentamicin	I-Entity
+	O
PDTC	I-Entity
,	O
and	O
28	O
with	O
0.15	O
M	O
NaCl	I-Entity
solution	O
.	O

Gentamicin	I-Entity
-	O
treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	I-Entity
levels	O
.	O

Increased	O
ED-1	O
,	O
MAP	O
kinases	O
and	O
NF	O
-	O
kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	O
cortex	O
from	O
all	O
gentamicin	I-Entity
-	O
treated	O
rats	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	I-Entity
in	O
the	O
renal	O
cortex	O
despite	O
the	O
recovery	O
of	O
renal	O
function	O
.	O

Treatment	O
with	O
PDTC	I-Entity
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	I-Entity
.	O

These	O
data	O
show	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B-Entity
nephritis	I-Entity
induced	O
by	O
gentamicin	I-Entity
.	O



Glucose	I-Entity
metabolism	O
in	O
patients	O
with	O
schizophrenia	I-Entity
treated	O
with	O
atypical	O
antipsychotic	O
agents	O
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	I-Entity
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O

While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-Entity
mellitus	I-Entity
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	I-Entity
treated	O
with	O
certain	O
atypical	O
antipsychotic	O
agents	O
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	I-Entity
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	I-Entity
and	O
olanzapine	I-Entity
)	O
and	O
risperidone	I-Entity
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	I-Entity
tolerance	O
test	O
.	O

A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	I-Entity
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	I-Entity
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	I-Entity
tolerance	O
test	O
.	O

Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	I-Entity
or	O
schizoaffective	B-Entity
disorder	I-Entity
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	I-Entity
,	O
olanzapine	I-Entity
,	O
or	O
risperidone	I-Entity
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Fasting	O
plasma	O
glucose	I-Entity
and	O
fasting	O
serum	O
insulin	O
levels	O
,	O
insulin	B-Entity
sensitivity	I-Entity
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Entity
resistance	I-Entity
,	O
and	O
glucose	I-Entity
effectiveness	O
.	O

28.9	O
months	O
(	O
clozapine	I-Entity
)	O
,	O
29.5	O
+	O
/-	O

17.5	O
months	O
(	O
olanzapine	I-Entity
)	O
,	O
and	O
40.9	O
+	O
/-	O

33.7	O
(	O
risperidone	I-Entity
)	O
.	O

Fasting	O
serum	O
insulin	O
concentrations	O
differed	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
3.35	O
;	O
P	O
=	O
.047	O
)	O
(	O
clozapine	I-Entity
>	O
olanzapine	I-Entity
>	O
risperidone	I-Entity
)	O
with	O
significant	O
differences	O
between	O
clozapine	I-Entity
and	O
risperidone	I-Entity
(	O
t(33	O
)	O
=	O
2.32	O
;	O
P	O
=	O
.03	O
)	O
and	O
olanzapine	I-Entity
and	O
risperidone	I-Entity
(	O
t(33	O
)	O
=	O
2.15	O
;	O
P	O
=	O
.04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	B-Entity
sensitivity	I-Entity
index	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
10.66	O
;	O
P<.001	O
)	O
(	O
clozapine	I-Entity
<	O
olanzapine	I-Entity
<	O
risperidone	I-Entity
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	I-Entity
and	O
olanzapine	I-Entity
exhibiting	O
significant	O
insulin	B-Entity
resistance	I-Entity
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	I-Entity
(	O
clozapine	I-Entity
vs	O
risperidone	I-Entity
,	O
t(33	O
)	O
=	O
-4.29	O
;	O
P<.001	O
;	O
olanzapine	I-Entity
vs	O
risperidone	I-Entity
,	O
t(33	O
)	O
=	O
-3.62	O
;	O
P	O
=	O
.001	O
[	O
P<.001	O
]	O
)	O
.	O

The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Entity
resistance	I-Entity
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
4.92	O
;	O
P	O
=	O
.01	O
)	O
(	O
clozapine	I-Entity
>	O
olanzapine	I-Entity
>	O
risperidone	I-Entity
)	O
(	O
clozapine	I-Entity
vs	O
risperidone	I-Entity
,	O
t(33	O
)	O
=	O
2.94	O
;	O
P	O
=	O
.006	O
;	O
olanzapine	I-Entity
vs	O
risperidone	I-Entity
,	O
t(33	O
)	O
=	O
2.42	O
;	O
P	O
=	O
.02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	I-Entity
effectiveness	O
(	O
F(30	O
)	O
=	O
4.18	O
;	O

P	O
=	O
.02	O
)	O
(	O
clozapine	I-Entity
<	O
olanzapine	I-Entity
<	O
risperidone	I-Entity
)	O
with	O
significant	O
differences	O
between	O
clozapine	I-Entity
and	O
risperidone	I-Entity
(	O
t(30	O
)	O
=	O
-2.59	O
;	O
P	O
=	O
.02	O
)	O
and	O
olanzapine	I-Entity
and	O
risperidone	I-Entity
(	O
t(30	O
)	O
=	O
-2.34	O
,	O
P	O
=	O
.03	O
)	O
.	O

Both	O
nonobese	O
clozapine-	I-Entity
and	O

olanzapine	I-Entity
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-Entity
resistance	I-Entity
and	O
impairment	O
of	O
glucose	I-Entity
effectiveness	O
compared	O
with	O
risperidone	I-Entity
-	O
treated	O
subjects	O
.	O

Patients	O
taking	O
clozapine	I-Entity
and	O
olanzapine	I-Entity
must	O
be	O
examined	O
for	O
insulin	B-Entity
resistance	I-Entity
and	O
its	O
consequences	O
.	O



Focal	O
cerebral	B-Entity
ischemia	I-Entity
in	O
rats	O
:	O
effect	O
of	O
phenylephrine	I-Entity
-	O
induced	O
hypertension	I-Entity
during	O
reperfusion	O
.	O

After	O
180	O
min	O
of	O
temporary	O
middle	B-Entity
cerebral	I-Entity
artery	I-Entity
occlusion	I-Entity
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
,	O
the	O
effect	O
of	O
phenylephrine	I-Entity
-	O
induced	O
hypertension	I-Entity
on	O
ischemic	B-Entity
brain	I-Entity
injury	I-Entity
and	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
determined	O
.	O

Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion	O
:	O
Control	O
,	O
normotensive	O
reperfusion	O
;	O
90/hypertension	I-Entity
(	O
90/HTN	I-Entity
)	O
,	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only	O
;	O
15/hypertension	I-Entity
(	O
15/HTN	I-Entity
)	O
,	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	I-Entity
and	O
75	O
min	O
of	O
normotension	O
.	O

Part	O
A	O
,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	B-Entity
injury	I-Entity
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2,3,5-triphenyltetrazolium	B-Entity
chloride	I-Entity
and	O
edema	I-Entity
was	O
evaluated	O
by	O
microgravimetry	O
.	O

Brain	B-Entity
injury	I-Entity
(	O
percentage	O
of	O
the	O
ischemic	B-Entity
hemisphere	I-Entity
)	O
was	O
less	O
in	O
the	O
15/HTN	I-Entity
group	O
(	O
16	O
+	O
/-	O

SD	O
)	O
versus	O
the	O
90/HTN	I-Entity
group	O
(	O
30	O
+	O
/-	O

Specific	O
gravity	O
was	O
greater	O
in	O
the	O
15/HTN	I-Entity
group	O
(	O
1.043	O
+	O
/-	O

0.002	O
)	O
versus	O
the	O
90/HTN	I-Entity
(	O
1.036	O
+	O
/-	O
0.003	O
)	O
and	O
control	O
(	O
1.037	O
+	O
/-	O

Evans	B-Entity
Blue	I-Entity
(	O
mug	O
g-1	O
of	O
brain	O
tissue	O
)	O
was	O
greater	O
in	O
the	O
90/HTN	I-Entity
group	O
(	O
24.4	O
+	O
/-	O

4.1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15/HTN	I-Entity
group	O
(	O
7.3	O
+	O
/-	O

This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion	O
,	O
a	O
short	O
interval	O
of	O
hypertension	I-Entity
decreases	O
brain	B-Entity
injury	I-Entity
and	O
edema	I-Entity
;	O
and	O
that	O
sustained	O
hypertension	I-Entity
increases	O
the	O
risk	O
of	O
vasogenic	B-Entity
edema	I-Entity
.	O



People	O
aged	O
over	O
75	O
in	O
atrial	B-Entity
fibrillation	I-Entity
on	O
warfarin	I-Entity
:	O
the	O
rate	O
of	O
major	O
hemorrhage	I-Entity
and	O
stroke	I-Entity
in	O
more	O
than	O
500	O
patient	O
-	O
years	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	I-Entity
and	O
stroke	I-Entity
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-Entity
fibrillation	I-Entity
on	O
adjusted	O
-	O
dose	O
warfarin	I-Entity
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O

Two	O
hundred	O
thirty	O
-	O
five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B-Entity
fibrillation	I-Entity
on	O
warfarin	I-Entity
were	O
enrolled	O
.	O

Information	O
regarding	O
major	O
bleeding	I-Entity
episodes	O
,	O
strokes	I-Entity
,	O
and	O
warfarin	I-Entity
use	O
was	O
obtained	O
from	O
patients	O
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfarin	I-Entity
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhages	I-Entity
,	O
for	O
an	O
annual	O
rate	O
of	O
10.0%	O
,	O
including	O
24	O
(	O
45.3%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9.4%	O
)	O
fatal	O
bleeds	O
.	O

The	O
annual	O
stroke	I-Entity
rate	O
after	O
initiation	O
of	O
warfarin	I-Entity
was	O
2.6%	O
.	O

The	O
rate	O
of	O
major	O
hemorrhage	I-Entity
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	I-Entity
rate	O
on	O
warfarin	I-Entity
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	I-Entity
treatment	O
is	O
.	O



Safety	O
of	O
celecoxib	I-Entity
in	O
patients	O
with	O
adverse	O
skin	B-Entity
reactions	I-Entity
to	O
acetaminophen	I-Entity
(	O
paracetamol	I-Entity
)	O
and	O
nimesulide	I-Entity
associated	O
or	O
not	O
with	O
common	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

BACKGROUND	O
:	O
Acetaminophen	I-Entity
(	O
paracetamol	I-Entity
--	O
P	I-Entity
)	O
and	O
Nimesulide	I-Entity
(	O
N	I-Entity
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	O
/	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

The	O
rate	O
of	O
adverse	O
hypersensitivity	I-Entity
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O

Celecoxib	I-Entity
(	O
CE	I-Entity
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX-2	O
enzyme	O
.	O

We	O
evaluated	O
the	O
tolerability	O
of	O
CE	I-Entity
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B-Entity
reactions	I-Entity
to	O
P	I-Entity
and	O
N	I-Entity
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	O
.	O

:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	I-Entity
to	O
P	I-Entity
and	O
N	I-Entity
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	O
.	O

The	O
diagnosis	O
of	O
P	I-Entity
and	O
N	I-Entity
-	O
induced	O
skin	B-Entity
reactions	I-Entity
was	O
based	O
in	O
vivo	O
challenge	O
.	O

After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	I-Entity
in	O
refracted	O
doses	O
were	O
given	O
.	O

The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	I-Entity
,	O
rush	O
or	O
urticaria	I-Entity
-	O
angioedema	I-Entity
.	O

No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88.8%	O
)	O
tolerated	O
CE	I-Entity
.	O

Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	I-Entity
of	O
the	O
lips	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	I-Entity
reaction	O
to	O
CE	I-Entity
was	O
documented	O
among	O
9	O
P	I-Entity
and	O
N	I-Entity
-	O
highly	O
NSAIDs	O
intolerant	O
patients	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	I-Entity
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	I-Entity
and	O
N.	I-Entity



Case	O
-	O
control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
use	O
and	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
.	O

Studies	O
on	O
the	O
association	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
aspirin	I-Entity
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
(	O
ESRD	I-Entity
)	O
have	O
given	O
conflicting	O
results	O
.	O

In	O
order	O
to	O
examine	O
this	O
association	O
,	O
a	O
case	O
-	O
control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	I-Entity
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	I-Entity
in	O
the	O
study	O
area	O
between	O
June	O
1	O
,	O
1995	O
and	O
November	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	I-Entity
.	O

For	O
specific	O
groups	O
of	O
drugs	O
,	O
the	O
risks	O
were	O
1.56	O
(	O
1.05	O
-	O
2.30	O
)	O
for	O
aspirin	I-Entity
,	O
1.03	O
(	O
0.60	O
-	O
1.76	O
)	O

for	O
pyrazolones	I-Entity
,	O
0.80	O
(	O
0.39	O
-	O
1.63	O
)	O
for	O
paracetamol	I-Entity
,	O
and	O
0.94	O
(	O
0.57	O
-	O
1.56	O
)	O
for	O
nonaspirin	O
NSAIDs	O
.	O

The	O
risk	O
of	O
ESRD	I-Entity
associated	O
with	O
aspirin	I-Entity
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	I-Entity
as	O
underlying	O
disease	O
[	O
2.35	O
(	O
1.17	O
-	O
4.72	O
)	O
]	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	I-Entity
.	O

However	O
,	O
the	O
chronic	O
use	O
of	O
aspirin	I-Entity
may	O
increase	O
the	O
risk	O
of	O
ESRD	I-Entity
.	O



Two	O
cases	O
of	O
amisulpride	I-Entity
overdose	I-Entity
:	O
a	O
cause	O
for	O
prolonged	B-Entity
QT	I-Entity
syndrome	I-Entity
.	O

Two	O
cases	O
of	O
deliberate	O
self	O
-	O
poisoning	I-Entity
with	O
5	O
g	O
and	O
3.6	O
g	O
of	O
amisulpride	I-Entity
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
cases	O
,	O
QT	B-Entity
prolongation	I-Entity
and	O
hypocalcaemia	I-Entity
were	O
noted	O
.	O

The	O
QT	B-Entity
prolongation	I-Entity
appeared	O
to	O
respond	O
to	O
administration	O
of	O
i.v	O
.	O

calcium	B-Entity
gluconate	I-Entity
.	O



Growth	O
-	O
associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	I-Entity
rats	O
treated	O
with	O
cycloheximide	I-Entity
.	O

GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	I-Entity
.	O

To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43-ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43-ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B-Entity
epilepticus	I-Entity
induced	O
by	O
pilocarpine	I-Entity
(	O
Pilo	I-Entity
)	O
,	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	I-Entity
(	O
CHX	I-Entity
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS	O
.	O

CHX	I-Entity
was	O
injected	O
before	O
the	O
Pilo	I-Entity
injection	O
in	O
adult	O
Wistar	O
rats	O
.	O

The	O
Pilo	I-Entity
group	O
was	O
injected	O
with	O
the	O
same	O
drugs	O
,	O
except	O
for	O
CHX	I-Entity
.	O

RESULTS	O
:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43-ir	O
in	O
the	O
IML	O
between	O
Pilo	I-Entity
,	O
CHX+Pilo	I-Entity
,	O
and	O
control	O
groups	O
.	O

However	O
,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX+Pilo	I-Entity
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(	O
p	O
=	O
0.03	O
)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	I-Entity
group	O
.	O

Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX+Pilo	I-Entity
group	O
have	O
a	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
controls	O
,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals	O
.	O

The	O
change	O
in	O
GAP43-ir	O
present	O
in	O
Pilo	I-Entity
-	O
treated	O
animals	O
was	O
a	O
thinning	O
of	O
the	O
band	O
to	O
a	O
very	O
narrow	O
layer	O
just	O
above	O
the	O
granule	O
cell	O
layer	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
loss	O
of	O
hilar	O
cell	O
projections	O
that	O
express	O
GAP-43	O
.	O



Nicotine	I-Entity
antagonizes	O

caffeine-	I-Entity
but	O
not	O
pentylenetetrazole	I-Entity
-	O
induced	O
anxiogenic	O
effect	O
in	O
mice	O
.	O

Nicotine	I-Entity
and	O
caffeine	I-Entity
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide	O
.	O

Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	I-Entity
responses	O
.	O

The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	I-Entity
on	O
anxiety	I-Entity
induced	O
by	O
caffeine	I-Entity
and	O
another	O
anxiogenic	O
drug	O
,	O
pentylenetetrazole	I-Entity
,	O
in	O
mice	O
.	O

test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	I-Entity
.	O

Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	I-Entity
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	I-Entity
(	O
70	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
or	O
pentylenetetrazole	I-Entity
(	O
15	O
and	O
30	O
mg	O

Nicotine	I-Entity
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	I-Entity
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	I-Entity
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	O
effect	O
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O

Nicotine	I-Entity
(	O
0.25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine-	I-Entity
but	O
not	O
pentylenetetrazole	I-Entity
-	O
induced	O
anxiety	I-Entity
.	O

Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	I-Entity
on	O
caffeine	I-Entity
-	O
induced	O
anxiety	I-Entity
is	O
specific	O
to	O
caffeine	I-Entity
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	I-Entity
and	O
caffeine	I-Entity
.	O



Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	B-Entity
symptoms	I-Entity
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B-Entity
disease	I-Entity
,	O
osteoporosis	I-Entity
and	O
dementia	I-Entity
in	O
older	O
women	O
but	O
the	O
evidence	O
supporting	O
its	O
use	O
for	O
these	O
indications	O
is	O
largely	O
observational	O
.	O

To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
heart	B-Entity
disease	I-Entity
,	O
venous	B-Entity
thromboembolism	I-Entity
,	O
stroke	I-Entity
,	O
transient	B-Entity
ischaemic	I-Entity
attacks	I-Entity
,	O
breast	B-Entity
cancer	I-Entity
,	O
colorectal	B-Entity
cancer	I-Entity
,	O
ovarian	B-Entity
cancer	I-Entity
,	O
endometrial	B-Entity
cancer	I-Entity
,	O
gallbladder	B-Entity
disease	I-Entity
,	O
cognitive	O
function	O
,	O
dementia	I-Entity
,	O
fractures	I-Entity
and	O
quality	O
of	O
life	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
double	O
-	O
blind	O
trials	O
of	O
HT	O
(	O
oestrogens	I-Entity
with	O
or	O
without	O
progestogens	I-Entity
)	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
's	O
use	O
)	O
,	O
stroke	I-Entity
(	O
after	O
3	O
years	O
)	O
,	O
breast	B-Entity
cancer	I-Entity
(	O
after	O
5	O
years	O
)	O
and	O
gallbladder	B-Entity
disease	I-Entity
.	O

Long	O
-	O
term	O
oestrogen	I-Entity
-	O
only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	I-Entity
and	O
gallbladder	B-Entity
disease	I-Entity
.	O

Overall	O
,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	I-Entity
and	O
colon	B-Entity
cancer	I-Entity
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	I-Entity
.	O

Among	O
women	O
with	O
cardiovascular	B-Entity
disease	I-Entity
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
.	O

However	O
,	O
one	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
-	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	I-Entity
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B-Entity
thromboembolism	I-Entity
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
;	O
their	O
absolute	O
risk	O
remained	O
very	O
low	O
.	O

HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	B-Entity
disease	I-Entity
.	O



Drug	B-Entity
-	I-Entity
induced	I-Entity
liver	I-Entity
injury	I-Entity
:	O
an	O
analysis	O
of	O
461	O
incidences	O
submitted	O
to	O
the	O
Spanish	O
registry	O
over	O
a	O
10-year	O
period	O
.	O

Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug	B-Entity
-	I-Entity
induced	I-Entity
liver	I-Entity
injury	I-Entity
(	O
DILI	I-Entity
)	O
and	O
outcome	O
predictability	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
systematic	O
programs	O
to	O
detect	O
bona	O
fide	O
cases	O
.	O

A	O
cooperative	O
network	O
was	O
created	O
in	O
1994	O
in	O
Spain	O
to	O
identify	O
all	O
suspicions	O
of	O
DILI	I-Entity
following	O
a	O
prospective	O
structured	O
report	O
form	O
.	O

The	O
liver	B-Entity
damage	I-Entity
was	O
characterized	O
according	O
to	O
hepatocellular	O
,	O
cholestatic	I-Entity
,	O
and	O
mixed	O
laboratory	O
criteria	O
and	O
to	O
histologic	O
criteria	O
when	O
available	O
.	O

Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
cases	O
,	O
involving	O
505	O
drugs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	I-Entity
.	O

The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin	B-Entity
-	I-Entity
clavulanate	I-Entity
accounting	O
for	O
the	O
12.8%	O
of	O
the	O
whole	O
series	O
.	O

Indeed	O
,	O
the	O
incidence	O
of	O
liver	O
transplantation	O
and	O
death	O
in	O
this	O
group	O
was	O
11.7%	O
if	O
patients	O
had	O
jaundice	I-Entity
at	O
presentation	O
,	O
whereas	O
the	O
corresponding	O
figure	O
was	O
3.8%	O
in	O
nonjaundiced	O
patients	O
(	O
P	O
<	O
.04	O
)	O
.	O

Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
were	O
female	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95%	O
CI	O
:	O
4.1	O
-	O
151	O
;	O
P	O

95%	O
CI	O
:	O
1.6	O
-	O
37	O
;	O
P	O
<	O
.009	O
)	O
,	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	I-Entity
value	O
(	O
OR	O
=	O
1.15	O
;	O
95%	O
CI	O
:	O
1.09	O
-	O
1.22	O
;	O
P	O

Patients	O
with	O
drug	O
-	O
induced	O
hepatocellular	O
jaundice	I-Entity
have	O
11.7%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation	O
.	O

Amoxicillin	B-Entity
-	I-Entity
clavulanate	I-Entity
stands	O
out	O
as	O
the	O
most	O
common	O
drug	O
related	O
to	O
DILI	I-Entity
.	O



Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d	B-Entity
-	I-Entity
ribose	I-Entity
on	O
adriamycin	I-Entity
-	O
evoked	O
cardiotoxicity	I-Entity
in	O
rats	O
.	O

The	O
influence	O
of	O
d	B-Entity
-	I-Entity
ribose	I-Entity
on	O
adriamycin	I-Entity
-	O
induced	O
myocardiopathy	I-Entity
in	O
rats	O
was	O
studied	O
.	O

Adriamycin	I-Entity
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
evoked	O
fully	O
developed	O
cardiac	B-Entity
toxicity	I-Entity
.	O

D	B-Entity
-	I-Entity
ribose	I-Entity
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
influence	O
ADR	I-Entity
cardiotoxicity	I-Entity
.	O



In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
:	O
protection	O
by	O
erdosteine	I-Entity
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	I-Entity
(	O
VCM)-induced	I-Entity
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	I-Entity
species	O
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	I-Entity
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	I-Entity
-	O
induced	O
renal	B-Entity
impairment	I-Entity
in	O
rats	O
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	I-Entity
and	O
VCM	I-Entity
plus	O
erdosteine	I-Entity
.	O

VCM	I-Entity
was	O
administrated	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O

Erdosteine	I-Entity
was	O
administered	O
orally	O
.	O

VCM	I-Entity
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	I-Entity
(	O
MDA	I-Entity
)	O
and	O
urinary	O

(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B-Entity
tubular	I-Entity
injury	I-Entity
)	O
excretion	O
but	O
decreased	O
superoxide	I-Entity
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O

Erdosteine	I-Entity
administration	O
with	O
VCM	I-Entity
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	I-Entity
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	I-Entity
alone	O
.	O

Erdosteine	I-Entity
showed	O
histopathological	O
protection	O
against	O
VCM	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	I-Entity
,	O
desquamation	I-Entity
,	O
and	O
necrosis	I-Entity
in	O
VCM	I-Entity
-	O
treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	I-Entity
groups	O
.	O

Erdosteine	I-Entity
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	I-Entity
reduces	O
the	O
VCM	I-Entity
-	O
induced	O
kidney	B-Entity
damage	I-Entity
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O



Does	O
domperidone	I-Entity
potentiate	O
mirtazapine	I-Entity
-	O
associated	O
restless	B-Entity
legs	I-Entity
syndrome	I-Entity
?	O

There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-Entity
legs	I-Entity
syndrome	I-Entity
(	O
RLS	I-Entity
)	O
.	O

For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	I-Entity
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	I-Entity
and	O
dopamine	I-Entity
agonists	O
,	O
whereas	O
central	O
dopamine	I-Entity
D2	O
receptor	O
antagonists	O
can	O
induce	O
or	O
aggravate	O
RLS	I-Entity
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	I-Entity
,	O
a	O
peripheral	O
dopamine	I-Entity
D2	O
receptor	O
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	I-Entity
.	O

Mirtazapine	I-Entity
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	I-Entity
in	O
several	O
recent	O
publications	O
.	O

The	O
authors	O
report	O
here	O
a	O
depressed	O
patient	O
comorbid	O
with	O
postprandial	B-Entity
dyspepsia	I-Entity
who	O
developed	O
RLS	I-Entity
after	O
mirtazapine	I-Entity
had	O
been	O
added	O
to	O
his	O
domperidone	I-Entity
therapy	O
.	O

Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	I-Entity
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	I-Entity
,	O
and	O
his	O
RLS	I-Entity
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	I-Entity
.	O

Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	I-Entity
and	O
the	O
symptoms	O
of	O
RLS	I-Entity
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	I-Entity
on	O
mirtazapine	I-Entity
-	O
associated	O
RLS	I-Entity
.	O

However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	I-Entity
can	O
be	O
associated	O
with	O
RLS	I-Entity
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	I-Entity
D2	O
receptor	O
antagonists	O
.	O



Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	B-Entity
arterial	I-Entity
disease	I-Entity
.	O

AIM	O
:	O
To	O
study	O
the	O
change	O
of	O
lipid	O
metabolism	O
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	B-Entity
cancer	I-Entity
.	O

We	O
studied	O
with	O
a	O
2.5	O
years	O
follow	O
-	O
up	O
the	O
changes	O
in	O
plasma	O
cholesterols	I-Entity
(	O
C	I-Entity
)	O
,	O
triglycerides	I-Entity
(	O
TG	I-Entity
)	O
,	O
lipoproteins	O
(	O
LP	O
)	O
,	O
and	O
apolipoproteins	O
(	O
Apo	O
)	O

fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	B-Entity
cancer	I-Entity
(	O
stage	O
:	O
T1cN0M0	O
,	O
Gleason	O
score	O
:	O
2	O
-	O
5	O
)	O
during	O
treatment	O
with	O
cyproterone	B-Entity
acetate	I-Entity
(	O
CPA	I-Entity
)	O
without	O
surgical	O
management	O
or	O
radiation	O
therapy	O
.	O

Significant	O
decreases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
increase	O
of	O
triglyceride	I-Entity
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	I-Entity
.	O

After	O
a	O
period	O
of	O
2.5	O
years	O
on	O
CPA	I-Entity
treatment	O
,	O
four	O
patients	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	B-Entity
heart	I-Entity
disease	I-Entity
.	O

Ischaemic	O
coronary	B-Entity
arteriosclerosis	I-Entity
with	O
an	O
incidence	O
rate	O
of	O
16.6%	O
as	O
caused	O
by	O
prolonged	O
CPA	I-Entity
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	I-Entity
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O

pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglyceridemic	B-Entity
effect	I-Entity
caused	O
by	O
estrogen	I-Entity
.	O



5-Fluorouracil	I-Entity
cardiotoxicity	I-Entity
induced	O
by	O
alpha	B-Entity
-	I-Entity
fluoro	I-Entity
-	I-Entity
beta	I-Entity
-	I-Entity
alanine	I-Entity
.	O

Cardiotoxicity	I-Entity
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
treatment	O
for	O
malignancies	I-Entity
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70-year	O
-	O
old	O
man	O
with	O
5-FU	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-Entity
-	I-Entity
fluoro	I-Entity
-	I-Entity
beta	I-Entity
-	I-Entity
alanine	I-Entity
(	O
FBAL	I-Entity
)	O
was	O
observed	O
.	O

The	O
patient	O
,	O
who	O
had	O
unresectable	O
colon	B-Entity
cancer	I-Entity
metastases	O
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O

After	O
admission	O
,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	I-Entity
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	B-Entity
pain	I-Entity
with	O
right	B-Entity
bundle	I-Entity
branch	I-Entity
block	I-Entity
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	I-Entity
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precordial	B-Entity
pain	I-Entity
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5-FU	I-Entity
.	O

As	O
the	O
precordial	B-Entity
pain	I-Entity
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5-FU	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
,	O
the	O
administration	O
of	O
5-FU	I-Entity
was	O
abandoned	O
.	O

Instead	O
,	O
oral	O
administration	O
of	O
S-1	O
(	O
a	O
derivative	O
of	O
5-FU	I-Entity
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S-1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	I-Entity
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5-FU	I-Entity
into	O
FBAL	I-Entity
.	O

The	O
serum	O
FBAL	I-Entity
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S-1	O
administration	O
.	O

Thereafter	O
,	O
no	O
cardiac	B-Entity
symptoms	I-Entity
were	O
observed	O
.	O

The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	I-Entity
is	O
related	O
to	O
5-FU	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

S-1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5-FU	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O



The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	I-Entity
and	O
doxorubicin	I-Entity
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
in	O
mice	O
.	O

Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	I-Entity
,	O
the	O
anthracyclin	O
doxorubicin	I-Entity
(	O
DOX	I-Entity
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O

DOX	I-Entity
-	O
induced	O
cardiac	B-Entity
damage	I-Entity
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	I-Entity
.	O

Reactive	O
oxygen	I-Entity
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O

The	O
semisynthetic	O
flavonoid	I-Entity
monohydroxyethylrutoside	I-Entity
(	O
monoHER	I-Entity
)	O
showed	O
cardioprotection	O
against	O
DOX	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
through	O
its	O
radical	O
scavenging	O
and	O
iron	I-Entity
chelating	O
properties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	I-Entity
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	I-Entity
and	O
DOX	I-Entity
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	I-Entity
.	O

Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	O
were	O
treated	O
with	O
saline	O
,	O
DOX	I-Entity
alone	O
or	O
DOX	I-Entity
(	O
4	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O

preceded	O
by	O
monoHER	I-Entity
(	O
500	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
with	O
an	O
interval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	B-Entity
damage	I-Entity
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	I-Entity
Treat	O
Rep	O
62(6):865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	I-Entity
alone	O
induced	O
significant	O
cardiac	B-Entity
damage	I-Entity
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P<0.001	O
)	O
.	O

The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9.6-fold	O
(	O
95%	O
CI	O
4.4	O
-	O
21.0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	I-Entity
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O

The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	I-Entity
preceded	O
by	O
monoHER	I-Entity
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1.6	O
to	O
2.8	O
(	O
mean	O
2.2	O
,	O
95%	O
CI	O
1.2	O
-	O
4.1	O
,	O
P=0.019	O
)	O
.	O

The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	I-Entity
before	O
DOX	I-Entity
led	O
to	O
a	O
significant	O
4.4-fold	O
reduction	O
(	O
P<0.001	O
,	O
95%	O
CI	O
2.3	O
-	O
8.2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O

This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	I-Entity
and	O
DOX	I-Entity
administration	O
(	O
P=0.345	O
)	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	I-Entity
may	O
be	O
administered	O
shortly	O
before	O
DOX	I-Entity
.	O



Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	I-Entity
administration	O
for	O
atrial	B-Entity
fibrillation	I-Entity
and	I-Entity
flutter	I-Entity
.	O

Bepridil	B-Entity
hydrochloride	I-Entity
(	O
Bpd	I-Entity
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	B-Entity
fibrillation	I-Entity
(	O
AF	I-Entity
)	O
and	O
atrial	B-Entity
flutter	I-Entity
(	O
AFL	I-Entity
)	O
.	O

However	O
,	O
serious	O
adverse	O
effects	O
,	O
including	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
(	O
Tdp	I-Entity
)	O
,	O
have	O
been	O
reported	O
.	O

Adverse	O
effects	O
of	O
Bpd	I-Entity
requiring	O
discontinuation	O
of	O
treatment	O
were	O
evaluated	O
.	O

Bpd	I-Entity
was	O
administered	O
to	O
459	O
patients	O
(	O
361	O
males	O
,	O
63+/-12	O
years	O
old	O
)	O
comprising	O
378	O
AF	I-Entity
and	O
81	O
AFL	I-Entity
cases	O
.	O

There	O
was	O
marked	O
QT	B-Entity
prolongation	I-Entity
greater	O
than	O
0.55	O
s	O
in	O
13	O
patients	O
,	O
bradycardia	I-Entity
less	O
than	O
40	O
beats	O
/	O

min	O
in	O
6	O
patients	O
,	O
dizziness	I-Entity
and	O
general	O
fatigue	I-Entity
in	O
1	O
patient	O
each	O
.	O

In	O
4	O
of	O
13	O
patients	O
with	O
QT	B-Entity
prolongation	I-Entity
,	O
Tdp	I-Entity
occurred	O
.	O

The	O
major	O
triggering	O
factors	O
of	O
Tdp	I-Entity
were	O
hypokalemia	I-Entity
and	O
sudden	O
decrease	O
in	O
heart	O
rate	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	I-Entity
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	I-Entity
.	O

CONCLUSION	O
:	O
Careful	O
observation	O
of	O
serum	O
potassium	I-Entity
concentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	I-Entity
administration	O
,	O
particularly	O
in	O
elderly	O
patients	O
.	O



Enhanced	O
isoproterenol	I-Entity
-	O
induced	O
cardiac	B-Entity
hypertrophy	I-Entity
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin	O
-	O
angiotensin	I-Entity
system	O
(	O
RAS	O
)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate	O
.	O

agonist	O
isoproterenol	I-Entity
(	O
Iso	I-Entity
)	O
.	O

In	O
isolated	O
hearts	O
,	O
Iso	I-Entity
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
and	O
maximal	O
contraction	O
(	O
+	O
dP	O
/	O
dt(max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

LV	B-Entity
hypertrophy	I-Entity
induced	O
by	O
Iso	I-Entity
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(	O
in	O
g	O
LV	O
wt/100	O

The	O
greater	O
LV	B-Entity
hypertrophy	I-Entity
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta	O
-	O
AR	O
and	O
upregulation	O
of	O
LV	O
beta	O
-	O
AR	O
kinase-1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats	O
.	O

The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta	O
-	O
AR	O
antagonist	O
metoprolol	I-Entity
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(	O
-9.9	O

1.5%	O
)	O
,	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	I-Entity
on	O
HR	O
was	O
similar	O
in	O
both	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta	O
-	O
AR	O
agonist	O
-	O
induced	O
cardiac	B-Entity
inotropic	I-Entity
response	O
and	O
hypertrophy	I-Entity
,	O
possibly	O
due	O
to	O
chronically	O
low	O
sympathetic	O
outflow	O
directed	O
to	O
the	O
heart	O
.	O



Drug	O
-	O
induced	O
long	B-Entity
QT	I-Entity
syndrome	I-Entity
in	O
injection	O
drug	O
users	O
receiving	O
methadone	I-Entity
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors	O
.	O

Drug	O
-	O
induced	O
long	B-Entity
QT	I-Entity
syndrome	I-Entity
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O

Methadone	I-Entity
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
the	O
inpatient	O
setting	O
,	O
the	O
frequency	O
of	O
QT	B-Entity
interval	I-Entity
prolongation	I-Entity
with	O
methadone	I-Entity
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O

:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	I-Entity
and	O
those	O
not	O
receiving	O
methadone	I-Entity
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5-year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	I-Entity
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	I-Entity
.	O

In	O
addition	O
to	O
methadone	I-Entity
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B-Entity
prolongation	I-Entity
.	O

Among	O
167	O
methadone	I-Entity
maintenance	O
patients	O
,	O
the	O
prevalence	O
of	O
QTc	O
prolongation	O
to	O
0.50	O
second((1/2	O
)	O
)	O
or	O
longer	O
was	O
16.2%	O
compared	O
with	O
0%	O
in	O
80	O
control	O
subjects	O
.	O

Six	O
patients	O
(	O
3.6%	O
)	O
in	O
the	O
methadone	I-Entity
group	O
presented	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
.	O

QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	I-Entity
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0.20	O
;	O
P<.01	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31.8%	O
of	O
QTc	O
variability	O
to	O
methadone	I-Entity
dose	O
,	O
cytochrome	O

P-450	O
3A4	O
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	I-Entity
,	O
and	O
altered	O
liver	O
function	O
.	O

QT	B-Entity
interval	I-Entity
prolongation	I-Entity
in	O
methadone	I-Entity
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O

Methadone	I-Entity
dose	O
,	O
presence	O
of	O
cytochrome	O
P-450	O
3A4	O
inhibitors	O
,	O
potassium	I-Entity
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B-Entity
prolongation	I-Entity
.	O

Long	B-Entity
QT	I-Entity
syndrome	I-Entity
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	I-Entity
.	O



Mechanisms	O
of	O
hypertension	I-Entity
induced	O
by	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O

Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
in	O
hypertension	I-Entity
is	O
a	O
hallmark	O
of	O
arterial	B-Entity
dysfunction	I-Entity
.	O

Experimental	O
hypertension	I-Entity
created	O
by	O
the	O
removal	O
of	O
NO	I-Entity
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O

We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	B-Entity
-	I-Entity
nitro	I-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
(	O
LNNA	I-Entity
)	O
hypertension	I-Entity
through	O
these	O
mechanisms	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
NO	I-Entity
synthase	O
inhibitor	O
LNNA	I-Entity
(	O
0.5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O

5	O
mm	O
Hg	O
in	O
LNNA	I-Entity
rats	O
(	O
P<0.05	O
)	O
.	O

Maximal	O
contraction	O
to	O
norepinephrine	I-Entity
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	I-Entity
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET-1	O
was	O
significantly	O
reduced	O
(	O
54%	O
control	O
)	O
.	O

Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	I-Entity
(	O
37%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET-1	O
was	O
observed	O
.	O

Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	I-Entity
hypertension	I-Entity
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	I-Entity
.	O

The	O
superoxide	I-Entity
scavenger	O
tempol	I-Entity
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg(-1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	I-Entity
rats	O
(	O
-18	O
+	O
/-	O

Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	I-Entity
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	I-Entity
hypertensive	I-Entity
rats	O
(	O
76	O
+	O
/-	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	I-Entity
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	I-Entity
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O

These	O
data	O
suggest	O
that	O
while	O
NO	I-Entity
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	I-Entity
.	O



Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	I-Entity
-	O
induced	O
extrapyramidal	B-Entity
syndrome	I-Entity
in	O
Chinese	O
schizophrenic	I-Entity
patients	O
.	O

Extrapyramidal	B-Entity
syndrome	I-Entity
(	O
EPS	I-Entity
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor	O
.	O

Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	I-Entity
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	I-Entity
-	O
induced	O
EPS	I-Entity
in	O
schizophrenic	I-Entity
patients	O
.	O

:	O
We	O
identified	O
seven	O
SNP(single	O
nucleotide	O
polymorphism	O
)	O
(	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	I-Entity
inpatients	O
(	O
59	O
with	O
EPS	I-Entity
and	O
87	O
without	O
EPS	I-Entity
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	I-Entity
after	O
8	O
weeks	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	I-Entity
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	I-Entity
.	O

Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	I-Entity
in	O
Caucasians	O
.	O



Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
the	O
rat	O
.	O

Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	I-Entity
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
problem	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long	O
-	O
term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	I-Entity
.	O

Thereafter	O
,	O
seizures	I-Entity
were	O
induced	O
by	O
pilocarpine	I-Entity
injections	O
in	O
trained	O
and	O
non	O
-	O
trained	O
control	O
groups	O
.	O

During	O
the	O
acute	O
period	O
of	O
status	B-Entity
epilepticus	I-Entity
,	O
we	O
measured	O
:	O
(	O
1	O
)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensity	O
of	O
seizures	I-Entity
,	O
(	O
3	O
)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6-h	O
observation	O
period	O
,	O
and	O
(	O
4	O
)	O
the	O
time	O
when	O
the	O
acute	O
period	O
ended	O
.	O

All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	I-Entity
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	B-Entity
epilepticus	I-Entity
.	O



Tonic	O
dopaminergic	O
stimulation	O
impairs	B-Entity
associative	I-Entity
learning	I-Entity
in	O
healthy	O
subjects	O
.	O

Endogenous	O
dopamine	I-Entity
plays	O
a	O
central	O
role	O
in	O
salience	O
coding	O
during	O
associative	O
learning	O
.	O

Administration	O
of	O
the	O
dopamine	I-Entity
precursor	O
levodopa	I-Entity
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	I-Entity
patients	O
.	O

Because	O
levodopa	I-Entity
increases	O
both	O
phasic	O
and	O
tonic	O
dopaminergic	O
neurotransmission	O
,	O
the	O
critical	O
mechanism	O
mediating	O
the	O
enhancement	O
of	O
learning	O
is	O
unresolved	O
.	O

Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine	I-Entity
-	O
receptor	O
agonist	O
pergolide	I-Entity
(	O
0.1	O
mg	O
)	O
vs	O
placebo	O
120	O
min	O
before	O
training	O
on	O
each	O
training	O
day	O
.	O

The	O
dopamine	I-Entity
agonist	O
significantly	O
impaired	B-Entity
novel	I-Entity
word	I-Entity
learning	I-Entity
compared	O
to	O
placebo	O
.	O

Subjects	O
treated	O
with	O
pergolide	I-Entity
also	O
showed	O
restricted	O
emotional	O
responses	O
compared	O
to	O
the	O
PLACEBO	O
group	O
.	O

The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergolide	I-Entity
was	O
related	O
to	O
the	O
degree	O
of	O
learning	O
inhibition	O
.	O

These	O
findings	O
suggest	O
that	O
tonic	O
occupation	O
of	O
dopamine	I-Entity
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	I-Entity
signals	O
.	O

Thus	O
,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	I-Entity
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	I-Entity
patients	O
.	O



Minocycline	I-Entity
-	O
induced	O
vasculitis	I-Entity
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	B-Entity
nodosa	I-Entity
.	O

A	O
47-year	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	I-Entity
for	O
palmoplantar	B-Entity
pustulosis	I-Entity
developed	O
fever	I-Entity
,	O
myalgias	I-Entity
,	O
polyneuropathy	I-Entity
,	O
and	O
testicular	B-Entity
pain	I-Entity
,	O
with	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
.	O

These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	B-Entity
nodosa	I-Entity
.	O

Stopping	O
minocycline	I-Entity
led	O
to	O
amelioration	O
of	O
symptoms	O
and	O
normalization	O
of	O
CRP	O
level	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline	I-Entity
-	O
induced	O
vasculitis	I-Entity
satisfying	O
the	O
criteria	O
.	O

Differential	O
diagnosis	O
for	O
drug	O
-	O
induced	O
disease	O
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	B-Entity
nodosa	I-Entity
.	O



Intramuscular	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
combined	O
with	O
lamivudine	I-Entity
in	O
prevention	O
of	O
hepatitis	B-Entity
B	I-Entity
recurrence	O
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Combined	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
(	O
HBIg	O
)	O
and	O
lamivudine	I-Entity
in	O
prophylaxis	O
of	O
the	O
recurrence	O
of	O
hepatitis	B-Entity
B	I-Entity
after	O
liver	O
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	I-Entity
positive	O
patients	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	O
transplantation	O
for	O
patients	O
with	O
hepatitis	B-Entity
B	I-Entity
virus	O
(	O
HBV	O
)	O
.	O

A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV	O
-	O
related	O
cirrhotic	B-Entity
diseases	I-Entity
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months	O
.	O

A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	I-Entity
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57.1%	O
(	O
4/7	O
)	O
and	O
62.5%	O
(	O
5/8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	I-Entity
positive	O
patients	O
respectively	O
to	O
convert	O
to	O
be	O
negative	O
.	O

Lamivudine	I-Entity
combined	O
with	O
intramuscular	O
HBIg	O
can	O
effectively	O
prevent	O
allograft	O
from	O
the	O
recurrence	O
of	O
HBV	O
after	O
liver	O
transplantation	O
.	O



Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-Entity
acetate	I-Entity
(	O
BIA	B-Entity
2	I-Entity
-	I-Entity
093	I-Entity
)	O
on	O
seizures	I-Entity
induced	O
by	O
microperfusion	O
of	O
picrotoxin	I-Entity
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	O
.	O

Eslicarbazepine	B-Entity
acetate	I-Entity
(	O
BIA	B-Entity
2	I-Entity
-	I-Entity
093	I-Entity
,	O
S-(-)-10-acetoxy-10,11-dihydro-5H	B-Entity
-	I-Entity
dibenzo	I-Entity
/	I-Entity
b	I-Entity
,	I-Entity
f	I-Entity
/	I-Entity
azepine-5-carboxamide	I-Entity
)	O
is	O
a	O
novel	O
antiepileptic	O
drug	O
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	I-Entity
(	O
CBZ	I-Entity
)	O
and	O
oxcarbazepine	I-Entity
(	O
OXC	I-Entity
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-Entity
acetate	I-Entity
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	I-Entity
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	I-Entity
patterns	O
.	O

In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	I-Entity
,	O
the	O
average	O
number	O
of	O
seizures	I-Entity
was	O
2.3+/-1.2	O
,	O
and	O
average	O
seizure	I-Entity
duration	O
was	O
39.5+/-8.4s	O
.	O

Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	I-Entity
microperfusion	O
prevented	O
seizures	I-Entity
in	O
the	O
75%	O
of	O
the	O
rats	O
.	O

Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	I-Entity
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O

kg	O
,	O
significant	O
reductions	O
in	O
seizures	I-Entity
duration	O
(	O
24.3+/-6.8s	O
)	O
and	O
seizure	I-Entity
number	O
(	O
1.6+/-0.34	O
)	O
were	O
found	O
.	O

No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-Entity
acetate	I-Entity
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	I-Entity
.	O

Chinese	B-Entity
herbal	I-Entity
medicine	O
preparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
public	O
as	O
natural	O
and	O
safe	O
remedies	O
for	O
a	O
variety	O
of	O
medical	O
conditions	O
.	O

Nephropathy	I-Entity
caused	O
by	O
Chinese	B-Entity
herbs	I-Entity
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	B-Entity
acids	I-Entity
.	O

We	O
report	O
a	O
23-year	O
-	O
old	O
woman	O
who	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
following	O
prolonged	O
use	O
of	O
a	O
proprietary	O
Chinese	B-Entity
herbal	I-Entity
slimming	O
pill	O
that	O
contained	O
anthraquinone	I-Entity
derivatives	O
,	O
extracted	O
from	O
Rhizoma	O
Rhei	O
(	O
rhubarb	O
)	O
.	O

The	O
renal	B-Entity
injury	I-Entity
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
diclofenac	I-Entity
.	O

Renal	O
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	I-Entity
.	O

Spontaneous	O
renal	O
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills	O
,	O
but	O
mild	O
interstitial	O
fibrosis	I-Entity
and	O
tubular	O
atrophy	I-Entity
was	O
still	O
evident	O
histologically	O
4	O
months	O
later	O
.	O

Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone	I-Entity
-	O
containing	O
herbal	O
agent	O
and	O
renal	B-Entity
injury	I-Entity
remains	O
to	O
be	O
proven	O
,	O
phytotherapy	O
-	O
associated	O
interstitial	O
nephropathy	I-Entity
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	B-Entity
failure	I-Entity
.	O



Chloroacetaldehyde	I-Entity
as	O
a	O
sulfhydryl	I-Entity
reagent	O
:	O
the	O
role	O
of	O
critical	O
thiol	I-Entity
groups	O
in	O
ifosfamide	I-Entity
nephropathy	I-Entity
.	O

Chloroacetaldehyde	I-Entity
(	O
CAA	I-Entity
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	I-Entity
(	O
IFO	I-Entity
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-Entity
damage	I-Entity
following	O
anti	O
-	O
tumor	I-Entity
therapy	O
with	O
IFO	I-Entity
.	O

Depletion	O
of	O
sulfhydryl	I-Entity
(	O
SH	I-Entity
)	O

In	O
this	O
work	O
the	O
effect	O
of	O
CAA	I-Entity
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	O
)	O
was	O
investigated	O
.	O

Toxicity	I-Entity
of	O
CAA	I-Entity
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	O
release	O
,	O
trypan	B-Entity
blue	I-Entity
exclusion	O
assay	O
and	O
caspase-3	O
activity	O
.	O

Free	O
thiols	I-Entity
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O

CAA	I-Entity
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	I-Entity
and	O
an	O
increase	O
in	O
necrosis	I-Entity
markers	O
.	O

CAA	I-Entity
but	O
not	O
acrolein	I-Entity
inhibited	O
the	O
cysteine	I-Entity

B.	O
Caspase	O
activation	O
by	O
cisplatin	I-Entity
was	O
inhibited	O
by	O
CAA	I-Entity
.	O

In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	I-Entity
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O

The	O
effects	O
of	O
CAA	I-Entity
on	O
cysteine	I-Entity
protease	O
activities	O
and	O
thiols	I-Entity
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	I-Entity
with	O
thiol	I-Entity
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	I-Entity
on	O
necrosis	I-Entity
markers	O
,	O
thiol	I-Entity
depletion	O
and	O
cysteine	I-Entity
protease	O
inhibition	O
in	O
living	O
cells	O
.	O

Thus	O
,	O
CAA	I-Entity
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	I-Entity
,	O
mediating	O
its	O
toxicity	I-Entity
on	O
hRPTEC	O
.	O

Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	I-Entity
nephropathy	I-Entity
in	O
patients	O
.	O



Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
in	O
the	O
adult	O
rat	O
.	O

Following	O
status	B-Entity
epilepticus	I-Entity
in	O
the	O
rat	O
,	O
dentate	O
granule	O
cell	O
neurogenesis	O
increases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
neurons	O
appear	O
to	O
develop	O
ectopically	O
,	O
in	O
the	O
hilar	O
region	O
of	O
the	O
hippocampal	O
formation	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	I-Entity
that	O
ultimately	O
develop	O
after	O
status	B-Entity
epilepticus	I-Entity
.	O

To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
.	O

The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	B-Entity
epilepticus	I-Entity
is	O
substantial	O
,	O
and	O
stable	O
over	O
time	O
.	O

Interestingly	O
,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	I-Entity
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	I-Entity
.	O

The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	I-Entity
model	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O



A	O
prospective	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	I-Entity
in	O
autistic	B-Entity
disorder	I-Entity
.	O

Post	O
-	O
mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	I-Entity
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	I-Entity
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator	O
,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	I-Entity
.	O

Thirteen	O
medication	O
-	O
free	O
children	O
with	O
autism	I-Entity
(	O
mean	O
age	O
,	O
8.8	O
+	O
/-	O

3.5	O
years	O
)	O
participated	O
in	O
a	O
12-week	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	I-Entity
.	O

Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent	O
-	O
rated	O
irritability	I-Entity
and	O
social	O
withdrawal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvements	O
in	O
emotional	O
lability	O
and	O
inattention	O
on	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
--	O
Revised	O
.	O

Overall	O
,	O
galantamine	I-Entity
was	O
well	O
-	O
tolerated	O
,	O
with	O
no	O
significant	O
adverse	O
effects	O
apart	O
from	O
headaches	I-Entity
in	O
one	O
patient	O
.	O

In	O
this	O
open	O
trial	O
,	O
galantamine	I-Entity
was	O
well	O
-	O
tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	I-Entity
,	O
particularly	O
aggression	I-Entity
,	O
behavioral	B-Entity
dyscontrol	I-Entity
,	O
and	O
inattention	I-Entity
.	O



Randomized	O
comparison	O
of	O
olanzapine	I-Entity
versus	O
risperidone	I-Entity
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	I-Entity
:	O
4-month	O
outcomes	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4-month	O
treatment	O
outcomes	O
for	O
olanzapine	I-Entity
versus	O
risperidone	I-Entity
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	I-Entity
spectrum	O
disorders	O
.	O

One	O
hundred	O
twelve	O
subjects	O
(	O
70%	O
male	O
;	O
mean	O
age=23.3	O
years	O
[	O
SD	O
=	O
5.1	O
]	O
)	O
with	O
first	O
-	O
episode	O
schizophrenia	I-Entity
(	O
75%	O
)	O
,	O
schizophreniform	B-Entity
disorder	I-Entity
(	O
17%	O
)	O
,	O
or	O
schizoaffective	B-Entity
disorder	I-Entity
(	O
8%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	I-Entity
(	O
2.5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	I-Entity
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O

Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	I-Entity
(	O
43.7%	O
,	O
95%	O
CI=28.8%-58.6%	O
)	O
and	O
risperidone	I-Entity
(	O
54.3%	O
,	O
95%	O
CI=39.9%-68.7%	O
)	O
.	O

Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	I-Entity
group	O
(	O
40.9%	O
,	O
95%	O
CI=16.8%-65.0%	O
)	O
than	O
in	O
the	O
risperidone	I-Entity
group	O
(	O
18.9%	O
,	O
95%	O
CI=0%-39.2%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O

Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	I-Entity
and	O
akathisia	I-Entity
did	O
not	O
differ	O
between	O
medications	O
.	O

Extrapyramidal	B-Entity
symptom	I-Entity
severity	O
scores	O
were	O
1.4	O
(	O
95%	O
CI=1.2	O
-	O
1.6	O
)	O
with	O
risperidone	I-Entity
and	O
1.2	O
(	O
95%	O
CI=1.0	O
-	O
1.4	O
)	O
with	O
olanzapine	I-Entity
.	O

Significantly	O
more	O
weight	B-Entity
gain	I-Entity
occurred	O
with	O
olanzapine	I-Entity
than	O
with	O
risperidone	I-Entity
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17.3%	O
(	O
95%	O
CI=14.2%-20.5%	O
)	O
with	O
olanzapine	I-Entity
and	O
11.3%	O
(	O
95%	O
CI=8.4%-14.3%	O
)	O
with	O
risperidone	I-Entity
.	O

Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24.3	O
(	O
95%	O
CI=22.8	O
-	O
25.7	O
)	O
versus	O
28.2	O
(	O
95%	O
CI=26.7	O
-	O
29.7	O
)	O
with	O
olanzapine	I-Entity
and	O
23.9	O
(	O
95%	O
CI=22.5	O
-	O
25.3	O
)	O
versus	O
26.7	O
(	O
95%	O
CI=25.2	O
-	O
28.2	O
)	O
with	O
risperidone	I-Entity
.	O

CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	I-Entity
were	O
equal	O
to	O
those	O
with	O
olanzapine	I-Entity
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O

Olanzapine	I-Entity
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O

Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-Entity
gain	I-Entity
,	O
but	O
weight	B-Entity
gain	I-Entity
was	O
greater	O
with	O
olanzapine	I-Entity
.	O



Early	O
paracentral	O
visual	B-Entity
field	I-Entity
loss	I-Entity
in	O
patients	O
taking	O
hydroxychloroquine	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	B-Entity
sulfate	I-Entity
who	O
attended	O
an	O
ophthalmic	O
screening	O
program	O
.	O

RESULTS	O
:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	I-Entity
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmology	O
were	O
reviewed	O
.	O

Thirty	O
-	O
five	O
patients	O
(	O
13.4%	O
)	O
had	O
visual	B-Entity
field	I-Entity
abnormalities	I-Entity
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	I-Entity
treatment	O
in	O
4	O
patients	O
(	O
1.5%	O
)	O
.	O

The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	O
assessment	O
,	O
funduscopy	O
,	O
and	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	B-Entity
field	I-Entity
defects	I-Entity
appeared	O
before	O
any	O
corresponding	O
changes	O
in	O
any	O
other	O
tested	O
clinical	O
parameters	O
;	O
the	O
defects	O
were	O
reproducible	O
and	O
the	O
test	O
parameters	O
were	O
reliable	O
.	O

Patients	O
taking	O
hydroxychloroquine	I-Entity
can	O
demonstrate	O
a	O
toxic	O
reaction	O
in	O
the	O
retina	O
despite	O
the	O
absence	O
of	O
known	O
risk	O
factors	O
.	O



Peri	O
-	O
operative	O
atrioventricular	B-Entity
block	I-Entity
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	I-Entity
and	O
paclitaxel	I-Entity
.	O

A	O
47-year	O
-	O
old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	B-Entity
of	I-Entity
the	I-Entity
breast	I-Entity
6	O
months	O
previously	O
.	O

In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
epirubicin	I-Entity
,	O
paclitaxel	I-Entity
(	O
Taxol	I-Entity
)	O
and	O
cyclophosphamide	I-Entity
.	O

She	O
was	O
found	O
to	O
be	O
bradycardic	I-Entity
at	O
pre	O
-	O
operative	O
assessment	O
but	O
had	O
no	O
cardiac	O
symptoms	O
.	O

Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	B-Entity
block	I-Entity
was	O
diagnosed	O
on	O
electrocardiogram	O
,	O
and	O
temporary	O
transvenous	O
ventricular	O
pacing	O
instituted	O
in	O
the	O
peri	O
-	O
operative	O
period	O
.	O

We	O
discuss	O
how	O
evidence	O
-	O
based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case	O
,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	I-Entity
that	O
may	O
develop	O
over	O
many	O
years	O
.	O



Risks	O
and	O
benefits	O
of	O
COX-2	B-Entity
inhibitors	I-Entity
vs	O
non	O
-	O
selective	O
NSAIDs	O
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O

The	O
risk	O
of	O
acute	B-Entity
myocardial	I-Entity
infarction	I-Entity
(	O
AMI	I-Entity
)	O
with	O
COX-2	B-Entity
inhibitors	I-Entity
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O

non	B-Entity
-	I-Entity
steroidal	I-Entity
anti	I-Entity
-	I-Entity
inflammatory	I-Entity
drugs	I-Entity
(	O
NSAIDs	O
)	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	I-Entity
and	O
GI	B-Entity
bleeding	I-Entity
among	O
elderly	O
patients	O
using	O
COX-2	B-Entity
inhibitors	I-Entity
,	O
NS	O
-	O
NSAIDs	O
and	O
acetaminophen	I-Entity
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	I-Entity
during	O
1999	O
-	O
2002	O
.	O

Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	I-Entity
were	O
:	O
75,761	O
to	O
acetaminophen	I-Entity
,	O
42,671	O
to	O
rofecoxib	I-Entity
65,860	O
to	O
celecoxib	I-Entity
,	O
and	O
37,495	O
to	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	I-Entity
,	O
they	O
were	O
:	O
14,671	O
to	O
rofecoxib	I-Entity
,	O
22,875	O
to	O
celecoxib	I-Entity
,	O
9,832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38,048	O
to	O
acetaminophen	I-Entity
.	O

Among	O
non	O
-	O
users	O
of	O
aspirin	I-Entity
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	I-Entity
/	O
GI	O
vs	O
the	O
acetaminophen	I-Entity
(	O
with	O
no	O
aspirin	I-Entity
)	O

group	O
were	O
:	O
rofecoxib	I-Entity
1.27	O
(	O
1.13	O
,	O
1.42	O
)	O
,	O
celecoxib	I-Entity
0.93	O
(	O
0.83	O
,	O
1.03	O
)	O
,	O
naproxen	I-Entity
1.59	O
(	O
1.31	O
,	O
1.93	O
)	O
,	O
diclofenac	I-Entity
1.17	O
(	O
0.99	O
,	O
1.38	O
)	O
and	O
ibuprofen	I-Entity
1.05	O
(	O
0.74	O
,	O
1.51	O
)	O
.	O

Among	O
users	O
of	O
aspirin	I-Entity
,	O
they	O
were	O
:	O
rofecoxib	I-Entity
1.73	O
(	O
1.52	O
,	O
1.98	O
)	O
,	O
celecoxib	I-Entity
1.34	O
(	O
1.19	O
,	O
1.52	O
)	O
,	O
ibuprofen	I-Entity
1.51	O
(	O
0.95	O
,	O
2.41	O
)	O
,	O
diclofenac	I-Entity
1.69	O
(	O
1.35	O
,	O
2.10	O
)	O
,	O
naproxen	I-Entity
1.35	O
(	O
0.97	O
,	O
1.88	O
)	O
and	O
acetaminophen	I-Entity
1.29	O
(	O
1.17	O
,	O
1.42	O
)	O
.	O

Among	O
non	O
-	O
users	O
of	O
aspirin	I-Entity
,	O
naproxen	I-Entity
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	I-Entity
/	O
GI	B-Entity
bleeding	I-Entity
.	O

The	O
AMI	I-Entity
/	O
GI	O
toxicity	I-Entity
of	O
celecoxib	I-Entity
was	O
similar	O
to	O
that	O
of	O
acetaminophen	I-Entity
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	I-Entity
and	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	I-Entity
,	O
both	O
celecoxib	I-Entity
and	O
naproxen	I-Entity
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O



Quinine	I-Entity
-	O
induced	O
arrhythmia	I-Entity
in	O
a	O
patient	O
with	O
severe	B-Entity
malaria	I-Entity
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B-Entity
malaria	I-Entity
patient	O
with	O
jaundice	I-Entity
who	O
presented	O
with	O
arrhythmia	I-Entity
(	O
premature	B-Entity
ventricular	I-Entity
contraction	I-Entity
)	O
while	O
getting	O
quinine	I-Entity
infusion	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	I-Entity
,	O
chill	I-Entity
,	O
vomiting	I-Entity
,	O
jaundice	I-Entity
.	O

On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	I-Entity
8.25	O
mg	O
/	O
dL	O
,	O
conjugated	O

bilirubin	I-Entity
4.36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	I-Entity
3.89	O
mg	O
/	O
dL	O
,	O
potassium	I-Entity

3.52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B-Entity
malaria	I-Entity
with	O
jaundice	I-Entity
and	O
got	O
quinine	I-Entity
infusion	O
in	O
dextrose	I-Entity
5%	O
500	O
mg/8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	I-Entity
,	O
diarrhea	I-Entity
,	O
tinnitus	I-Entity
,	O
loss	B-Entity
of	I-Entity
hearing	I-Entity
.	O

After	O
30	O
hours	O
of	O
quinine	I-Entity
infusion	O
the	O
patient	O
felt	O
palpitation	I-Entity
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B-Entity
ventricular	I-Entity
contraction	I-Entity
(	O
PVC	I-Entity
)	O

>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
--	O
sinoatrial	B-Entity
block	I-Entity
,	O
positive	O
U	O
wave	O
.	O

He	O
was	O
treated	O
with	O
lidocaine	I-Entity
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	I-Entity
5%/24	O
hour	O
and	O
potassium	B-Entity
aspartate	I-Entity
tablet	O
.	O

Quinine	I-Entity
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	I-Entity
tablets	O
.	O

Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	I-Entity
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	I-Entity
level	O
was	O
3.34	O
meq	O
/	O
L.	O

Quinine	I-Entity
,	O
like	O
quinidine	I-Entity
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti	O
-	O
arrhythmic	I-Entity
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	I-Entity
that	O
can	O
cause	O
various	O
arrhythmias	I-Entity
,	O
including	O
severe	O
arrhythmia	I-Entity
such	O
as	O
multiple	O
PVC	I-Entity
.	O

Administration	O
of	O
parenteral	O
quinine	I-Entity
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	I-Entity
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B-Entity
diseases	I-Entity
or	O
patients	O
with	O
electrolyte	B-Entity
disorder	I-Entity
(	O
hypokalemia	I-Entity
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	I-Entity
and	O
or	O
diarrhea	I-Entity
in	O
malaria	I-Entity
cases	O
.	O



Penicillamine	I-Entity
-	O
related	O
lichenoid	B-Entity
dermatitis	I-Entity
and	O
utility	O
of	O
zinc	B-Entity
acetate	I-Entity
in	O
a	O
Wilson	B-Entity
disease	I-Entity
patient	O
with	O
hepatic	O
presentation	O
,	O
anxiety	I-Entity
and	O
SPECT	O
abnormalities	O
.	O

Wilson	B-Entity
's	I-Entity
disease	I-Entity
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	I-Entity
metabolism	O
with	O
consequent	O
copper	I-Entity
accumulation	O
and	O
toxicity	I-Entity
in	O
many	O
tissues	O
and	O
consequent	O
hepatic	B-Entity
,	I-Entity
neurologic	I-Entity
and	I-Entity
psychiatric	I-Entity
disorders	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
with	O
chronic	B-Entity
liver	I-Entity
disease	I-Entity
;	O
moreover	O
,	O
in	O
our	O
patient	O
,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	I-Entity
without	O
depression	I-Entity
,	O
99mTc	O
-	O
ECD	O
-	O
SPECT	O
showed	O
cortical	O
hypoperfusion	O
in	O
frontal	O
lobes	O
,	O
more	O
marked	O
on	O
the	O
left	O
frontal	O
lobe	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patient	O
,	O
penicillamine	I-Entity
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	B-Entity
dermatitis	I-Entity
,	O
and	O
zinc	B-Entity
acetate	I-Entity
permitted	O
to	O
continue	O
the	O
successful	O
treatment	O
of	O
the	O
patient	O
without	O
side	O
-	O
effects	O
.	O

In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	B-Entity
acetate	I-Entity
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
patient	O
in	O
which	O
penicillamine	I-Entity
-	O
related	O
side	O
effects	O
appeared	O
.	O

The	O
safety	O
of	O
the	O
zinc	B-Entity
acetate	I-Entity
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs	O
;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Since	O
most	O
of	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
penicillamine	I-Entity
-	O
treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	B-Entity
lesion	I-Entity
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genetic	O
factor	O
is	O
involved	O
in	O
drug	O
response	O
.	O

Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
therapy	O
,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
phenotypes	O
.	O



A	O
dramatic	O
drop	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
following	O
prehospital	O
GTN	I-Entity
administration	O
.	O

A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B-Entity
pain	I-Entity
awoke	O
with	O
chest	B-Entity
pain	I-Entity
following	O
an	O
afternoon	O
sleep	O
.	O

The	O
patient	O
's	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	I-Entity
via	O
a	O
face	O
mask	O
and	O
glyceryl	B-Entity
trinitrate	I-Entity
(	O
GTN	I-Entity
)	O
.	O

Several	O
minutes	O
after	O
the	O
GTN	I-Entity
the	O
patient	O
experienced	O
a	O
sudden	O
drop	B-Entity
in	I-Entity
blood	I-Entity
pressure	I-Entity
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	B-Entity
sulphate	I-Entity
and	O
a	O
fluid	O
challenge	O
.	O

Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	B-Entity
episode	I-Entity
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	O
accordingly	O
.	O



Acute	B-Entity
encephalopathy	I-Entity
and	O
cerebral	B-Entity
vasospasm	I-Entity
after	O
multiagent	O
chemotherapy	O
including	O
PEG	B-Entity
-	I-Entity
asparaginase	I-Entity
and	O
intrathecal	O
cytarabine	I-Entity
for	O
the	O
treatment	O
of	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
.	O

A	O
7-year	O
-	O
old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B	O
-	O
cell	O
acute	B-Entity
lymphoblastic	I-Entity
leukemia	I-Entity
(	O
ALL	I-Entity
)	O
is	O
described	O
.	O

The	O
patient	O
developed	O
acute	B-Entity
encephalopathy	I-Entity
evidenced	O
by	O
behavioral	O
changes	O
,	O
aphasia	I-Entity
,	O
incontinence	I-Entity
,	O
visual	B-Entity
hallucinations	I-Entity
,	O
and	O
right	O
-	O
sided	O
weakness	I-Entity
with	O
diffuse	O
cerebral	B-Entity
vasospasm	I-Entity
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	I-Entity
.	O

Vincristine	I-Entity
,	O
dexamethasone	I-Entity
,	O
and	O
polyethylene	B-Entity
glycol	I-Entity
-	I-Entity
asparaginase	I-Entity
were	O
also	O
administered	O
before	O
the	O
episode	O
as	O
part	O
of	O
induction	O
therapy	O
.	O



Comparison	O
of	O
valsartan	I-Entity
/	O
hydrochlorothiazide	I-Entity
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320/25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	I-Entity
adults	O
.	O

One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	I-Entity
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O

Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	I-Entity
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	I-Entity
therapies	O
.	O

This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	I-Entity
(	O
VAL	I-Entity
)	O
or	O
hydrochlorothiazide	I-Entity
(	O
HCTZ)-monotherapy	I-Entity
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	O
with	O
essential	B-Entity
hypertension	I-Entity
.	O

Patients	O
with	O
essential	B-Entity
hypertension	I-Entity
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	I-Entity
160	O
or	O
320	O
mg	O
;	O
HCTZ	I-Entity
12.5	O
or	O
25	O
mg	O
;	O
VAL	I-Entity
/	O
HCTZ	I-Entity
160/12.5	O
,	O
320/12.5	O
,	O
or	O
320/25	O
mg	O
;	O
or	O
placebo	O
.	O

VAL	I-Entity
/	O
HCTZ	I-Entity
320/12.5	O
and	O
320/25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54-week	O
,	O
open	O
-	O
label	O
extension	O
.	O

All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8-week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	I-Entity
and	O
HCTZ	I-Entity
,	O
P	O

The	O
mean	O
reduction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	I-Entity
/	O
HCTZ	I-Entity
320/25	O
mg	O
was	O
24.7/16.6	O
mm	O
Hg	O
,	O
compared	O
with	O
5.9/7.0	O
mm	O
Hg	O
with	O
placebo	O
.	O

The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	I-Entity
/	O
HCTZ	I-Entity
320/25	O
mg	O
compared	O
with	O
VAL	I-Entity
/	O
HCTZ	I-Entity
160/12.5	O
mg	O
(	O
P	O
<	O
0.002	O
)	O
.	O

The	O
incidence	O
of	O
hypokalemia	I-Entity
was	O
lower	O
with	O
VAL	I-Entity
/	O
HCTZ	I-Entity
combinations	O
(	O
1.8%-6.1%	O
)	O
than	O
with	O
HCTZ	I-Entity
monotherapies	O
(	O
7.1%-13.3%	O
)	O
.	O

The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	I-Entity
/	O
HCTZ	I-Entity
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	O
)	O
.	O

In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL	I-Entity
/	O
HCTZ	I-Entity
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	I-Entity
than	O
HCTZ	I-Entity
alone	O
.	O



Succimer	I-Entity
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead	I-Entity
-	O
exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B-Entity
impairment	I-Entity
in	O
the	O
absence	O
of	O
lead	I-Entity
exposure	O
.	O

BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	I-Entity
levels	O
.	O

However	O
,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	I-Entity
-	O
exposed	O
children	O
,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	I-Entity
exposure	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	I-Entity
exposure	O
and	O
treatment	O
with	O
succimer	I-Entity
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B-Entity
poisoning	I-Entity
.	O

Pb	I-Entity
exposure	O
produced	O
lasting	O
impairments	B-Entity
in	I-Entity
learning	I-Entity
,	I-Entity
attention	I-Entity
,	I-Entity
inhibitory	I-Entity
control	I-Entity
,	I-Entity
and	I-Entity
arousal	I-Entity
regulation	I-Entity
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	I-Entity
-	O
exposed	O
children	O
.	O

Succimer	I-Entity
treatment	O
of	O
the	O
Pb	I-Entity
-	O
exposed	O
rats	O
significantly	O
improved	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	I-Entity
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O

In	O
contrast	O
,	O
succimer	I-Entity
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	I-Entity
produced	O
lasting	O
and	O
pervasive	O
cognitive	B-Entity
and	I-Entity
affective	I-Entity
dysfunction	I-Entity
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	I-Entity
exposure	O
regimen	O
.	O

These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-Entity
deficits	I-Entity
due	O
to	O
Pb	I-Entity
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	I-Entity
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	I-Entity
-	O
exposed	O
children	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	I-Entity
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	I-Entity
or	O
other	O
heavy	O
metals	O
.	O



Caffeine	I-Entity
challenge	O
test	O
in	O
panic	B-Entity
disorder	I-Entity
and	O
depression	I-Entity
with	O
panic	B-Entity
attacks	I-Entity
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B-Entity
disorder	I-Entity
(	O
PD	I-Entity
)	O
and	O
patients	O
with	O
major	B-Entity
depression	I-Entity
with	O
panic	B-Entity
attacks	I-Entity
(	O
MDP	I-Entity
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Entity
Disorders	I-Entity
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B-Entity
attacks	I-Entity
by	O
an	O
oral	O
caffeine	I-Entity
challenge	O
test	O
.	O

We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	I-Entity
,	O
27	O
with	O
MDP	I-Entity
,	O
25	O
with	O
major	B-Entity
depression	I-Entity
without	O
panic	B-Entity
attacks	I-Entity
(	O
MD	I-Entity
)	O
,	O
and	O
28	O
healthy	O
volunteers	O
.	O

In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	I-Entity
and	O
a	O
caffeine	I-Entity
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	I-Entity
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O

A	O
total	O
of	O
58.6%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	I-Entity
,	O
44.4%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	I-Entity
,	O
12.0%	O

(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	I-Entity
,	O
and	O
7.1%	O
(	O
n=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B-Entity
attack	I-Entity
after	O
the	O
480-mg	O
caffeine	I-Entity
challenge	O
test	O
(	O
chi(2)(3	O
)	O
=	O
16.22	O
,	O
P	O
=	O
.001	O
)	O
.	O

The	O
patients	O
with	O
PD	I-Entity
and	O
MDP	I-Entity
were	O
more	O
sensitive	O
to	O
caffeine	I-Entity
than	O
were	O
patients	O
with	O
MD	I-Entity
and	O
healthy	O
volunteers	O
.	O

No	O
panic	B-Entity
attack	I-Entity
was	O
observed	O
after	O
the	O
caffeine	I-Entity
-	O
free	O
solution	O
intake	O
.	O

The	O
patients	O
with	O
MD	I-Entity
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2-way	O
analysis	O
of	O
variance	O
,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse	O
-	O
Geisser	O
correction	O
:	O
F(3,762	O
)	O
=	O
2.85	O
,	O
P	O
=	O
.026	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B-Entity
attacks	I-Entity
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	I-Entity
or	O
MDP	I-Entity
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	I-Entity
challenge	O
test	O
.	O



Mitral	O
annuloplasty	O
as	O
a	O
ventricular	O
restoration	O
method	O
for	O
the	O
failing	B-Entity
left	I-Entity
ventricle	I-Entity
:	O
a	O
pilot	O
study	O
.	O

Undersized	O
mitral	O
annuloplasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	B-Entity
cardiomyopathy	I-Entity
and	O
functional	O
mitral	B-Entity
regurgitation	I-Entity
(	O
MR	I-Entity
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	I-Entity
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilated	O
left	O
ventricular	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	I-Entity
remain	O
incompletely	O
understood	O
.	O

The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	B-Entity
failure	I-Entity
.	O

Acute	O
heart	B-Entity
failure	I-Entity
was	O
induced	O
by	O
propranolol	I-Entity
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
;	O
an	O
absence	O
of	O
MR	I-Entity
was	O
confirmed	O
by	O
echocardiography	O
.	O

Data	O
were	O
acquired	O
at	O
baseline	O
,	O
after	O
induction	O
of	O
acute	O
heart	B-Entity
failure	I-Entity
,	O
and	O
after	O
MAP	O
.	O

:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension	O
/	O
function	O
in	O
acute	O
heart	B-Entity
failure	I-Entity
,	O
even	O
in	O
the	O
absence	O
of	O
MR	I-Entity
.	O

However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B-Entity
failure	I-Entity
.	O



Piperacillin	B-Entity
/	I-Entity
tazobactam	I-Entity
-	O
induced	O
seizure	I-Entity
rapidly	O
reversed	O
by	O
high	O
flux	O
hemodialysis	O
in	O
a	O
patient	O
on	O
peritoneal	O
dialysis	O
.	O

Despite	O
popular	O
use	O
of	O
piperacillin	I-Entity
,	O
the	O
dire	O
neurotoxicity	I-Entity
associated	O
with	O
piperacillin	I-Entity
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
delay	O
in	O
appropriate	O
management	O
.	O

We	O
report	O
a	O
57-year	O
-	O
old	O
woman	O
with	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
slurred	O
speech	O
,	O
tremor	I-Entity
,	O
bizarre	O
behavior	O
,	O
progressive	O
mental	O
confusion	I-Entity
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizure	I-Entity
(	O
GTCS	I-Entity
)	O
after	O
5	O
doses	O
of	O
piperacillin	B-Entity
/	I-Entity
tazobactam	I-Entity
(	O
2	O
g/250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectasis	I-Entity
with	O
secondary	B-Entity
infection	I-Entity
.	O

The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	I-Entity
levels	O
but	O
leukocytosis	I-Entity
.	O

Neurologic	O
examinations	O
showed	O
dysarthria	I-Entity
and	O
bilateral	O
Babinski	O
sign	O
.	O

Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	I-Entity
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin	B-Entity
/	I-Entity
tazobactam	I-Entity
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	I-Entity
and	O
organic	B-Entity
brain	I-Entity
lesions	I-Entity
.	O

Piperacillin	I-Entity
-	O
induced	O
encephalopathy	I-Entity
should	O
be	O
considered	O
in	O
any	O
uremic	I-Entity
patients	O
with	O
unexplained	O
neurological	O
manifestations	O
.	O

CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	I-Entity
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin	I-Entity
-	O
induced	O
encephalopathy	I-Entity
.	O



Frequency	O
of	O
transient	O
ipsilateral	O
vocal	B-Entity
cord	I-Entity
paralysis	I-Entity
in	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O

Temporary	O
ipsilateral	O
vocal	B-Entity
nerve	I-Entity
palsies	I-Entity
due	O
to	O
local	O
anesthetics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
contralateral	O
paralysis	I-Entity
.	O

Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ropivacaine	I-Entity
)	O
and	O
short	O
-	O
acting	O
(	O
prilocaine	I-Entity
)	O
anesthetic	O
.	O

Twelve	O
patients	O
(	O
43%	O
)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	B-Entity
cord	I-Entity
paralysis	I-Entity
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	B-Entity
cord	I-Entity
paralysis	I-Entity
compared	O
with	O
those	O
without	O
.	O

CONCLUSION	O
:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	B-Entity
cord	I-Entity
paralysis	I-Entity
in	O
almost	O
half	O
of	O
these	O
patients	O
.	O

Because	O
pre	O
-	O
existing	O
paralysis	I-Entity
is	O
of	O
a	O
relevant	O
frequency	O
(	O
up	O
to	O
3%	O
)	O
,	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	I-Entity
.	O

In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	B-Entity
cord	I-Entity
paralysis	I-Entity
,	O
surgery	O
under	O
general	O
anesthesia	O
should	O
be	O
considered	O
.	O



Neuroprotective	O
effects	O
of	O
melatonin	I-Entity
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	I-Entity
-	O
induced	O
cortical	B-Entity
dysplasia	I-Entity
.	O

Cortical	B-Entity
dysplasia	I-Entity
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
,	O
migration	O
and	O
maturation	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine-[1,3-bis	B-Entity
(	I-Entity
2-chloroethyl)-1-nitrosoure	I-Entity
]	O
(	O
BCNU	I-Entity
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	I-Entity
upon	O
cerebellar	O
BCNU	I-Entity
-	O
induced	O
cortical	B-Entity
dysplasia	I-Entity
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O

Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
,	O
saline	O
-	O
control	O
,	O
melatonin	I-Entity
-	O
treated	O
,	O
BCNU	I-Entity
-	O
exposed	O
and	O
BCNU	I-Entity
-	O
exposed	O
plus	O
melatonin	I-Entity
.	O

Rats	O
were	O
exposed	O
to	O
BCNU	I-Entity
on	O
embryonic	O
day	O
15	O
and	O
melatonin	I-Entity
was	O
given	O
until	O
delivery	O
.	O

Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	I-Entity
and	O
superoxide	I-Entity
dismutase	O
were	O
determined	O
.	O

Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	I-Entity
-	O
exposed	O
cortical	B-Entity
dysplasia	I-Entity
group	O
.	O

There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	I-Entity
-	O
exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	I-Entity
significantly	O
reversed	O
these	O
changes	O
.	O

Malondialdehyde	I-Entity
level	O
in	O
BCNU	I-Entity
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	I-Entity
decreased	O
malondialdehyde	I-Entity
levels	O
in	O
BCNU	I-Entity
group	O
(	O
P<0.01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	I-Entity
dismutase	O
levels	O
between	O
these	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	I-Entity
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	I-Entity
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	I-Entity
.	O



Myo	B-Entity
-	I-Entity
inositol-1-phosphate	I-Entity
(	O
MIP	I-Entity
)	O

Lithium	I-Entity
and	O
valproate	I-Entity
are	O
the	O
prototypic	O
mood	O
stabilizers	O
and	O
have	O
diverse	O
structures	O
and	O
targets	O
.	O

Both	O
drugs	O
influence	O
inositol	I-Entity
metabolism	O
.	O

Lithium	I-Entity
inhibits	O
IMPase	O
and	O
valproate	I-Entity
inhibits	O
MIP	I-Entity
synthase	O
.	O

This	O
study	O
shows	O
that	O
MIP	I-Entity
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	I-Entity
in	O
the	O
inositol	I-Entity
sensitive	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
model	O
.	O

This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
synthesis	O
to	O
cellular	O
inositol	I-Entity
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de	O
-	O
novo	O
synthesis	O
by	O
lithium	I-Entity
itself	O
.	O



Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
-	O
associated	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
with	O
granular	O
tubular	O
basement	O
membrane	O
deposits	O
.	O

Acute	B-Entity
tubulo	I-Entity
-	I-Entity
interstitial	I-Entity
nephritis	I-Entity
(	O
ATIN	I-Entity
)	O
is	O
an	O
important	O
cause	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
resulting	O
from	O
a	O
variety	O
of	O
insults	O
,	O
including	O
immune	O
complex	O
-	O
mediated	O
tubulo	B-Entity
-	I-Entity
interstitial	I-Entity
injury	I-Entity
,	O
but	O
drugs	O
such	O
as	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
frequent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	I-Entity
remains	O
under	O
-	O
diagnosed	O
,	O
as	O
symptoms	O
resolve	O
spontaneously	O
if	O
the	O
medication	O
is	O
stopped	O
.	O

We	O
report	O
on	O
a	O
14-year	O
-	O
old	O
boy	O
who	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
2	O
weeks	O
after	O
aortic	O
valve	O
surgery	O
.	O

He	O
was	O
put	O
on	O
aspirin	I-Entity
following	O
surgery	O
and	O
took	O
ibuprofen	I-Entity
for	O
fever	I-Entity
for	O
nearly	O
a	O
week	O
prior	O
to	O
presentation	O
.	O

He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
(	O
BUN	I-Entity
)	O
concentration	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatinine	I-Entity
of	O
15.3	O
mg	O
/	O
dl	O
and	O
serum	O
potassium	I-Entity
of	O
8.7	O
mEq	O
/	O
l	O
.	O

A	O
kidney	O
biopsy	O
showed	O
inflammatory	O
infiltrate	O
consistent	O
with	O
ATIN	I-Entity
.	O

He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	I-Entity
for	O
6	O
months	O
.	O

His	O
renal	O
recovery	O
and	O
disappearance	O
of	O
proteinuria	I-Entity
took	O
a	O
year	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
report	O
of	O
NSAIDs	O
-	O
associated	O
ATIN	I-Entity
,	O
showing	O
deposits	O
of	O
granular	O
immune	O
complex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glomeruli	O
.	O



Rifampicin	I-Entity
-	O
associated	O
segmental	O
necrotizing	O
glomerulonephritis	I-Entity
in	O
staphylococcal	B-Entity
endocarditis	I-Entity
.	O

necrotising	O
glomerulonephritis	I-Entity
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	I-Entity
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	I-Entity
.	O

Changing	O
epidemiology	O
of	O
infections	I-Entity
such	O
as	O
infective	B-Entity
endocarditis	I-Entity
(	O
IE	I-Entity
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	I-Entity
for	O
Staphylococcal	B-Entity
infections	I-Entity
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	B-Entity
IE	I-Entity
who	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	I-Entity
while	O
being	O
treated	O
with	O
rifampicin	I-Entity
,	O
and	O
review	O
the	O
literature	O
regarding	O
this	O
complication	O
of	O
rifampicin	I-Entity
therapy	O
.	O



Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	I-Entity
-	O
untreated	O
Iranian	O
patients	O
with	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
virus	I-Entity
infection	I-Entity
.	O

Lamivudine	I-Entity
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
patients	O
.	O

Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(	O
resistant	O
hepatitis	B-Entity
B	I-Entity
virus	O
)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine	I-Entity
-	O
untreated	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
patients	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	I-Entity
-	O
untreated	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
patients	O
in	O
Iran	O
.	O

A	O
total	O
of	O
77	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	I-Entity
were	O
included	O
in	O
the	O
study	O
.	O

All	O
patients	O
were	O
also	O
tested	O
for	O
liver	O
enzymes	O
,	O
anti	O
-	O
HCV	O
,	O
HBeAg	I-Entity
,	O
and	O
anti	O
-	O
HBe	O
.	O

HBeAg	I-Entity
was	O
positive	O
in	O
40%	O
and	O
anti	O
-	O
HBe	O
in	O
60%	O
of	O
the	O
patients	O
.	O

YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	O
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	I-Entity
or	O
anti	O
-	O
HBe	O
.	O

CONCLUSION	O
:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	I-Entity
-	O
untreated	O
patients	O
with	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
has	O
been	O
reported	O
,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine	I-Entity
-	O
untreated	O
chronic	B-Entity
hepatitis	I-Entity
B	I-Entity
patients	O
.	O



Branch	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
and	O
fluoxetine	I-Entity
.	O

A	O
case	O
of	O
branch	O
retinal	B-Entity
vein	I-Entity
occlusion	I-Entity
associated	O
with	O
fluoxetine	I-Entity
-	O
induced	O
secondary	O
hypertension	I-Entity
is	O
described	O
.	O

Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitor	O
therapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	I-Entity
because	O
this	O
class	O
of	O
drugs	O
is	O
widely	O
prescribed	O
.	O



The	O
differential	O
effects	O
of	O
bupivacaine	I-Entity
and	O
lidocaine	I-Entity
on	O
prostaglandin	B-Entity
E2	I-Entity
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	I-Entity
in	O
a	O
clinical	O
pain	I-Entity
model	O
.	O

In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	I-Entity
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	I-Entity
on	O
local	O
prostaglandin	B-Entity
E2	I-Entity
(	O
PGE2	I-Entity
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B-Entity
pain	I-Entity
in	O
human	O
subjects	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2%	O
lidocaine	I-Entity
or	O
0.5%	O
bupivacaine	I-Entity
before	O
surgery	O
and	O
either	O
rofecoxib	I-Entity
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	I-Entity
and	O
thromboxane	B-Entity
B2	I-Entity
(	O
TXB2	I-Entity
)	O
measurements	O
.	O

The	O
bupivacaine	I-Entity
/	O
rofecoxib	I-Entity
group	O
reported	O
significantly	O
less	O
pain	I-Entity
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h.	O

However	O
,	O
the	O
bupivacaine	I-Entity
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	I-Entity
at	O
24	O
h	O
and	O
PGE2	I-Entity
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O

Moreover	O
,	O
bupivacaine	I-Entity
significantly	O
increased	O
COX-2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	I-Entity
/	O
placebo	O
group	O
.	O

Thromboxane	I-Entity
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX-2	O
,	O
but	O
not	O
COX-1	O
.	O

These	O
results	O
suggest	O
that	O
bupivacaine	I-Entity
stimulates	O
COX-2	O
gene	O
expression	O
after	O
tissue	B-Entity
injury	I-Entity
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	I-Entity
production	O
and	O
pain	I-Entity
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O



p75NTR	O
expression	O
in	O
rat	O
urinary	O
bladder	O
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
.	O

Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	I-Entity
kinase	O
receptors	O
(	O
Trks	O
)	O
in	O
micturition	O
reflexes	O
with	O
urinary	B-Entity
bladder	I-Entity
inflammation	I-Entity
.	O

The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF	O
,	O
p75(NTR	O
)	O
,	O
after	O
various	O
durations	O
of	O
bladder	B-Entity
inflammation	I-Entity
induced	O
by	O
cyclophosphamide	I-Entity
(	O
CYP	I-Entity
)	O
.	O

CYP	I-Entity
-	O
induced	O
cystitis	I-Entity
increased	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O

The	O
number	O
of	O
p75(NTR)-immunoreactive	O
(	O
-IR	O
)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
with	O
CYP	I-Entity
-	O
induced	O
cystitis	I-Entity
(	O
acute	O
,	O
intermediate	O
,	O
and	O
chronic	O
)	O
.	O

Quantitative	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
in	O
p75(NTR	O
)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP	I-Entity
-	O
induced	O
cystitis	I-Entity
.	O

In	O
bladder	O
afferent	O
cells	O
in	O
DRG	O
,	O
p75(NTR)-IR	O
was	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
with	O
cystitis	I-Entity
.	O

These	O
studies	O
demonstrate	O
that	O
p75(NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	B-Entity
inflammation	I-Entity
.	O



Azathioprine	I-Entity
-	O
induced	O
suicidal	O
erythrocyte	O
death	O
.	O

Azathioprine	I-Entity
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O

The	O
side	O
effects	O
of	O
azathioprine	I-Entity
include	O
anemia	I-Entity
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	O
marrow	O
suppression	O
.	O

Alternatively	O
,	O
anemia	I-Entity
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	I-Entity
(	O
PS	I-Entity
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O

METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	I-Entity
influences	O
eryptosis	O
.	O

According	O
to	O
annexin	O
V	O
binding	O
,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	I-Entity
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	I-Entity
.	O

In	O
a	O
second	O
series	O
,	O
cytosolic	O
Ca2	I-Entity
+	O
activity	O
(	O
Fluo3	I-Entity
fluorescence	O
)	O
,	O
cell	O
volume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS	I-Entity
-	O
exposure	O
(	O
annexin	O
V	O
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O

Exposure	O
to	O
azathioprine	I-Entity
(	O
>	O
or	O
=	O
2	O
microg	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	I-Entity
+	O
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O

The	O
effect	O
of	O
azathioprine	I-Entity
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	I-Entity
+	O
.	O

Azathioprine	I-Entity
triggers	O
suicidal	O
erythrocyte	O
death	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	I-Entity
-	O
induced	O
anemia	I-Entity
.	O



BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	O
-	O
spinal	O
block	O
hypotension	I-Entity
.	O

In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0.5%	O
hyperbaric	O
bupivacaine	I-Entity
through	O
a	O
25-gauge	O
spinal	O
needle	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	I-Entity
saturation	O
were	O
monitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
patients	O
(	O
8.1%	O
)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13.5%	O
)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	I-Entity
,	O
P=	O
0.71	O
.	O

Four	O
(	O
10.8%	O
)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2.7%	O
)	O
in	O
the	O
unilateral	O
group	O
,	O
P=	O
0.17	O
required	O
epinephrine	I-Entity
infusion	O
to	O
treat	O
hypotension	I-Entity
.	O

The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	I-Entity
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar	O
.	O

Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	I-Entity
saturation	O
.	O



Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
patients	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O

The	O
most	O
common	O
regimens	O
were	O
3TC	I-Entity
+	O
d4	B-Entity
T	I-Entity
+	O
nevirapine	I-Entity
(	O
NVP	I-Entity
)	O
(	O
54.8%	O
)	O
,	O
zidovudine	I-Entity
(	O
AZT	I-Entity
)	O

+	O
3TC	I-Entity
+	O
NVP	I-Entity
(	O
14.5%	O
)	O
,	O
3TC	I-Entity
+	O

d4	B-Entity
T	I-Entity
+	O
efavirenz	I-Entity
(	O
EFV	I-Entity
)	O
(	O
20.1%	O
)	O
,	O
and	O
AZT	I-Entity
+	O
3TC	I-Entity
+	O
EFV	I-Entity
(	O
5.4%	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	I-Entity
(	O
15.2%	O
;	O
CD4	O
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B-Entity
neuropathy	I-Entity
(	O
9.0%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O

Clinically	O
significant	O
anemia	I-Entity
(	O
hemoglobin	O

<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5.4%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	I-Entity
(	O
clinical	O
jaundice	I-Entity
with	O
alanine	I-Entity
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3.5%	O
of	O
patients	O
(	O
CD4	O
,	O
260	O
cells	O
/	O
microL	O
)	O
.	O

Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B-Entity
acidosis	I-Entity
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B-Entity
reconstitution	I-Entity
syndrome	I-Entity
(	O
p	O
<	O
0.05	O
)	O
.	O

Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
,	O
NVP	I-Entity
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	I-Entity
and	O
d4	B-Entity
T	I-Entity
therapy	O
with	O
developing	O
peripheral	B-Entity
neuropathy	I-Entity
(	O
p	O
<	O
0.05	O
)	O
.	O

Anemia	I-Entity
and	O
hepatitis	I-Entity
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O

Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	I-Entity
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O



Thalidomide	I-Entity
and	O
sensory	B-Entity
neurotoxicity	I-Entity
:	O
a	O
neurophysiological	O
study	O
.	O

Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	B-Entity
axonal	I-Entity
neuropathy	I-Entity
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	I-Entity
.	O

The	O
study	O
's	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(	O
SAP	O
)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	B-Entity
lupus	I-Entity
erythematosus	I-Entity
(	O
CLE	I-Entity
)	O
treated	O
with	O
thalidomide	I-Entity
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	I-Entity
potential	O
of	O
thalidomide	I-Entity
and	O
the	O
recovery	O
capacity	O
of	O
sensory	O
fibres	O
after	O
discontinuation	O
of	O
treatment	O
.	O

Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	I-Entity
during	O
treatment	O
with	O
thalidomide	I-Entity
and	O
up	O
to	O
47	O
months	O
after	O
discontinuation	O
of	O
treatment	O
were	O
analysed	O
.	O

Five	O
patients	O
complained	O
of	O
paresthesias	I-Entity
and	O
leg	O
cramps	I-Entity
.	O

After	O
thalidomide	I-Entity
treatment	O
,	O
sural	O
SAP	O
amplitude	O
recovered	O
in	O
3	O
patients	O
.	O

At	O
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
,	O
the	O
median	O
thalidomide	I-Entity
cumulative	O
dose	O
was	O
21.4	O
g.	O
The	O
threshold	O
neurotoxic	I-Entity
dosage	O
is	O
lower	O
than	O
previously	O
reported	O
.	O

This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	I-Entity
potential	O
of	O
thalidomide	I-Entity
but	O
is	O
not	O
helpful	O
in	O
predicting	O
the	O
appearance	O
of	O
sensory	O
symptoms	O
.	O



Amiodarone	I-Entity
-	O
related	O
pulmonary	B-Entity
mass	I-Entity
and	O
unique	O
membranous	B-Entity
glomerulonephritis	I-Entity
in	O
a	O
patient	O
with	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
:	O
Diagnostic	O
pitfall	O
and	O
new	O
findings	O
.	O

Amiodarone	I-Entity
is	O
an	O
anti	O
-	O
arrhythmic	I-Entity
drug	O
for	O
life	O
-	O
threatening	O
tachycardia	I-Entity
,	O
but	O
various	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	B-Entity
mass	I-Entity
(	O
1.5	O
cm	O
in	O
diameter	O
)	O
and	O
proteinuria	I-Entity
(	O
2.76	O
g	O
/	O
day	O
)	O
after	O
treatment	O
with	O
amiodarone	I-Entity
for	O
a	O
long	O
time	O
.	O

The	O
lung	B-Entity
mass	I-Entity
was	O
highly	O
suspected	O
to	O
be	O
lung	B-Entity
cancer	I-Entity
on	O
CT	O
and	O
positron	O
emission	O
tomography	O
,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra	O
-	O
alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone	I-Entity
-	O
related	O
lesion	O
.	O

In	O
addition	O
,	O
the	O
lung	O
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	I-Entity
deposition	O
,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	I-Entity
lung	O
portions	O
outside	O
the	O
mass	O
.	O

Autoimmune	B-Entity
diseases	I-Entity
,	O
viral	B-Entity
hepatitis	I-Entity
,	O
malignant	O
neoplasms	I-Entity
or	O
other	O
diseases	O
with	O
a	O
known	O
relationship	O
to	O
membranous	B-Entity
glomerulonephritis	I-Entity
were	O
not	O
found	O
.	O

The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone	I-Entity
-	O
related	O
pulmonary	B-Entity
lesion	I-Entity
and	O
a	O
neoplasm	I-Entity
can	O
be	O
very	O
difficult	O
radiologically	O
,	O
and	O
suggests	O
that	O
membranous	B-Entity
glomerulonephritis	I-Entity
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	I-Entity
treatment	O
.	O



Risk	O
of	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
associated	O
with	O
initial	O
sulphonylurea	I-Entity
treatment	O
of	O
patients	O
with	O
type	B-Entity
2	I-Entity
diabetes	I-Entity
:	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O

This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
(	O
CAD	I-Entity
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B-Entity
2	I-Entity
diabetes	I-Entity
with	O
different	O
sulphonylureas	I-Entity
.	O

METHODS	O
:	O
In	O
type	B-Entity
2	I-Entity
diabetic	I-Entity
patients	O
,	O
cases	O
who	O
developed	O
CAD	I-Entity
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O

The	O
20-year	O
risk	O
of	O
CAD	I-Entity
at	O
diagnosis	O
of	O
diabetes	I-Entity
,	O
using	O
the	O
UKPDS	O
risk	O
engine	O
,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O

The	O
76	O
cases	O
of	O
CAD	I-Entity
were	O
compared	O
with	O
152	O
controls	O
.	O

The	O
hazard	O
of	O
developing	O
CAD	I-Entity
(	O
95%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2.4-fold	O
(	O
1.3	O
-	O
4.3	O
,	O
P=0.004	O
)	O
with	O
glibenclamide	I-Entity
;	O
2-fold	O
(	O
0.9	O
-	O
4.6	O
,	O
P=0.099	O
)	O
with	O
glipizide	I-Entity
;	O
2.9-fold	O
(	O
1.6	O
-	O
5.1	O
,	O
P=0.000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	I-Entity
.	O

The	O
hazard	O
decreased	O
0.3-fold	O
(	O
0.7	O
-	O
1.7	O
,	O
P=0.385	O
)	O
with	O
glimepiride	I-Entity
,	O
0.4-fold	O
(	O
0.7	O
-	O
1.3	O
,	O
P=0.192	O
)	O
with	O
gliclazide	I-Entity
,	O
and	O
0.4-fold	O
(	O
0.7	O
-	O
1.1	O
,	O
P=0.09	O
)	O
with	O
either	O
.	O

CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B-Entity
2	I-Entity
diabetes	I-Entity
with	O
glibenclamide	I-Entity
or	O
glipizide	I-Entity
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	I-Entity
in	O
comparison	O
to	O
gliclazide	I-Entity
or	O
glimepiride	I-Entity
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	I-Entity
,	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O



Reduced	O
progression	O
of	O
adriamycin	I-Entity
nephropathy	I-Entity
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
treated	O
by	O
losartan	I-Entity
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	B-Entity
II	I-Entity
type-1	O
receptor	O
blocker	O
,	O
losartan	I-Entity
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B-Entity
disease	I-Entity
progression	O
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	I-Entity
(	O
ADR	I-Entity
)	O

nephropathy	I-Entity
.	O

Groups	O
ADR(6	I-Entity
)	O
,	O
ADR+LOS(6	I-Entity
)	O
and	O
ADR(12	I-Entity
)	O
,	O
and	O
ADR+LOS(12	I-Entity
)	O
received	O
ADR	I-Entity
(	O
2	O
mg	O
/	O
kg	O
/	O
b.w	O
.	O

Group	O
ADR+LOS(6	I-Entity
)	O
received	O
losartan	I-Entity

(	O
10	O
mg	O
/	O
kg	O
/	O
b.w./day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR+LOS(12	I-Entity
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	I-Entity
.	O

Short	O
-	O
term	O
losartan	I-Entity
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	I-Entity
resulting	O
in	O
decreased	O
proteinuria	I-Entity
.	O

Prolonged	O
treatment	O
with	O
losartan	I-Entity
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	I-Entity
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	I-Entity
and	O
interstitial	B-Entity
fibrosis	I-Entity
,	O
thus	O
preventing	O
heavy	O
proteinuria	I-Entity
and	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
.	O

Losartan	I-Entity
reduced	O
uraemia	I-Entity
and	O
increased	O
urea	I-Entity
clearance	O
in	O
advanced	O
ADR	I-Entity
nephropathy	I-Entity
in	O
SHR	O
.	O

Histological	O
examination	O
showed	O
that	O
losartan	I-Entity
could	O
prevent	O
tubular	O
atrophy	I-Entity
,	O
interstitial	O
infiltration	O
and	O
fibrosis	I-Entity
in	O
ADR	I-Entity
nephropathy	I-Entity
.	O

CONCLUSION	O
:	O
Losartan	I-Entity
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	I-Entity
-	O
induced	O
focal	B-Entity
segmental	I-Entity
glomerulosclerosis	I-Entity
to	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
in	O
SHR	O
.	O



The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	B-Entity
acid	I-Entity
in	O
cardiac	O
surgery	O
:	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
of	O
1188	O
consecutive	O
patients	O
.	O

BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	O
complications	O
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	B-Entity
acid	I-Entity
in	O
an	O
unselected	O
,	O
consecutive	O
cohort	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patients	O
received	O
aprotinin	O
(	O
Group	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	B-Entity
acid	I-Entity
(	O
Group	O
T	O
)	O
.	O

Postoperatively	O
,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	I-Entity
was	O
found	O
in	O
Group	O
T	O
(	O
4.6%	O
vs	O
1.2%	O
,	O
P	O

Persistent	O
atrial	O
fibrillation	O
(	O
7.9%	O
vs	O
2.3%	O
,	O
P	O
=	O
0.020	O
)	O
and	O
renal	B-Entity
failure	I-Entity
(	O
9.7%	O
vs	O
1.7%	O
,	O
P	O
=	O
0.002	O
)	O
were	O
also	O
more	O
common	O
in	O
Group	O
T	O
,	O
in	O
the	O
primary	O
valve	O
surgery	O
subgroup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients	O
,	O
there	O
were	O
more	O
acute	O
myocardial	B-Entity
infarctions	I-Entity
and	O
renal	B-Entity
dysfunction	I-Entity
in	O
Group	O
A	O
(	O
5.8%	O
vs	O
2.0%	O
,	O
P	O
=	O
0.027	O
;	O
22.5%	O
vs	O
15.2%	O
,	O
P	O
=	O
0.036	O
,	O
respectively	O
)	O
.	O

Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients	O
,	O
whereas	O
administration	O
of	O
tranexamic	B-Entity
acid	I-Entity
is	O
not	O
recommended	O
in	O
valve	O
surgery	O
.	O



The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	I-Entity
and	O
their	O
effects	O
on	O
cardiac	B-Entity
arrhythmias	I-Entity
.	O
1	O
.	O

The	O
optical	O
isomers	O
of	O
propranolol	I-Entity
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities.2	O
.	O

In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	I-Entity
,	O
(	O
+	O
)	O

-propranolol	I-Entity
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(	O
-)-propranolol	I-Entity
.	O

At	O
dose	O
levels	O
of	O
(	O
+	O
)	O
-propranolol	I-Entity
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	I-Entity
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.3	O
.	O

The	O
metabolic	O
responses	O
to	O
isoprenaline	I-Entity
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	I-Entity
,	O
lactate	I-Entity
and	O
free	O
fatty	B-Entity
acids	I-Entity
)	O
were	O
all	O
blocked	O
by	O
(	O
-)-propranolol	I-Entity
.	O

-Propranolol	I-Entity
had	O
no	O
effect	O
on	O
fatty	B-Entity
acid	I-Entity
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	I-Entity
and	O
glucose.4	I-Entity
.	O

Both	O
isomers	O
of	O
propranolol	I-Entity
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	O
-	O
pigs.5	O
.	O

The	O
isomers	O
of	O
propranolol	I-Entity
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	I-Entity
.	O

Both	O
isomers	O
of	O
propranolol	I-Entity
were	O
capable	O
of	O
preventing	O
adrenaline	I-Entity
-	O
induced	O
cardiac	B-Entity
arrhythmias	I-Entity
in	O
cats	O
anaesthetized	O
with	O
halothane	I-Entity
,	O
but	O
the	O
mean	O
dose	O
of	O
(	O
-)-propranolol	I-Entity
was	O
0.09+/-0.02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-propranolol	I-Entity
was	O
4.2+/-1.2	O
mg	O
/	O
kg	O
.	O

-propranolol	I-Entity
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O

Blockade	O
of	O
arrhythmias	I-Entity
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline.7	I-Entity
.	O

Both	O
isomers	O
of	O
propranolol	I-Entity
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-Entity
tachycardia	I-Entity
caused	O
by	O
ouabain	I-Entity
in	O
anaesthetized	O
cats	O
and	O
dogs	O
.	O

The	O
dose	O
of	O
(	O
-)-propranolol	I-Entity
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-propranolol	I-Entity
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade.8	O
.	O



Topotecan	I-Entity
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	I-Entity
:	O
a	O
phase	O
2	O
study	O
.	O

Improving	O
glioblastoma	B-Entity
multiforme	I-Entity
(	O
GBM	I-Entity
)	O
treatment	O
with	O
radio	O
-	O
chemotherapy	O
remains	O
a	O
challenge	O
.	O

Topotecan	I-Entity
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	I-Entity
as	O
well	O
as	O
brain	O
penetration	O
.	O

The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(	O
60	O
Gy/30	O
fractions/40	O
days	O
)	O
and	O
topotecan	I-Entity
(	O
0.9	O
mg	O
/	O
m(2)/day	O
on	O
days	O
1	O
-	O
5	O
on	O
weeks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
adults	O
with	O
histologically	O
proven	O
and	O
untreated	O
GBM	I-Entity
.	O

The	O
incidence	O
of	O
non	O
-	O
hematological	O
toxicities	I-Entity
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	I-Entity
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	I-Entity
and	O
neutropenia	I-Entity
)	O
.	O

Topotecan	I-Entity
in	O
combination	O
with	O
radiotherapy	O
was	O
well	O
tolerated	O
.	O

However	O
,	O
while	O
response	O
and	O
stabilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patients	O
,	O
the	O
study	O
did	O
not	O
show	O
increased	O
benefits	O
in	O
terms	O
of	O
survival	O
in	O
patients	O
with	O
unresectable	O
GBM	I-Entity
.	O



Long	O
-	O
term	O
lithium	I-Entity
therapy	O
leading	O
to	O
hyperparathyroidism	I-Entity
:	O
a	O
case	O
report	O
.	O

This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	I-Entity
therapy	O
on	O
serum	O
calcium	I-Entity
level	O
and	O
parathyroid	O
glands	O
,	O
its	O
pathogenesis	O
,	O
and	O
treatment	O
options	O
.	O

We	O
examined	O
the	O
case	O
of	O
a	O
lithium	I-Entity
-	O
treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	I-Entity
to	O
better	O
understand	O
the	O
disease	O
process	O
.	O

CONCLUSION	O
:	O
Primary	B-Entity
hyperparathyroidism	I-Entity
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
long	O
-	O
term	O
lithium	I-Entity
therapy	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15%	O
of	O
lithium	I-Entity
-	O
treated	O
patients	O
become	O
hypercalcemic	I-Entity
.	O

By	O
routinely	O
monitoring	O
serum	O
calcium	I-Entity
levels	O
,	O
healthcare	O
providers	O
can	O
improve	O
the	O
quality	O
of	O
life	O
of	O
this	O
patient	O
group	O
.	O



The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions	O
,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	I-Entity
as	O
well	O
as	O
intraoperative	O
blood	O
pressure	O
,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(	O
FESS	O
)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(	O
FRLMA	O
)	O
versus	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
in	O
maintaining	O
controlled	O
hypotension	I-Entity
anesthesia	O
induced	O
by	O
propofol	I-Entity
-	O
remifentanil	I-Entity
total	O
i.v	O
.	O

METHODS	O
:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I	O
-	O
II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	I-Entity
anesthesia	O
caused	O
by	O
propofol	I-Entity
-	O
remifentanil	I-Entity
-	O
TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
:	O
group	O
I	O
,	O
FRLMA	O
;	O
group	O
II	O
,	O
ETT	O
.	O

Hemorrhage	I-Entity
was	O
measured	O
and	O
the	O
visibility	O
of	O
the	O
operative	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

Controlled	O
hypotension	I-Entity
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	I-Entity
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	I-Entity
.	O

In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	I-Entity
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	O
loss	O
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	I-Entity
with	O
low	O
doses	O
of	O
remifentanil	I-Entity
during	O
TIVA	O
in	O
patients	O
undergoing	O
FESS	O
.	O



Nonalcoholic	B-Entity
fatty	I-Entity
liver	I-Entity
disease	I-Entity
during	O
valproate	I-Entity
therapy	O
.	O

Valproic	B-Entity
acid	I-Entity
(	O
VPA	I-Entity
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	I-Entity
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	O
weight	O
.	O

We	O
report	O
a	O
case	O
of	O
nonalcoholic	B-Entity
fatty	I-Entity
liver	I-Entity
disease	I-Entity
(	O
NAFLD	I-Entity
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	I-Entity
during	O
VPA	I-Entity
treatment	O
.	O

Laboratory	O
data	O
revealed	O
hyperinsulinemia	I-Entity
with	O
insulin	B-Entity
resistance	I-Entity
.	O

After	O
the	O
withdrawal	O
of	O
VPA	I-Entity
therapy	O
,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	B-Entity
loss	I-Entity
,	O
a	O
decrease	O
of	O
body	O
mass	O
index	O
,	O
and	O
normalization	O
of	O
metabolic	O
and	O
endocrine	O
parameters	O
;	O
moreover	O
,	O
ultrasound	O
measurements	O
showed	O
a	O
complete	O
normalization	O
.	O

The	O
present	O
case	O
suggests	O
that	O
obesity	I-Entity
,	O
hyperinsulinemia	I-Entity
,	O
insulin	B-Entity
resistance	I-Entity
,	O
and	O
long	O
-	O
term	O
treatment	O
with	O
VPA	I-Entity
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	I-Entity
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	I-Entity
withdrawal	O
.	O



Carbimazole	I-Entity
induced	O
ANCA	B-Entity
positive	I-Entity
vasculitis	I-Entity
.	O

Anti	B-Entity
-	I-Entity
thyroid	I-Entity
drugs	I-Entity
,	O
like	O
carbimazole	I-Entity
and	O
propylthiouracil	I-Entity
(	O
PTU	I-Entity
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	I-Entity
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effects	O
of	O
antithyroid	B-Entity
medications	I-Entity
.	O

Antineutrophil	B-Entity
cytoplasmic	I-Entity
antibody	I-Entity
(	I-Entity
ANCA)--associated	I-Entity
vasculitis	I-Entity
is	O
a	O
potentially	O
life	O
-	O
threatening	O
adverse	O
effect	O
of	O
antithyroidmedications	I-Entity
.	O

We	O
report	O
a	O
patient	O
with	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
who	O
developed	O
ANCA	O
positive	O
carbimazole	I-Entity
induced	O
vasculitis	I-Entity
.	O

The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	I-Entity
skin	B-Entity
rash	I-Entity
associated	O
with	O
large	O
joint	O
arthritis	I-Entity
,	O
pyrexia	I-Entity
and	O
parotiditis	I-Entity
but	O
no	O
renal	O
or	O
pulmonary	O
involvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	I-Entity
.	O

Carbimazole	I-Entity
and	O
methimazole	I-Entity
have	O
a	O
lower	O
incidence	O
of	O
reported	O
ANCA	O
positive	O
side	O
effects	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	I-Entity
induced	O
vasculitis	I-Entity
case	O
reported	O
from	O
India	O
.	O



Aspirin	I-Entity
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	O
events	O
:	O
an	O
update	O
of	O
the	O
evidence	O
for	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
.	O

Coronary	B-Entity
heart	I-Entity
disease	I-Entity
and	O
cerebrovascular	B-Entity
disease	I-Entity
are	O
leading	O
causes	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

In	O
2002	O
,	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	I-Entity
with	O
adults	O
who	O
are	O
at	O
increased	O
risk	O
for	O
coronary	B-Entity
heart	I-Entity
disease	I-Entity
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	I-Entity
for	O
the	O
primary	O
prevention	O
of	O
myocardial	B-Entity
infarctions	I-Entity
,	O
strokes	I-Entity
,	O
and	O
death	O
.	O

STUDY	O
SELECTION	O
:	O
English	O
-	O
language	O
randomized	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
;	O
case	O
-	O
control	O
studies	O
;	O
meta	O
-	O
analyses	O
;	O
and	O
systematic	O
reviews	O
of	O
aspirin	I-Entity
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	B-Entity
disease	I-Entity
(	O
CVD	I-Entity
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions	O
:	O
Does	O
aspirin	I-Entity
decrease	O
coronary	O
heart	O
events	O
,	O
strokes	I-Entity
,	O
death	O
from	O
coronary	O
heart	O
events	O
or	O
stroke	I-Entity
,	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
adults	O
without	O
known	O

CVD	I-Entity
?	O

Does	O
aspirin	I-Entity
increase	O
gastrointestinal	B-Entity
bleeding	I-Entity
or	O
hemorrhagic	B-Entity
strokes	I-Entity
?	O

DATA	O
SYNTHESIS	O
:	O
New	O
evidence	O
from	O
1	O
good	O
-	O
quality	O
RCT	O
,	O
1	O
good	O
-	O
quality	O
meta	O
-	O
analysis	O
,	O
and	O
2	O
fair	O
-	O
quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	I-Entity
use	O
reduces	O
the	O
number	O
of	O
CVD	I-Entity
events	O
in	O
patients	O
without	O
known	O
CVD	I-Entity
.	O

Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	B-Entity
infarctions	I-Entity
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	I-Entity
.	O

Aspirin	I-Entity
does	O
not	O
seem	O
to	O
affect	O
CVD	I-Entity
mortality	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
either	O
men	O
or	O
women	O
.	O

The	O
use	O
of	O
aspirin	I-Entity
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	I-Entity
events	O
,	O
primarily	O
gastrointestinal	B-Entity
bleeding	I-Entity
events	O
,	O
in	O
both	O
men	O
and	O
women	O
.	O

Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	B-Entity
strokes	I-Entity
with	O
aspirin	I-Entity
use	O
.	O

A	O
new	O
RCT	O
and	O
meta	O
-	O
analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	B-Entity
strokes	I-Entity
in	O
women	O
is	O
not	O
statistically	O
significantly	O
increased	O
.	O

New	O
evidence	O
on	O
aspirin	I-Entity
for	O
the	O
primary	O
prevention	O
of	O
CVD	I-Entity
is	O
limited	O
.	O

The	O
dose	O
of	O
aspirin	I-Entity
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
estimation	O
of	O
the	O
most	O
appropriate	O
dose	O
for	O
primary	O
prevention	O
.	O

Aspirin	I-Entity
reduces	O
the	O
risk	O
for	O
myocardial	B-Entity
infarction	I-Entity
in	O
men	O
and	O
strokes	I-Entity
in	O
women	O
.	O

Aspirin	I-Entity
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	I-Entity
events	O
.	O



Reducing	O
harm	O
associated	O
with	O
anticoagulation	O
:	O
practical	O
considerations	O
of	O
argatroban	I-Entity
therapy	O
in	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
.	O

Argatroban	I-Entity
is	O
a	O
hepatically	O
metabolized	O
,	O
direct	O
thrombin	O
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	I-Entity
in	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
(	O
HIT	I-Entity
)	O
and	O
for	O
patients	O
with	O
or	O
at	O
risk	O
of	O
HIT	I-Entity
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	I-Entity
therapy	O
in	O
HIT	I-Entity
.	O

The	O
US	O
FDA	O
-	O
recommended	O
argatroban	I-Entity
dose	O
in	O
HIT	I-Entity
is	O
2	O
microg	O
/	O
kg	O
/	O
min	O
(	O
reduced	O
in	O
patients	O
with	O
hepatic	B-Entity
impairment	I-Entity
and	O
in	O
paediatric	O
patients	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	O
times	O
(	O
aPTTs	O
)	O
1.5	O
-	O
3	O
times	O
baseline	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experiences	O
indicate	O
that	O
reduced	O
doses	O
are	O
also	O
needed	O
in	O
patients	O
with	O
conditions	O
associated	O
with	O
hepatic	O
hypoperfusion	O
,	O
e.g.	O
heart	B-Entity
failure	I-Entity
,	O
yet	O
are	O
unnecessary	O
for	O
renal	B-Entity
dysfunction	I-Entity
,	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	I-Entity
.	O

Argatroban	I-Entity
0.5	O
-	O
1.2	O

For	O
PCI	O
,	O
argatroban	I-Entity
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients	O
;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	I-Entity
,	O
and	O
lesser	O
doses	O
may	O
be	O
adequate	O
with	O
concurrent	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibition	O
.	O

Argatroban	I-Entity
prolongs	O
the	O
International	O
Normalized	O
Ratio	O
,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban	I-Entity
-	O
to	O
-	O
warfarin	I-Entity
transition	O
should	O
be	O
followed	O
.	O

Major	O
bleeding	I-Entity
with	O
argatroban	I-Entity
is	O
0	O
-	O
10%	O
in	O
the	O
non	O
-	O
interventional	O
setting	O
and	O
0	O
-	O
5.8%	O
periprocedurally	O
.	O

Argatroban	I-Entity
has	O
no	O
specific	O
antidote	O
,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs	O
,	O
argatroban	I-Entity
infusion	O
should	O
be	O
stopped	O
or	O
reduced	O
.	O

Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	I-Entity
therapy	O
in	O
HIT	I-Entity
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	I-Entity
(	O
e.g.	O
fewer	O
thromboses	O
)	O
or	O
its	O
treatment	O
(	O
e.g.	O
fewer	O
argatroban	I-Entity
medication	O
errors	O
)	O
.	O



Rhabdomyolysis	I-Entity
and	O
brain	O
ischemic	B-Entity
stroke	I-Entity
in	O
a	O
heroin	I-Entity
-	O
dependent	O
male	O
under	O
methadone	I-Entity
maintenance	O
therapy	O
.	O

OBJECTIVE	O
:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	B-Entity
abuse	I-Entity
,	O
some	O
of	O
which	O
are	O
life	O
-	O
threatening	O
.	O

Methadone	I-Entity
may	O
aggravate	O
this	O
problem	O
.	O

A	O
33-year	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyolysis	I-Entity
and	O
cerebral	O
ischemic	B-Entity
stroke	I-Entity
after	O
intravenous	O
heroin	I-Entity
.	O

He	O
had	O
used	O
heroin	I-Entity
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadone	I-Entity
daily	O
for	O
6	O
months	O
.	O

He	O
was	O
found	O
unconsciousness	I-Entity
at	O
home	O
and	O
was	O
sent	O
to	O
our	O
hospital	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolysis	I-Entity
,	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
and	O
acute	O
respiratory	B-Entity
failure	I-Entity
.	O

After	O
transfer	O
to	O
an	O
internal	O
ward	O
,	O
we	O
noted	O
aphasia	I-Entity
and	O
weakness	I-Entity
of	O
his	O
left	O
limbs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cerebral	B-Entity
ischemic	I-Entity
infarction	I-Entity
.	O

Those	O
using	O
methadone	I-Entity
and	O
heroin	I-Entity
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	I-Entity
and	O
ischemic	B-Entity
stroke	I-Entity
.	O

Patients	O
under	O
methadone	I-Entity
maintenance	O
therapy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adverse	O
events	O
.	O

Hypotheses	O
of	O
heroin	I-Entity
-	O
related	O
rhabdomyolysis	I-Entity
and	O
stroke	I-Entity
in	O
heroin	I-Entity
abusers	O
are	O
discussed	O
.	O



Increased	O
vulnerability	O
to	O
6-hydroxydopamine	I-Entity
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	I-Entity
in	O
mice	O
lacking	O
CB1	O
cannabinoid	O
receptors	O
.	O

Motor	O
impairment	O
,	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
neuronal	O
activity	O
and	O
proenkephalin	I-Entity
(	O
PENK	I-Entity
)	O
gene	O
expression	O
in	O
the	O
caudate	O
-	O
putamen	O
(	O
CPu	O
)	O
were	O
measured	O
in	O
6-OHDA	I-Entity
-	O
lesioned	O
and	O
treated	O
(	O
L	B-Entity
-	I-Entity
DOPA+benserazide	I-Entity
)	O

A	O
lesion	O
induced	O
by	O
6-OHDA	I-Entity
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	I-Entity
neurons	O
and	O
increased	O
PENK	I-Entity
gene	O
expression	O
in	O
the	O
CPu	O
.	O

CB1	O
KO	O
mice	O
exhibited	O
higher	O
MDA	I-Entity
levels	O
and	O
iNOS	O
protein	O
expression	O
in	O
the	O
CPu	O
and	O
Cg	O
compared	O
to	O
WT	O
mice	O
.	O

Treatment	O
with	O
L	B-Entity
-	I-Entity
DOPA+benserazide	I-Entity
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	I-Entity
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mice	O
.	O

The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	I-Entity
lesion	O
,	O
and	O
reduced	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O



Animal	O
model	O
of	O
mania	I-Entity
induced	O
by	O
ouabain	I-Entity
:	O
Evidence	O
of	O
oxidative	O
stress	O
in	O
submitochondrial	O
particles	O
of	O
the	O
rat	O
brain	O
.	O

The	O
intracerebroventricular	O
(	O
ICV	O
)	O
administration	O
of	O
ouabain	I-Entity
(	O
a	O
Na(+)/K(+)-ATPase	I-Entity
inhibitor	O
)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	B-Entity
mania	I-Entity
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	B-Entity
disorder	I-Entity
may	O
be	O
related	O
to	O
mitochondrial	B-Entity
dysfunction	I-Entity
.	O

Herein	O
,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	I-Entity
in	O
rats	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effects	O
of	O
ouabain	I-Entity
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(	O
at	O
concentrations	O
of	O
10(-2	O
)	O
and	O
10(-3)M	O
)	O
on	O
locomotion	O
was	O
measured	O
using	O
the	O
open	O
-	O
field	O
test	O
.	O

Additionally	O
,	O
thiobarbituric	B-Entity
acid	I-Entity
reactive	O
substances	O
(	O
TBARSs	O
)	O
and	O

superoxide	I-Entity
production	O
were	O
measured	O
in	O
submitochondrial	O
particles	O
of	O
the	O
prefrontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
amygdala	O
.	O

Our	O
findings	O
demonstrated	O
that	O
ouabain	I-Entity
at	O
10(-2	O
)	O
and	O
10(-3)M	O
induced	O
hyperlocomotion	I-Entity
in	O
rats	O
,	O
and	O
this	O
response	O
remained	O
up	O
to	O
7	O
days	O
following	O
a	O
single	O
ICV	O
injection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	O
levels	O
and	O
superoxide	I-Entity
generation	O
in	O
submitochondrial	O
particles	O
in	O
the	O
prefrontal	O
cortex	O
,	O
striatum	O
and	O
amygdala	O
.	O

In	O
conclusion	O
,	O
ouabain	I-Entity
-	O
induced	O
mania	I-Entity
-	O
like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	B-Entity
disorder	I-Entity
.	O



Intraoperative	O
dialysis	O
during	O
liver	O
transplantation	O
with	O
citrate	I-Entity
dialysate	O
.	O

Liver	O
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	B-Entity
liver	I-Entity
failure	I-Entity
carries	O
high	O
intraoperative	O
and	O
immediate	O
postoperative	O
risks	O
.	O

These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	B-Entity
kidney	I-Entity
injury	I-Entity
(	O
AKI	I-Entity
)	O
and	O
intraoperative	O
dialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplant	O
to	O
proceed	O
.	O

The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	B-Entity
liver	I-Entity
failure	I-Entity
can	O
lead	O
to	O
difficulties	O
with	O
anticoagulation	O
during	O
dialysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operating	O
room	O
.	O

Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	I-Entity
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	O
carries	O
the	O
risk	O
of	O
citrate	I-Entity
toxicity	I-Entity
.	O

Citrate	I-Entity
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	B-Entity
acid	I-Entity
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
can	O
not	O
tolerate	O
heparin	I-Entity
or	O
regional	O
citrate	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
a	O
40-year	O
-	O
old	O
female	O
with	O
acetaminophen	I-Entity
-	O
induced	O
fulminant	B-Entity
liver	I-Entity
failure	I-Entity
with	O
associated	O
AKI	I-Entity
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	O
transplantation	O
anticoagulated	O
with	O
citrate	I-Entity
dialysate	O
during	O
the	O
entire	O
procedure	O
.	O

The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	I-Entity
toxicity	I-Entity
and	O
maintained	O
adequate	O
anticoagulation	O
for	O
patency	O
of	O
the	O
dialysis	O
circuit	O
.	O

Citrate	I-Entity
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	O
transplantation	O
in	O
fulminant	B-Entity
liver	I-Entity
failure	I-Entity
.	O



Delirium	I-Entity
in	O
a	O
patient	O
with	O
toxic	O
flecainide	I-Entity
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	I-Entity
-	O
induced	O
delirium	I-Entity
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	I-Entity
.	O

A	O
69-year	O
-	O
old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	I-Entity
and	O
paranoia	I-Entity
over	O
the	O
past	O
several	O
days	O
.	O

On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	I-Entity
12	O
mg	O
twice	O
daily	O
,	O
warfarin	I-Entity
2	O
mg	O
/	O
day	O
,	O
folic	B-Entity
acid	I-Entity
1	O
mg	O
/	O
day	O
,	O
levothyroxine	I-Entity
100	O
microg	O

/	O
day	O
,	O
pantoprazole	I-Entity
40	O
mg	O
/	O
day	O
,	O
paroxetine	I-Entity
40	O
mg	O
/	O
day	O
,	O
and	O
flecainide	I-Entity
100	O
mg	O
twice	O
daily	O
.	O

Flecainide	I-Entity
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B-Entity
fibrillation	I-Entity
.	O

Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	I-Entity
plasma	O
concentration	O
of	O
1360	O
microg	O
/	O
L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	I-Entity
and	O
paroxetine	I-Entity
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O

Paroxetine	I-Entity
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	I-Entity
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily	O
.	O

Her	O
delirium	I-Entity
resolved	O
3	O
days	O
later	O
.	O

DISCUSSION	O
:	O
Flecainide	I-Entity
and	O

pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	I-Entity
channels	O
may	O
cause	O
delirium	I-Entity
in	O
susceptible	O
patients	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966-January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	I-Entity
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	I-Entity
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	I-Entity
-	O
induced	O
delirium	I-Entity
.	O

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	I-Entity
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
's	O
delirium	I-Entity
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	I-Entity
and	O
paroxetine	I-Entity
.	O

Supratherapeutic	O
flecainide	I-Entity
plasma	O
concentrations	O
may	O
cause	O
delirium	I-Entity
.	O

Because	O
toxicity	I-Entity
may	O
occur	O
when	O
flecainide	I-Entity
is	O
prescribed	O
with	O
paroxetine	I-Entity
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	I-Entity
plasma	O
concentrations	O
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
CYP2D6	O
inhibitors	O
.	O



Efficacy	O
of	O
everolimus	I-Entity
(	O
RAD001	I-Entity
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	I-Entity
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors	O
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B-Entity
-	I-Entity
small	I-Entity
-	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
(	O
NSCLC	I-Entity
)	O
patients	O
.	O

RAD001	I-Entity
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	I-Entity
(	O
mTOR	O
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	I-Entity
.	O

METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	I-Entity
patients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	I-Entity
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	I-Entity
kinase	O
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	I-Entity
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	I-Entity
.	O

Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	I-Entity
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O

Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	I-Entity
,	O
dyspnea	I-Entity
,	O
stomatitis	I-Entity
,	O
anemia	I-Entity
,	O
and	O
thrombocytopenia	I-Entity
.	O

Pneumonitis	I-Entity
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1/2	O
,	O
occurred	O
in	O
25%	O
.	O

RAD001	I-Entity
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	I-Entity
.	O

Evaluation	O
of	O
RAD001	I-Entity
plus	O
standard	O
therapy	O
for	O
metastatic	O

NSCLC	I-Entity
continues	O
.	O



Posttransplant	O
anemia	I-Entity
:	O
the	O
role	O
of	O
sirolimus	I-Entity
.	O

Posttransplant	O
anemia	I-Entity
is	O
a	O
common	O
problem	O
that	O
may	O
hinder	O
patients	O
'	O
quality	O
of	O
life	O
.	O

A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	I-Entity
,	O
of	O
which	O
the	O
level	O
of	O
renal	O
function	O
is	O
most	O
important	O
.	O

Sirolimus	I-Entity
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	I-Entity
inhibitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	I-Entity
.	O

This	O
review	O
considers	O
anemia	I-Entity
associated	O
with	O
sirolimus	I-Entity
,	O
including	O
its	O
presentation	O
,	O
mechanisms	O
,	O
and	O
management	O
.	O



Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low	O
-	O
risk	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
.	O

Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
are	O
admitted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
""""	O
rule	O
out	O
acute	B-Entity
coronary	I-Entity
syndrome	I-Entity
""""	O
protocol	O
,	O
often	O
with	O
noninvasive	O
testing	O
prior	O
to	O
discharge	O
.	O

In	O
patients	O
without	O
cocaine	I-Entity
use	O
,	O
coronary	O
computerized	O
tomography	O
angiography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	O
low	O
risk	O
for	O
cardiac	O
events	O
who	O
can	O
be	O
safely	O
discharged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
,	O
as	O
coronary	B-Entity
vasospasm	I-Entity
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	I-Entity
.	O

We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
could	O
identify	O
a	O
subset	O
safe	O
for	O
discharge	O
.	O

:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low	O
-	O
risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassociated	O
chest	B-Entity
pain	I-Entity
(	O
self	O
-	O
reported	O
or	O
positive	O
urine	O
test	O
)	O
.	O

Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	I-Entity
less	O
than	O
50%	O
)	O
were	O
discharged	O
.	O

The	O
main	O
outcome	O
was	O
30-day	O
cardiovascular	O
death	O
or	O
myocardial	B-Entity
infarction	I-Entity
.	O

A	O
total	O
of	O
59	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
chest	B-Entity
pain	I-Entity
were	O
evaluated	O
.	O

Six	O
patients	O
had	O
coronary	B-Entity
stenosis	I-Entity
>	O

During	O
the	O
30-day	O
follow	O
-	O
up	O
period	O
,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(	O
0%	O
;	O
95%	O
CI	O
,	O
0	O
-	O
6.1%	O
)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	B-Entity
infarction	I-Entity
(	O
0%	O
;	O
95%	O
CI	O
,	O
0	O
-	O
6.1%	O
)	O
.	O

Although	O
cocaine	I-Entity
-	O
associated	O
myocardial	B-Entity
ischemia	I-Entity
can	O
result	O
from	O
coronary	O
vasoconstriction	O
,	O
patients	O
with	O
cocaine	I-Entity
associated	O
chest	B-Entity
pain	I-Entity
,	O
a	O
non	O
-	O
ischemic	I-Entity
ECG	O
,	O
and	O
a	O
TIMI	O
risk	O
score	O



Late	O
fulminant	O
posterior	B-Entity
reversible	I-Entity
encephalopathy	I-Entity
syndrome	I-Entity
after	O
liver	O
transplant	O
.	O

Posterior	B-Entity
leukoencephalopathy	I-Entity
due	O
to	O
calcineurin	O
-	O
inhibitor	O
-	O
related	O
neurotoxicity	I-Entity
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	O
agents	O
(	O
primarily	O
those	O
administered	O
after	O
a	O
liver	O
or	O
kidney	O
transplant	O
)	O
.	O

:	O
We	O
report	O
the	O
case	O
of	O
a	O
46-year	O
-	O
old	O
woman	O
who	O
received	O
a	O
liver	O
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	B-Entity
cirrhosis	I-Entity
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	B-Entity
leukoencephalopathy	I-Entity
or	O
posterior	B-Entity
reversible	I-Entity
encephalopathy	I-Entity
syndrome	I-Entity
developed	O
110	O
days	O
after	O
transplant	O
.	O

Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	I-Entity
to	O
cyclosporine	I-Entity
did	O
not	O
improve	O
the	O
clinical	O
situation	O
.	O

Posterior	B-Entity
reversible	I-Entity
encephalopathy	I-Entity
syndrome	I-Entity
after	O
liver	O
transplant	O
is	O
rare	O
.	O



Prolonged	O
hypothermia	I-Entity
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B-Entity
edema	I-Entity
and	O
intracranial	B-Entity
hypertension	I-Entity
associated	O
with	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
.	O

BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B-Entity
edema	I-Entity
complicating	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
(	O
FHF	I-Entity
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	I-Entity
.	O

METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27-year	O
-	O
old	O
female	O
with	O
FHF	I-Entity
from	O
acetaminophen	I-Entity
and	O
resultant	O
cerebral	B-Entity
edema	I-Entity
.	O

Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	I-Entity
from	O
acetaminophen	I-Entity
which	O
was	O
ingested	O
over	O
a	O
2-day	O
period	O
.	O

Initial	O
evaluation	O
confirmed	O
FHF	I-Entity
from	O
acetaminophen	I-Entity
and	O
cerebral	B-Entity
edema	I-Entity
.	O

The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	I-Entity
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	I-Entity
.	O

We	O
then	O
initiated	O
therapeutic	O
hypothermia	I-Entity
which	O
was	O
continued	O
for	O
5	O
days	O
.	O

At	O
re	O
-	O
warming	O
,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B-Entity
edema	I-Entity
and	O
intracranial	B-Entity
hypertension	I-Entity
.	O

In	O
patients	O
with	O
FHF	I-Entity
and	O
cerebral	B-Entity
edema	I-Entity
from	O
acetaminophen	I-Entity
overdose	I-Entity
,	O
prolonged	O
therapeutic	O
hypothermia	I-Entity
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O

A	O
clinical	O
trial	O
of	O
hypothermia	I-Entity
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O



Binasal	B-Entity
visual	I-Entity
field	I-Entity
defects	I-Entity
are	O
not	O
specific	O
to	O
vigabatrin	I-Entity
.	O

This	O
study	O
investigated	O
the	O
visual	B-Entity
defects	I-Entity
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	I-Entity
(	O
VGB	I-Entity
)	O
.	O

Two	O
hundred	O
four	O
people	O
with	O
epilepsy	I-Entity
were	O
grouped	O
on	O
the	O
basis	O
of	O
antiepileptic	O
drug	O
therapy	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
exposure	O
to	O
VGB	I-Entity
)	O
.	O

Groups	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
,	O
and	O
seizure	I-Entity
frequency	O
.	O

Bilateral	O
visual	O
field	O
constriction	O
was	O
observed	O
in	O
59%	O
of	O
patients	O
currently	O
taking	O
VGB	I-Entity
,	O
43%	O
of	O
patients	O
who	O
previously	O
took	O
VGB	I-Entity
,	O
and	O
24%	O
of	O
patients	O
with	O
no	O
exposure	O
to	O
VGB	I-Entity
.	O

Assessment	O
of	O
retinal	O
function	O
revealed	O
abnormal	O
responses	O
in	O
48%	O
of	O
current	O
VGB	I-Entity
users	O
and	O
22%	O
of	O
prior	O
VGB	I-Entity
users	O
,	O
but	O
in	O
none	O
of	O
the	O
patients	O
without	O
previous	O
exposure	O
to	O
VGB	I-Entity
.	O

Bilateral	B-Entity
visual	I-Entity
field	I-Entity
abnormalities	I-Entity
are	O
common	O
in	O
the	O
treated	O
epilepsy	I-Entity
population	O
,	O
irrespective	O
of	O
drug	O
history	O
.	O

Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	B-Entity
toxicity	I-Entity
associated	O
with	O
VGB	I-Entity
.	O



Smoking	O
of	O
crack	B-Entity
cocaine	I-Entity
as	O
a	O
risk	O
factor	O
for	O
HIV	B-Entity
infection	I-Entity
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B-Entity
cocaine	I-Entity
has	O
on	O
the	O
incidence	O
of	O
HIV	B-Entity
infection	I-Entity
.	O

Given	O
the	O
increasing	O
use	O
of	O
crack	B-Entity
cocaine	I-Entity
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B-Entity
infection	I-Entity
.	O

To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B-Entity
seroconversion	I-Entity
among	O
daily	O
smokers	O
of	O
crack	B-Entity
cocaine	I-Entity
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996-Nov	O
.	O
30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec.	O
1	O
,	O
1999-Nov	O
.	O
30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec.	O
1	O
,	O
2002-Dec	O
.	O
30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B-Entity
infection	I-Entity
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B-Entity
cocaine	I-Entity
increased	O
from	O
11.6%	O
in	O
period	O
1	O
to	O
39.7%	O
in	O
period	O
3	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B-Entity
seroconversion	I-Entity
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-Entity
cocaine	I-Entity
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.03	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.57	O
-	O
1.85	O
;	O
period	O
2	O
:	O
HR	O
1.68	O
,	O
95%	O

INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B-Entity
cocaine	I-Entity
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B-Entity
seroconversion	I-Entity
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O

This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B-Entity
cocaine	I-Entity
.	O



Fluoxetine	I-Entity
improves	O
the	O
memory	B-Entity
deficits	I-Entity
caused	O
by	O
the	O
chemotherapy	O
agent	O
5-fluorouracil	I-Entity
.	O

Cancer	I-Entity
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O

A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O

In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	I-Entity
antidepressant	O
Fluoxetine	I-Entity
.	O

In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5-FU	I-Entity
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	I-Entity
either	O
separately	O
or	O
in	O
combination	O
with	O
5-FU	I-Entity
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	O
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5-FU	I-Entity
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

Animals	O
treated	O
only	O
with	O
5-FU	I-Entity
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	I-Entity
improved	O
their	O
performance	O
.	O

5-FU	I-Entity
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	I-Entity
was	O
co	O
administered	O
with	O
5-FU	I-Entity
.	O

Fluoxetine	I-Entity
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O

These	O
findings	O
suggest	O
that	O
5-FU	I-Entity
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	I-Entity
.	O



Liver	O
-	O
specific	O
ablation	O
of	O
integrin	O
-	O
linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	I-Entity
after	O
phenobarbital	I-Entity
administration	O
.	O

This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	O
enlargement	O
induced	O
by	O
phenobarbital	I-Entity
(	O
PB	I-Entity
)	O
.	O

liver-/-	O
mice	O
were	O
given	O
PB	I-Entity
(	O
0.1%	O
in	O
drinking	O
water	O
)	O
for	O
10	O
days	O
.	O

Livers	O
were	O
harvested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
days	O
during	O
PB	I-Entity
administration	O
.	O

There	O
were	O
slightly	O
increased	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
cells	O
in	O
the	O
ILK	O
/	O
liver-/-	O
animals	O
at	O
day	O
2	O
as	O
compared	O
to	O
WT	O
after	O
PB	I-Entity
administration	O
.	O

/	O
liver-/-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	O
different	O
time	O
points	O
during	O
PB	I-Entity
administration	O
.	O

Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	O
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens	O
,	O
such	O
as	O
PB	I-Entity
.	O



Decreased	O
Expression	O
of	O
Na	I-Entity
/	O
K	I-Entity
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin	I-Entity
-	O
induced	O
Nephropathy	I-Entity
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin	I-Entity
-	O
induced	O
nephropathy	I-Entity
.	O

Sprague	O
-	O
Dawley	O
male	O
rats	O
(	O
200~250	O
g	O
)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	I-Entity
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
)	O
for	O
7	O
days	O
,	O
and	O
the	O
expression	O
of	O
tubular	O
transporters	O
was	O
determined	O
by	O
immunoblotting	O
and	O
immunohistochemistry	O
.	O

Gentamicin	I-Entity
-	O
treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	I-Entity
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	I-Entity
levels	O
.	O

Accordingly	O
,	O
the	O
fractional	O
excretion	O
of	O
sodium	I-Entity
increased	O
.	O

Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na(+)/K(+)-ATPase	I-Entity
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin	I-Entity
-	O
treated	O
rats	O
.	O

Gentamicin	I-Entity
-	O
induced	O
nephropathy	I-Entity
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na(+)/K(+)-ATPase	I-Entity
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O



Longitudinal	O
association	O
of	O
alcohol	I-Entity
use	O
with	O
HIV	B-Entity
disease	I-Entity
progression	O
and	O
psychological	O
health	O
of	O
women	O
with	O
HIV	O
.	O

We	O
evaluated	O
the	O
association	O
of	O
alcohol	I-Entity
consumption	O
and	O
depression	I-Entity
,	O
and	O
their	O
effects	O
on	O
HIV	B-Entity
disease	I-Entity
progression	O
among	O
women	O
with	O
HIV	O
.	O

The	O
participants	O
had	O
physical	O
examination	O
,	O
medical	O
record	O
extraction	O
,	O
and	O
venipuncture	O
,	O
CD4+T	O
-	O
cell	O
counts	O
determination	O
,	O
measurement	O
of	O
depression	I-Entity
symptoms	O
(	O
using	O
the	O
self	O
-	O
report	O
Center	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	I-Entity
Scale	O
)	O
,	O
and	O
alcohol	I-Entity
use	O
assessment	O
at	O
enrollment	O
,	O
and	O
semiannually	O
until	O
March	O
2000	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	I-Entity
use	O
and	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
.	O

When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
association	O
between	O
alcohol	I-Entity
and	O
CD4	O
+	O
T	O
-	O
cell	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
association	O
between	O
alcohol	I-Entity
consumption	O
and	O
depression	I-Entity
was	O
significant	O
(	O
p<0.001	O
)	O
.	O

Depression	I-Entity
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findings	O
suggest	O
that	O
alcohol	I-Entity
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	I-Entity
.	O

Moreover	O
,	O
depression	I-Entity
is	O
associated	O
with	O
HIV	B-Entity
disease	I-Entity
progression	O
.	O

Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	I-Entity
use	O
interventions	O
and	O
psychological	O
resources	O
to	O
improve	O
the	O
health	O
of	O
women	O
with	O
HIV	O
.	O



Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	I-Entity
-	O
induced	O
status	B-Entity
epilepticus	I-Entity
.	O

Neuroinflammation	I-Entity
occurs	O
after	O
seizures	I-Entity
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O

CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	I-Entity
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O

In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B-Entity
epilepticus	I-Entity
(	O
SE	I-Entity
)	O
induced	O
by	O
pilocarpine	I-Entity
injection	O
.	O

METHODS	O
:	O
SE	I-Entity
was	O
induced	O
by	O
pilocarpine	I-Entity
injection	O
.	O

Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	I-Entity
.	O

Five	O
days	O
after	O
SE	I-Entity
,	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O

Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	I-Entity
.	O

Seizures	I-Entity
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	O
.	O

Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	I-Entity
.	O

Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2-labeled	O
cells	O
in	O
SE	I-Entity
rats	O
.	O

In	O
addition	O
,	O
rats	O
that	O
experienced	O
SE	I-Entity
exhibited	O
CCR2-labeling	O
in	O
populations	O
of	O
hypertrophied	I-Entity
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O

Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	I-Entity
.	O

CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	I-Entity
-	O
induced	O
SE	I-Entity
.	O

Seizures	I-Entity
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O

These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	I-Entity
changes	O
that	O
occur	O
following	O
seizures	I-Entity
.	O



Metallothionein	I-Entity
induction	O
reduces	O
caspase-3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	I-Entity
-	O
treated	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	I-Entity
(	O
MT	I-Entity
)	O
by	O
ZnSO(4	B-Entity
)	I-Entity
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	I-Entity
induction	O
on	O
carmustine	I-Entity
(	O
BCNU)-induced	I-Entity
hippocampal	O
cognitive	B-Entity
dysfunction	I-Entity
in	O
rats	O
.	O

A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15/group	O
)	O
:	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i.c.v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	I-Entity
solvent	O
(	O
i.v	O
)	O
.	O

The	O
second	O
group	O
administered	O
ZnSO(4	B-Entity
)	I-Entity
(	O
0.1	O
micromol/10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
,	O
once	O
)	O

then	O
BCNU	I-Entity
solvent	O
(	O
i.v	O
)	O
after	O
24	O
h.	O
Third	O
group	O
received	O
BCNU	I-Entity
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O

Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO(4	B-Entity
)	I-Entity
(	O
0.1	O
micromol/10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
)	O
then	O
BCNU	I-Entity
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O
after	O
24	O
h.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	I-Entity
administration	O
resulted	O
in	O
deterioration	B-Entity
of	I-Entity
learning	I-Entity
and	I-Entity
short	I-Entity
-	I-Entity
term	I-Entity
memory	I-Entity
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	I-Entity
reductase	O
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	I-Entity
(	O
GSH	I-Entity
)	O
content	O
.	O

Also	O
,	O
BCNU	I-Entity
administration	O
increased	O
serum	O
tumor	I-Entity
necrosis	I-Entity
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
,	O
hippocampal	O
MT	I-Entity
and	O
malondialdehyde	I-Entity
(	O
MDA	I-Entity
)	O
contents	O
as	O
well	O
as	O
caspase-3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O

ZnSO(4	B-Entity
)	I-Entity
pretreatment	O
counteracted	O
BCNU	I-Entity
-	O
induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	I-Entity
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	I-Entity
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase-3	O
.	O

The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO(4	B-Entity
)	I-Entity

+	O
BCNU	I-Entity
compared	O
to	O
only	O
BCNU	I-Entity
-	O
treated	O
animals	O
.	O

In	O
conclusion	O
,	O
MT	I-Entity
induction	O
halts	O
BCNU	I-Entity
-	O
induced	O
hippocampal	O
toxicity	I-Entity
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	I-Entity
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	O
,	O
MDA	I-Entity
and	O
caspase-3	O
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O



Fatal	O
carbamazepine	I-Entity
induced	O
fulminant	B-Entity
eosinophilic	I-Entity
(	O
hypersensitivity	I-Entity
)	O

myocarditis	I-Entity
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-Entity
hypersensitivity	I-Entity
and	O
differential	O
diagnosis	O
.	O

The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	I-Entity
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O

A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	I-Entity
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	I-Entity
)	O

myocarditis	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
hypersensitivity	I-Entity
myocarditis	I-Entity
secondary	O
to	O
administration	O
of	O
carbamazepine	I-Entity
.	O

Acute	O
hypersensitivity	I-Entity
myocarditis	I-Entity
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O

Clinically	O
,	O
death	O
was	O
due	O
to	O
cardiogenic	B-Entity
shock	I-Entity
.	O

To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	I-Entity
induced	O
myocarditis	I-Entity
reported	O
in	O
English	O
literature	O
.	O



Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	I-Entity
marmoset	O
model	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
.	O

These	O
symptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisation	O
'	O
following	O
repeated	O
levodopa	I-Entity
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	I-Entity
on	O
the	O
disease	O
state	O
.	O

The	O
levodopa	I-Entity
-	O
treated	O
MPTP	I-Entity
-	O
lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	B-Entity
symptoms	I-Entity
in	O
PD	I-Entity
patients	O
.	O

Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa	I-Entity
-	O
induced	O
motor	O
fluctuations	O
and	O
neuropsychiatric	B-Entity
-	I-Entity
like	I-Entity
behaviors	I-Entity
to	O
determine	O
the	O
relationship	O
between	O
duration	O
of	O
treatment	O
and	O
onset	O
of	O
symptoms	O
.	O

Marmosets	O
were	O
administered	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	I-Entity
(	O
2.0	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O

for	O
five	O
days	O
,	O
resulting	O
in	O
stable	O
parkinsonism	I-Entity
.	O

Levodopa	I-Entity
(	O
15	O
mg	O
/	O
kg	O
and	O
benserazide	I-Entity
,	O
3.75	O
mg	O
/	O
kg	O
)	O

Animals	O
were	O
evaluated	O
for	O
parkinsonian	B-Entity
disability	I-Entity
,	O
dyskinesia	I-Entity
and	O
on	O
-	O
time	O
(	O
motor	O
fluctuations	O
)	O
and	O
neuropsychiatric	B-Entity
-	I-Entity
like	I-Entity
behaviors	I-Entity
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	I-Entity
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater	O
,	O
blind	O
to	O
the	O
treatment	O
day	O
.	O

The	O
neuropsychiatric	B-Entity
-	I-Entity
like	I-Entity
behavior	I-Entity
rating	O
scale	O
demonstrated	O
high	O
interrater	O
reliability	O
between	O
three	O
trained	O
raters	O
of	O
differing	O
professional	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	I-Entity
-	O
induced	O
motor	O
fluctuations	O
,	O
dyskinesia	I-Entity
and	O
wearing	O
-	O
off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	I-Entity
therapy	O
.	O

In	O
contrast	O
,	O
levodopa	I-Entity
-	O
induced	O
neuropsychiatric	B-Entity
-	I-Entity
like	I-Entity
behaviors	I-Entity
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	I-Entity
treatment	O
and	O
their	O
severity	O
did	O
not	O
correlate	O
with	O
duration	O
of	O
treatment	O
.	O

The	O
data	O
suggest	O
that	O
neuropsychiatric	B-Entity
disorders	I-Entity
in	O
PD	I-Entity
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	I-Entity
and	O
the	O
disease	O
state	O
than	O
a	O
consequence	O
of	O
sensitisation	O
to	O
repeated	O
dopaminergic	O
therapy	O
.	O



Contrast	B-Entity
medium	I-Entity
nephrotoxicity	I-Entity
after	O
renal	O
artery	O
and	O
coronary	O
angioplasty	O
.	O

Renal	B-Entity
dysfunction	I-Entity
induced	O
by	O
iodinated	O
contrast	B-Entity
medium	I-Entity
(	O
CM	I-Entity
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	O
angioplasty	O
(	O
PTRA	O
)	O
.	O

To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	I-Entity
effect	O
of	O
CM	I-Entity
in	O
patients	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patients	O
submitted	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(	O
PTRA	O
group	O
,	O
mean	O
age	O
70+/-12	O
years	O
,	O
23	O
female	O
,	O
basal	O
creatinine	I-Entity
1.46+/-0.79	O
,	O
range	O
0.7	O
-	O
4.9	O
mg	O
/	O
dl	O
)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
group	O
)	O
,	O
matched	O
for	O
basal	O
creatinine	I-Entity
(	O
1.44+/-0.6	O
,	O
range	O
0.7	O
-	O
3.4	O
mg	O
/	O
dl	O
)	O
,	O
gender	O
,	O
and	O
age	O
.	O

serum	O
creatinine	I-Entity
was	O
measured	O
.	O

RESULTS	O
:	O
Postprocedural	O
creatinine	I-Entity
level	O
decreased	O
nonsignificantly	O
in	O
the	O
PTRA	O
group	O
(	O
1.46+/-0.8	O
vs.	O
1.34+/-0.5	O
mg	O
/	O
dl	O
,	O

Changes	O
in	O
serum	O
creatinine	I-Entity
after	O
intervention	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
groups	O
(	O
-0.12+/-0.5	O
vs.	O
0.13+/-0.3	O
,	O
P=0.014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	I-Entity
administered	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	B-Entity
damage	I-Entity
induced	O
by	O
CM	I-Entity
administration	O
than	O
PCI	O
patients	O
.	O

The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	O
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	I-Entity
toxicity	I-Entity
.	O



Medical	O
and	O
psychiatric	O
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
:	O
a	O
case	O
-	O
control	O
study	O
.	O

Acetaminophen	I-Entity
-	O
induced	O
hepatotoxicity	I-Entity
is	O
the	O
most	O
common	O
cause	O
of	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
(	O
ALF	I-Entity
)	O
in	O
the	O
UK	O
.	O

:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness	O
,	O
psychiatric	O
co	O
-	O
morbidity	O
,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	O
transplantation	O
(	O
LT	O
)	O
emergently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
(	O
n=36	O
)	O
with	O
age-	O
and	O
sex	O
-	O
matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non	O
-	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
(	O
n=35	O
)	O
and	O
elective	O
LT	O
for	O
chronic	B-Entity
liver	I-Entity
disease	I-Entity
(	O
CLD	I-Entity
,	O
n=34	O
)	O
.	O

Acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre	O
-	O
LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O

Twenty	O
(	O
56%	O
)	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
patients	O
had	O
a	O
formal	O
psychiatric	O
diagnosis	O
before	O
LT	O
(	O
non	O
-	O
acetaminophen	I-Entity
-	O
induced	O
ALF=0/35	I-Entity
,	O
CLD=2/34	I-Entity
;	O
P<0.01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25%	O
)	O
had	O
a	O
previous	O
suicide	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
median	O
5	O
years	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
)	O
,	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
1	O
year	O
87%	O
,	O
5	O
years	O
75%	O
;	O
non	O
-	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
88%	O
,	O
78%	O
;	O
CLD	I-Entity
93%	O
,	O
82%	O
:	O
P>0.6	O
log	O
rank	O
)	O
.	O

Two	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
patients	O
reattempted	O
suicide	O
post	O
-	O
LT	O
(	O
one	O
died	O
8	O
years	O
post	O
-	O
LT	O
)	O
.	O

Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	O
disturbance	O
,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non	O
-	O
acetaminophen	I-Entity
-	O
induced	O
ALF	I-Entity
and	O
electively	O
for	O
CLD	I-Entity
.	O



Studies	O
of	O
synergy	O
between	O
morphine	I-Entity
and	O
a	O
novel	O
sodium	I-Entity
channel	O
blocker	O
,	O
CNSB002	I-Entity
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-Entity
pain	I-Entity
.	O

This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	I-Entity
,	O
a	O
sodium	I-Entity
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	I-Entity
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-Entity
pain	I-Entity
.	O

Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	I-Entity
and	O
CNSB002	I-Entity
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	I-Entity
models	O
:	O
carrageenan	I-Entity
-	O
induced	O
paw	O
inflammation	I-Entity
and	O
streptozotocin	I-Entity
(	O
STZ)-induced	I-Entity
diabetic	B-Entity
neuropathy	I-Entity
.	O

The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	I-Entity
,	O
3.2	O
mg	O
/	O
kg	O
;	O
CNSB002	I-Entity
10.0	O
mg	O
/	O
kg	O
;	O
5.0	O
mg	O
/	O
kg	O
CNSB002	I-Entity
with	O
morphine	I-Entity
3.2	O
mg	O
/	O
kg	O
in	O
combination	O
.	O

The	O
doses	O
calculated	O
to	O
cause	O
50%	O
reversal	O
of	O
hyperalgesia	I-Entity
(	O
ED50	O
)	O
were	O
7.54	O
(	O
1.81	O
)	O
and	O
4.83	O
(	O
1.54	O
)	O
in	O
the	O
carrageenan	I-Entity
model	O
and	O
44.18	O
(	O
1.37	O
)	O
and	O
9.14	O
(	O
1.24	O
)	O
in	O
the	O
STZ	I-Entity
-	O
induced	O
neuropathy	I-Entity
model	O
for	O
CNSB002	I-Entity
and	O
morphine	I-Entity
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
ED50	O
values	O
for	O
morphine	I-Entity
when	O
given	O
in	O
combination	O
with	O
CNSB002	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0.56	O
(	O
1.55	O
)	O
in	O
the	O
carrageenan	I-Entity
model	O
and	O
1.37	O
(	O
1.23	O
)	O
in	O
the	O
neuropathy	I-Entity
model	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antinociception	O
after	O
morphine	I-Entity
(	O
3.2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	O
-	O
administration	O
with	O
CNSB002	I-Entity
from	O
28.0	O
and	O
31.7%	O
to	O
114.6	O
and	O
56.9%	O
reversal	O
of	O
hyperalgesia	I-Entity
in	O
the	O
inflammatory	O
and	O
neuropathic	I-Entity
models	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
;	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
-	O
significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
)	O
.	O

The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	I-Entity
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	I-Entity
.	O



Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
:	O
a	O
practical	O
review	O
.	O

Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
(	O
HIT	I-Entity
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devastating	O
outcomes	O
.	O

It	O
begins	O
when	O
heparin	I-Entity
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin	I-Entity
-	O
platelet	O
factor	O
4	O
antibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
release	O
of	O
procoagulant	O
platelet	O
particles	O
.	O

Thrombosis	I-Entity
and	O
thrombocytopenia	I-Entity
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	I-Entity
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascular	O
complications	O
.	O

The	O
prevalence	O
of	O
HIT	I-Entity
varies	O
among	O
several	O
subgroups	O
,	O
with	O
greater	O
incidence	O
in	O
surgical	O
as	O
compared	O
with	O
medical	O
populations	O
.	O

HIT	I-Entity
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	I-Entity
and	O
suspected	O
whenever	O
thrombosis	I-Entity
occurs	O
after	O
heparin	I-Entity
exposure	O
.	O

The	O
treatment	O
of	O
HIT	I-Entity
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	I-Entity
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	B-Entity
thrombin	I-Entity
inhibitor	I-Entity
.	O

Current	O
""""	O
diagnostic	O
""""	O
tests	O
,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	I-Entity
.	O

Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	I-Entity
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment	O
.	O

Direct	B-Entity
thrombin	I-Entity
inhibitors	I-Entity
are	O
appropriate	O
,	O
evidence	O
-	O
based	O
alternatives	O
to	O
heparin	I-Entity
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	I-Entity
,	O
who	O
need	O
to	O
undergo	O
percutaneous	O
coronary	O
intervention	O
.	O

As	O
heparin	I-Entity
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	I-Entity
with	O
every	O
heparin	I-Entity
exposure	O
,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	I-Entity
is	O
initiated	O
.	O



Abductor	O
paralysis	I-Entity
after	O
botox	I-Entity
injection	O
for	O
adductor	B-Entity
spasmodic	I-Entity
dysphonia	I-Entity
.	O

Botulinum	O
toxin	O
(	O
Botox	I-Entity

)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	B-Entity
spasmodic	I-Entity
dysphonia	I-Entity
(	O
ADSD	I-Entity
)	O
.	O

Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness	O
,	O
throat	B-Entity
pain	I-Entity
,	O
and	O
difficulty	O
with	O
swallowing	O
liquids	O
.	O

Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	I-Entity
following	O
Botox	I-Entity
injections	O
for	O
ADSD	I-Entity
,	O
a	O
complication	O
previously	O
unreported	O
.	O

Patients	O
that	O
received	O
Botox	I-Entity
injections	O
for	O
spasmodic	B-Entity
dysphonia	I-Entity
between	O
January	O
2000	O
and	O
October	O
2009	O
were	O
evaluated	O
.	O

Patients	O
with	O
ADSD	I-Entity
were	O
identified	O
.	O

For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	I-Entity
,	O
age	O
,	O
sex	O
,	O
paralytic	O
Botox	I-Entity
dose	O
,	O
prior	O
Botox	I-Entity
dose	O
,	O
and	O
course	O
following	O
paralysis	I-Entity
were	O
noted	O
.	O

From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	I-Entity
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	I-Entity
.	O

Of	O
these	O
352	O
patients	O
,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	I-Entity
,	O
and	O
two	O
suffered	O
this	O
complication	O
twice	O
.	O

Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	I-Entity
and	O
continued	O
receiving	O
after	O
paralysis	I-Entity
.	O

The	O
incidence	O
of	O
abductor	O
paralysis	I-Entity
after	O
Botox	I-Entity
injection	O
for	O
ADSD	I-Entity
was	O
0.34%	O
.	O

Bilateral	O
abductor	O
paralysis	I-Entity
is	O
a	O
rare	O
complication	O
of	O
Botox	I-Entity
injections	O
for	O
ADSD	I-Entity
,	O
causing	O
difficulty	O
with	O
breathing	O
upon	O
exertion	O
.	O

The	O
likely	O
mechanism	O
of	O
paralysis	I-Entity
is	O
diffusion	O
of	O
Botox	I-Entity
around	O
the	O
muscular	O
process	O
of	O
the	O
arytenoid	O
to	O
the	O
posterior	O
cricoarytenoid	O
muscles	O
.	O

The	O
paralysis	I-Entity
is	O
temporary	O
,	O
and	O
watchful	O
waiting	O
with	O
restriction	O
of	O
activity	O
is	O
the	O
recommended	O
management	O
.	O



Mitochondrial	B-Entity
impairment	I-Entity
contributes	O
to	O
cocaine	I-Entity
-	O
induced	O
cardiac	B-Entity
dysfunction	I-Entity
:	O
Prevention	O
by	O
the	O
targeted	O
antioxidant	O
MitoQ.	I-Entity

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	I-Entity
-	O
induced	O
cardiac	B-Entity
dysfunction	I-Entity
.	O

We	O
hypothesized	O
that	O
cocaine	B-Entity
abuse	I-Entity
may	O
lead	O
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
.	O

Seven	O
days	O
of	O
cocaine	I-Entity
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	I-Entity
consumption	O
detected	O
in	O
cardiac	O
fibers	O
,	O
specifically	O
through	O
complex	O
I	O
and	O
complex	O
III	O
.	O

In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	I-Entity
synthesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemmal	O
mitochondria	O
.	O

This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short	O
-	O
term	O
exposure	O
to	O
cocaine	I-Entity
,	O
suggesting	O
that	O
these	O
mitochondrial	B-Entity
abnormalities	I-Entity
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	I-Entity
.	O

MitoQ	I-Entity
,	O
a	O
mitochondrial	O
-	O
targeted	O
antioxidant	O
,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	B-Entity
abnormalities	I-Entity
as	O
well	O
as	O
cardiac	B-Entity
dysfunction	I-Entity
characterized	O
here	O
by	O
a	O
diastolic	B-Entity
dysfunction	I-Entity
studied	O
with	O
a	O
conductance	O
catheter	O
to	O
obtain	O
pressure	O
-	O
volume	O
data	O
.	O

Taken	O
together	O
,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine	I-Entity
-	O
induced	O
cardiac	B-Entity
dysfunction	I-Entity
may	O
be	O
due	O
to	O
a	O
mitochondrial	B-Entity
defect	I-Entity
.	O



Trimethoprim	I-Entity
-	O
induced	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	O
hemolytic	O
transfusion	O
reaction	O
.	O

A	O
10-year	O
-	O
old	O
male	O
with	O
acute	B-Entity
leukemia	I-Entity
presented	O
with	O
post	O
-	O
chemotherapy	O
anemia	I-Entity
.	O

During	O
red	O
cell	O
transfusion	O
,	O
he	O
developed	O
hemoglobinuria	I-Entity
.	O

Drug	O
-	O
induced	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
was	O
suspected	O
because	O
of	O
positive	O
direct	O
antiglobulin	O
test	O
,	O
negative	O
eluate	O
,	O
and	O
microspherocytes	O
on	O
smear	O
pre-	O
and	O
post	O
-	O
transfusion	O
.	O

Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	I-Entity
and	O
trimethoprim	B-Entity
-	I-Entity
sulfamethoxazole	I-Entity
but	O
negative	O
with	O
sulfamethoxazole	I-Entity
.	O

Other	O
causes	O
of	O
anemia	I-Entity
should	O
be	O
considered	O
in	O
patients	O
with	O
worse	O
-	O
than	O
-	O
expected	O
anemia	I-Entity
after	O
chemotherapy	O
.	O

Furthermore	O
,	O
hemolysis	I-Entity
during	O
transfusion	O
is	O
not	O
always	O
a	O
transfusion	O
reaction	O
.	O



Blockade	O
of	O
endothelial	O
-	O
mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

OBJECTIVE	O
:	O
A	O
multicenter	O
,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin	O
-	O
angiotensin	I-Entity
system	O
in	O
patients	O
with	O
type	B-Entity
1	I-Entity
diabetes	I-Entity
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	I-Entity
,	O
suggesting	O
that	O
other	O
mechanism(s	O
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	B-Entity
nephropathy	I-Entity
(	O
diabetic	B-Entity
nephropathy	I-Entity
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
endothelial	O
-	O
mesenchymal	O
-	O
transition	O
(	O
EndoMT	O
)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	O
interstitial	O
fibrosis	I-Entity
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	I-Entity
(	O
STZ)-induced	I-Entity
diabetes	I-Entity
.	O

In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
in	O
Tie2-Cre;Loxp	O
-	O
EGFP	O
mice	O
.	O

/	O
Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT	O
,	O
reduced	O
renal	O
fibrosis	I-Entity
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	I-Entity
.	O

EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	B-Entity
nephropathy	I-Entity
and	O
other	O
diabetes	B-Entity
complications	I-Entity
.	O



Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	I-Entity
in	O
refractory	O
mantle	B-Entity
cell	I-Entity
lymphoma	I-Entity
.	O

Mantle	B-Entity
cell	I-Entity
lymphoma	I-Entity
(	O
MCL	I-Entity
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-Entity
-	I-Entity
cell	I-Entity
non	I-Entity
-	I-Entity
Hodgkin	I-Entity
's	I-Entity
lymphoma	I-Entity
.	O

However	O
,	O
a	O
38%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	I-Entity
treated	O
with	O
temsirolimus	I-Entity
,	O
a	O
mTOR	O
inhibitor	O
.	O

Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	I-Entity
who	O
had	O
tumor	I-Entity
regression	O
two	O
months	O
after	O
temsirolimus	I-Entity
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	I-Entity
therapy	O
.	O

Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	I-Entity
inhibited	O
tumor	I-Entity
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	I-Entity
cells	O
.	O

Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	I-Entity
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	I-Entity
microvessel	O
density	O
and	O
of	O
VEGF	O
expression	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	I-Entity
tissue	O
repair	O
,	O
were	O
found	O
after	O
6-month	O
temsirolimus	I-Entity
therapy	O
.	O

Thus	O
,	O
temsirolimus	I-Entity
reduced	O
tumor	I-Entity
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O

This	O
dual	O
effect	O
of	O
temsirolimus	I-Entity
on	O
tumor	I-Entity
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	I-Entity
resistant	O
to	O
conventional	O
chemotherapy	O
.	O



Syncope	I-Entity
caused	O
by	O
hyperkalemia	I-Entity
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	I-Entity
.	O

A	O
76	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-Entity
infarction	I-Entity
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B-Entity
of	I-Entity
consciousness	I-Entity
due	O
to	O
marked	O
bradycardia	I-Entity
caused	O
by	O
hyperkalemia	I-Entity
.	O

The	O
concentration	O
of	O
serum	O
potassium	I-Entity
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	I-Entity
level	O
.	O

The	O
cause	O
of	O
hyperkalemia	I-Entity
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	I-Entity
,	O
an	O
aldosterone	I-Entity
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	I-Entity
,	O
an	O
ACE	O
inhibitor	O
.	O

Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	I-Entity
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE	O
/	O
ARB	O
in	O
combination	O
with	O
potassium	I-Entity
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-Entity
disturbance	I-Entity
.	O



Diffuse	O
skeletal	O
pain	I-Entity
after	O
administration	O
of	O
alendronate	I-Entity
.	O

Osteoporosis	I-Entity
is	O
caused	O
by	O
bone	O
resorption	O
in	O
excess	O
of	O
bone	O
formation	O
,	O
and	O
bisphosphonates	I-Entity
,	O
are	O
used	O
to	O
inhibit	O
bone	O
resorption	O
.	O

Alendronate	I-Entity
,	O
a	O
biphosphonate	I-Entity
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	I-Entity
in	O
postmenopausal	O
women	O
.	O

Musculoskeletal	B-Entity
pain	I-Entity
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patients	O
.	O

We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out	O
-	O
patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	I-Entity
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	I-Entity
.	O

We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	I-Entity
can	O
report	O
pain	I-Entity
,	O
and	O
bisphosphonate	I-Entity
-	O
related	O
pain	I-Entity
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	I-Entity
.	O



Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	I-Entity
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	I-Entity
-	O
sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	I-Entity
with	O
suspected	O
MSSA	O
meningitis	I-Entity
treated	O
with	O
high	O
-	O
dose	O
daptomycin	I-Entity
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O

A	O
54-year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	I-Entity
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	I-Entity
shown	O
on	O
chest	O
radiograph	O
.	O

Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	I-Entity
,	O
levofloxacin	I-Entity
,	O
and	O
piperacillin	I-Entity
/	O
tazobactam	I-Entity
.	O

Blood	O
cultures	O
revealed	O
S.	O
aureus	O
susceptible	O
to	O
oxacillin	I-Entity
.	O

Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	I-Entity
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
patient	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
(	O
serum	O
creatinine	I-Entity
1.9	O
mg	O
/	O
dL	O
,	O
increased	O
from	O
1.2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0.8	O
mg	O
/	O
dL	O
on	O
admission	O
)	O
.	O

The	O
patient	O
's	O
Glasgow	O
Coma	O
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-Entity
arrest	I-Entity
on	O
day	O
10	O
.	O

The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	I-Entity
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	I-Entity
.	O

Nafcillin	I-Entity
was	O
discontinued	O
and	O
daptomycin	I-Entity
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	I-Entity
and	O
was	O
continued	O
until	O
the	O
patient	O
's	O
death	O
on	O
day	O
16	O
.	O

Daptomycin	I-Entity
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11.21	O
ug	O
/	O
mL	O
and	O
0.52	O

Creatine	I-Entity
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	I-Entity
therapy	O
and	O
were	O
not	O
reassessed	O
.	O

Daptomycin	I-Entity
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	I-Entity
-	O
induced	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
and	O
relapsing	O
bacteremia	I-Entity
.	O

High	O
-	O
dose	O
daptomycin	I-Entity
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	I-Entity
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
can	O
not	O
tolerate	O
standard	O
therapy	O
.	O

Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	I-Entity
is	O
warranted	O
.	O



The	O
role	O
of	O
nitric	B-Entity
oxide	I-Entity
in	O
convulsions	I-Entity
induced	O
by	O
lindane	I-Entity
in	O
rats	O
.	O

Lindane	I-Entity
is	O
an	O
organochloride	O
pesticide	O
and	O
scabicide	O
.	O

It	O
evokes	O
convulsions	I-Entity
mainly	O
trough	O
the	O
blockage	O
of	O
GABA(A	I-Entity
)	O
receptors	O
.	O

Nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
,	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	B-Entity
-	I-Entity
arginine	I-Entity
,	O
precursor	O
of	O
NO	I-Entity
syntheses	O
(	O
NOS	O
)	O
,	O
and	O
L	B-Entity
-	I-Entity
NAME	I-Entity
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	I-Entity
models	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	I-Entity
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	I-Entity
-	O
induced	O
epilepsy	I-Entity
in	O
male	O
Wistar	O
albino	O
rats	O
.	O

The	O
administration	O
of	O
L	B-Entity
-	I-Entity
arginine	I-Entity
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O

in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	I-Entity
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	I-Entity
elicited	O
by	O
lower	O
lindane	I-Entity
dose	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L	B-Entity
-	I-Entity
NAME	I-Entity
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O

decreased	O
convulsion	I-Entity
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	I-Entity
following	O
injection	O
with	O
a	O
convulsive	I-Entity
dose	O
of	O
lindane	I-Entity
(	O
8	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l	B-Entity
-	I-Entity
arginine	I-Entity
prior	O
to	O
lindane	I-Entity
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L	B-Entity
-	I-Entity
NAME	I-Entity
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	I-Entity
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	I-Entity
seizures	I-Entity
.	O



Long	O
-	O
term	O
oral	O
galactose	I-Entity
treatment	O
prevents	O
cognitive	B-Entity
deficits	I-Entity
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	I-Entity
.	O

Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	I-Entity
of	O
sporadic	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
(	O
sAD	O
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	O
-	O
receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	I-Entity
transport	O
via	O
glucose	I-Entity
transporter	O
GLUT4	O
and	O
decreased	O
glucose	I-Entity
metabolism	O
in	O
brain	O
cells	O
.	O

An	O
alternative	O
source	O
of	O
energy	O
is	O
d	B-Entity
-	I-Entity
galactose	I-Entity
(	O
the	O
C-4-epimer	O
of	O
d	B-Entity
-	I-Entity
glucose	I-Entity
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	O
-	O
independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	I-Entity
via	O
the	O
Leloir	O
pathway	O
.	O

Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	I-Entity
induce	O
memory	B-Entity
deterioration	I-Entity
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	I-Entity
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	I-Entity
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-Entity
deficits	I-Entity
in	O
streptozotocin	I-Entity
-	O
induced	O
(	O
STZ	I-Entity
-	O
icv	O
)	O
rat	O
model	O
of	O
sAD	O
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O

One	O
month	O
of	O
oral	O
galactose	I-Entity
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	I-Entity
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	I-Entity
-	O
icv	O
-	O
induced	O
cognitive	B-Entity
deficits	I-Entity
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	I-Entity
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	I-Entity
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O

Additionally	O
,	O
oral	O
galactose	I-Entity
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	I-Entity
in	O
the	O
blood	O
.	O

The	O
increase	O
of	O
galactose	I-Entity
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	I-Entity
dose	O
.	O

Oral	O
galactose	I-Entity
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-Entity
deficits	I-Entity
associated	O
with	O
glucose	B-Entity
hypometabolism	I-Entity
in	O
AD	I-Entity
.	O


